Document:

EX-4.17

 Exhibit 4.17  

 
  

GSK CONSUMER HEALTHCARE CAPITAL US LLC 

AND 
 GSK CONSUMER HEALTHCARE
CAPITAL UK PLC 
 as ISSUERS 

GLAXOSMITHKLINE PLC 
 AND

 HALEON PLC 
 as
GUARANTORS 
 AND 
 DEUTSCHE
BANK TRUST COMPANY AMERICAS 
 as TRUSTEE, PRINCIPAL PAYING AGENT, TRANSFER AGENT and REGISTRAR 

$700,000,000 3.024% CALLABLE FIXED RATE SENIOR NOTES DUE 2024 

$300,000,000 CALLABLE FLOATING RATE SENIOR NOTES DUE 2024 

$1,750,000,000 3.125% FIXED RATE SENIOR NOTES DUE 2025 

$2,000,000,000 3.375% FIXED RATE SENIOR NOTES DUE 2027 

$1,000,000,000 3.375% FIXED RATE SENIOR NOTES DUE 2029 

$2,000,000,000 3.625% FIXED RATE SENIOR NOTES DUE 2032 

$1,000,000,000 4.000% FIXED RATE SENIOR NOTES DUE 2052 
  

 
 Indenture

 Dated as of March 24, 2022 
  

 
  

							
		
	 ARTICLE I. DEFINITIONS
	  	 	1	 
			
	 Section 1.1.
	 	 Definitions
	  	 	1	 
			
	 Section 1.2.
	 	 Rules of Construction
	  	 	16	 
		
	 ARTICLE II. THE NOTES
	  	 	17	 
			
	 Section 2.1.
	 	 Form and Dating
	  	 	17	 
			
	 Section 2.2.
	 	 Execution and Authentication
	  	 	17	 
			
	 Section 2.3.
	 	 Paying Agent, Transfer Agent, Registrar
	  	 	19	 
			
	 Section 2.4.
	 	 Paying Agent to Hold Money in Trust
	  	 	20	 
			
	 Section 2.5.
	 	 Holder Lists
	  	 	21	 
			
	 Section 2.6.
	 	 Book-Entry Provisions for Global Notes
	  	 	21	 
			
	 Section 2.7.
	 	 Restrictive Legend
	  	 	23	 
			
	 Section 2.8.
	 	 Transfer and Exchange
	  	 	24	 
			
	 Section 2.9.
	 	 Mutilated, Destroyed, Lost or Stolen Notes
	  	 	27	 
			
	 Section 2.10.
	 	 Temporary Notes
	  	 	28	 
			
	 Section 2.11.
	 	 Cancellation
	  	 	28	 
			
	 Section 2.12.
	 	 CUSIP Numbers
	  	 	28	 
			
	 Section 2.13.
	 	 Further Issues
	  	 	29	 
			
	 Section 2.14.
	 	 Purchases of the Notes by the Guarantor or any of its Affiliates
	  	 	29	 
		
	 ARTICLE III. INTEREST CALCULATION IN RESPECT OF THE NOTES
	  	 	29	 
			
	 Section 3.1.
	 	 Interest rate terms specific to the Fixed Rate Notes
	  	 	29	 
			
	 Section 3.2.
	 	 Interest Rate Terms Specific to the Callable Floating Rate Notes
	  	 	30	 
			
	 Section 3.3.
	 	 Calculation of the Benchmark
	  	 	31	 
			
	 Section 3.4.
	 	 Benchmark Transitional Provisions
	  	 	32	 
			
	 Section 3.5.
	 	 Agreement with Respect to the Benchmark Replacement
	  	 	34	 
		
	 ARTICLE IV. COVENANTS
	  	 	35	 
			
	 Section 4.1.
	 	 Payment of Notes; Additional Amounts
	  	 	35	 
			
	 Section 4.2.
	 	 Limitation on Liens
	  	 	38	 
			
	 Section 4.3.
	 	 Maintenance of Office or Agency
	  	 	38	 
			
	 Section 4.4.
	 	 Maintenance of Corporate Existence and Corporate Separateness
	  	 	38	 
			
	 Section 4.5.
	 	 Compliance Certificate
	  	 	39	 
			
	 Section 4.6.
	 	 Reports to Holders
	  	 	39	 
		
	 ARTICLE V. DEMERGER CAPITAL REDUCTION
	  	 	39	 
			
	 Section 5.1.
	 	 Demerger Capital Reduction
	  	 	39	 

  

							
		
	 ARTICLE VI. SUCCESSOR ENTITY
	  	 	39	 
			
	 Section 6.1.
	 	 When an Issuer May Merge, Etc.
	  	 	39	 
			
	 Section 6.2.
	 	 Successor Substituted
	  	 	40	 
			
	 Section 6.3.
	 	 When the Guarantor May Merge, Etc.
	  	 	40	 
			
	 Section 6.4.
	 	 Successor Guarantor Substituted
	  	 	41	 
			
	 Section 6.5.
	 	 Substitution of either Issuer
	  	 	41	 
		
	 ARTICLE VII. REDEMPTION
	  	 	42	 
			
	 Section 7.1.
	 	 Redemption; General
	  	 	42	 
			
	 Section 7.2.
	 	 Optional Redemption for Tax Reasons
	  	 	42	 
			
	 Section 7.3.
	 	 Deposit of Redemption Price
	  	 	44	 
			
	 Section 7.4.
	 	 Unredeemed Portions of Partially Redeemed Note
	  	 	44	 
			
	 Section 7.5.
	 	 Fixed Rate Notes Make-Whole and Par Redemption
	  	 	44	 
			
	 Section 7.6.
	 	 Floating Rate Notes Par Redemption
	  	 	45	 
			
	 Section 7.7.
	 	 Special Mandatory Early Redemption
	  	 	45	 
			
	 Section 7.8.
	 	 Redemption upon a Change of Control Put Event
	  	 	46	 
			
	 Section 7.9.
	 	 Redemption at Maturity
	  	 	47	 
		
	 ARTICLE VIII. DEFEASANCE
	  	 	47	 
			
	 Section 8.1.
	 	 Defeasance
	  	 	47	 
		
	 ARTICLE IX. DEFAULTS AND REMEDIES
	  	 	48	 
			
	 Section 9.1.
	 	 Events of Default
	  	 	48	 
			
	 Section 9.2.
	 	 Notice of Event of Default
	  	 	49	 
			
	 Section 9.3.
	 	 Acceleration
	  	 	49	 
			
	 Section 9.4.
	 	 Other Remedies
	  	 	50	 
			
	 Section 9.5.
	 	 Waiver of Past Defaults
	  	 	50	 
			
	 Section 9.6.
	 	 Rights of Holders to Receive Payment
	  	 	50	 
			
	 Section 9.7.
	 	 Collection Suit by Trustee
	  	 	50	 
			
	 Section 9.8.
	 	 Trustee May File Proofs of Claim, Etc.
	  	 	51	 
			
	 Section 9.9.
	 	 Application of Proceeds
	  	 	51	 
			
	 Section 9.10.
	 	 Restoration of Rights and Remedies
	  	 	51	 
			
	 Section 9.11.
	 	 Undertaking for Costs
	  	 	52	 
			
	 Section 9.12.
	 	 Rights and Remedies Cumulative
	  	 	52	 
			
	 Section 9.13.
	 	 Delay or Omission Not Waiver
	  	 	52	 

  
 ii 

							
		
	 ARTICLE X. TRUSTEE, PAYING AGENT, TRANSFER AGENT AND REGISTRAR
	  	 	52	 
			
	 Section 10.1.
	 	 Duties of Trustee
	  	 	52	 
			
	 Section 10.2.
	 	 Certain Rights of Trustee, Paying Agent, Transfer Agent and Registrar
	  	 	54	 
			
	 Section 10.3.
	 	 Individual Rights of Trustee
	  	 	56	 
			
	 Section 10.4.
	 	 Disclaimer
	  	 	56	 
			
	 Section 10.5.
	 	 Notice of Defaults
	  	 	56	 
			
	 Section 10.6.
	 	 Compensation and Indemnity
	  	 	57	 
			
	 Section 10.7.
	 	 Replacement of Trustee
	  	 	57	 
			
	 Section 10.8.
	 	 Successor Trustee by Merger
	  	 	59	 
			
	 Section 10.9.
	 	 Eligibility; Disqualification
	  	 	59	 
			
	 Section 10.10.
	 	 Communications
	  	 	59	 
			
	 Section 10.11.
	 	 Resignation of Agents
	  	 	59	 
		
	 ARTICLE XI. AMENDMENTS
	  	 	60	 
			
	 Section 11.1.
	 	 Without Consent of Holders
	  	 	60	 
			
	 Section 11.2.
	 	 With Consent of Holders
	  	 	61	 
			
	 Section 11.3.
	 	 Revocation and Effect of Consents and Waivers
	  	 	62	 
			
	 Section 11.4.
	 	 Notation on or Exchange of Notes
	  	 	62	 
			
	 Section 11.5.
	 	 Trustee to Sign Amendments
	  	 	63	 
		
	 ARTICLE XII. RANKING
	  	 	63	 
			
	 Section 12.1.
	 	 Ranking of U.S. Issuer Notes
	  	 	63	 
			
	 Section 12.2.
	 	 Ranking of UK Issuer Notes
	  	 	63	 
		
	 ARTICLE XIII. THE GUARANTEES
	  	 	63	 
			
	 Section 13.1.
	 	 The Guarantees
	  	 	63	 
			
	 Section 13.2.
	 	 The GSK Guarantee
	  	 	64	 
			
	 Section 13.3.
	 	 The Haleon Guarantee
	  	 	67	 
		
	 ARTICLE XIV. MISCELLANEOUS
	  	 	69	 
			
	 Section 14.1.
	 	 Notices
	  	 	69	 
			
	 Section 14.2.
	 	 Certificate and Opinion as to Conditions Precedent
	  	 	71	 
			
	 Section 14.3.
	 	 Statements Required in Certificate or Opinion
	  	 	71	 
			
	 Section 14.4.
	 	 Rules by Trustee, Paying Agent and Registrar
	  	 	71	 
			
	 Section 14.5.
	 	 Payment Date Other Than a Business Day
	  	 	72	 
			
	 Section 14.6.
	 	 Governing Law, Etc.
	  	 	72	 
			
	 Section 14.7.
	 	 No Recourse Against Others
	  	 	73	 

  
 iii 

							
			
	 Section 14.8.
	 	 Successors
	  	 	73	 
			
	 Section 14.9.
	 	 Duplicate and Counterpart Originals
	  	 	73	 
			
	 Section 14.10.
	 	 Severability
	  	 	73	 
			
	 Section 14.11.
	 	 Judgment Currency
	  	 	74	 
			
	 Section 14.12.
	 	 USA Patriot Act
	  	 	74	 
			
	 Section 14.13.
	 	 No Personal Liability of Incorporators, Stockholders, Officers, Directors or Employees
	  	 	74	 
			
	 Section 14.14.
	 	 Table of Contents; Headings
	  	 	75	 
			
	 Section 14.15.
	 	 Force Majeure
	  	 	75	 

 EXHIBIT A FORM OF 2025 FIXED RATE GLOBAL NOTE 

EXHIBIT B FORM OF 2027 FIXED RATE GLOBAL NOTE 
 EXHIBIT
C FORM OF 2029 FIXED RATE GLOBAL NOTE 
 EXHIBIT D FORM OF 2032 FIXED RATE GLOBAL NOTE 

EXHIBIT E FORM OF 2052 FIXED RATE GLOBAL NOTE 
 EXHIBIT
F FORM OF CALLABLE FIXED RATE GLOBAL NOTE 
 EXHIBIT G FORM OF CALLABLE FLOATING RATE GLOBAL NOTE 

EXHIBIT H FORM OF CERTIFICATED NOTE 
 EXHIBIT I FORM OF
CERTIFICATE FOR TRANSFER TO QIB 
 EXHIBIT J FORM OF CERTIFICATE FOR TRANSFER PURSUANT TO REGULATION S 

EXHIBIT K FORM OF CERTIFICATE FOR TRANSFER PURSUANT TO RULE 144 
  

  
 iv 

 THIS INDENTURE, dated as of March 24, 2022, is among GSK Consumer Healthcare Capital US
LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer”), GSK Consumer Healthcare Capital UK plc, a public limited company incorporated under the laws of England and Wales (the “UK
Issuer”, and together with the U.S. Issuer, the “Issuers”), GlaxoSmithKline plc, a public limited company incorporated under the laws of England and Wales (“GSK”), Haleon plc, a public limited company
incorporated under the laws of England and Wales (“Haleon”), as guarantors (each, a “Guarantor” and, together, the “Guarantors”), and Deutsche Bank Trust Company Americas, as trustee (in such
capacity, the “Trustee”), principal paying agent (in such capacity, the “Principal Paying Agent”), transfer agent (in such capacity, the “Transfer Agent”) and registrar (in such capacity, the
“Registrar”). 
 Each party agrees as follows for the benefit of the other parties and for the equal and ratable benefit of
the Holders of the Notes (as defined below) issued hereunder. 
 ARTICLE I. 

DEFINITIONS 

Section 1.1. Definitions 

“2025 Fixed Rate Global Notes” means registered Global Notes for the 2025 Fixed Rate Notes, substantially in the form of
Exhibit A. 
 “2025 Fixed Rate Notes” means the 3.125% Senior Notes due 2025 issued by the UK Issuer and
authenticated pursuant to this Indenture. 
 “2025 Fixed Rate Notes Maturity Date” means March 24, 2025. 

“2027 Fixed Rate Global Notes” means registered Global Notes for the 2027 Fixed Rate Notes, substantially in the form of
Exhibit B. 
 “2027 Fixed Rate Notes” means the 3.375% Senior Notes due 2027 issued by the U.S. Issuer and
authenticated pursuant to this Indenture. 
 “2027 Fixed Rate Notes Maturity Date” means March 24, 2027. 

“2027 Fixed Rate Notes Par Call Date” means February 24, 2027. 

“2029 Fixed Rate Global Notes” means registered Global Notes for the 2029 Fixed Rate Notes, substantially in the form of
Exhibit C. 
 “2029 Fixed Rate Notes” means the 3.375% Senior Notes due 2029 issued by the U.S. Issuer and
authenticated pursuant to this Indenture. 
 “2029 Fixed Rate Notes Maturity Date” means March 24, 2029. 

“2029 Fixed Rate Notes Par Call Date” means January 24, 2029. 

  
 1 

 “2032 Fixed Rate Global Notes” means registered Global Notes for the 2032
Fixed Rate Notes, substantially in the form of Exhibit D. 
 “2032 Fixed Rate Notes” means the 3.625% Senior
Notes due 2032 issued by the U.S. Issuer and authenticated pursuant to this Indenture. 
 “2032 Fixed Rate Notes Maturity
Date” means March 24, 2032. 
 “2032 Fixed Rate Notes Par Call Date” means December 24, 2031. 

“2052 Fixed Rate Global Notes” means registered Global Notes for the 2052 Fixed Rate Notes, substantially in the form of
Exhibit E. 
 “2052 Fixed Rate Notes” means the 4.000% Senior Notes due 2052 issued by the U.S. Issuer and
authenticated pursuant to this Indenture. 
 “2052 Fixed Rate Notes Maturity Date” means March 24, 2052. 

“2052 Fixed Rate Notes Par Call Date” means September 24, 2051. 

“Additional Amounts” has the meaning ascribed thereto in Section 4.1(d). 

“Additional Notes” means Notes of any series issued after the Issue Date pursuant to Section 2.13,
including any replacement Notes issued therefor. 
 “Affiliate” means, with respect to a Person, another Person
controlling, controlled by or under common control with such Person. For the purposes of this definition, control of a Person shall mean the power, direct or indirect, (i) to vote more than 50% of the securities having ordinary voting power for
the election of directors of such Person, or (ii) to direct or cause the direction of the management and policies of such Person whether by contract or otherwise. 

“Agents” has the meaning ascribed thereto in Section 10.2(a). 

“Agent Members” has the meaning ascribed to it in Section 2.6(e). 

“Authenticating Agent” has the meaning ascribed to it in Section 2.2(c). 

“Authorized Agent” has the meaning ascribed to it in Section 14.6(c). 

“Authorized Person” means any person who is designated in writing by an Issuer from time to time to give Instructions to the
Trustee and/or an Agent under the terms of this Indenture. 
 “authorized denomination” means denominations of $250,000 and
multiples of $1,000 in excess thereof. 
 “Benchmark” has the meaning ascribed thereto in
Section 3.3(a). 

  
 2 

 “Benchmark Replacement” has the meaning ascribed thereto in
Section 3.4(b). 
 “Benchmark Replacement Adjustment” means the first alternative set forth in
the order below that can be determined by the U.S. Issuer or its designee (in consultation with the U.S. Issuer) as of the Benchmark Replacement Date: 

(a) the spread adjustment (which may be a positive or negative value or zero) that has been (i) selected or recommended by the Relevant
Governmental Body or (ii) determined by the U.S. Issuer or its designee (in consultation with the U.S. Issuer) in accordance with the method for calculating or determining such spread adjustment that has been selected or recommended by the
Relevant Governmental Body, in each case for the applicable Unadjusted Benchmark Replacement; 
 (b) if the applicable Unadjusted Benchmark
Replacement is equivalent to the ISDA Fallback Rate, then the ISDA Fallback Adjustment; 
 (c) the spread adjustment (which may be a
positive or negative value or zero) that has been selected by the U.S. Issuer or its designee (in consultation with the U.S. Issuer) giving due consideration to industry-accepted spread adjustments (if any), or method for calculating or determining
such spread adjustment, for the replacement of the then-current Benchmark with the applicable Unadjusted Benchmark Replacement for U.S. dollar-denominated floating rate notes at such time. 

“Benchmark Replacement Conforming Changes” has the meaning ascribed thereto in Section 3.4(c). 

“Benchmark Replacement Date” means the earliest to occur of the following events with respect to the then-current Benchmark:

 (a) in the case of clause (a) or (b) of the definition of “Benchmark Transition Event,” the later of (i) the date of
the public statement or publication of information referenced therein and (ii) the date on which the administrator of the Benchmark permanently or indefinitely ceases to provide the Benchmark; or 

(b) in the case of clause (c) of the definition of “Benchmark Transition Event,” the date of the public statement or
publication of information referenced therein. 
 For the avoidance of doubt, if the event giving rise to the Benchmark Replacement Date occurs on the same
day as, but earlier than, the Reference Time in respect of any determination, the Benchmark Replacement Date will be deemed to have occurred prior to the Reference Time for such determination. 

“Benchmark Transition Event” means the occurrence of one or more of the following events with respect to the then-current
Benchmark: 
 (a) a public statement or publication of information by or on behalf of the administrator of the Benchmark announcing that
such administrator has ceased or will cease to provide the Benchmark, permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide the Benchmark;

  
 3 

 (b) a public statement or publication of information by the regulatory supervisor for the
administrator of the Benchmark, the central bank for the currency of the Benchmark, an insolvency official with jurisdiction over the administrator for the Benchmark, a resolution authority with jurisdiction over the administrator for the Benchmark
or a court or an entity with similar insolvency or resolution authority over the administrator for the Benchmark, which states that the administrator of the Benchmark has ceased or will cease to provide the Benchmark permanently or indefinitely,
provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide the Benchmark; or 

(c) a public statement or publication of information by the regulatory supervisor for the administrator of the Benchmark announcing that the
Benchmark is no longer representative. 
 “Business Day” means any day other than a Saturday, a Sunday or a day on which
banking institutions in the City of New York or London, England are authorized or obligated by law, regulation or executive order to be closed. 

“Callable Fixed Rate Global Notes” means registered Global Notes for the Callable Fixed Rate Notes, substantially in the form
of Exhibit F. 
 “Callable Fixed Rate Notes” means the 3.024% Callable Senior Notes due 2024 issued by the
U.S. Issuer and authenticated pursuant to this Indenture. 
 “Callable Fixed Rate Notes Maturity Date” means March 24,
2024. 
 “Callable Fixed Rate Notes Par Call Date” means March 24, 2023. 

“Callable Floating Rate Global Notes” means registered Global Notes for the Callable Floating Rate Notes, substantially in
the form of Exhibit G. 
 “Callable Floating Rate Notes” means the Callable Senior Floating Rate Notes due 2024
issued by the US Issuer and authenticated pursuant to this Indenture. 
 “Callable Floating Rate Notes Interest Payment
Date” has the meaning ascribed to it in Section 3.2(c). 
 “Callable Floating Rate Notes Interest
Period” means the period beginning on (and including) a Floating Rate Notes Interest Payment Date and ending on (but excluding) the next succeeding Floating Rate Notes Interest Payment Date; provided that the first Floating Rate
Notes Interest Period will begin on (and include) the Issue Date and will end on (but exclude) the first Floating Rate Notes Interest Payment Date. 

“Callable Floating Rate Notes Margin” has the meaning ascribed thereto in Section 3.2(a). 

“Callable Floating Rate Notes Maturity Date” means March 24, 2024. 

  
 4 

 “Callable Floating Rate Notes Par Call Date” means March 24, 2023.

 “Certificated Note” means a Rule 144A Certificated Note or a Regulation S Certificated Note. 

A “Change of Control” will be deemed to occur if, after the Guarantee Assumption Date: 

(a) with respect to any Notes, a Person or Persons acting in concert (as defined in the City Code on Takeovers and Mergers), other than a
holding company (as defined in Section 1159 of the UK Companies Act 2006, as amended) whose shareholders are or are to be substantially similar to the pre-existing shareholders of Haleon or any holding
company of Haleon, shall become interested (within the meaning of Part 22 of the UK Companies Act 2006, as amended) in (A) more than 50% of the issued or allotted ordinary share capital of Haleon (or any holding company of Haleon or
(B) shares in the capital of Haleon (or any holding company of Haleon) carrying more than 50% of the voting rights normally exercisable at a general meeting of Haleon or any holding company of Haleon; or 

(b) with respect to the U.S. Issuer Notes, Haleon ceases to own directly or indirectly more than 50% of the outstanding share capital of the
U.S. Issuer carrying voting rights normally exercisable at a general meeting of the U.S. Issuer; or 
 (c) with respect to the UK Issuer
Notes, Haleon ceases to own directly or indirectly more than 50% of the outstanding share capital of the UK Issuer carrying voting rights normally exercisable at a general meeting of the UK Issuer. 

“Change of Control Period” means the period commencing on and including the Relevant Announcement Date and ending on and
including the date falling 90 days after the Change of Control (or such longer period for which the relevant series of Notes are under consideration (such consideration having been announced publicly within the period described above) for rating
review or, as the case may be, rating by a Rating Agency, such period not to exceed 60 days from and including the public announcement of such consideration). 

“Change of Control Put Event” will be deemed to occur if a Change of Control has occurred and during the Change of Control
Period either (i) a withdrawal or downgrade occurs to any one or more credit ratings assigned to the relevant series of Notes so that none of the Rating Agencies then rating such series of Notes assign an Investment Grade rating to such series
of Notes and, within the Change of Control Period, any one or more of such ratings is not subsequently (in the case of a downgrade) upgraded or (in the case of a withdrawal) reinstated to an Investment Grade; provided that (A) where a
rating has been changed, the relevant Rating Agency announces publicly or confirms in writing to the relevant Issuer or Haleon that such change resulted, in whole or in part, in anticipation of, or as a result of the occurrence of, the Change of
Control; (B) in the case of a Potential Change of Control Announcement, a Change of Control Put Event will be deemed to have occurred only if and when the Change of Control referred to in such Potential Change of Control Announcement
subsequently occurs; and (C) if there is only one credit rating assigned to the relevant series of Notes, a Change of Control Put Event can only occur if that credit rating changes so that the relevant Rating Agency does not

  
 5 

 
assign an Investment Grade rating to the Notes or (ii) a Negative Rating Event occurs. For the avoidance of doubt, a Change of Control Put Event will not have occurred, where the Notes were
rated by the Rating Agencies below Investment Grade on or before a Change of Control has occurred and such rating has not been withdrawn or downgraded as a result of the Change of Control. 

“Change of Control Put Event Notice” has the meaning ascribed thereto in Section 7.8(b). 

“Change of Control Put Date” has the meaning ascribed thereto in Section 7.8(c). 

“Change of Control Put Notice” has the meaning ascribed thereto in Section 7.8(c). 

“Change of Control Put Period” has the meaning ascribed thereto in Section 7.8(b). 

“Change of Control Redemption Amount” means a redemption price equal to 101% of the principal amount of the Notes to be
redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 
 “Compounded Daily
SOFR” has the meaning ascribed to it in Section 3.3(b). 
 “Corporate Trust Office”
means the principal corporate trust office of the Trustee, which office at the date hereof is located at Deutsche Bank Trust Company Americas, 1 Columbus Circle, 17th Floor, Mail Stop NYC01-1710, New York, NY, 10019, or such other address as the
Trustee may designate from time to time by notice to the Holders and the Issuer, or the principal corporate trust office of any Successor Trustee or such other address as such Successor Trustee may designate from time to time by notice to the
Holders and the Issuer. 
 “Corresponding Tenor” with respect to a Benchmark Replacement means a tenor (including
overnight) having approximately the same length (disregarding business day adjustments) as the applicable tenor for the then-current Benchmark. 

“Default” means any Event of Default or any occurrence that is, or with notice or the lapse of time or both would become, an
Event of Default. 
 “Demerger” means the proposed demerger of at least 80% of GSK’s interest in GlaxoSmithKline
Consumer Healthcare Holdings (No.2) Limited and its consolidated subsidiaries, to be effected by way of an interim dividend, in specie, proposed to be declared by the board of directors of GSK to be satisfied by the transfer of GSK of A Ordinary
Shares in GlaxoSmithKline Consumer Healthcare Holdings Limited to Haleon in consideration for the issuance by Haleon of shares to the GSK shareholders as of the relevant record time in accordance with a demerger agreement between Haleon and GSK.

 “Demerger Capital Reduction” means a court-confirmed reduction in the capital of Haleon within six months of the
completion of the Demerger. 

  
 6 

 “Demerger Completion Notice” means a notice in writing signed by two
directors of GSK, addressed to the Trustee and copied to the Holders certifying that the Demerger has occurred. 

“Depositary” means, with respect to each Global Note, the Person specified in Section 2.6(a) as the
Depositary with respect to such Notes, until a successor shall have been appointed and become such pursuant to the applicable provisions of this Indenture, and thereafter, “Depositary” shall mean or include such successor. 

“designee” means an Affiliate or any other agent of the U.S. Issuer. 

“Distribution Compliance Period” means, in respect of any Regulation S Global Note, the 40 consecutive days beginning on and
including the later of (a) the day on which any Notes represented thereby are offered to persons other than “distributors” (as defined in Regulation S under the Securities Act) pursuant to Regulation S and (b) the issue date for
such Notes. 
 “Event of Default” has the meaning ascribed thereto in Section 9.1. 

“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended. 

“Exchange Notes” means, with respect to the Notes, notes issued in exchange for the Notes pursuant to the terms of the
Registration Rights Agreement or, with respect to any Additional Notes, notes issued in exchange for such Additional Notes pursuant to the terms of a registration rights agreement among the Issuer and the initial purchasers of such Additional Notes.

 “Exchange Offer” has the meaning ascribed to it in the Registration Rights Agreement. 

“Executed Documentation” has the meaning ascribed thereto in Section 2.2(b). 

“Fitch” means Fitch Ratings Ltd and its successors. 

“Fixed Rate Notes” means the 2025 Fixed Rate Notes, the 2027 Fixed Rate Notes, the 2029 Fixed Rate Notes, the 2032 Fixed Rate
Notes, the 2052 Fixed Rate Notes and the Callable Fixed Rate Notes. 
 “Fixed Rate Notes Interest Payment Date” has the
meaning ascribed thereto in Section 3.1(b). 
 “Fixed Rate Notes Maturity Date” means each of the
2025 Fixed Rate Notes Maturity Date, the 2027 Fixed Rate Notes Maturity Date, the 2029 Fixed Rate Notes Maturity Date, the 2032 Fixed Rate Notes Maturity Date, the 2052 Fixed Rate Notes Maturity Date and the Callable Fixed Rate Notes Maturity Date.

  
 7 

 “Fixed Rate Notes Par Call Date” means any of the 2027 Fixed Rate Notes Par
Call Date, the 2029 Fixed Rate Notes Par Call Date, the 2032 Fixed Rate Notes Par Call Date, the 2052 Fixed Rate Notes Par Call Date or the Callable Fixed Rate Notes Par Call Date. 

“Global Notes” means individually and collectively, each of the Global Notes deposited with or on behalf of and registered in
the name of the Depositary with respect to each series of the Notes, that will be issued in an initial amount equal to the principal amount of the relevant series of the Notes initially resold in reliance on Rule 144A and Regulation S, substantially
in the form of Exhibits A to Exhibit G hereto with respect to the relevant series of Notes, issued in accordance with Section 2.6 and Section 2.7. 

“GSK Guarantee” means the guarantee of the Notes by GSK prior to the Guarantee Assumption Date, as endorsed on each Note
authenticated and delivered pursuant to this Indenture and shall include the guarantee of GSK set forth in Section 13.2 and shall include all other obligations and covenants of GSK contained in this Indenture and the Notes.

 “Guarantee Assumption Date” means the date on which GSK ceases to hold a direct or indirect interest in the share
capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger. 

“Guarantee Assumption Notice” means a notice in writing signed by two directors of GSK, addressed to the Trustee and copied
to the Holders, certifying that the Guarantee Assumption Date has occurred. 
 “Guarantees” means the GSK Guarantee and the
Haleon Guarantee and “Guarantee” means either of the GSK Guarantee or the Haleon Guarantee, as applicable. 

“Guarantor” means, at any time, each Person guaranteeing the Issuer’s obligations under this Indenture and the Notes at
such time pursuant to ARTICLE XIII. 
 “H.15” has the meaning ascribed to it in the definition of “Treasury
Rate” in this Section 1.1. 
 “Haleon Group” means Haleon and its subsidiaries. 

“Haleon Guarantee” means the guarantee of the Notes by Haleon with effect from (and including) the Guarantee Assumption Date,
as endorsed on each Note authenticated and delivered pursuant to this Indenture and shall include the guarantee of Haleon set forth in Section 13.3 and shall include all other obligations and covenants of Haleon contained
in this Indenture and the Notes. 
 “Holder” means the Person in whose name a Note is registered in the Note Register. 

“Indenture” means this Indenture, including all exhibits hereto, in each case as amended or supplemented from time to time.

  
 8 

 “Initial Purchasers” has the meaning ascribed thereto in
Section 2.1(a). 
 “Instructions” means any written notices, written directions or written
instructions received by the Trustee and/or an Agent under the terms of this Indenture from an Authorized Person or from a person reasonably believed by the Trustee and/or an Agent to be an Authorized Person. 

“Interest Determination Date” has the meaning ascribed thereto in Section 3.2(b). 

“Investment Grade” means in relation to the Notes: (a) a credit rating of BBB-
or higher by S&P (or its equivalent under any successor rating category of S&P); (b) a credit rating of Baa3 or higher by Moody’s (or its equivalent under any successor rating category of Moody’s); or (c) a credit rating of BBB- or higher by Fitch (or its equivalent under any successor rating category of Fitch); or (d) an equivalent rating to either BBB or Baa3, or higher, by any other Rating Agency. 

“ISDA” means the the International Swaps and Derivatives Association, Inc. 

“ISDA Definitions” means the 2021 ISDA Interest Rate Derivatives Definitions published by ISDA or any successor thereto, as
amended or supplemented from time to time, or any successor definitional booklet for interest rate derivatives published from time to time. 

“ISDA Fallback Adjustment” means the spread adjustment (which may be a positive or negative value or zero) that would apply
for derivatives transactions referencing the ISDA Definitions to be determined upon the occurrence of an index cessation event with respect to the Benchmark for the applicable tenor. 

“ISDA Fallback Rate” means the rate that would apply for derivatives transactions referencing the ISDA Definitions to be
effective upon the occurrence of an index cessation date with respect to the Benchmark for the applicable tenor excluding the applicable ISDA Fallback Adjustment. 

“Issue Date” means March 24, 2022. 

“Issue Date Notes” means the Notes originally issued on the Issue Date, and any replacement Notes issued therefor in
accordance with this Indenture. 
 “Issuers” means the parties named as such in the introductory paragraph to this
Indenture and their successors and assigns, including any Successor Entity that becomes such in accordance with ARTICLE VI and “Issuer” means any one of them, as applicable. 

“Issuer Order” has the meaning ascribed thereto in Section 2.2(e). 

“Liens” has the meaning ascribed thereto in Section 4.2. 

“Losses” means any and all claims, losses, liabilities, damages, costs, expenses and judgments (including legal fees and
expenses) sustained by any party to this Indenture. 

  
 9 

 “Maturity Date” means any of a Fixed Rate Notes Maturity Date or a Callable
Floating Rate Notes Maturity Date, as applicable. 
 “Merger” means a merger, reorganization, spin-off, split-off, compromise, liquidation, dissolution, or similar matter (whether or not involving liquidation or dissolution). 

“Moody’s” means Moody’s Investors Services Limited and its successors. 

A “Negative Rating Event” shall be deemed to have occurred if at any time there is no rating assigned to the Notes by a
Rating Agency and the relevant Issuer does not, by the end of the Change of Control Period, obtain an Investment Grade rating in respect of such Notes. 

“Note Register” has the meaning ascribed to it in Section 2.3(a). 

“Non-U.S. Person” means a person who is not a U.S. person, as defined in Regulation
S. 
 “Notes” means the Fixed Rate Notes and the Callable Floating Rate Notes. 

“NY Federal Reserve” has the meaning ascribed to it in the definition of “Relevant Governmental Body” in this
Section 1.1. 
 “NY Federal Reserve’s Website” means the website of the Federal Reserve Bank
of New York at http://www.newyorkfed.org (or any successor website). 
 “Observation Period” has the meaning ascribed to it
in Section 3.3(b). 
 “Offering Memorandum” means the Offering Memorandum, dated March 24,
2022, relating to the Notes. 
 “Officer” means, with respect to an Issuer or a Guarantor, either any director or officer
thereof, including the Secretary, assistant secretary, or any authorized signatory appointed by a resolution of the board of the relevant Issuer or the applicable Guarantor, as the case may be, or granted a power of attorney. 

“Officer’s Certificate” means a certificate executed by any Officer of the relevant Issuer or of the applicable
Guarantor, as the case may be, and in each case delivered to the Trustee. 
 “Opinion of Counsel” means a written opinion
of counsel, who may be an employee of or counsel for the relevant Issuer, the applicable Guarantor or the Trustee. 

“Outstanding” means, in respect of each series of Notes as of the date of determination, those Notes in the relevant series
of Notes theretofore authenticated and delivered under this Indenture, except: 
  

	 	(i)	 Notes theretofore cancelled by the Trustee or delivered to the Trustee for cancellation; 

  
 10 

 (ii) Notes, or portions thereof, for whose payment or redemption money
sufficient to pay all principal and other amounts, if any, payable on that date with respect to the Notes has been theretofore deposited with any Paying Agent (other than the relevant Issuer) in trust or set aside and segregated in trust by the
relevant Issuer (if the relevant Issuer shall act as Paying Agent) for the Holders of such Notes and the Paying Agent is not prohibited from paying such money to the Holders on that date pursuant to the terms of this Indenture; provided that,
if the Notes are to be redeemed, a notice of redemption with respect thereto shall have been duly given pursuant to this Indenture or provision therefor satisfactory to the Trustee has been made; and 

(iii) Notes which have been surrendered pursuant to Section 2.8 or in exchange for or in lieu of
which other Notes have been authenticated and delivered pursuant to this Indenture, other than any such Notes in respect of which there shall have been presented to the Trustee proof satisfactory to it that such Notes are held by a bona fide
purchaser in whose hands such Notes are valid obligations of the relevant Issuer; 
 provided, however, that in determining whether the
Holders of the requisite principal amount of the Outstanding Notes have given any request, demand, authorization, direction, notice, consent or waiver hereunder, Notes owned by the relevant Issuer, the applicable Guarantor or any other obligor upon
the Notes or any Affiliate of the relevant Issuer, the applicable Guarantor or of such other obligor shall be disregarded and deemed not to be Outstanding, except that, in determining whether the Trustee shall be protected in relying upon any such
request, demand, authorization, direction, notice, consent or waiver, only Notes which a Trust Officer of the Trustee actually knows to be so owned shall be so disregarded. Notes so owned which have been pledged in good faith may be regarded as
Outstanding if the pledgee establishes to the satisfaction of the Trustee the pledgee’s right so to act with respect to such Notes and that the pledgee is not the relevant Issuer, the applicable Guarantor or any other obligor upon the Notes or
any Affiliate of the relevant Issuer, the applicable Guarantor or such other obligor. 
 “participants” has the meaning
ascribed to it in Section 2.6(b). 
 “Participating Broker-Dealer” has the meaning ascribed to it
in the Registration Rights Agreement. 
 “Paying Agent” means the Principal Paying Agent and/or any additional Paying Agent
appointed by the Issuer, as applicable. 
 “Person” means any individual, company, corporation, firm, partnership, joint
venture, undertaking, association, organization, trust, state or agency (in each case whether or not being a separate legal entity). 

“Potential Change of Control Announcement” means the earliest of any public announcement or statement by or on behalf of the
relevant Issuer or Haleon, any actual or potential bidder or any adviser acting on behalf of any actual or potential bidder relating to any potential Change of Control where within 180 days following the date of such announcement or statement, a
Change of Control occurs. 

  
 11 

 “Price Determination Date” has the meaning ascribed to it in the definition
of “Treasury Rate” in this Section 1.1. 
 “Principal Paying Agent” means, initially,
Deutsche Bank Trust Company Americas, at Deutsche Bank Trust Company Americas, 1 Columbus Circle, 17th Floor, Mail Stop NYC01-1710, New York, NY, 10019, and any successor thereto appointed by the Issuers. 

“Private Placement Legend” means the private placement legend specified on the face of each Restricted Note pursuant to
Section 2.7. 
 “Purchase Agreement” has the meaning ascribed to it in
Section 2.1(a). 
 “QIB” means any “qualified institutional buyer” (as defined in
Rule 144A). 
 “Rating Agencies” means (a) S&P; (b) Moody’s; (c) Fitch or (d) if at least
two of S&P, Moody’s or Fitch do not make a rating of the Notes publicly available, any other internationally recognized rating agency appointed by the relevant Issuer to assign a credit rating to the Notes which shall be substituted for
S&P, Moody’s or Fitch or all of them, as the case may be, and each, a “Rating Agency”. 
 “Reference
Time” means (1) if the Benchmark is Compounded Daily SOFR, for each USGS Business Day, 3:00 p.m. (New York time) on the next succeeding USGS Business Day, and (2) if the Benchmark is not Compounded Daily SOFR, the time determined
by the U.S. Issuer or its designee (in consultation with the U.S. Issuer) in accordance with the Benchmark Replacement Conforming Changes. 

“Registrar” means, initially, means, initially, Deutsche Bank Trust Company Americas, at Deutsche Bank Trust Company
Americas, 1 Columbus Circle, 17th Floor, Mail Stop NYC01-1710, New York, NY, 10019, and any successor thereto appointed by the Issuers. 

“Registration Rights Agreement” means the Registration Rights Agreement related to the Notes, dated as of the Issue Date,
among the Issuers, GSK, Haleon and BofA Securities, Inc., Citigroup Global Markets, Inc. and Goldman Sachs International, as representatives of the Initial Purchasers and, with respect to any Additional Notes, one or more registration rights
agreements between the Issuers and the other parties thereto, relating to rights given by the Issuers to the purchasers of Additional Notes to register such Additional Notes, or exchange such Additional Notes for registered notes, under the
Securities Act. 
 “Regular Record Date” means the 15th calendar day preceding each Fixed Rate Notes Interest Payment Date
or Callable Floating Rate Notes Interest Payment Date, whether or not a Business Day. 
 “Regulation S” means Regulation S
under the Securities Act or any successor regulation. 
 “Regulation S Certificated Note” means any Note issued pursuant to
Regulation S in fully registered certificated form (other than a Global Note), substantially in the form of Exhibit H-B. 

  
 12 

 “Regulation S Global Notes” has the meaning ascribed to it in
Section 2.1(h). 
 “Relevant Announcement Date” means the date that is the earlier of
(a) the date of the first public announcement, by or on behalf of the relevant Issuer, Haleon, any bidder or any designated adviser, of the relevant Change of Control and (b) the date of the Potential Change of Control Announcement (if
any). 
 “Relevant Indebtedness” means any indebtedness of a Guarantor that: 

(i) is in the form of or represented by bonds, notes, loan stock, depositary receipts or other securities issued (otherwise
than to constitute or represent advances made by banks or other lending institutions); and 
 (ii) at its date of issue is,
or is intended by the applicable Guarantor to become, quoted, listed, traded or dealt in on any stock exchange, over-the-counter market or other securities market. 

“Relevant Governmental Body” means the Federal Reserve and/or the Federal Reserve Bank of New York (“NY Federal
Reserve”), or a committee officially endorsed or convened by the Federal Reserve and/or the NY Federal Reserve or any successor thereto. 

“Remaining Life” has the meaning ascribed to it in the definition of “Treasury Rate” in this
Section 1.1. 
 “Resale Restriction Termination Date” means, for any Restricted Note (or
beneficial interest therein), the date on which the holding period in relation to such Restricted Note as required pursuant to Rule 144(d) under the Securities Act has expired. 

“Restricted Note” means any Issue Date Note (or beneficial interest therein) or any Additional Note (or beneficial interest
therein) not originally issued and sold pursuant to an effective registration statement under the Securities Act, until such time as: 

(i) such Note is a Rule 144A Global Note and the Resale Restriction Termination Date therefor has passed; 

(ii) such Note is a Regulation S Global Note and the Distribution Compliance Period therefor has terminated; or 

(iii) the Private Placement Legend therefor has otherwise been removed pursuant to Section 2.8(d) or,
in the case of a beneficial interest in a Global Note, such beneficial interest has been exchanged for an interest in a Global Note not bearing a Private Placement Legend. 

“Rule 144A” means Rule 144A under the Securities Act (or any successor rule). 

“Rule 144A Certificated Note” means any Note issued pursuant to Rule 144A in fully registered certificated form (other than a
Global Note), substantially in the form of Exhibit H-A. 

  
 13 

 “Rule 144A Global Notes” has the meaning ascribed to it in
Section 2.1(g). 
 “S&P” means S&P Global Ratings UK Limited and its successors. 

“SEC” means the Securities and Exchange Commission. 

“Securities Act” means the U.S. Securities Act of 1933, as amended. 

“SOFR” has the meaning ascribed to it in Section 3.3(b). 

“Special Mandatory Redemption Amount” means a price representing 101% of the principal amount of the relevant series of
Notes. 
 “Special Mandatory Redemption Event” means (i) the Demerger not having completed by the first anniversary of
the Issue Date; or (ii) if earlier, GSK releasing an announcement which makes public that it no longer intends to pursue the Demerger. 

“Subsidiary” means, in relation to any Person and at any particular time, any entity of which more than 50% of the issued
share capital is then beneficially owned by such Person and/or one or more of its Subsidiaries. 
 “Substituted Obligor”
has the meaning ascribed to it in Section 6.5. 
 “Successor Entity” has the meaning ascribed to
it in Section 6.2. 
 “Transfer Agent” means, initially, Deutsche Bank Trust Company Americas, at
Deutsche Bank Trust Company Americas, 1 Columbus Circle, 17th Floor, Mail Stop NYC01-1710, New York, NY, 10019, and any successor thereto appointed by the Issuers. 

“Treasury Rate” means, with respect to any redemption date, the yield determined by the relevant Issuer in accordance with
the following: 
 (a) The Treasury Rate shall be determined by the relevant Issuer after 4:15 p.m., New York City time (or after such time as
yields on U.S. government securities are posted daily by the Board of Governors of the Federal Reserve System), on the third Business Day preceding the redemption date (the “Price Determination Date”) based upon the yield or yields
for the most recent day that appear after such time on such day in the most recent statistical release published by the Board of Governors of the Federal Reserve System designated as “Selected Interest Rates (Daily) - H.15” (or any
successor designation or publication) (“H.15”) under the caption “U.S. government securities–Treasury constant maturities–Nominal” (or any successor caption or heading). In determining the Treasury Rate, the
relevant Issuer shall select, as applicable: (1) the yield for the Treasury constant maturity on H.15 exactly equal to the period from the redemption date to (a) in the case of any series of U.S. Issuer Fixed Rate Notes, the applicable
Fixed Rate Notes Par Call Date, and (b) in the case of the 2025 Fixed Rate Notes, the 2025 Fixed Rate Notes Maturity Date (in each case, the “Remaining Life”); or (2) if there is no such Treasury constant maturity on H.15
exactly equal to the Remaining Life, the two yields – one yield corresponding to the Treasury constant maturity on H.15 immediately shorter than and one yield corresponding to the Treasury constant maturity on H.15 immediately longer than the
Remaining Life – and 

  
 14 

 
shall interpolate (a) in the case of any series of U.S. Issuer Fixed Rate Notes, to the applicable Fixed Rate Notes Par Call Date, and (b) in the case of the 2025 Fixed Rate Notes, to
the 2025 Fixed Rate Notes Maturity Date, in each case on a straight-line basis (using the actual number of days) using such yields and rounding the result to three decimal places; or (3) if there is no such Treasury constant maturity on H.15
shorter than or longer than the Remaining Life, the yield for the single Treasury constant maturity on H.15 closest to the Remaining Life. For purposes of this paragraph, the applicable Treasury constant maturity or maturities on H.15 shall be
deemed to have a maturity date equal to the relevant number of months or years, as applicable, of such Treasury constant maturity from the redemption date. 

(b) If on the Price Determination Date, H.15 or any successor designation or publication is no longer published, the relevant Issuer shall
calculate the Treasury Rate based on the rate per annum equal to the semi-annual equivalent yield to maturity at 11:00 a.m., New York City time, on the second Business Day preceding such redemption date of the United States Treasury security
maturing on, or with a maturity that is closest to (a) in the case of any series of U.S. Issuer Fixed Rate Notes, the applicable Fixed Rate Notes Par Call Date, and (b) in the case of the 2025 Fixed Rate Notes, the 2025 Fixed Rate Notes
Maturity Date, as applicable. If there is no United States Treasury security maturing on (a) in the case of any series of U.S. Issuer Fixed Rate Notes, the applicable Fixed Rate Notes Par Call Date, and (b) in the case of the 2025 Fixed
Rate Notes, the 2025 Fixed Rate Notes Maturity Date but there are two or more United States Treasury securities with a maturity date equally distant from (a) in the case of any series of U.S. Issuer Fixed Rate Notes, the applicable Fixed Rate
Notes Par Call Date, and (b) in the case of the 2025 Fixed Rate Notes, the 2025 Fixed Rate Notes Maturity Date, one with a maturity date preceding (a) in the case of any series of U.S. Issuer Fixed Rate Notes, the applicable Fixed Rate
Notes Par Call Date, and (b) in the case of the 2025 Fixed Rate Notes, the 2025 Fixed Rate Notes Maturity Date and one with a maturity date following (a) in the case of any series of U.S. Issuer Fixed Rate Notes, the applicable Fixed Rate
Notes Par Call Date, and (b) in the case of the 2025 Fixed Rate Notes, the 2025 Fixed Rate Notes Maturity Date, the relevant Issuer shall select the United States Treasury security with a maturity date preceding (a) in the case of any
series of U.S. Issuer Fixed Rate Notes, the applicable Fixed Rate Notes Par Call Date, and (b) in the case of the 2025 Fixed Rate Notes, the 2025 Fixed Rate Notes Maturity Date. If there are two or more United States Treasury securities
maturing on (a) in the case of any series of U.S. Issuer Fixed Rate Notes, the applicable Fixed Rate Notes Par Call Date and (b) in the case of the 2025 Fixed Rate Notes, the 2025 Fixed Rate Notes Maturity Date, or two or more United
States Treasury securities meeting the criteria of the preceding sentence, the relevant Issuer shall select from among these two or more United States Treasury securities the United States Treasury security that is trading closest to par based upon
the average of the bid and asked prices for such United States Treasury securities at 11:00 a.m., New York City time. In determining the Treasury Rate in accordance with the terms of this paragraph, the semi-annual yield to maturity of the
applicable United States Treasury security shall be based upon the average of the bid and asked prices (expressed as a percentage of principal amount) at 11:00 a.m., New York City time, of such United States Treasury security, and rounded to three
decimal places. 
 “Trustee” means the party named as such in the introductory paragraph of this Indenture until a
successor replaces it in accordance with the terms of this Indenture and, thereafter, means the successor. 

  
 15 

 “Trust Officer” means, when used with respect to the Trustee, any officer
within the corporate trust department of the Trustee, including any vice president, assistant vice president, assistant secretary, associate or any other officer of the Trustee who customarily performs functions similar to those performed by the
persons who at the time shall be such officers, respectively, or to whom any corporate trust matter is referred because of such person’s knowledge of and familiarity with the particular subject and who shall have direct responsibility for the
administration of this Indenture. 
 “UK Issuer Notes” means the 2025 Fixed Rate Notes. 

“Unadjusted Benchmark Replacement” means the Benchmark Replacement excluding the Benchmark Replacement Adjustment. 

“USGS Business Day” means any day except for a Saturday, Sunday or a day on which the Securities Industry and Financial
Market Association or any successor thereto recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in U.S. government securities. 

“U.S. Issuer Fixed Rate Notes” means, collectively, the 2027 Fixed Rate Notes, the 2029 Fixed Rate Notes, the 2032 Fixed Rate
Notes, the 2052 Fixed Rate Notes and the Callable Fixed Rate Notes. 
 “U.S. Issuer Notes” means, collectively, the 2027
Fixed Rate Notes, the 2029 Fixed Rate Notes, the 2032 Fixed Rate Notes, the 2052 Fixed Rate Notes, the Callable Fixed Rate Notes and the Callable Floating Rate Notes. 

“USA Patriot Act” has the meaning ascribed to it in Section 14.12. 

Section 1.2. Rules of Construction 

Unless the context otherwise requires: 

(1) a term has the meaning assigned to it; 

(2) “or” is not exclusive; 

(3) “including” means including without limitation; 

(4) words in the singular include the plural and words in the plural include the singular; 

(5) “herein,” “hereof” and other words of similar import refer to this Indenture as a whole and not to any
particular Article, Section or other subdivision; 
 (6) provisions apply to successive events and transactions; and 

(7) an accounting term not otherwise defined as the meaning assigned to it in accordance with generally accepted accounting
principles in the United Kingdom or such other generally accepted accounting principles under which the applicable Guarantor may in the future prepare its financial statements. 

  
 16 

 ARTICLE II. 

THE NOTES 

Section 2.1. Form and Dating 

(a) The UK Issuer Notes are being originally offered and sold by the UK Issuer pursuant to a Purchase Agreement (the “Purchase
Agreement”), dated March 21, 2022, among the Issuers, the Guarantors and the initial purchasers named therein (the “Initial Purchasers”). 

(b) The U.S. Issuer Notes are being originally offered and sold by the U.S. Issuer pursuant to the Purchase Agreement. 

(c) The Notes will be issued in book-entry form only, and only in denominations of $250,000 and multiples of $1,000 in excess thereof. 

(d) The terms and provisions of the U.S. Issuer Notes, the forms of which are in Exhibits B to G, shall constitute, and are
hereby expressly made, a part of this Indenture, and, to the extent applicable, the U.S. Issuer, the Guarantors and the Trustee, by their execution and delivery of this Indenture, expressly agree to such terms and provisions and to be bound thereby.

 (e) The terms and provisions of the UK Issuer Notes, the form of which is in Exhibit A, shall constitute, and are hereby expressly
made, a part of this Indenture, and, to the extent applicable, the UK Issuer, the Guarantors and the Trustee, by their execution and delivery of this Indenture, expressly agree to such terms and provisions and to be bound thereby. 

(f) The Notes may have notations, legends or endorsements as specified in Section 2.7 or as otherwise required by
law, stock exchange rule or rule or usage of the Depositary. The UK Issuer (with respect to the UK Issuer Notes), or the U.S. Issuer (with respect to the U.S. Issuer Notes), as applicable, and the Trustee shall approve the form of the Notes and any
notation, legend or endorsement on them. Each Note shall be dated the date of its authentication. 
 (g) Notes originally issued to QIBs in
reliance on Rule 144A will be issued in the form of one or more permanent Global Notes (each, a “Rule 144A Global Note”). 

(h) Notes originally issued in offshore transactions to non-U.S. persons in reliance on Regulation S
will be issued in the form of one or more permanent Global Notes (each, a “Regulation S Global Note”). 
 Section 2.2.
Execution and Authentication 
 (a) The U.S. Issuer Notes shall be executed by an Officer of the U.S. Issuer, and the UK Issuer Notes
shall be executed by an Officer of the UK Issuer, by electronic, facsimile or manual signature; and the GSK Guarantee with respect to the Notes shall be executed by an Officer of GSK, and the Haleon Guarantee with respect to the Notes shall be
executed by an Officer of Haleon by electronic, facsimile or manual signature. If an Officer whose signature is on a Note or the Guarantees no longer holds that office at the time the Note or the Guarantees are authenticated, the Note or the
Guarantees, as the case may be, shall nevertheless be valid. 

  
 17 

 (b) Facsimile, documents executed, scanned and transmitted electronically and electronic
signatures, including those created or transmitted through a software platform or application, shall be deemed original signatures for purposes of the Indenture and all other related documents and all matters and agreements related thereto, with
such facsimile, scanned and electronic signatures having the same legal effect as original signatures. The parties agree that this Indenture or any other related document or any instrument, agreement or document necessary for the consummation of the
transactions contemplated by the Indenture or the other related documents (including, without limitation, addendums, amendments, notices, instructions, communications with respect to the delivery of securities or the wire transfer of funds or other
communications) (“Executed Documentation”) may be accepted, executed or agreed to through the use of an electronic signature in accordance with applicable laws, rules and regulations in effect from time to time applicable to the
effectiveness and enforceability of electronic signatures. Any Executed Documentation accepted, executed or agreed to in conformity with such laws, rules and regulations will be binding on all parties hereto to the same extent as if it were
physically executed and each party hereby consents to the use of any third party electronic signature capture service providers as may be reasonably chosen by a signatory hereto or thereto. When the Trustee or the Agents act on any Executed
Documentation sent by electronic transmission, the Trustee and the Agents will not be responsible or liable for any Losses, costs or expenses arising directly or indirectly from its reliance upon and compliance with such Executed Documentation,
notwithstanding that such Executed Documentation (a) may not be an authorized or authentic communication of the party involved or in the form such party sent or intended to send (whether due to fraud, distortion or otherwise) or (b) may
conflict with, or be inconsistent with, a subsequent written instruction or communication; it being understood and agreed that the Trustee and the Agents shall conclusively presume that Executed Documentation that purports to have been sent by an
authorized officer of a Person has been sent by an authorized officer of such Person. The party providing Executed Documentation through electronic transmission or otherwise with electronic signatures agrees to assume all risks arising out of such
electronic methods, including, without limitation, the risk of the Trustee or the Agents acting on unauthorized instructions and the risk of interception and misuse by third parties. 

(c) The Trustee may appoint an authenticating agent acceptable to the Issuers (the “Authenticating Agent”) to authenticate
Notes. The Authenticating Agent may authenticate Notes whenever the Trustee may do so. Each reference in this Indenture to authentication by the Trustee includes authentication by such Authenticating Agent. 

(d) A Note shall not be valid until the Trustee or Authenticating Agent signs the certificate of authentication on the Note by electronic,
facsimile or manual signature. The signature shall be conclusive evidence that the Note has been duly and validly authenticated and issued under this Indenture. 

  
 18 

 (e) At any time and from time to time after the execution and delivery of this Indenture,
the Trustee shall authenticate and make available for delivery Notes upon a written order of the relevant Issuer signed by an Officer of the relevant Issuer (the “Issuer Order”). An Issuer Order shall specify the amount of the Notes
to be authenticated, the number of Certificated Notes to be authenticated, the registered Holder of each Note, delivery instructions and the date on which the original issue of Notes is to be authenticated. 

(f) In the event that an Issuer should consolidate, amalgamate, merge with or into, or be replaced by, or assign, convey, transfer or lease
its properties and assets substantially as an entirety to any Person in accordance with ARTICLE VI, subject to the restrictions set forth in ARTICLE VI, and the Successor Entity resulting from or surviving such consolidation,
amalgamation, merger or replacement, or having received such assignment, conveyance, transfer or lease, as the case may be, shall have executed an indenture supplemental hereto with the Trustee pursuant to ARTICLE VI, any of the Notes
authenticated or delivered prior to such transaction may, from time to time, at the request of the Successor Entity, be exchanged for other Notes executed in the name of the Successor Entity with such changes in phraseology and form as may be
appropriate, but otherwise identical to the Notes surrendered for such exchange and of like principal amount; and the Trustee, upon Issuer Order of the Successor Entity, shall authenticate and deliver Notes as specified in such order for the purpose
of such exchange. If Notes shall at any time be authenticated and delivered in any new name of a Successor Entity pursuant to this Section 2.2 in exchange or substitution for or upon registration of transfer of any Notes,
such Successor Entity, at the option of the Holders but without expense to them, shall provide for the exchange of all Notes at the time Outstanding for Notes authenticated and delivered in such new name. 

Section 2.3. Paying Agent, Transfer Agent, Registrar 

(a) Each Issuer shall appoint (i) a Principal Paying Agent with an office in the Borough of Manhattan, The City of New York, where Notes
may be presented for payment or registration for transfer; (ii) a Transfer Agent with an office in the Borough of Manhattan, The City of New York, where Notes may be presented for transfer; (iii) an office or agency in the Borough of
Manhattan, The City of New York where notices and demands to or upon the relevant Issuer in respect of the Notes and this Indenture may be served. The Issuers shall also appoint a Registrar and shall cause it to keep a register of the Notes and of
their transfer (the “Note Register”). Such registration in the Note Register shall be conclusive evidence of the ownership of Notes. The Registrar shall include in the books and records for the Notes notations as to whether such
Notes have been paid or transferred, canceled, lost, stolen, mutilated or destroyed and whether such Notes have been replaced. In the case of the replacement of any of the Notes, the Registrar shall keep a record of the Note so replaced and the Note
issued in replacement thereof. In the case of the cancellation of any of the Notes, the Registrar shall keep a record of the Note so canceled and the date on which such Note was canceled. The Issuers may have one or more co-Registrars and one or more additional Paying Agents. Each Issuer may change the Paying Agent or Registrar without prior notice to the relevant Holders and such Issuer may act as Paying Agent or Registrar. 

(b) Each Issuer shall enter into an appropriate agency agreement with any Agent not a party to this Indenture. The agreement shall implement
the provisions of this Indenture that relate to such Agent. An Issuer shall give prompt written notice to the Trustee of the name and address of any Agent and any change in the name or address of an Agent. If an Issuer fails to

  
 19 

 
maintain a Registrar or if an Issuer or the applicable Guarantor fails to maintain a Paying Agent, the Trustee shall act as Registrar and Paying Agent. An Issuer or the applicable Guarantor may
remove any Agent appointed by it upon written notice to such Agent and the Trustee; provided that no such removal shall become effective until (i) the acceptance of an appointment by a successor Agent to such Agent as evidenced by an
appropriate agency agreement entered into by an Issuer or the applicable Guarantor and such successor Agent and delivered to the Trustee or (ii) notification to the Trustee that the Trustee shall serve as such Agent until the appointment of a
successor Agent in accordance with clause (i) of this proviso. The Issuer, the Guarantor or any Affiliate of the Issuer or the Guarantor may act as Paying Agent or Registrar. 

(c) The Issuer initially appoints Deutsche Bank Trust Company Americas as Principal Paying Agent, Transfer Agent and Registrar, in each case,
until such time as another Person is appointed as such. Deutsche Bank Trust Company Americas hereby accepts such appointments. 

Section 2.4. Paying Agent to Hold Money in Trust 

The Issuers shall require each Paying Agent other than the Trustee (including where acting as the Principal Paying Agent) to agree in writing
that such Paying Agent shall hold in trust for the benefit of the Holders or the Trustee all money held by the Paying Agent for the payment of the principal, interest and other amounts, if any, on the Notes (whether such money has been paid to it by
the Issuers or any other obligor on the Notes), and such Paying Agent shall promptly notify the Trustee in writing of any default by any Issuer (or any other obligor on the Notes) in making any such payment. An Issuer at any time may require the
Paying Agent to pay all money held by it to the Trustee and account for any funds disbursed, and the Trustee may at any time during the continuance of any payment default, upon written request to a Paying Agent, require such Paying Agent to pay all
money held by it to the Trustee and to account for any funds disbursed. Upon doing so, the Paying Agent shall have no further liability for the money so paid over to the Trustee. If an Issuer or any Affiliate of an Issuer acts as Paying Agent, it
shall, on or before each due date of any payment of principal or other amounts, if any, on the Notes, segregate and hold in a separate trust fund for the benefit of the Holders a sum of money sufficient to pay such principal or other amounts, if
any, so becoming due until such sum of money shall be paid to such Holders or otherwise disposed of as provided in this Indenture, and shall promptly notify the Trustee in writing of its action or failure to act. 

The Trustee shall have no obligation or duty to monitor, determine or inquire as to compliance with any restrictions on transfer imposed under
this Indenture or under applicable law with respect to any transfer of any interest in any Note (including any transfers between or among Depositary participants or beneficial owners of interests in any Global Note) other than to require delivery of
such certificates and other documentation or evidence as are expressly required by, and to do so if and when expressly required by the terms of, this Indenture, and to examine the same to determine substantial compliance as to form with the express
requirements hereof. 
 Neither the Trustee nor any Agent shall have any responsibility for any actions taken or not taken by the
Depositary. 

  
 20 

 Section 2.5. Holder Lists 

The Registrar shall preserve in as current a form as is reasonably practicable the most recent list available to it of the names and addresses
of Holders. If the Trustee is not the Registrar: 
 (a) the U.S. Issuer shall furnish to the Trustee, in writing at such times as the Trustee
may request in writing, a list in such form and as of such date as the Trustee may reasonably require of the names and addresses of Holders of the U.S. Issuer Notes, including the aggregate principal amount of U.S. Issuer Notes held by each relevant
Holder; and 
 (b) the UK Issuer shall furnish to the Trustee, in writing at such times as the Trustee may request in writing, a list in
such form and as of such date as the Trustee may reasonably require of the names and addresses of Holders of the UK Issuer Notes, including the aggregate principal amount of UK Issuer Notes held by each relevant Holder. 

Section 2.6. Book-Entry Provisions for Global Notes 

(a) Notes will be initially issued in the form of one or more registered Notes in global form bearing the legend set forth in
Section 2.7(a). Each Issuer initially appoints The Depository Trust Company to act as Depositary with respect to each Global Note. Initially, each Global Note shall be issued to the Depositary, registered in the name of
Cede & Co., as the nominee of the Depositary, and deposited with the Trustee as custodian for Cede & Co. The Depositary shall be a clearing agency registered under the Exchange Act. The aggregate principal amount of the Global
Notes may from time to time be increased or decreased by adjustments made by the Registrar on Schedule A to the Global Note and recorded in the Register, as hereinafter provided. 

(b) Ownership of beneficial interests in a Global Note shall be shown on, and the transfer of that ownership shall be effected only through,
records maintained by the Depositary or its nominee (with respect to interests of persons who have accounts with the Depositary (“participants”)) and the records of participants (with respect to interests of persons other than
participants). So long as the Depositary or its nominee, is the registered owner or holder of a Global Note, the Depositary or its nominee shall be considered the sole owner or Holder of the Notes represented by such Global Notes for all purposes
under this Indenture and the Notes. No beneficial owner of an interest in a Global Note shall be able to transfer that interest except in accordance with the applicable procedures of the Depositary, in addition to those provided under this
Indenture. Transfers of beneficial ownership in the Global Notes shall occur only through the Depositary. 
 (c) Payments of the principal
of and other amounts on, a Global Note (including, without limitation, any principal or other amounts due upon redemption) shall be made to the Depositary or its nominee as the registered owner thereof. None of the Issuers, the Guarantors, the
Trustee, Transfer Agent or any Paying Agent shall have any responsibility or liability for any aspect of the records relating to or payments made on account of beneficial ownership interests in a Global Note or for maintaining, supervising or
reviewing any records relating to such beneficial ownership interests. 

  
 21 

 (d) Transfers between participants in the Depositary shall be effected in the ordinary way
in accordance its rules and operating procedures. 
 None of the Issuers, the Guarantors or the Trustee shall have any responsibility for
the performance by the Depositary or its participants or indirect participants of their respective obligations under the rules and procedures governing their operations. 

(e) Members of, or participants in, the Depositary (“Agent Members”) shall have no rights under this Indenture with respect
to any Global Note held on their behalf by the Depositary or any custodian of the Depositary, or under such Global Note, and the Depositary or its nominee may be treated by the Issuers, the Trustee, any Paying Agent, the Transfer Agent and the
Registrar, and any of their respective agents, as the absolute owner of such Global Note for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall prevent the Issuers, the Trustee, any Paying Agent, the Transfer Agent or the
Registrar, or any of their respective agents, from giving effect to any written certification, proxy or other authorization furnished by the Depositary, or impair, as between the Depositary and its respective Agent Members, the operation of
customary practices of the Depositary governing the exercise of the rights of an owner of a beneficial interest in any Global Note. The registered Holder of a Global Note may grant proxies and otherwise authorize any person, including Agent Members
and persons that may hold interests through Agent Members, to take any action that a Holder is entitled to take under this Indenture or the Notes. 

(f) Except as provided below, owners of beneficial interests in Global Notes will not be entitled to receive physical delivery of Certificated
Notes. Certificated Notes shall be issued to all owners of beneficial interests in a Global Note in exchange for such interests if: 

(i) the Depositary at any time notifies the relevant Issuer that it is unwilling or unable to continue as a depository or
clearing system, as applicable, for the Global Notes, and a successor depositary is not appointed by the relevant Issuer within 90 days of the time such notice is given; 

(ii) the Depositary ceases to be registered as a clearing agency under the Exchange Act and a successor depositary is not
appointed within 90 days; or 
 (iii) an Event of Default with respect to the Notes has occurred and is continuing and such
beneficial owner requests that its Notes be issued in physical, certificated form. 
 In connection with the exchange of an entire Global
Note for Certificated Notes pursuant to this paragraph (f), such Global Note shall be deemed to be surrendered to the Trustee or the Paying Agent, as the case may be, for cancellation, and the Issuer shall execute, and the Trustee or the
Paying Agent, as the case may be, shall authenticate and deliver, to each beneficial owner identified by the Depositary in exchange for its beneficial interest in such Global Note, an equal aggregate principal amount of Certificated Notes of
authorized denominations. 

  
 22 

 Any Certificated Notes issued pursuant to provisions of this paragraph (f) shall
bear the legend and otherwise comply as to form as required by Section 2.7 of this Indenture. Holders of an interest in a Global Note may receive such Certificated Notes, which shall be printed and distributed to the
Holders by mail to the last available address of such Holders as appears on the Note Register in accordance with the applicable rules and procedures of the Depositary in addition to those provided for under this Indenture. In such an event, the U.S.
Issuer shall notify the Holders of U.S. Issuer Notes and the UK Issuer shall notify the Holders of UK Issuer Notes, in the manner set forth in Section 14.1, of the applicable procedures for the payment of principal and
other amounts, the procedures for transfer of Notes and the identity and contact information with respect to the then-applicable Paying Agent or Transfer Agent. 

Section 2.7. Restrictive Legend 

(a) Each Rule 144A Global Note and Rule 144A Certificated Note shall bear a legend to the following effect unless otherwise agreed to by the
relevant Issuer: 
 “THIS NOTE AND THE GUARANTEES OF THIS NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE
ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”)
HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED
WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, THE HOLDER (A) REPRESENTS, WARRANTS, ACKNOWLEDGES AND AGREES FOR THE BENEFIT OF THE ISSUER,
THE GUARANTORS AND THE TRUSTEE THAT IT IS A ‘‘QUALIFIED INSTITUTIONAL BUYER’’ (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) PURCHASING THE SECURITIES FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED
INSTITUTIONAL BUYERS; (B) AGREES THAT IT WILL NOT RESELL OR OTHERWISE TRANSFER THE SECURITIES OTHER THAN (1) TO THE ISSUER, (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, (3) IN THE UNITED STATES TO
A PERSON WHO THE SELLER REASONABLY BELIEVES IS A QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS IN A TRANSACTION
MEETING THE REQUIREMENTS OF RULE 144A, OR (4) IN AN OFFSHORE TRANSACTION TO A NON-U.S. PERSON IN COMPLIANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE
WITH ALL APPLICABLE SECURITIES LAWS OF THE STATES OF THE UNITED STATES AND ANY OTHER JURISDICTION; AND (C) AGREES THAT IT WILL DELIVER TO EACH PERSON TO WHOM THIS NOTE IS TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND.”

  
 23 

 (b) Each Regulation S Global Note and Regulation S Certificated Note shall bear a legend to
the following effect unless otherwise agreed to by the relevant Issuer: 
 “THIS NOTE AND THE GUARANTEES OF THE NOTE BY
GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED
AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE
OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT OR
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT. UNTIL THE EXPIRY OF THE PERIOD OF 40 DAYS AFTER THE LATER OF (i) THE DATE ON WHICH THE OFFERING OF THIS NOTE TO PERSONS OTHER THAN THE DISTRIBUTORS IN RELIANCE ON
REGULATION S COMMENCED AND (ii) THE DATE OF ISSUANCE OF SUCH NOTE, SALES MAY NOT BE MADE IN THE UNITED STATES OR TO U.S. PERSONS UNLESS MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED IN, AND IN TRANSACTIONS PURSUANT TO, RULE 144A UNDER THE
SECURITIES ACT.” 
 Section 2.8. Transfer and Exchange 

(a) If (1) the owner of a beneficial interest in a Rule 144A Global Note that is a Restricted Note wishes to transfer such interest (or
portion thereof) to a Non-U.S. Person pursuant to Regulation S and (2) such Non-U.S. Person wishes to hold its interest in the Notes through a beneficial interest
in the Regulation S Global Note, (x) upon receipt by the Registrar and Transfer Agent of: 
  

	 	(1)	 instructions from the Holder of the Rule 144A Global Note directing the Registrar and Transfer Agent to credit
or cause to be credited a beneficial interest in the Regulation S Global Note equal to the principal amount of the beneficial interest in the Rule 144A Global Note to be transferred; and 

 

	 	(2)	 a certificate in the form of Exhibit J from the transferor, and, (y) subject to the rules and
procedures of DTC, the Transfer Agent and Registrar shall increase the Regulation S Global Note and decrease the Rule 144A Global Note by such amount in accordance with the foregoing. 

  
 24 

 (b) If (1) the owner of an interest in a Regulation S Global Note that is a Restricted
Note wishes to transfer such interest (or any portion thereof) to a QIB pursuant to Rule 144A and (2) such QIB wishes to hold its interest in the Notes through a beneficial interest in the Rule 144A Global Note, (x) upon receipt by the
Transfer Agent and Registrar of: 
  

	 	(1)	 instructions from the Holder of the Regulation S Global Note directing the Transfer Agent and Registrar to
credit or cause to be credited a beneficial interest in the Rule 144A Global Note equal to the principal amount of the beneficial interest in the Regulation S Global Note to be transferred; and 

 

	 	(2)	 a certificate in the form of Exhibit I duly executed by the transferor, 

and, (y) in accordance with the rules and procedures of DTC, the Transfer Agent and Registrar shall increase the Rule 144A Global Note and decrease the
Regulation S Global Note by such amount in accordance with the foregoing. 
 (c) Other Transfers. Any transfer of Restricted Notes
not described above (other than a transfer of a beneficial interest in a Global Note that does not involve an exchange of such interest for a Certificated Note or a beneficial interest in another Global Note, which must be effected in accordance
with applicable law and the rules and procedures of DTC, but is not subject to any procedure required by this Indenture) shall be made only upon receipt by the Registrar and Transfer Agent (with a copy to the Trustee) of such Opinions of Counsel,
certificates and/or other information reasonably required by and satisfactory to the relevant Issuer in order to ensure compliance with the Securities Act or in accordance with paragraph (d) of this Section 2.8. 

(d) Use and Removal of Private Placement Legends. Upon the transfer, exchange or replacement of Notes (or beneficial interests in a
Global Note) not bearing (or not required to bear upon such transfer, exchange or replacement) a Private Placement Legend, the Registrar and Transfer Agent shall exchange such Notes (or beneficial interests) for beneficial interests in a Global Note
(or Certificated Notes if they have been issued pursuant to Section 2.6(f)) that does not bear a Private Placement Legend. Upon the transfer, exchange or replacement of Notes (or beneficial interests in a Global Note)
bearing a Private Placement Legend, the Registrar and Transfer Agent shall deliver only Notes (or beneficial interests in a Global Note) that bear a Private Placement Legend unless: 

 

	 	(1)	 such Notes (or beneficial interests) are transferred pursuant to Rule 144 upon delivery to the Transfer Agent
of a certificate of the transferor in the form of Exhibit K and an Opinion of Counsel reasonably satisfactory to the relevant Issuer; 

  

	 	(2)	 such Notes (or beneficial interests) are transferred, replaced or exchanged after the Resale Restriction
Termination Date therefor if such Note is a Rule 144A Global Note or the Distribution Compliance Period if such Note is a Regulation S Global Note; or 

  
 25 

	 	(3)	 in connection with such transfer, exchange or replacement the Transfer Agent and the relevant Issuer shall have
received an Opinion of Counsel and other evidence satisfactory to the relevant Issuer to the effect that neither such Private Placement Legend nor the related restrictions on transfer are required in order to maintain compliance with the provisions
of the Securities Act. 

 The Private Placement Legend on any Note shall be removed at the written request of the Holder on or after the
Resale Restriction Termination Date therefor if such Note is a Rule 144A Global Note or the Distribution Compliance Period if such Note is a Regulation S Global Note. The Holder of a Global Note may exchange an interest therein for an equivalent
interest in a Global Note not bearing a Private Placement Legend upon transfer of such interest pursuant to any of clauses (1) through (3) of this paragraph (d). 

All Notes issued upon any registration of transfer of Notes shall be the valid obligations of the relevant Issuer evidencing the same
indebtedness, and entitled to the same benefits under this Indenture, as the Notes surrendered upon such registration of transfer. 

Neither the Issuers nor the Trustee, any Paying Agent, the Transfer Agent or Registrar shall be required (i) to issue or register the
transfer of any Note during a period beginning at the opening of 15 Business Days before the day of the mailing of a notice of redemption of Notes selected for redemption under ARTICLE VII and ending at the close of business on the day of
such mailing, or (ii) to register the transfer of any Note so selected for redemption in whole or in part, except the unredeemed portion of any Note being redeemed in part. 

(e) Other Exchanges. In the event that a Global Note is exchanged for Notes in definitive registered form without interest coupons
pursuant to Section 2.10 hereof, such Notes may be exchanged for one another only in accordance with such procedures as are substantially consistent with the provisions above, and as may be from time to time adopted by the
relevant Issuer and the Trustee. 
 (f) Certain Transfers in Connection with and After the Exchange Offer under the Registration Rights
Agreement. Notwithstanding any other provision of this Indenture: 
 (i) no Exchange Notes issued may be exchanged by the
Holder thereof for a Note; 
 (ii) accrued and unpaid interest on the Notes being exchanged in the Exchange Offer shall be
due and payable, in respect of the Fixed Rate Notes on the next Fixed Rate Notes Interest Payment Date, and in respect of the Callable Floating Rate Notes, on the next Callable Floating Rate Notes Interest Payment Date, as applicable, following the
Exchange Offer and shall be paid to the Holder on the relevant record date of the Exchange Notes issued in respect of the Notes being exchanged; and 

(iii) interest on the Notes being exchanged in the Exchange Offer shall cease to accrue on (and including) the date of
completion of the Exchange Offer. 

  
 26 

 (g) Exchange Offer. Upon the occurrence of the Exchange Offer with respect to the
Notes of a series, the relevant Issuer will issue, and upon a written order of the relevant Issuer the Trustee will authenticate: 

(i) one or more Global Notes of such series not bearing the Private Placement Legend in an aggregate principal amount equal to
the principal amount of the beneficial interests in the Global Notes of such series bearing the Private Placement Legend that are accepted for exchange in the Exchange Offer by Persons that (A) are not Participating Broker-Dealers, (B) are
not participating in a distribution of the Exchange Notes and (C) are not Affiliates of the relevant Issuer, as evidenced by an Officer’s Certificate from the relevant Issuer to such effect; or 

(ii) one or more authenticated Notes of such series not bearing the Private Placement Legend in an aggregate principal amount
equal to the principal amount of the authenticated Notes of such series bearing the Private Placement Legend that are accepted for exchange in the Exchange Offer by Persons that (A) are not Participating Broker-Dealers, (B) are not
participating in a distribution of the Exchange Notes and (C) are not Affiliates of the relevant Issuer, as evidenced by an Officer’s Certificate from the relevant Issuer to such effect. 

Section 2.9. Mutilated, Destroyed, Lost or Stolen Notes 

(a) Should any Certificated Note be lost, stolen, mutilated, defaced or destroyed, it may be replaced at the specified office of the
Registrar. Mutilated or defaced Notes must be surrendered before replacements will be issued. If required by the Trustee or the relevant Issuer, a claimant shall furnish an affidavit of loss and indemnity bond sufficient in the judgment of the
relevant Issuer and the Trustee to protect the relevant Issuer, the Trustee, the Paying Agents, the Transfer Agent and the Registrar from any loss that any of them may suffer if a Certificated Note is replaced. In the absence of notice to the
relevant Issuer or the Trustee that such Certificated Note has been acquired by a bona fide purchaser, the relevant Issuer shall execute and the Trustee shall authenticate and make available for delivery, in exchange for any such mutilated Note
or in lieu of any such destroyed, lost or stolen Note, a new Note of like tenor and principal amount, bearing a number not contemporaneously Outstanding. 

(b) Upon the issuance of any new Certificated Note under this Section 2.9, the relevant Issuer or the Trustee may
require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee and any Paying Agent, the Transfer Agent or the
Registrar) in connection therewith. 
 (c) If at the time a mutilated, lost, destroyed or wrongfully taken Certificated Note is presented
such Certificated Note has become or is about to become due and payable, the relevant Issuer may pay such Certificated Note instead of issuing a new Certificated Note in replacement thereof. 

(d) Every new Certificated Note issued pursuant to this Section 2.9 in exchange for any mutilated Certificated Note,
or in lieu of any defaced, destroyed, lost or stolen Certificated 

  
 27 

 
Note, shall constitute an original additional contractual obligation of the relevant Issuer, the applicable Guarantor and any other obligor upon the Certificated Notes, whether or not the
mutilated, defaced, destroyed, lost or stolen Certificated Note shall be at any time enforceable by anyone, and every new Certificated Note shall be entitled to all benefits of this Indenture equally and proportionately with any and all other
Certificated Notes duly issued hereunder. 
 Section 2.10. Temporary Notes 

Until definitive Notes are ready for delivery, the U.S. Issuer may execute temporary U.S. Issuer Notes and the UK Issuer may execute temporary
UK Issuer Notes and each Issuer may issue an Issuer Order to the Trustee to authenticate such temporary Notes. Temporary Notes will be substantially in the form of definitive Notes but may have variations that the relevant Issuer considers
appropriate for temporary Notes. Without unreasonable delay, the U.S. Issuer will prepare and execute definitive U.S. Issuer Notes and the UK Issuer will prepare and execute definitive UK Issuer Notes, and each Issuer will issue an Issuer Order to
the Trustee to authenticate such definitive Notes. After the preparation of definitive Notes, the temporary Notes will be exchangeable for definitive Notes upon surrender of the temporary Notes at any office or agency maintained by the relevant
Issuer for that purpose and such exchange shall be without charge to the Holder. Upon surrender for cancellation of any one or more temporary Notes, the relevant Issuer will execute one or more definitive Notes representing an equal principal amount
of Notes and issue an Issuer Order to the Trustee to authenticate and make available for delivery in exchange therefor such definitive Notes. Until so exchanged, the Holder of temporary Notes shall in all respects be entitled to the same benefits
under this Indenture as a Holder of definitive Notes. 
 Section 2.11. Cancellation 

The U.S. Issuer at any time may deliver U.S. Issuer Notes, and the UK Issuer at any time may deliver UK Issuer Notes, to the Trustee for
cancellation. All Notes that are redeemed or exchanged in accordance with the terms of this Indenture will be cancelled. Each of the Transfer Agent and the Paying Agent shall forward to the Trustee for cancellation any Notes surrendered to it for
registration of transfer, payment or redemption, as the case may be. The Trustee and no one else shall cancel and dispose of cancelled Notes in accordance with its customary procedures or return to the relevant Issuer all Notes surrendered for
registration of transfer, exchange, payment, redemption or cancellation. The Issuers may not issue new Notes to replace Notes it has paid or delivered to the Trustee for cancellation for any reason other than in connection with a transfer or
exchange upon Issuer Order. 
 Section 2.12. CUSIP Numbers 

Each Issuer in issuing the Notes may use “CUSIP” numbers (if then generally in use). No representation is made as to the accuracy of
such numbers either as printed on the Notes or as contained in any such notice and reliance may be placed only on the other identification numbers placed on the Notes. Each Issuer will promptly notify the Trustee, in writing, of any change in the
“CUSIP” number. 

  
 28 

 Section 2.13. Further Issues 

The U.S. Issuer, in respect of U.S. Issuer Notes, and the UK Issuer, in respect of UK Issuer Notes, may from time to time without the consent
of the Holders create and issue further securities either having the same terms and conditions as any series of the U.S. Issuer Notes or the UK Issuer Notes, as applicable, in all respects (or in all respects except for the issue date) and so that
such further issue shall be consolidated and form a single series with the Outstanding Notes of the relevant series of U.S. Issuer Notes or UK Issuer Notes, as applicable, or upon such terms as the U.S. Issuer or UK Issuer, as applicable may
determine at the time of their issue. Any further securities shall be issued under a separate CUSIP or ISIN number unless such securities are otherwise treated as part of the same “issue” of debt instruments as the Outstanding Notes for
U.S. federal income tax purposes. 
 Section 2.14. Purchases of the Notes by the Guarantor or any of its Affiliates 

The Guarantor may at any time and from time to time purchase Notes at any price in the open market or otherwise. Any Note so purchased, while
held by or on behalf of the Guarantor, shall not entitle the holder thereof to vote at any meeting of the Holders and shall not be deemed to be outstanding for the purpose of calculating the percentage of Outstanding Notes in respect of which
Holders have consented to any action. 
 ARTICLE III. 

INTEREST CALCULATION IN RESPECT OF THE NOTES 

Section 3.1. Interest rate terms specific to the Fixed Rate Notes 

(a) The following terms relating to the Fixed Rate Notes are hereby established: 

(i) Interest on the 2025 Fixed Rate Notes will be payable at a rate of 3.125% per annum. 

(ii) Interest on the 2027 Fixed Rate Notes will be payable at a rate of 3.375% per annum. 

(iii) Interest on the 2029 Fixed Rate Notes will be payable at a rate of 3.375% per annum. 

(iv) Interest on the 2032 Fixed Rate Notes will be payable at a rate of 3.625% per annum. 

(v) Interest on the 2052 Fixed Rate Notes will be payable at a rate of 4.000% per annum. 

(vi) Interest on the Callable Fixed Rate Notes will be payable at a rate of 3.024% per annum. 

  
 29 

 (b) Interest on the Fixed Rate Notes will be payable semi-annually in arrear on
24 March and 24 September of each year, commencing on September 24, 2022 (each a “Fixed Rate Notes Interest Payment Date”), to the person in whose name the applicable Fixed Rate Note is registered at the close of
business on the Regular Record Date that precedes the applicable Fixed Rate Notes Interest Payment Date. 
 (c) The Fixed Rate Notes will
each bear interest at the applicable interest rate described in Section 3.1(a) above and will accrue interest from (and including) the Issue Date, or from the most recent Fixed Rate Notes Interest Payment Date, to (but
excluding) the next succeeding Fixed Rate Notes Interest Payment Date. 
 (d) Interest on the Fixed Rate Notes will be paid on the basis of
twelve 30-day months assuming a 360-day year. 
 (e) If a
Fixed Rate Notes Interest Payment Date, a redemption date for the Fixed Rate Notes, or a Fixed Rate Notes Maturity Date, as the case may be, would fall on a day that is not a Business Day, then the required payment will be made on the next
succeeding Business Day, but no additional interest shall be paid unless the U.S. Issuer, with respect to U.S. Issuer Fixed Rate Notes, or the UK Issuer, with respect to the 2025 Fixed Rate Notes, as applicable, fails to make payment on such next
succeeding Business Day. 
 Section 3.2. Interest Rate Terms Specific to the Callable Floating Rate Notes 

(a) The initial interest rate on the Callable Floating Rate Notes for the first Callable Floating Rate Notes Interest Period will be equal to
the Benchmark plus 0.89% per annum (the “Callable Floating Rate Notes Margin”). Thereafter, the interest rate on the Callable Floating Rate Notes for any Callable Floating Rate Notes Interest Period will be a per annum rate equal to
the Benchmark, as determined on the applicable Interest Determination Date plus the Callable Floating Rate Notes Margin. 
 (b) The interest
rate on the Callable Floating Rate Notes will be calculated quarterly on the date that is two USGS Business Days before each Callable Floating Rate Notes Interest Payment Date (each such date, an “Interest Determination Date”). 

(c) Interest on the Callable Floating Rate Notes will be payable quarterly in arrear on 24 March, 24 June, 24 September and
24 December of each year, commencing on June 24, 2022 (each a “Callable Floating Rate Notes Interest Payment Date”), to the person in whose name a Callable Floating Rate Note is registered at the close of business on the
Regular Record Date that precedes the applicable Callable Floating Rate Notes Interest Payment Date. 
 (d) Interest on the Callable
Floating Rate Notes will be calculated on the basis of the actual number of days in each Callable Floating Rate Notes Interest Period, assuming a 360-day year. 

(e) If any scheduled Callable Floating Rate Notes Interest Payment Date (other than a Callable Floating Rate Notes Maturity Date), is not a
Business Day, such Callable Floating Rate Notes Interest Payment Date will be postponed to the next day that is a Business Day; provided that if the Business Day falls in the next succeeding calendar month, such Callable Floating Rate

  
 30 

 
Notes Interest Payment Date will the immediately preceding Business Day. If any such Callable Floating Rate Notes Interest Payment Date (other than a Callable Floating Rate Notes Maturity Date),
is postponed or brought forward pursuant to this Section 3.2(e), the payment of interest due on such postponed or brought forward Callable Floating Rate Notes Interest Payment Date will include interest accrued to but excluding such
postponed or brought forward Callable Floating Rate Notes Interest Payment Date. If a Callable Floating Rate Notes Maturity Date or date of redemption or repayment of the Callable Floating Rate Notes is not a Business Day, the U.S. Issuer may pay
interest and principal on the next succeeding Business Day, but interest on that payment will not accrue during the period from and after the Callable Floating Rate Notes Maturity Date or date of redemption or repayment of the Callable Floating Rate
Notes. If a date of redemption or repayment of any of the Callable Floating Rate Notes does not occur on a Callable Floating Rate Notes Interest Payment Date, (i) the related Interest Determination Date shall be deemed to be the date that is
two USGS Business Days prior to such date of redemption or repayment, (ii) the related Observation Period shall be deemed to end on (but exclude) the date that is two USGS Business Days falling prior to such date of redemption or repayment,
(iii) the Callable Floating Rate Notes Interest Period will be deemed to be shortened accordingly and (iv) corresponding adjustments will be deemed to be made to the Compounded Daily SOFR formula. 

Section 3.3. Calculation of the Benchmark 

(a) The “Benchmark” means, initially, Compounded Daily SOFR; provided that if a Benchmark Transition Event and related
Benchmark Replacement Date have occurred with respect to SOFR or the then-current Benchmark, then “Benchmark” means the applicable Benchmark Replacement. 

(b) “Compounded Daily SOFR” means, in relation to a Callable Floating Rate Notes Interest Period, the rate of return of a
daily compound interest investment (with SOFR as reference rate for the calculation of interest) during the related Observation Period and will be calculated by the calculation agent on the related Interest Determination Date as follows: 

 
 

 
 Where: 

“d” means, in relation to any Observation Period, the number of calendar days in such Observation Period; 

“d0” means, in relation to any Observation Period, the number of USGS
Business Days in such Observation Period; 
 “i” means, in relation to any Observation Period, a series of whole numbers from one
to d0, each representing the relevant USGS Business Day in chronological order from (and including) the first USGS Business Day in such Observation Period; 

  
 31 

 “ni” means, in relation to
any USGS Business Day “i” in the relevant Observation Period, the number of calendar days from (and including) such USGS Business Day “i” up to (but excluding) the following USGS Business Day; 

“Observation Period” means, in respect of each Callable Floating Rate Notes Interest Period, the period from (and including)
the date that is two USGS Business Days falling prior to the first date in such Callable Floating Rate Notes Interest Period to (but excluding) the date that is two USGS Business Days preceding the Callable Floating Rate Notes Interest Payment Date
for such Callable Floating Rate Notes Interest Period; provided that the first Observation Period shall commence on (and include) the date that is two USGS Business Days falling prior to
the Issue Date; 
 “SOFR” means, in relation to any day, the rate determined by the calculation agent in accordance with
the following provisions: 
 (i) the daily Secured Overnight Financing Rate for trades made on such day, available at or
around the Reference Time on the NY Federal Reserve’s Website; and 
 (ii) if the rate specified in (i) above is
not available at or around the Reference Time for such day (and a Benchmark Transition Event and its related Benchmark Replacement Date have not occurred), the daily Secured Overnight Financing Rate in respect of the last USGS Business Day for which
such rate was published on the NY Federal Reserve’s Website; and 

“SOFRi” means, in relation to any USGS Business Day “i” in the
relevant Observation Period, SOFR in respect of such USGS Business Days. 
 (c) Notwithstanding clauses (i) and (ii) of the definition
of “SOFR” in Section 3.3(b) above, if the U.S. Issuer or its designee (in consultation with the U.S. Issuer) determines on or prior to the relevant Interest Determination Date that a Benchmark Transition Event and
related Benchmark Replacement Date have occurred with respect to SOFR, then Section 3.4 will thereafter apply to all determinations of the rate of interest payable on the Callable Floating Rate Notes. 

In accordance with and subject to Section 3.4, after a Benchmark Transition Event and related Benchmark Replacement
Date have occurred, the amount of interest that will be payable for each Callable Floating Rate Notes Interest Period will be determined by reference to a rate per annum equal to the Benchmark Replacement plus the Callable Floating Rate Notes
Margin. 
 Section 3.4. Benchmark Transitional Provisions 

(a) If the U.S. Issuer or its designee (in consultation with the U.S. Issuer) determines that a Benchmark Transition Event and related
Benchmark Replacement Date have occurred prior to the applicable Reference Time in respect of any determination of the Benchmark on any date, the applicable Benchmark Replacement will replace the then-current Benchmark for all purposes relating to
the Callable Floating Rate Notes in respect of such determination on such date and all determinations on all subsequent dates; provided that, if the U.S. Issuer or its 

  
 32 

 
designee (in consultation with the U.S. Issuer) is unable to or do not determine Benchmark Replacement in accordance with the provisions below prior to 5:00 p.m. (New York time) on the relevant
Interest Determination Date, the interest rate for the related Callable Floating Rate Notes Interest Period will be equal to the interest rate in effect for the immediately preceding Callable Floating Rate Notes Interest Period or, in the case of
the Interest Determination Date prior to the first Callable Floating Rate Notes Interest Payment Date, the initial rate of interest which would have been applicable to the Callable Floating Rate Notes for the first Callable Floating Rate Notes
Interest Period had the Callable Floating Rate Notes been outstanding for a period equal in duration to the scheduled first Callable Floating Rate Notes Interest Period but ending on (and excluding) the Issue Date (and applying the Callable Floating
Rate Notes Margin). 
 (b) “Benchmark Replacement” means the first alternative set forth in the order below that can be
determined by the U.S. Issuer or its designee (in consultation with the U.S. Issuer) as of the Benchmark Replacement Date: 

(i) the sum of: (a) the alternate rate of interest that has been selected or recommended by the Relevant Governmental Body
as the replacement for the then-current Benchmark for the applicable Corresponding Tenor (if any) and (b) the Benchmark Replacement Adjustment; 

(ii) the sum of: (a) the ISDA Fallback Rate and (b) the Benchmark Replacement Adjustment; and 

(iii) the sum of: (a) the alternate rate of interest that has been selected by the U.S. Issuer or its designee (in
consultation with the U.S. Issuer) as the replacement for the then-current Benchmark for the applicable Corresponding Tenor giving due consideration to any industry-accepted rate of interest as a replacement for the then-current Benchmark for U.S.
dollar-denominated floating rate notes at such time and (b) the Benchmark Replacement Adjustment. 
 (c) In connection with the
implementation of a Benchmark Replacement, the U.S. Issuer or its designee (in consultation with the U.S. Issuer) will have the right to make changes to (1) any Interest Determination Date, Callable Floating Rate Notes Interest Payment Date,
Reference Time, business day convention or Callable Floating Rate Notes Interest Period, (2) the manner, timing and frequency of determining the rate and amounts of interest that are payable on the Callable Floating Rate Notes and the
conventions relating to such determination and calculations with respect to interest, (3) rounding conventions, (4) tenors and (5) any other terms or provisions of the Callable Floating Rate Notes, in each case that the U.S. Issuer or
its designee (in consultation with the U.S. Issuer) determines, from time to time, to be appropriate to reflect the determination and implementation of such Benchmark Replacement in a manner substantially consistent with market practice (or, if the
U.S. Issuer or its designee (in consultation with the U.S. Issuer) decides that implementation of any portion of such market practice is not administratively feasible or determine that no market practice for use of the Benchmark Replacement exists,
in such other manner as the U.S. Issuer or its designee (in consultation with the U.S. Issuer) determines is appropriate (acting in good faith)) (the “Benchmark Replacement Conforming Changes”). Any Benchmark Replacement Conforming
Changes will apply to the Callable Floating Rate Notes for all future Callable Floating Rate Notes Interest Periods. 

  
 33 

 (d) The U.S. Issuer will promptly give notice of the determination of the Benchmark
Replacement, the Benchmark Replacement Adjustment and any Benchmark Replacement Conforming Changes to the Trustee, the Paying Agent, the calculation agent and the Holders of the Callable Floating Rate Notes; provided that failure to provide
such notice will have no impact on the effectiveness of, or otherwise invalidate, any such determination. 
 (e) All determinations,
decisions, elections and any calculations made by the U.S. Issuer or its designee (in consultation with the U.S. Issuer), and the calculation agent or its designee for the purposes of calculating the applicable interest on the Callable Floating Rate
Notes will be conclusive and binding on the Holders of the Callable Floating Rate Notes, the U.S. Issuer, the Trustee and the Paying Agent, absent manifest error. If made by the U.S. Issuer, such determinations, decisions, elections and calculations
will be made in consultation with the calculation agent, to the extent practicable. If made by its respective designee, such determinations, decisions, elections and calculations will be made after consulting with the U.S. Issuer, and its designees
will not make any such determination, decision, election or calculation to which the U.S. Issuer objects. Notwithstanding any provisions to the contrary in this Indenture or in the Callable Floating Rate Notes, any determinations, decisions,
calculations or elections made in accordance with this Section 3.4 will become effective without consent from the Holders of the Callable Floating Rate Notes or any other party. 

(f) Any determination, decision or election relating to the Benchmark not made by the calculation agent will be made on the basis described in
Section 3.3 or Section 3.4 as applicable. The calculation agent shall have no liability for not making any such determination, decision or election. In addition, the U.S. Issuer may designate an entity (which
may be its affiliate) to make any determination, decision or election that the U.S. Issuer has the right to make in connection with the determination of the Benchmark. 

Section 3.5. Agreement with Respect to the Benchmark Replacement 

By its acquisition of Callable Floating Rate Notes of any series, each Holder of a Callable Floating Rate Note (which, for these purposes,
includes each beneficial owner) (i) will acknowledge, accept, consent and agree to be bound by the U.S. Issuer’s or its designee’s determination of a Benchmark Transition Event, a Benchmark Replacement Date, the Benchmark Replacement,
the Benchmark Replacement Adjustment and any Benchmark Replacement Conforming Changes, including as may occur without any prior notice from the U.S. Issuer and without the need for the U.S. Issuer to obtain any further consent from such Holder,
(ii) will waive any and all claims, in law and/or in equity, against the Trustee, the Paying Agent and the calculation agent or the U.S. Issuer’s designee for, agree not to initiate a suit against the Trustee, the Paying Agent and the
calculation agent or the U.S. Issuer’s designee in respect of, and agree that none of the Trustee, the Paying Agent or the calculation agent or the U.S. Issuer’s designee will be liable for, the determination of or the failure to determine
any Benchmark Transition Event, any Benchmark Replacement Date, any Benchmark Replacement, any Benchmark Replacement Adjustment and any Benchmark Replacement Conforming Changes, and any Losses suffered in connection therewith and (iii) will
agree that none of the Trustee, the Paying Agent or the calculation agent or the U.S. Issuer’s designee will have any obligation to determine any Benchmark Transition Event, any Benchmark Replacement Date, any Benchmark Replacement, any
Benchmark Replacement Adjustment and any Benchmark 

  
 34 

 
Replacement Conforming Changes (including any adjustments thereto), including in the event of any failure by the U.S. Issuer to determine any Benchmark Transition Event, any Benchmark Replacement
Date, any Benchmark Replacement, any Benchmark Replacement Adjustment and any Benchmark Replacement Conforming Changes. 
 ARTICLE IV.

 COVENANTS 

Section 4.1. Payment of Notes; Additional Amounts 

(a) The U.S. Issuer (failing whom, the applicable Guarantor pursuant to the applicable Guarantee) covenants and agrees for the benefit of the
Holders of U.S. Issuer Notes that it shall duly and punctually pay the principal of and any other amounts due on the U.S. Issuer Notes on the dates and in the manner provided in the U.S. Issuer Notes and in this Indenture. Not later than
11:00 a.m. New York City time on the due date for any payment due in respect of any series of U.S. Issuer Notes and on the relevant Maturity Date, the U.S. Issuer shall deposit with the relevant Paying Agent in same day immediately available
funds an amount sufficient to make cash payments due on such due date of payments of any other amounts or the Maturity Date, as the case may be. 

(b) The UK Issuer (failing whom, the applicable Guarantor pursuant to the applicable Guarantee) covenants and agrees for the benefit of the
Holders of UK Issuer Notes that it shall duly and punctually pay the principal of and any other amounts due on the UK Issuer Notes on the dates and in the manner provided in the UK Issuer Notes and in this Indenture. Not later than 11:00 a.m.
New York City time on the due date for any payment due in respect of any series of UK Issuer Notes and on the relevant Maturity Date, the UK Issuer shall deposit with the relevant Paying Agent in same day immediately available funds an amount
sufficient to make cash payments due on such due date of payments of any other amounts or the Maturity Date, as the case may be. 
 (c) For
the avoidance of doubt, the Principal Paying Agent shall only be obliged to remit money to Holders if it has actually received such money from the relevant Issuer. If the Issuers, the Guarantors or an Affiliate of the Issuers or the applicable
Guarantor is acting as Paying Agent, the Issuers, the applicable Guarantor or such Affiliate shall, not later than 11:00 a.m. New York City time on each due date of payments of any other amounts and the Maturity Date, segregate and hold in
trust an amount sufficient to make cash payments due on such due date of payments of amounts or the Maturity Date, as the case may be. Principal and any other amounts on the Notes shall be considered paid on the date due if on such date the Trustee
or the Paying Agent (other than the Issuers, the applicable Guarantor or an Affiliate of the Issuers or the applicable Guarantor) holds in accordance with this Indenture an amount in cash designated for and sufficient to pay all principal and any
other amounts then due, the Trustee or the Paying Agent, as the case may be, is not prohibited from paying such money to the Holders on that date pursuant to the terms of this Indenture and the Trustee or the Paying Agent, as the case may be, is
satisfied that full payment has been received from the Issuers or, upon failure of the Issuers, the Guarantor. 

  
 35 

 (d) All payments and deliveries made by the U.S. Issuer and the UK Issuer under or with
respect to the U.S. Issuer Notes or the UK Issuer Notes, respectively, shall be free and clear of and without withholding or deduction for or on account of any present or future tax, duty, levy, impost, assessment or other governmental charge of any
nature whatsoever imposed or levied by or on behalf of (i) the government of the United Kingdom or of any territory of the United Kingdom or by any authority or agency therein or thereof having the power to tax or (ii) the government of
the United States or any state or territory of the United States or by any authority or agency therein or thereof having the power to tax (collectively, “Taxes”), except to the extent such Taxes are required to be withheld or
deducted by law or by the interpretation or administration thereof. 
 (e) If an Issuer is required to withhold or deduct any amount for or
on account of Taxes from any payment made or amount delivered with respect to the Notes, such Issuer shall pay such additional amounts (“Additional Amounts”) as may be necessary such that the net amount received by each Holder
(including such Additional Amounts) after such withholding or deduction shall not be less than the amount such Holder would have received if the Taxes had not been withheld or deducted; provided that no Additional Amounts will be payable with
respect to Taxes: 
 (i) that would not have been imposed but for the existence of any present or former connection between
such Holder or beneficial owner of the Notes (or between a fiduciary, settlor, beneficiary, member or shareholder of, or possessor of a power over, such Holder or beneficial owner, if such Holder or beneficial owner is an estate, trust, partnership
or corporation) and the United Kingdom or United States or any political subdivision or territory or possession thereof or therein or area subject to its jurisdiction, including, without limitation, such Holder or beneficial owner (or such
fiduciary, settlor, beneficiary, member, shareholder or possessor) being or having been a citizen or resident thereof or treated as a resident thereof or domiciled thereof or a national thereof or being or having been present or engaged in trade or
business therein or having or having had a permanent establishment therein; 
 (ii) that are estate, inheritance, gift,
sales, transfer, personal property, wealth or similar taxes, duties, assessments or other governmental charges; 
 (iii) that
are payable other than by withholding from payments of principal of or premium, if any, or interest on the Notes; 
 (iv)
that would not have been imposed but for the failure of the applicable recipient of such payment to comply with any certification, identification, information, documentation or other reporting requirement to the extent such compliance is required by
applicable law or administrative practice or an applicable treaty as a precondition to exemption from, or reduction in, the rate of deduction or withholding of such Taxes; 

(v) that would not have been imposed but for the presentation of the Notes (where presentation is required) for payment on a
date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof was duly provided for, whichever occurred later; 

  
 36 

 (vi) that would not have been imposed if presentation for payment of the
Notes had been made to a Paying Agent other than the Paying Agent to which the presentation was made; 
 (vii) that are
imposed solely by reason of the Holder or beneficial owner owning or having owned, actually or constructively, 10% or more of the total combined voting power of all classes of such Issuer’s stock entitled to vote; 

(viii) that would not have been imposed but for a failure by the Holder or beneficial owner (or any financial institution
through which the Holder or beneficial owner holds any Note through which payment on the Note is made) to comply with any certification, information, identification, documentation or other reporting requirements (including entering into and
complying with an agreement with the U.S. Internal Revenue Service) imposed pursuant to Sections 1471 through 1474 of the U.S. Internal Revenue Code as in effect on the date of issuance of the Notes or any successor or amended version of such
provisions; or 
 (ix) any combination of the foregoing clauses (i) through (viii); 

nor shall Additional Amounts be paid with respect to any payment of the principal of or premium, if any, or interest on the Note to any such Holder who is a
fiduciary or a partnership or a beneficial owner who is other than the sole beneficial owner of such payment to the extent a beneficiary or settlor with respect to such fiduciary or a member of such partnership or a beneficial owner would not have
been entitled to such Additional Amounts had it been the Holder of the Note. 
 The U.S. Issuer shall maintain in respect of the U.S. Issuer
Notes, at least one Paying Agent located outside the United Kingdom. 
 The UK Issuer shall maintain, in respect of the UK Issuer Notes, at
least one Paying Agent located outside the United Kingdom. 
 The obligation of the U.S. Issuer to pay Additional Amounts if and when due
will survive the termination of this Indenture and the payment of all amounts in respect of the U.S. Issuer Notes. 
 The obligation of the
UK Issuer to pay Additional Amounts if and when due will survive the termination of this Indenture and the payment of all amounts in respect of the UK Issuer Notes. 

Wherever in this Indenture or in the Notes there is in any provision any reference to the payment or delivery of amounts due on the Notes,
whether at maturity or pursuant to any earlier redemption or repayment or otherwise, references to such amounts shall be deemed to include such Additional Amounts if, as and to the extent such Additional Amounts are payable with respect to such
payment or delivery in accordance with the terms of this Indenture and the Notes, whether or not express mention to such Additional Amounts shall be made in any such provision. 

  
 37 

 Section 4.2. Limitation on Liens 

Each Guarantor shall not, and shall not permit any of its Subsidiary to, incur or assume any mortgage, charge, security interest, pledge,
hypothecation, assignment, deposit arrangement, encumbrance, lien or other security agreement (collectively, “Liens”) on or with respect to any of its or its Subsidiaries’ property, assets or revenues, present or future, to
secure any Relevant Indebtedness without making, or causing any such Subsidiary to make, effective provision for securing the Notes equally and ratably with or prior to such Relevant Indebtedness as to such property, assets or revenues for as long
as such Relevant Indebtedness is so secured. 
 Such restrictions on Liens shall not apply to: 

(i) Liens arising by operation of law; 

(ii) Liens on property, assets or revenues of any Person, which Liens are existing at the time such Person becomes a
Subsidiary; or 
 (iii) Liens on property, assets or revenues of any Person existing at the time such Person is merged with
or into or consolidated with the Guarantor or any of its Subsidiaries, or at the time of a sale, lease or other disposition to the Guarantor of the properties of a Person as an entirety or substantially as an entirety. 

Section 4.3. Maintenance of Office or Agency 

(a) The Issuers shall maintain each office or agency required under Section 2.3. The Issuers will give prompt
written notice to the Trustee of any change in the location of any such office or agency. If at any time the Issuers shall fail to maintain any such required office or agency or shall fail to furnish to the Trustee with the address thereof, such
presentations, surrenders, notices and demands in respect of the Notes and this Indenture may be made or services at the Corporate Trust Office, and the Issuers hereby appoint the Trustee as its agent to receive all such presentations, surrenders,
notices and demands. 
 (b) The Issuers may also from time to time designate one or more other offices or agencies (in or outside of New
York) where the Notes may be presented or surrendered for any or all such purposes and may from time to time rescind any such designation; provided, however, that no such designation or rescission shall in any manner relieve the Issuers or
the applicable Guarantor of their obligation to maintain an office or agency in the Borough of Manhattan, The City of New York for such purposes. The Issuers and the applicable Guarantor, as appropriate, will give prompt written notice to the
Trustee of any such designation or rescission and of any changes in the location of any such other office or agency. 
 Section 4.4.
Maintenance of Corporate Existence and Corporate Separateness 
 Subject to ARTICLE VI, the Issuers and the applicable
Guarantor will each do or cause to be done all things necessary to preserve and keep in full force and effect its corporate existence. 

  
 38 

 Section 4.5. Compliance Certificate 

Each Issuer and the applicable Guarantor (for as long as its respective Guarantee is in force) will furnish to the Trustee annually, within
120 days after the end of each fiscal year, a brief certificate from its principal executive, financial or accounting officer as to his or her knowledge of the compliance of the relevant Issuer or the applicable Guarantor, as the case may be, with
all conditions and covenants under this Indenture (such compliance to be determined without regard to any period of grace or requirement of notice provided under this Indenture) and, in the event of any Default, specifying such Default and the
nature and status thereof of which such person may have knowledge. 
 Section 4.6. Reports to Holders 

At any time when the applicable Guarantor is not subject to or is not current in any applicable SEC reporting obligations, the U.S. Issuer
(with respect to U.S. Issuer Notes), the UK Issuer (with respect to UK Issuer Notes) and the applicable Guarantor shall upon request make available to any Holder or any prospective purchaser of Notes the information required by it by Rule 144A(d)(4)
under the Securities Act. 
 ARTICLE V. 

DEMERGER CAPITAL REDUCTION 

Section 5.1. Demerger Capital Reduction 

By their holding of the Notes, each Holder shall be deemed without the need for any further action to have unconditionally and irrevocably
(i) consented to any reduction in the capital of Haleon which is implemented within 6 months of the Demerger, (ii) agreed not to object to the Demerger Capital Reduction, and (iii) appointed the Issuer of such Holder’s Notes, or
such person (other than the Trustee) as such Issuer shall nominate as its agent to undertake all such acts and take all such steps on its behalf (including, without limitation, the execution and delivery of any documents to any court) as may be
necessary or desirable for Haleon to implement the Demerger Capital Reduction. 
 ARTICLE VI. 

SUCCESSOR ENTITY 

Section 6.1. When an Issuer May Merge, Etc. 

Each Issuer shall not consolidate with, merge with or into any other Person, or convey or transfer all or substantially all of their
respective properties and assets to any Person (except that each Issuer’s finance Subsidiaries may merge into such Issuer), unless: 

  
 39 

 (a) the relevant Issuer is the continuing Person, or the successor expressly assumes by
supplemental indenture their respective obligations under this Indenture; 
 (b) the continuing Person is a U.S. or U.K. company or is
organized and validly existing under the laws of a jurisdiction that is a member country of the Organization for Economic Cooperation and Development (or any successor) and, if it is not a U.S. or U.K. company, the continuing Person agrees by
supplemental indenture to be bound by a covenant comparable to that described in Section 4.1 with respect to taxes imposed in the continuing Person’s jurisdiction or organization (in which case the continuing Person
will benefit from a redemption option comparable to that described below under Section 7.2 in the event of changes in taxes in that jurisdiction after the date of the consolidation, merger or sale); 

(c) immediately after the transaction, no Default or Event of Default under the U.S. Issuer Notes (with respect to the U.S. Issuer) or the UK
Issuer Notes (with respect to the UK Issuer), as the case may be, has occurred and is continuing; and 
 (d) the relevant Issuer delivers to
the Trustee an Officer’s Certificate and, if the relevant Issuer is not the continuing Person, an Opinion of Counsel, in each case stating, among other things, that the transaction and the supplemental indenture, if required, comply with this
Section 6.1 and this Indenture. 
 Section 6.2. Successor Substituted 

Upon any consolidation or merger, or any sale or other disposition of all or substantially all of the property and assets of an Issuer in
accordance with Section 6.1 of this Indenture, the successor Person formed by such consolidation or into which the relevant Issuer is merged or to which such sale or other disposition (the “Successor
Entity”) is made shall succeed to, and be substituted for, and may exercise every right and power of, the relevant Issuer under this Indenture with the same effect as if such successor Person had been named as the relevant Issuer herein.

 Section 6.3. When the Guarantor May Merge, Etc. 

Each Guarantor, for so long as its respective Guarantee is in place, shall not consolidate with, merge with or into any other Person, or
convey or transfer all or substantially of their respective properties and assets to any Person (except that each Guarantor’s finance subsidiaries may merge into the applicable Guarantor), unless: 

(a) the applicable Guarantor is the continuing Person, or the successor expressly assumes by supplemental indenture their respective
obligations under this Indenture; 
 (b) the continuing Person is a U.S. or U.K. company or is organized and validly existing under the laws
of a jurisdiction that is a member country of the Organization for Economic Cooperation and Development (or any successor) and, if it is not a U.S. or U.K. company, the continuing Person agrees by supplemental indenture to be bound by a covenant
comparable to that described in Section 4.1 with respect to taxes imposed in the continuing Person’s jurisdiction or organization (in which case the continuing Person will benefit from a redemption option comparable to
that described below under Section 7.2 in the event of changes in taxes in that jurisdiction after the date of the consolidation, merger or sale); 

  
 40 

 (c) immediately after the transaction, no Default or Event of Default under the Notes has
occurred and is continuing; and 
 (d) the applicable Guarantor delivers to the Trustee an Officer’s Certificate and, if the applicable
Guarantor is not the continuing Person, an Opinion of Counsel, in each case stating, among other things, that the transaction and the supplemental indenture, if required, comply with this Section 6.1 and this Indenture.

 Section 6.4. Successor Guarantor Substituted 

Upon any consolidation or merger, or any sale or other disposition of all or substantially all of the property and assets of a Guarantor in
accordance with Section 6.1 of this Indenture, the successor Person formed by such consolidation or into which the Guarantor is merged or to which such sale or other disposition is made shall succeed to, and be substituted for,
and may exercise every right and power of, the applicable Guarantor under this Indenture with the same effect as if such successor Person had been named as the applicable Guarantor herein. 

Section 6.5. Substitution of either Issuer 

Each of the Issuers may at its option at any time, without the consent of any Holders, arrange for and cause Haleon or any of their respective
subsidiaries (the “Substituted Obligor”) to assume the obligations of the U.S. Issuer under the U.S. Issuer Notes, and of the UK Issuer under the UK Issuer Notes, respectively; provided that: 

(a) the new obligor executes a supplemental indenture, in form and substance satisfactory to the Trustee, in which it agrees to be bound by the
terms of the Notes and the Indenture, with any consequential amendments that may be required, as fully as if the Substituted Obligor had been named in this Indenture and on the Notes of such series in place of the U.S. Issuer or UK Issuer, as
applicable; 
 (b) the Substituted Obligor is organized and validly existing under the laws of the U.S. or the U.K., or is organized and
validly existing under the laws of a jurisdiction that is a member country of the Organization for Economic Cooperation and Development (or any successor) and, if such Substituted Obligor is not organized and validly existing under the laws of the
U.S. or the U.K., such Substituted Obligor must also agree in the supplemental indenture to be bound by a covenant comparable to that described in Section 4.1 with respect to taxes imposed in its jurisdiction of
organization (in which case the new obligor will benefit from a redemption option comparable to that described under Section 7.2 in the event of changes in taxes in that jurisdiction after the date of the consolidation, merger or
sale), in each case in form and substance satisfactory to the Trustee; and 
 (c) unless the Substituted Obligor is the applicable
Guarantor, the obligations of the Substituted Obligor under the Indenture and the Notes of such series are guaranteed by the applicable Guarantor on the same terms as the applicable Guarantee of the U.S. Issuer’s obligations in respect of such
U.S. Issuer Notes or the UK Issuer’s obligations in respect of such UK Issuer Notes, as applicable, immediately prior to such substitution. 

In the case of such a substitution, the relevant Issuer will be relieved of any further obligation under the relevant Notes. 

  
 41 

 ARTICLE VII. 

REDEMPTION 

Section 7.1. Redemption; General 

The Notes will not be subject to any sinking fund. 

Unless otherwise specified in this ARTICLE VII, with respect to any series of Notes, notice of any redemption by the U.S. Issuer or UK
Issuer, as applicable, will be mailed by the relevant Issuer, or by the Trustee on the relevant Issuer’s behalf at least 15 days but not more than 60 days before the redemption date to each registered Holder of the Notes of such series to be
redeemed by the relevant Issuer. The relevant Issuer will give notice of any such redemption to any exchange on which such series of Notes are listed. On and after any redemption date, interest will cease to accrue on such series of Notes or
portions thereof called for redemption. 
 Section 7.2. Optional Redemption for Tax Reasons 

(a) The U.S. Issuer may redeem any series of U.S. Issuer Notes in whole but not in part at any time prior to maturity, at a redemption price
equal to 100% of their principal amount plus accrued interest to the date fixed for redemption, if: 
 (i) the U.S. Issuer
determines that, as a result of any change in or amendment to the laws or any regulations or rulings promulgated thereunder of the United Kingdom (or of any political subdivision or taxing authority thereof) or the United States (or of any political
subdivision or taxing authority thereof), or any change in the application or official interpretation of such laws, regulations or rulings, or any change in the application or official interpretation of, or any execution of or amendment to, any
treaty or treaties affecting taxation to which any such jurisdiction is a party, which change, execution or amendment becomes effective on or after the Issue Date: 

(A) the U.S. Issuer would be required to pay Additional Amounts with respect to the U.S. Issuer Notes on the next succeeding Interest Payment
Date and the payment of such Additional Amounts cannot be avoided by the use of reasonable measures available to the U.S. Issuer or the applicable Guarantor; or 

(B) withholding tax has been or would be required to be withheld with respect to interest income received or receivable by the U.S. Issuer
directly from the applicable Guarantor (or any Affiliate) and such withholding tax obligation cannot be avoided by the use of reasonable measures available to the U.S. Issuer or the applicable Guarantor (or any Affiliate); or 

  
 42 

 (ii) the U.S. Issuer determines, based upon an opinion of independent
counsel of recognized standing that, as a result of any action taken by any legislative body of, taxing authority of, or any action brought in a court of competent jurisdiction in, the United Kingdom (or any political subdivision or taxing authority
thereof) or the United States (or any political subdivision or taxing authority thereof) (whether or not such action was taken or brought with respect to the U.S. Issuer or the applicable Guarantor, as the case may be), which action is taken or
brought on or after the Issue Date, there is a substantial probability that the circumstances described above would exist; provided, however, that no such notice of redemption may be given earlier than 90 days prior to the earliest
date on which the U.S. Issuer would be obligated to pay such Additional Amounts. 
 (b) The UK Issuer may redeem the UK Issuer Notes in
whole but not in part at any time prior to maturity, at a redemption price equal to 100% of their principal amount plus accrued interest to the date fixed for redemption, if: 

(i) the UK Issuer determines that, as a result of any change in or amendment to the laws or any regulations or rulings
promulgated thereunder of the United Kingdom (or of any political subdivision or taxing authority thereof) or the United States (or of any political subdivision or taxing authority thereof), or any change in the application or official
interpretation of such laws, regulations or rulings, or any change in the application or official interpretation of, or any execution of or amendment to, any treaty or treaties affecting taxation to which any such jurisdiction is a party, which
change, execution or amendment becomes effective on or after the Issue Date: 
 (A) the UK Issuer would be required to pay Additional Amounts
with respect to the UK Issuer Notes on the next succeeding Interest Payment Date and the payment of such additional amounts cannot be avoided by the use of reasonable measures available to the UK Issuer or the applicable Guarantor; or 

(B) withholding tax has been or would be required to be withheld with respect to interest income received or receivable by the UK Issuer
directly from the applicable Guarantor (or any Affiliate) and such withholding tax obligation cannot be avoided by the use of reasonable measures available to the UK Issuer or the applicable Guarantor (or any Affiliate); or 

(ii) the UK Issuer determines, based upon an opinion of independent counsel of recognized standing that, as a result of any
action taken by any legislative body of, taxing authority of, or any action brought in a court of competent jurisdiction in, the United Kingdom (or any political subdivision or taxing authority thereof) or the United States (or any political
subdivision or taxing authority thereof) (whether or not such action was taken or brought with respect to the UK Issuer or the applicable Guarantor, as the case may be), which action is taken or brought on or after the Issue Date, there is a
substantial probability that the circumstances described above would exist; provided, however, that no such notice of redemption may be given earlier than 90 days prior to the earliest date on which the UK Issuer would be obligated to
pay such Additional Amounts. 
 (c) The relevant Issuer or the applicable Guarantor will also pay to each Holder of any series of Notes to
be redeemed, or make available for payment to each such Holder, on the redemption date any Additional Amounts resulting from the payment of such redemption price. Prior to the delivery of any notice of redemption, the relevant Issuer or the
applicable Guarantor will deliver to the Trustee: 

  
 43 

 (i) an Officer’s Certificate stating that the relevant Issuer is
entitled to effect a redemption and setting forth a statement of facts showing that the conditions precedent of the right so to redeem have occurred; or 

(ii) an Opinion of Counsel to the effect that the conditions specified above have been satisfied. 

Any notice of redemption will be irrevocable once the relevant Issuer delivers the Officer’s Certificate to the Trustee. 

Section 7.3. Deposit of Redemption Price 

On or before 11:00am New York City time on the redemption date, the U.S. Issuer or the UK Issuer will deposit with the Paying Agent or the
Trustee (or, if the Issuer is acting as Paying Agent, segregate and hold in trust as provided in Section 2.4) money sufficient to pay the redemption price of and accrued interest on the relevant series of Notes to be redeemed on
that date. If less than all of the Notes of such series are to be redeemed, the Notes to be redeemed shall be selected by lot or in accordance with the procedures of The Depository Trust Company, in the case of Notes represented by a Global Note, or
by the Trustee by such method as the Trustee deems to be fair and appropriate, in the case of Notes that are not represented by a Global Note. 

Section 7.4. Unredeemed Portions of Partially Redeemed Note 

Upon surrender of a Note that is to be redeemed in part, the U.S. Issuer (in respect of U.S. Issuer Notes) or the UK Issuer (in respect of UK
Issuer Notes), as applicable, shall execute, and the Trustee shall authenticate and make available for delivery to the Holder of the Note at the expense of the relevant Issuer, a new Note or Notes, of any authorized denomination as requested by the
Holder, in an aggregate principal amount equal to, and in exchange for, the unredeemed portion of the principal of the Note surrendered, provided that each new Note will be in a principal amount of $250,000 and integral multiples of $1,000 in
excess thereof. 
 Section 7.5. Fixed Rate Notes Make-Whole and Par Redemption 

(a) Prior to the applicable Fixed Rate Notes Par Call Date, the U.S. Issuer may redeem any series of the U.S. Issuer Fixed Rate Notes and, at
any time before the 2025 Fixed Rate Notes Maturity Date, the UK Issuer may redeem the 2025 Fixed Rate Notes, in whole or in part, at their option at any time and from time to time at a redemption price (expressed as a percentage of principal amount
and rounded to three decimal places) equal to the greater of (i) 100% of the principal amount of the Fixed Rate Notes to be redeemed on that redemption date and (ii) as determined by such Issuer, (a) with respect to any series of U.S.
Issuer Fixed Rate Notes: the sum of the present values of the remaining scheduled payments of principal of and interest on the Fixed Rate Notes to be redeemed on that redemption date (not including any portion of such payments of interest accrued as
of the redemption date) that would be due if the relevant series of U.S. Issuer Fixed Rate Notes matured on the applicable Fixed Rate Notes Par 

  
 44 

 
Call Date, discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve
30-day months) at the Treasury Rate plus 20 basis points in the case of the 2027 Fixed Rate Notes, 20 basis points in the case of the 2029 Fixed Rate Notes, 25 basis points in the case of the 2032 Fixed Rate
Notes, 25 basis points in the case of the 2052 Fixed Rate Notes or 15 basis points in the case of the Callable Fixed Rate Notes, and (b) with respect to the 2025 Fixed Rate Notes: the sum of the present values of the remaining scheduled
payments of principal and interest on the 2025 Fixed Rate Notes to be redeemed on that redemption date (not including any portion of such payments of interest accrued as of the redemption date) discounted to the redemption date on a semi-annual
basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 15 basis points; in each case plus accrued and unpaid interest, if any,
thereon to, but excluding, the redemption date. 
 (b) On or after the applicable Fixed Rate Notes Par Call Date, the U.S. Issuer may redeem
any series of the U.S. Issuer Fixed Rate Notes, in whole or in part, at its option at any time and from time to time at a redemption price equal to 100% of the principal amount of the applicable series of U.S. Issuer Fixed Rate Notes to be redeemed,
plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 
 (c) Notwithstanding the foregoing, instalments
of interest on the Fixed Rate Notes to be redeemed that are due and payable on a Fixed Rate Notes Interest Payment Date falling on or prior to a redemption date will be payable on the Fixed Rate Notes Interest Payment Date to the registered Holders
as of the close of business on the relevant Regular Record Date according to the Fixed Rate Notes and the Indenture, as applicable. 
 (d)
Each Issuer’s actions and determinations in determining the redemption price shall be conclusive and binding for all purposes, absent manifest error. 

Section 7.6. Floating Rate Notes Par Redemption 

(a) On or after the Callable Floating Rate Notes Par Call Date, the U.S. Issuer may redeem the Callable Floating Rate Notes, in whole or in
part, at its option at any time and from time to time at a redemption price equal to 100% of the principal amount of the Callable Floating Rate Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption
date. 
 (b) Notwithstanding the foregoing, instalments of interest on the Callable Floating Rate Notes to be redeemed that are due and
payable on a Callable Floating Rate Notes Interest Payment Date falling on or prior to a redemption date will be payable on the Callable Floating Rate Notes Interest Payment Date to the Holders as of the close of business on the relevant Regular
Record Date according to the Callable Floating Rate Notes and the Indenture, as applicable. 
 Section 7.7. Special Mandatory Early
Redemption 
 (a) The U.S. Issuer shall promptly notify, in writing, the Trustee, the Paying Agent and the Holders of the U.S. Issuer
Notes within 15 days of the occurrence of a Special Mandatory Redemption Event (which notice shall be irrevocable and shall specify the date fixed for redemption). Within 45 days from (and including) the date of such notice, the U.S. Issuer shall
redeem the U.S. Issuer Notes in whole, but not in part, at the Special Mandatory Redemption Amount, together with interest accrued (but unpaid) to (but excluding) the date fixed for redemption. 

  
 45 

 (b) The UK Issuer shall promptly notify, in writing, the Trustee, the Paying Agent and the
Holders of the UK Issuer Notes within 15 days of the occurrence of a Special Mandatory Redemption Event (which notice shall be irrevocable and shall specify the date fixed for redemption). Within 45 days from (and including) the date of such notice,
the UK Issuer shall redeem the UK Issuer Notes in whole, but not in part, at the Special Mandatory Redemption Amount, together with interest accrued (but unpaid) to (but excluding) the date fixed for redemption. 

(c) The Trustee is under no obligation whatsoever to ascertain whether a Special Mandatory Redemption Event or any event which could lead to
the occurrence of or could constitute a Special Mandatory Redemption Event has occurred and, until a responsible officer of the Trustee shall have received actual written notice pursuant to Section 7.7(a) and/or
Section 7.7(b) to the contrary, the Trustee may assume that no Special Mandatory Redemption Event or other such event has occurred. 

Section 7.8. Redemption upon a Change of Control Put Event 

(a) If a Change of Control Put Event occurs with respect to a series of Notes, the Holders of such Series will have the option (a
“Change of Control Put Option”) (unless prior to the giving of the relevant Change of Control Put Event Notice the Issuer of such series of Notes has given notice of redemption pursuant to any of Section 7.2,
Section 7.5, Section 7.6 or Section 7.7 as applicable) to require the relevant Issuer to redeem or, at such Issuer’s option, purchase (or procure the purchase of) the whole,
but not part, of such Holders’ Notes on the Change of Control Put Date at the Change of Control Redemption Amount together with interest accrued (but unpaid) to (but excluding) the Change of Control Put Date. 

(b) Promptly, and in any event not later than seven calendar days, after becoming aware of the occurrence of a Change of Control Put Event,
the relevant Issuer shall notify the Trustee in writing and give notice (a “Change of Control Put Event Notice”) to the Holders specifying: (A) the nature of the Change of Control Put Event, (B) the procedure for
exercising the Change of Control Put Option, (C) that a Change of Control Put Notice once given may not be revoked, (D) the last day of the Paying Agent’s normal business hours falling within the period (the “Change of Control
Put Period”) and (E) the Change of Control Put Date. 
 (c) To exercise the Change of Control Put Option, the relevant Holder
must deliver, at the specified office of the Paying Agent at any time during the Change of Control Put Period of 45 calendar days after a Change of Control Put Event Notice is given, accompanied by a duly signed and completed notice of exercise in
the form (for the time being current) obtainable from the specified office of the Paying Agent (a “Change of Control Put Notice”) and in which the Holder must specify a bank account (or, if payment is required to be made by check,
an address) to which payment is to be made pursuant to this Section 7.8, accompanied by, if the relevant Note is in definitive form, the relevant Note or evidence satisfactory to the Paying Agent concerned that the relevant
Note will, following delivery of the Change of Control Put Notice, be held to its order or under its control. The “Change of Control Put Date” shall be the date falling seven London business days after the expiration of the Change
of Control Put Period. 

  
 46 

 (d) A Change of Control Put Notice, once given, shall be irrevocable, except where prior to
the Change of Control Put Date, an Event of Default has occurred and is continuing; in which event, the relevant Holder, at its option, may elect by notice to the relevant Issuer to withdraw the Change of Control Put Notice and instead to instruct
the Trustee, in writing, to give notice that the relevant Notes the subject of the Change of Control Put Notice are immediately due and payable pursuant to ARTICLE IX. The relevant Notes shall then become immediately due and payable, as long
as the Trustee declares all of the relevant Notes immediately due and payable. 
 (e) The relevant Issuer shall redeem or purchase (or
procure the purchase of) the relevant Notes on the Change of Control Put Date unless previously redeemed (or purchased) and cancelled. 

(f) The Trustee is under no obligation whatsoever to ascertain whether a Change of Control Put Event or any event which could lead to the
occurrence of or could constitute a Change of Control Put Event has occurred and, until a responsible officer of the Trustee shall have received actual written notice pursuant to this Section 7.8 to the contrary, the
Trustee may assume that no Change of Control Put Event or other such event has occurred. 
 Section 7.9. Redemption at Maturity

 Unless previously redeemed and cancelled as herein provided, each series of U.S. Issuer Notes will be repaid by the U.S. Issuer at their
respective principal amounts on the applicable Maturity Date. 
 Unless previously redeemed and cancelled as herein provided, the UK Issuer
Notes will be repaid by the UK Issuer at their principal amounts on the applicable Maturity Date. 
 ARTICLE VIII. 

DEFEASANCE 

Section 8.1. Defeasance 

(a) If an Issuer deposits with the Trustee sufficient cash or government securities (if government securities, as deemed sufficient in the
opinion of a nationally recognized firm of public accountants) to pay the principal, interest, any premium and any other sums due to the stated Maturity Date or a redemption date of the relevant Notes, then at its option: 

(i) such Issuer will be discharged from its respective obligations with respect to the relevant Notes; or 

  
 47 

 (ii) such Issuer will no longer be under any obligation to comply with the
restrictive covenants, if any, contained in the Indenture and any supplemental indenture or board resolution with respect to the relevant Notes, and the Events of Default relating to failures to comply with covenants will no longer apply to the
relevant Issuer. 
 (b) If Section 8.1(a) applies, the Holders will not be entitled to the benefits of the
Indenture except for registration of transfer of Notes and replacement of lost, stolen or mutilated Notes. Instead, the Holders will only be able to rely on the deposited funds or obligations for payment. 

(c) The relevant Issuer must deliver to the Trustee an Opinion of Counsel to the effect that the deposit and related defeasance would not
cause the Holders to recognize income, gain or loss for U.S. federal income tax purposes. The relevant Issuer may, in lieu of an Opinion of Counsel, deliver a ruling to such effect received from or published by the U.S. Internal Revenue Service.

 ARTICLE IX. 

DEFAULTS AND REMEDIES 

Section 9.1. Events of Default 

An “Event of Default” with respect to a series of Notes will occur upon any of the following: 

(a) default in payment of the principal of any Note of such series when due (including upon any redemption of such series of Notes), and, in
the case of technical or administrative difficulties, the continuance of that default for more than two Business Days; 
 (b) default in
payment of interest on, or any additional amounts payable in respect of, any Note of such series when due and payable, and the continuance of that default for 30 days; 

(c) (i) with respect to the U.S. Issuer Notes, default in performing any other covenant of the U.S. Issuer and (ii) with respect to the
UK Issuer Notes, default in performing any other covenant of the UK Issuer, or the applicable Guarantor in this Indenture for 90 days after the receipt of written notice specifying such default from the Trustee or from the Holders of 25% in
principal amount of the Notes of that series; 
 (d) default under any bond, debenture, note or other evidence of indebtedness for money
borrowed of the U.S. Issuer, with respect to the U.S. Issuer Notes, or the UK Issuer, with respect to the UK Issuer Notes, or the applicable Guarantor, as the case may be (not including any indebtedness for which recourse is limited to property
purchased), having in any particular case an outstanding principal amount in excess of £100,000,000 (or its equivalent in any other currency) where any such failure results in such indebtedness being accelerated and becoming due and payable
prior to its stated maturity and such acceleration shall not have been rescinded or annulled or such indebtedness shall not have been discharged; provided that there shall not be deemed to be an event of default if such acceleration is
rescinded or annulled or such payment is made within 10 days after there has been given to the applicable Issuer and the applicable 

  
 48 

 
Guarantor by the Trustee, or to the applicable Issuer, the applicable Guarantor and the Trustee by the Holders representing 25% or more in aggregate principal amount of such series of the Notes a
written notice specifying such default and requiring it to be remedied and stating that such notice is a “Notice of Default” hereunder; 

(e) with respect to the U.S. Issuer Notes, the Haleon Guarantee ceases to be, or is claimed by the U.S. Issuer or Haleon not to be, in full
force and effect; 
 (f) with respect to the UK Issuer Notes, the Haleon Guarantee ceases to be, or is claimed by the UK Issuer or Haleon
not to be, in full force and effect; or 
 (g) commencement by the relevant Issuer or the applicable Guarantor of a voluntary case under any
applicable bankruptcy, insolvency or other similar law now or hereafter in effect, or the relevant Issuer’s or the applicable Guarantor’s consent to the entry of an order for relief in an involuntary case under any such law, or consent to
the appointment of or taking possession by a receiver, liquidator, assignee, custodian, trustee, sequestrator or similar official of the relevant Issuer or the applicable Guarantor or for all or substantially all of the property and assets of the
relevant Issuer or the applicable Guarantor, or any general assignment by the applicable Issuer or the applicable Guarantor for the benefit of creditors. 

An Event of Default with respect to a particular series of Notes will not necessarily constitute an Event of Default with respect to any other
series of Notes. 
 Section 9.2. Notice of Event of Default 

If an Event of Default with respect to a series of Notes occurs and is continuing of which a responsible officer of the Trustee has received
written notice, the Trustee will mail to the Holders of the Notes of such series a notice of the Event of Default within 90 days after it occurs. However, except in the case of a Default in any payment in respect of a series of Notes, the Trustee
shall be protected in withholding notice of an Event of Default if it determines in good faith that this is in the interests of the Holders of the relevant series of Notes. 

Section 9.3. Acceleration 

(a) If an Event of Default described in Section 9.1(a) or Section 9.1(b) occurs with respect to
any series of Notes, then the Trustee or the Holders of at least 25% of the aggregate principal amount of such series of Notes can accelerate the entire principal of such series of Notes with written notice to the Trustee. 

(b) If an Event of Default described in Section 9.1(c), Section 9.1(d),
Section 9.1(e) or Section 9.1(f) occurs because of a failure to perform any other covenant in this Indenture or any covenant for the benefit of one or more, but not all, of the series of the Notes,
then the Trustee or the Holders of at least 25% of the aggregate principal amount of Notes of all series affected, voting as one class, can accelerate all of the affected series of Notes. 

(c) If an Event of Default described in Section 9.1(g) occurs, then the entire principal of the Notes under the Indenture
will be accelerated automatically without further action. 

  
 49 

 (d) The Holders representing a majority of the aggregate principal amount of the affected
series of Notes can rescind this accelerated payment requirement. 
 Section 9.4. Other Remedies 

No Holder will be entitled to pursue any remedy under this Indenture unless the Trustee fails to act for 60 days after it is given: 

(i) notice of Default by that Holder; 

(ii) a written request to enforce this Indenture by the Holders of not less than 25% in principal amount of all Outstanding
Notes of any affected series; and 
 (iii) an indemnity and/or security to the Trustee, reasonably satisfactory to the
Trustee; 
 and during this 60-day period the Holders representing at least a majority in principal amount of all
Outstanding Notes of such affected series do not give a direction to the Trustee that is inconsistent with the enforcement request. These provisions will not prevent any Holder from enforcing payment of the principal of (and premium, if any) and
interest on the Notes at the relevant due dates. 
 Section 9.5. Waiver of Past Defaults 

Subject to Section 9.6 and Section 11.2, the Holders representing a majority of the aggregate
principal amount of the affected series of Notes may waive any past Default or Event of Default or allow noncompliance with any provision of this Indenture. However, the Holders cannot waive a Default in payment of principal of or interest on any
series of the Notes when due otherwise than as a result of acceleration. Upon any such waiver, such Default shall cease to exist, and any Event of Default with respect to the Notes arising therefrom shall be deemed to have been cured, for every
purpose of this Indenture; but no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent thereto. 

Section 9.6. Rights of Holders to Receive Payment 

Notwithstanding any other provision of this Indenture, the right of any Holder of any series of Notes to receive payment of the principal,
interest or Additional Amounts payable in respect of such Holder’s Note on or after the respective due dates therefor, or to bring suit for the enforcement of any such payment on or after such respective dates, shall not be impaired or affected
without the consent of such Holder. 
 Section 9.7. Collection Suit by Trustee 

If an Event of Default with respect to the Notes in payment of the principal or interest as specified in Section 9.1(a) or
Section 9.1(b) occurs and is continuing, the Trustee may recover judgment in its own name and as trustee of an express trust against the relevant Issuer and the applicable Guarantor for the whole amount of such principal of the
Notes and such further amount as shall be sufficient to cover all amounts owing the Trustee under Section 10.6. 

  
 50 

 Section 9.8. Trustee May File Proofs of Claim, Etc. 

The Trustee may file such proofs of claim and other papers or documents as may be necessary or advisable in order to have the claims of the
Trustee (including any claim for amounts due the Trustee under Section 10.6) and the Holders allowed in any judicial proceedings relative to the relevant Issuer, the applicable Guarantor, the creditors of the relevant
Issuer or the applicable Guarantor, or the property of the relevant Issuer or the applicable Guarantor and shall be entitled and empowered to collect and receive any moneys, securities or other property payable or deliverable upon any such claims
and to distribute the same, and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee and, in the event
that the Trustee shall consent to the making of such payments directly to the Holders, to pay to the Trustee any amount due to it under Section 10.6. Nothing herein contained shall be deemed to empower the Trustee to
authorize or consent to, or accept or adopt on behalf of any Holder, any plan of reorganization, arrangement, adjustment or composition affecting the Notes, the Guarantees or the rights of any Holder under the Notes or the Guarantees, or to
authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding. 
 Section 9.9. Application of
Proceeds 
 Any moneys collected by the Trustee pursuant to this ARTICLE IX in respect of any series of Notes shall be applied in
the following order at the date or dates fixed by the Trustee and, in case of the distribution of such moneys on account of principal or Additional Amounts, if any, upon presentation of the several Notes in respect of which moneys have been
collected and noting thereon the payment, or issuing Notes in reduced principal amounts in exchange for the presented Notes if only partially paid, or upon surrender thereof if fully paid: 

FIRST: to the Trustee and the Agents for amounts due under Section 10.6; 

SECOND: In case the principal or interest of a series of Notes shall have become and shall be then due and payable, to the
payment of the whole amount then owing and unpaid upon the relevant series of Notes for principal, interest and Additional Amounts, if any; and in case such moneys shall be insufficient to pay in full the whole amount so due and unpaid upon the
relevant series of Notes, then to the payment of such principal or interest without preference or priority of any Note over any other Note in the relevant series, ratably to the aggregate of such principal; and 

THIRD: To the payment of the remainder, if any, to the relevant Issuer, or to the extent the Trustee collects any amount
pursuant to a Guarantee, the applicable Guarantor, or any other person lawfully entitled thereto. 
 Section 9.10. Restoration of
Rights and Remedies  
 If the Trustee or any Holder has instituted any proceeding to enforce any right or remedy under this
Indenture and such proceeding has been discontinued or abandoned for any reason, or has been determined adversely to the Trustee or to such Holder, then, and in every such case, subject to any determination in such proceeding, the relevant Issuer,
the applicable Guarantor, the Trustee and the Holders shall be restored to their former positions hereunder and thereafter all rights and remedies of the relevant Issuer, the applicable Guarantor, Trustee and the Holders shall continue as though no
such proceeding had been instituted. 

  
 51 

 Section 9.11. Undertaking for Costs 

In any suit for the enforcement of any right or remedy under this Indenture or in any suit against the Trustee for any action taken or omitted
by it as Trustee, in either case in respect of any series of Notes, a court may require any party litigant in such suit (other than the Trustee) to file an undertaking to pay the costs of the suit, and the court may assess reasonable costs,
including reasonable attorneys’ fees and expenses, against any party litigant (other than the Trustee) in the suit having due regard to the merits and good faith of the claims or defenses made by the party litigant. This
Section 9.11 does not apply to a suit by Holders representing more than 10% in principal amount of all Outstanding Notes of the affected series. 

Section 9.12. Rights and Remedies Cumulative 

Except as otherwise provided with respect to the replacement or payment of mutilated, destroyed, lost or wrongfully taken Notes in
Section 2.9, no right or remedy herein conferred upon or reserved to the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by law, be
cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent
assertion or employment of any other appropriate right or remedy. 
 Section 9.13. Delay or Omission Not Waiver 

No delay or omission of the Trustee or of any Holder to exercise any right or remedy accruing upon any Event of Default shall impair any such
right or remedy or constitute a waiver of any such Event of Default or an acquiescence therein. Every right and remedy given by this ARTICLE IX or by law to the Trustee or to the Holders may be exercised from time to time, and as often as may
be deemed expedient, by the Trustee or by the Holders, as the case may be. 
 ARTICLE X. 

TRUSTEE, PAYING AGENT, TRANSFER AGENT AND REGISTRAR 

Section 10.1. Duties of Trustee 

(a) If a Default or an Event of Default has occurred and is continuing of which a responsible officer of the Trustee has received written
notice, the Trustee shall exercise the rights and powers vested in it by this Indenture and use the same degree of care and skill in their exercise as a prudent person would exercise or use under the circumstances in the conduct of his own affairs.

  
 52 

 (b) Except during the continuance of a Default or an Event of Default: 

(i) the Trustee undertakes to perform such duties and only such duties as are specifically set forth in this Indenture and no
implied covenants or obligations shall be read into this Indenture against the Trustee; and 
 (ii) in the absence of gross
negligence on its part, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon certificates or opinions furnished to the Trustee and conforming to the requirements of this
Indenture. 
 However, in the case of any such certificates or opinions which by any provisions hereof are specifically required to be
furnished to the Trustee, the Trustee shall examine such certificates and opinions to determine whether or not they conform to the requirements of this Indenture (but need not confirm or investigate the accuracy of mathematical calculations or other
facts stated therein). 
 (c) The Trustee may not be relieved from liability for its own negligent action, its own negligent failure to act
or its own willful misconduct, except that: 
 (i) this paragraph (c) does not limit the effect of paragraph (b) of
this Section 10.1; 
 (ii) the Trustee shall not be liable for any error of judgment made in good
faith by a Trust Officer unless it is proved that the Trustee was negligent in ascertaining the pertinent facts; and 
 (iii)
the Trustee shall not be liable with respect to any action it takes or omits to take in good faith in accordance with a direction received by it pursuant to Section 9.5, Section 9.7 or
Section 9.8; and 
 (d) Neither the Trustee nor the Principal Paying Agent shall be liable for interest on any money
received by it except as the Trustee may agree in writing with each Issuer. 
 (e) Money held in trust by the Trustee need not be segregated
from other funds except to the extent required by law. 
 (f) No provision of this Indenture shall require the Trustee to expend or risk its
own funds or otherwise incur financial liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers, if it shall have reasonable grounds to believe that repayment of such funds or adequate indemnity
and/or security against such risk or liability is not reasonably assured to it. 
 (g) Every provision of this Indenture relating to the
conduct or affecting the liability of or affording protection to the Trustee shall be subject to the provisions of this ARTICLE X. 

(h) Unless otherwise specifically provided in this Indenture, any demand, request, direction or notice from an Issuer shall be sufficient if
signed by an Officer of the relevant Issuer. 

  
 53 

 (i) The Trustee shall be under no obligation to exercise any of the rights or powers vested
in it by this Indenture at the request or direction of any of the Holders unless such Holders shall have offered to the Trustee reasonable security or indemnity against the costs, expenses (including documented attorneys’ fees and expenses) and
liabilities that might properly be incurred by it in compliance with such request or direction. 
 (j) Notwithstanding anything to the
contrary in this Indenture, the Trustee may refuse to follow any direction that would involve the Trustee in personal liability. 
 (k)
Notwithstanding anything to the contrary in this Indenture and for the avoidance of doubt, the parties hereto acknowledge and agree that all sums held by the Trustee or the Agents shall be held as banker rather than as trustee, and therefore will
not be held in accordance with the client money rules of the United Kingdom’s Financial Services Authority or any successor regulatory body. 

Section 10.2. Certain Rights of Trustee, Paying Agent, Transfer Agent and Registrar 

Subject to Section 10.1: 

(a) The Trustee and each of the Paying Agents, the Transfer Agent and the Registrar (together, excluding the Trustee, the
“Agents”) may conclusively rely on and shall be protected in acting or refraining from acting upon any resolution, Officer’s Certificate, or any other certificate, statement, instrument, opinion, report, notice, request,
consent, order, security or other document believed by it to be genuine and to have been signed or presented by the proper Person whether or not such document is addressed to it. The Trustee and each of the Agents shall not investigate any fact or
matter stated in any such document, but the Trustee and each of the Agents may make such further inquiry or investigation into such facts or matters as it may see fit, and, if the Trustee or any Agent shall determine to make such further inquiry or
investigation, it shall be entitled, following reasonable notice, to make reasonable examination of the books, records and premises of the relevant Issuer or the applicable Guarantor, as the case may be, personally or by agent or attorney at the
sole cost of the relevant Issuer or the applicable Guarantor, as the case may be, and shall incur no liability or additional liability of any kind by reason of such inquiry or investigation. 

(b) Before the Trustee or any of the Agents acts or refrains from acting, it may require an Officer’s Certificate or an Opinion of
Counsel, which shall conform to Section 14.2. Neither the Trustee nor any of the Agents shall be liable for any action it takes or omits to take in good faith in reliance on an Officer’s Certificate or Opinion of Counsel.
Subject to Section 10.1, whenever in the administration of the trusts of this Indenture the Trustee shall deem it necessary or desirable that a matter be proved or established prior to taking or omitting to take any action
hereunder, such matter (unless other evidence in respect thereof be herein specifically prescribed) may, in the absence of negligence or bad faith on the part of the Trustee, be deemed to be conclusively proved and established by an Officer’s
Certificate delivered to the Trustee, and such certificate, in the absence of negligence or bad faith on the part of the Trustee, shall be full warrant to the Trustee for any action taken, suffered or omitted to be taken by it under the provisions
of this Indenture in good faith and in reliance thereon. 

  
 54 

 (c) The Trustee and each of the Agents may act through its attorneys, agents, custodians and
nominees not regularly in its employ and shall not be responsible for the misconduct or negligence of any agent, attorney, custodian and nominee appointed with due care; provided that the Trustee shall be required to terminate any such agent,
attorney, custodian or nominee if it has actual knowledge of any failure by such Person to perform its delegated duties. 
 (d) Any request,
direction, order or demand of an Issuer or a Guarantor mentioned herein shall be sufficiently evidenced by an Officer’s Certificate (unless other evidence in respect thereof be herein specifically prescribed), and any board resolution may be
evidenced to the Trustee by a copy thereof certified by the secretary or an assistant secretary of the relevant Issuer or the applicable Guarantor, as the case may be. 

(e) The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request, order or
direction of any of the Holders, unless such Holders shall have offered to the Trustee security or indemnity satisfactory to it against the costs, expenses and liabilities that might be incurred by it in compliance with such request, order or
direction. 
 (f) The Trustee shall not be liable for any action it takes or omits to take in good faith that it believes to be authorized
or within its rights or powers or for any action it takes or omits to take in accordance with the direction of the Holders in accordance with Section 9.4 relating to the time, method and place of conducting any proceeding
for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture. 
 (g) The
Trustee may consult with counsel of its selection and the advice of such counsel or any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted to be taken by it hereunder in
good faith and in reliance thereon. 
 (h) Prior to the occurrence of an Event of Default hereunder and after the curing or waiving of all
Events of Default, the Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, Officer’s Certificate, Opinion of Counsel, board resolution, statement, instrument, opinion, report,
notice, request, consent, order, approval, appraisal, bond, debenture, note, coupon, security, or other paper or document unless requested in writing so to do by the Holders of not less than a majority in aggregate principal amount of the Notes
affected then Outstanding. 
 (i) The rights, privileges, protections, immunities and benefits given to the Trustee, including, without
limitation, its right to be indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder, and to each agent, custodian and other Person employed to act hereunder. 

(j) The Trustee or any of the Agents may request that each Issuer deliver an Officer’s Certificate setting forth the names of individuals
and/or titles of officers authorized at such time to take specified actions pursuant to this Indenture, which Officer’s Certificate may be signed by any person authorized to sign an Officer’s Certificate, including any person specified as
so authorized in any such certificate previously delivered and not superseded. 

  
 55 

 (k) In no event shall the Trustee or any of the Agents be responsible or liable for special,
indirect, punitive or consequential loss or damage of any kind whatsoever (including, but not limited to, loss of profit) as a result of claims brought by any Holder irrespective of whether the Trustee or any of the Agents has been advised of the
likelihood of such loss or damage and regardless of the form of action. 
 (l) The Trustee shall not be required to give any bond or surety
in respect of the performance of its powers and duties hereunder. 
 (m) The Trustee may execute any of the trusts or powers hereunder or
perform any duties hereunder either directly or by or through agents or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder. 

Section 10.3. Individual Rights of Trustee 

The Trustee in its individual or any other capacity may become the owner or pledgee of Notes and may otherwise deal with the Issuers, the
Guarantors or any of their Affiliates with the same rights it would have if it were not Trustee. Any Agent may do the same with like rights. 

Section 10.4. Disclaimer 

The recitals contained herein and in the Notes (except the Trustee’s certificate of authentication) shall be taken as statements of the
relevant Issuer or the applicable Guarantor and not of the Trustee, and the Trustee assumes no responsibility for the correctness of the same. Neither the Trustee nor any of its agents makes any representation as to the validity or adequacy of this
Indenture, the Notes or the Guarantee, except that the Trustee represents that it is duly authorized to execute and deliver this Indenture, authenticate Notes and perform its obligations hereunder. Neither the Trustee nor any of its agents shall be
accountable for any Issuer’s or any Guarantor’s use or application of the proceeds from the Notes or for moneys paid over to the Issuers or the Guarantors pursuant to this Indenture. 

Section 10.5. Notice of Defaults 

If any Default or Event of Default with respect to a series of Notes occurs and is continuing and if such Default is known to a Trust Officer
of the Trustee, the Trustee shall mail to each Holder of such series of Notes, at the expense of the relevant Issuer, notice of such Default or Event of Default within 90 days after the occurrence thereof, unless such Default or Event of Default
shall have been cured or waived before the mailing; provided, however, that, except in the case of a Default or Event of Default in the payment of the principal, interest or other amount with respect to a series of Notes, the Trustee shall be
fully protected in withholding such notice if and so long as the Trustee in good faith determines that the withholding of such notice is in the interests of the Holders; and provided further that in the case of any default or breach of the
character specified in Section 9.1(c) with respect to a series of Notes, no such 

  
 56 

 
notice to Holders of such series of Notes shall be given until at least 90 days after the occurrence thereof. The Trustee shall not be deemed to have notice of any Default or Event of Default
unless a responsible officer of the Trustee has actual knowledge thereof or unless written notice of any event which is in fact such a default is received by the Trustee at the Corporate Trust Office, and such notice references the Securities and
this Indenture. 
 Section 10.6. Compensation and Indemnity 

(a) Each Issuer, or failing which, the applicable Guarantor, shall pay to the Trustee such compensation as shall be agreed upon in writing
from time to time for its services. The compensation of the Trustee shall not be limited by any law on compensation of a trustee of an express trust. Each Issuer, or failing which, the applicable Guarantor, shall reimburse the Trustee promptly upon
request for all reasonable out-of-pocket expenses, disbursements and advances incurred or made by the Trustee (including the reasonable expenses and disbursements of its
agents and counsel), except any such expense, disbursement or advance as may be attributable to its negligence or bad faith. 
 (b) Each
Issuer, or failing which, the applicable Guarantor, shall indemnify the Trustee for, and hold it harmless against, any loss, liability, claim, damage or expense, including taxes (other than income taxes), incurred by it without negligence or bad
faith on its part arising out of or in connection with the acceptance or administration of this Indenture and the Notes or the trusts hereunder and the performance of its duties under this Indenture and the Notes, including the costs and expenses of
defending itself against or investigating any claim asserted by any person or liability in connection with the exercise or performance of any of its powers or duties under this Indenture and the Notes or in connection with enforcing the provisions
of this Section 10.6. 
 (c) The obligations of each Issuer and the applicable Guarantor under this
Section 10.6 to compensate and indemnify the Trustee and each predecessor Trustee and to pay or reimburse the Trustee and each predecessor Trustee for expenses, disbursements and advances shall constitute additional
indebtedness hereunder and shall survive the satisfaction and discharge of this Indenture or the rejection or termination of this Indenture under bankruptcy, insolvency or similar law or the earlier resignation or removal of the Trustee. Such
additional indebtedness shall be a senior claim to that of the Notes upon all property and funds held or collected by the Trustee as such, except funds held in trust for the benefit of the Holders of particular Notes, and the Notes are hereby
subordinated to such senior claim. If the Trustee renders services and incurs expenses following an Event of Default under Section 9.1(a) hereof, the parties hereto and the Holders by their acceptance of the Notes hereby
agree that such expenses are intended to constitute expenses of administration under any bankruptcy, insolvency or similar law 

Section 10.7. Replacement of Trustee 

(a) A resignation or removal of the Trustee as Trustee with respect to the Notes and appointment of a successor Trustee as Trustee with
respect to the Notes shall become effective only upon the successor Trustee’s acceptance of appointment as provided in this Section 10.7. 

  
 57 

 (b) The Trustee may resign as Trustee at any time by so notifying the Issuers and the
applicable Guarantor in writing. The Holders of a majority in principal amount of the Outstanding Notes may remove the Trustee as Trustee by so notifying the Trustee in writing and may appoint a successor Trustee with respect thereto with the
consent of the Issuers. The Issuers may remove the Trustee if: (i) the Trustee is no longer eligible under Section 10.9 of this Indenture; (ii) the Trustee is adjudged a bankrupt or insolvent; (iii) a receiver or
other public officer takes charge of the Trustee or its property; or (iv) the Trustee becomes incapable of acting. 
 (c) If the
Trustee resigns or is removed as Trustee with respect to the Notes, or if a vacancy exists in the office of Trustee with respect to the Notes for any reason, the Issuers shall promptly appoint a successor Trustee with respect thereto. Within one
year after the successor Trustee takes office, the Holders of a majority in principal amount of the Outstanding Notes of a series of Notes may appoint a successor Trustee in respect of such series of Notes to replace the successor Trustee appointed
by the Issuers. If the successor Trustee with respect to the Notes does not deliver its written acceptance required by the next succeeding paragraph of this Section 10.7(d) within 30 days after the retiring Trustee resigns or is
removed, the retiring Trustee (at the Issuers’ expense), the Issuers or the Holders of a majority in principal amount of the Outstanding Notes may petition any court of competent jurisdiction for the appointment of a successor Trustee with
respect thereto. 
 (d) A successor Trustee with respect to the Notes shall deliver a written acceptance of its appointment to the retiring
Trustee, to the Issuers and to the applicable Guarantor. Immediately after the delivery of such written acceptance, subject to the lien provided for in Section 10.6 and subject to the payment of any and all amounts then due and
owing to the retiring Trustee, (i) the retiring Trustee shall transfer all property held by it as Trustee in respect of the Notes to the successor Trustee (ii) the resignation or removal of the retiring Trustee in respect of the Notes
shall become effective and (iii) the successor Trustee shall have all the rights, powers and duties of the Trustee in respect of the Notes under this Indenture. A successor Trustee shall mail notice of its succession to each Holder of Notes.

 (e) Upon request of any such successor Trustee, the Issuers and the applicable Guarantor shall execute any and all instruments for more
fully and certainly vesting in and confirming to such successor Trustee all such rights, powers and trusts referred to in the preceding paragraph. 

(f) The Issuers shall give notice of any resignation and any removal of the Trustee with respect to the Notes and each appointment of a
successor Trustee in respect of the Notes to all Holders of Notes. Each notice shall include the name of the successor Trustee and the address of its Corporate Trust Office. Notwithstanding replacement of the Trustee with respect to the Notes
pursuant to this Section 10.7, the Issuers’ and the applicable Guarantor’s obligations under Section 10.6 shall continue for the benefit of the retiring Trustee. 

  
 58 

 Section 10.8. Successor Trustee by Merger 

If the Trustee consolidates with, merges or converts into, or transfers all or substantially all its corporate trust business or assets to,
another corporation, banking association or any other entity, the resulting, surviving or transferee corporation, banking association or other entity without any further act shall be the successor Trustee with the same effect as if the successor
Trustee had been named as the Trustee herein; provided that such successor Trustee shall be otherwise qualified and eligible under this ARTICLE X. 

Section 10.9. Eligibility; Disqualification 

The Trustee shall at all times be a Trustee hereunder that is a corporation organized and doing business under the laws of the United States
or of any state thereof that is authorized under such laws to exercise corporate trustee power, that is subject to supervision or examination by federal or state authorities and that has, together with parent, a combined capital and surplus of at
least $50,000,000 as set forth in its most recent published annual report of condition. 
 Section 10.10. Communications 

In no event shall the Agents or the Trustee be liable for any Losses arising in regards to receiving or transmitting any data from any Issuer,
any Authorized Person or any party to the transaction via any non-secure method of transmission or communication, such as, but without limitation, by facsimile or email. The Issuer accepts that some methods of
communication are not secure and the Agents shall incur no liability for receiving instructions via any such non-secure method. The Agents are authorized to comply with and rely upon any such notice,
instructions or other communications reasonably believed by it to have been sent or given by an Authorized Person or an appropriate party to the transaction (or authorized representative thereof). Each Issuer or Authorized Person should use all
reasonable endeavors to ensure that instructions transmitted to the Agents or the Trustee pursuant to this Indenture are complete and correct. Any instructions shall be conclusively deemed to be valid instructions from any Issuer or Authorized
Person to the Agents or the Trustee for the purposes of this Indenture. 
 Section 10.11. Resignation of Agents 

(a) Any Agent may resign its appointment hereunder at any time without the need to give any reason and without being responsible for any costs
associated therewith by giving to the appointing Issuer, the applicable Guarantor and the Trustee and (except in the case of resignation of the Principal Paying Agent) the Principal Paying Agent 30 days’ written notice to that effect
(waivable by the Issuer and the Trustee); provided that in the case of resignation of the Principal Paying Agent no such resignation shall take effect until a new Principal Paying Agent (approved in advance in writing by the Trustee) shall
have been appointed by the Issuers to exercise the powers and undertake the duties hereby conferred and imposed upon the Principal Paying Agent. Following receipt of a notice of resignation from any Agent, the Issuers shall promptly give notice
thereof to the Holders in accordance with Section 14.1. Such notice shall expire at least 30 days before or after any due date for payment in respect of the Notes. 

(b) If any Agent gives notice of its resignation in accordance with this Section 10.11 and a replacement Agent is
required and by the 10th day before the expiration of such notice such replacement has not been duly appointed, such Agent may itself appoint as its replacement 

  
 59 

 
any reputable and experienced financial institution. Immediately following such appointment, the Issuers shall give notice of such appointment to the Trustee, the remaining Agents and the
Holders, whereupon the Issuers, the Trustee, the remaining Agents and the replacement Agent shall acquire and become subject to the same rights and obligations among themselves as if they had entered into an agreement in the form mutatis mutandis
of this Indenture. 
 (c) Upon its resignation becoming effective, the Principal Paying Agent shall forthwith transfer all moneys held
by it hereunder to the successor Principal Paying Agent or, if none, the Trustee or to the Trustee’s order, but shall have no other duties or responsibilities hereunder, and shall be entitled to the payment by the Issuers of its remuneration
for the services previously rendered hereunder and to the reimbursement of all expenses (including legal fees) properly incurred in connection therewith. 

ARTICLE XI. 
 AMENDMENTS

 Section 11.1. Without Consent of Holders 

(a) If each of the Issuers and the Trustee agree, this Indenture may be amended without notifying any Holders or seeking their consent if the
amendment does not materially and adversely affect any Holder. 
 (b) Each of the Issuers may amend this Indenture without notice to or
consent of any Holder, to: 
 (i) cure any ambiguity, defect or inconsistency in this Indenture; 

(ii) comply with sections of this Indenture governing when the each of the Issuers may merge and substitute obligors; 

(iii) evidence and provide for the acceptance by a successor trustee of appointment under this Indenture with respect to the
Notes of any or all series; 
 (iv) establish the form or forms or terms of the Notes of any series or of the coupons
appertaining to such Notes as permitted under this Indenture; 
 (v) provide for uncertificated Notes in addition to or in
place of certificated Notes and to make all appropriate changes for such purpose; 
 (vi) provide for a further guarantee
from a third party on Outstanding Notes of any series and the debt securities of any series that may be issued under the Indenture; 

(vii) change or eliminate any provision of this Indenture; provided that any such change or elimination will become
effective only when there are no Outstanding Notes of any series created prior to the execution of such supplemental indenture that is entitled to the benefit of such provision; 

  
 60 

 (viii) supplement any of the provisions of this Indenture to such extent as
will be necessary to permit or facilitate the defeasance and discharge of any series of Notes pursuant to the Indenture; provided that any such action will not adversely affect the interests of the Holders in any material respect; or 

(ix) make any change that does not materially and adversely affect the rights of any Holder. 

(c) After an amendment under this Section 11.1 becomes effective, the relevant Issuer shall mail to all Holders a
notice briefly describing such amendment. The failure to give such notice to all such Holders, or any defect therein, shall not impair or affect the validity of an amendment under this Section 11.1. 

(d) Any amendment or supplement made solely to conform the provisions of this Indenture and Notes to the description of this Indenture and the
Notes contained the Offering Memorandum will be deemed not to materially or adversely affect the rights of any Holder of Notes. 
 (e) The
consent of the Holders is not necessary under this Indenture to approve the particular form of any proposed amendment. It is sufficient that such consent approves the substance of the proposed amendment. 

(f) In formulating its opinion on such matters, the Trustee shall be entitled to require and rely on such evidence as it deems appropriate,
including an Opinion of Counsel and an Officer’s Certificate. 
 Section 11.2. With Consent of Holders 

(a) The rights and obligations of each of the Issuers and the Holders under this Indenture may be modified if the Holders of a majority in
aggregate principal amount of the Outstanding Notes of each series affected by the modification consent to such modification. However, unless each affected Holder agrees, an amendment cannot: 

(i) make any adverse change to any payment term of a Note such as extending the maturity date, extending the date on which an
Issuer has to pay interest, reducing the interest rate, reducing the amount of principal an Issuer has to repay, changing the currency in which the relevant Issuer has to make any payment of principal, premium or interest, modifying any redemption
or repurchase right, or right to convert or exchange any Note, to the detriment of the relevant Holder and impairing any right of a Holder to bring suit for payment; 

(ii) change in any manner materially adverse to the interests of the Holders the terms and conditions of the obligations of any
Guarantor in respect of the due and punctual payment of the principal thereof (and premium, if any) and any interest thereon; 

(iii) waive any payment default; 

  
 61 

 (iv) reduce the percentage of the aggregate principal amount of Notes needed
to make any amendment to the Indenture or to waive any covenant or default; or 
 (v) make any other change to the amendment
provisions of the Indenture. 
 (b) It shall not be necessary for the consent of the Holders under this
Section 11.2 to approve the particular form of any proposed amendment, but it shall be sufficient if such consent approves the substance thereof. 

(c) After an amendment under this Section 11.2 becomes effective, the relevant Issuer shall mail to Holders of the
series of Notes impacted by the amendment a notice in the manner specified in Section 14.1 briefly describing such amendment. The failure to give such notice to all such Holders, or any defect therein, shall not impair or
affect the validity of an amendment under this Section 11.2. 
 Section 11.3. Revocation and Effect of
Consents and Waivers 
 (a) A consent to an amendment or a waiver by a Holder of a Note shall bind the Holder and every subsequent
Holder of that Note or portion of the Note that evidences the same debt as the consenting Holder’s Note, even if notation of the consent or waiver is not made on the Note. However, any such Holder or subsequent Holder may revoke the consent or
waiver as to such Holder’s Note or portion of the Note if the Trustee receives the notice of revocation before the date the amendment or waiver becomes effective. After an amendment or waiver becomes effective, it shall bind every Holder. An
amendment or waiver shall become effective upon receipt by the Trustee of the requisite number of written consents under Section 11.2. 

(b) Each Issuer may, but shall not be obligated to, fix a record date for the purpose of determining the Holders entitled to give their
consent or take any other action described above or required or permitted to be taken pursuant to this Indenture. If a record date is fixed, then notwithstanding the immediately preceding paragraph, those Persons who were Holders at such record date
(or their duly designated proxies), and only those Persons, shall be entitled to give such consent or to revoke any consent previously given or to take any such action, whether or not such Persons continue to be Holders after such record date. No
such consent shall become valid or effective more than 90 days after such record date. 
 Section 11.4. Notation on or Exchange
of Notes 
 If an amendment changes the terms of a Note, the Trustee may require the Holder of the Note to deliver it to the Trustee.
The Trustee may place an appropriate notation on the Note regarding the changed terms and return it to the Holder. Alternatively, if the relevant Issuer or the Trustee so determines, the relevant Issuer in exchange for the Note will execute and upon
Issuer Order the Trustee will authenticate a new Note that reflects the changed terms. Failure to make the appropriate notation or to issue a new Note shall not affect the validity of amendment made in accordance with the provisions of this
Indenture. 

  
 62 

 Section 11.5. Trustee to Sign Amendments 

The Trustee shall sign any amendment authorized pursuant to this ARTICLE XI if the amendment does not adversely affect the rights,
duties, liabilities or immunities of the Trustee. If it does, the Trustee may but need not sign it. In signing such amendment, the Trustee shall be entitled to receive indemnity and/or security reasonably satisfactory to it and to receive, and
(subject to Section 10.1 and Section 10.2) shall be fully protected in relying upon, such evidence as it deems appropriate, including, without limitation, on an Opinion of Counsel and an
Officer’s Certificate stating that such amendment is authorized or permitted by this Indenture and such amendment is the legal, valid and binding obligation of the Issuers, enforceable against it in accordance with its terms, subject to
customary exceptions. Such Opinion shall be an expense of the Issuers. 
 ARTICLE XII. 

RANKING 

Section 12.1. Ranking of U.S. Issuer Notes 

The U.S. Issuer Notes will be the unsubordinated and (other than pursuant to the Guarantees) unsecured obligations of the U.S. Issuer and will
rank at least pari passu, without any preference or priority among themselves, with all existing and future unsubordinated and unsecured obligations of the U.S. Issuer (except for obligations which may rank senior by operation of applicable
law), and senior to all existing and future subordinated obligations of the U.S. Issuer. 
 Section 12.2. Ranking of UK Issuer
Notes 
 The UK Issuer Notes will be the unsubordinated and (other than pursuant to the Guarantees) unsecured obligations of the UK
Issuer and will rank at least pari passu, without any preference or priority among themselves, with all existing and future unsubordinated and unsecured obligations of the UK Issuer (except for obligations which may rank senior by operation
of applicable law), and senior to all existing and future subordinated obligations of the UK Issuer. 
 ARTICLE XIII. 

THE GUARANTEES 

Section 13.1. The Guarantees 

(a) Prior to the Guarantee Assumption Date, the Notes will be fully and unconditionally guaranteed by GSK substantially on the terms set out
in Section 13.2 (the “GSK Guarantee”). With effect from (and including) the Guarantee Assumption Date, (i) the GSK Guarantee will be automatically and unconditionally terminated and released without
requiring any Holder consent and (ii) the Notes will be fully and unconditionally guaranteed by Haleon substantially on the terms set out in Section 13.3 (the “Haleon Guarantee”). 

  
 63 

 (b) GSK will cease to be a Guarantor with effect from (and including) the Guarantee
Assumption Date and Haleon will only be liable under the Guarantee from (and including) the Guarantee Assumption Date. With effect from (and including) the Guarantee Assumption Date any liability incurred by GSK as Guarantor prior to the Guarantee
Assumption Date will be irrevocably and unconditionally assumed by Haleon. 
 (c) GSK will deliver a Guarantee Assumption Notice or Demerger
Completion Notice, as applicable, to the Trustee and the Holders promptly following the occurrence of the Guarantee Assumption Date or the Demerger, respectively. 

(d) If, for any reason, while the GSK Guarantee is in place, (A) the U.S. Issuer does not make any required payment in respect of the
U.S. Issuer Notes when due, or (B) the UK Issuer does not make any required payment in respect of the UK Issuer Notes when due, whether on the normal due date, on acceleration, redemption or otherwise, GSK will cause the payment to be made to
or to the order of the Trustee. Holders of the relevant series of Notes that have not received the required payment from the relevant Issuer will be entitled to payment under the GSK Guarantee without taking any action whatsoever against the
relevant Issuer. If, for any reason, while the Haleon Guarantee is in place, (A) the U.S. Issuer does not make any required payment in respect of the U.S. Issuer Notes when due, or (B) the UK Issuer does not make any required payment in
respect of the UK Issuer Notes when due, whether on the normal due date, on acceleration, redemption or otherwise, Haleon will cause the payment to be made to or to the order of the Trustee. Holders of the relevant series of Notes that have not
received the required payment from the relevant Issuer will be entitled to payment under the Haleon Guarantee without taking any action whatsoever against the relevant Issuer. 

(e) For the avoidance of doubt, the Notes will not be guaranteed by any other Subsidiary of GSK or Haleon and the obligations under the
Guarantees will effectively be junior to obligations of any other Subsidiary of GSK or Haleon, as applicable. 
 Section 13.2. The
GSK Guarantee 
 GSK by its execution of this Indenture hereby agrees with each Holder of the Notes authenticated and delivered by the
Trustee, and with the Trustee, on behalf of each such Holder, to be unconditionally bound by the terms and provisions of the GSK Guarantee with respect to the Notes prior to the Guarantee Assumption Date and authorizes the Trustee to confirm such
GSK Guarantee to the Holder of each such Note by its execution and delivery of each such Note, with such GSK Guarantee endorsed thereon, authenticated and delivered by the Trustee. 

  
 64 

 The GSK Guarantee to be endorsed on the Notes shall be in substantially the form set forth
below: 
 “GUARANTEE 
 OF

 GLAXOSMITHKLINE PLC 
 For
value received, GlaxoSmithKline plc, a public limited company incorporated under the laws of England and Wales, having its principal executive offices at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “GSK
Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this GSK Guarantee is endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which
this GSK Guarantee is endorsed and to the Trustee on behalf of each such Holder prior to the date on which GSK ceases to hold a direct or indirect interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than
as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee Assumption Date”) the due payment of all principal of and other amounts on, each Note payable by the Issuer
under this Indenture. In case of the failure of GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer,” which term includes any successor Person under such
Indenture), to punctually make any such payment or satisfy any such obligation in respect of the U.S. Issuer Notes, or the failure of GSK Consumer Healthcare Capital UK plc, a public limited company incorporated under the laws of England and Wales
(the “UK Issuer,” which term includes any successor Person under such Indenture), to punctually make any such payment or satisfy any such obligation in respect of the UK Issuer Notes, in each case prior to the Guarantee Assumption
Date, the GSK Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date or by declaration of
acceleration, call for redemption or otherwise, and as if such payment were made by the relevant Issuer. 
 The indebtedness evidenced by
this GSK Guarantee constitutes an unsubordinated and unsecured obligation of the GSK Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the GSK Guarantor (except for obligations which
may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the GSK Guarantor. 
 The
GSK Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be unaffected by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the
provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the Issuer with respect thereto, by the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable
discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or indulgence shall, without the consent of the GSK Guarantor, increase the principal of such Note, or increase the amounts due in
respect of the Notes, or alter the stated maturity date thereof. The GSK Guarantor hereby 

  
 65 

 
waives diligence, presentment, demand of payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer or UK Issuer, as applicable, any right to require a
proceeding first against the U.S. Issuer or UK Issuer, as applicable, protest or notice with respect to such Note or the indebtedness evidenced thereby or with respect to any sinking fund or analogous payment required under such Note and all demands
whatsoever, and covenants that this GSK Guarantee will not be discharged except by payment or satisfaction in full of the principal of and Additional Amounts, if any, payable in respect of such Note. This GSK Guarantee is a guarantee of payment and
not of collection. 
 The GSK Guarantor shall be subrogated to all rights of the Holder of such Note and the Trustee against the U.S. Issuer
or UK Issuer, as applicable, in respect of any amounts paid to such Holder by the GSK Guarantor pursuant to the provisions of this GSK Guarantee; provided, however, that the GSK Guarantor shall not be entitled to enforce, or to receive any
payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the GSK Guarantor, which are
absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this GSK Guarantee is endorsed. 

This GSK Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this GSK Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This GSK Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 
 IN WITNESS WHEREOF, the GSK Guarantor has caused this GSK Guarantee to be duly executed
this 24th day of March 2022. 
  

			
	 GLAXOSMITHKLINE PLC,
 as the GSK
Guarantor

		
	By:	 	 
		 	Name:
		 	Title:
		
	By:	 	 
		 	Name:
		 	Title:

  
 66 

 Section 13.3. The Haleon Guarantee 

Haleon by its execution of this Indenture hereby agrees with each Holder of the Notes authenticated and delivered by the Trustee, and with the
Trustee, on behalf of each such Holder, to be unconditionally bound by the terms and provisions of the Haleon Guarantee with respect to the Notes on and from the Guarantee Assumption Date and authorizes the Trustee to confirm such Haleon Guarantee
to the Holder of each such Note by its execution and delivery of each such Note, with such Haleon Guarantee endorsed thereon, authenticated and delivered by the Trustee. 

The Haleon Guarantee to be endorsed on the Notes shall be in substantially the form set forth below: 

“GUARANTEE 
 OF 

HALEON 
 For value received,
Haleon, a public limited company incorporated under the laws of England and Wales, having its principal executive offices at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “Haleon Guarantor,” which term includes any
Person as a successor Guarantor under the Indenture referred to in the Note upon which this Haleon Guarantee is endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this Haleon Guarantee is endorsed and to the
Trustee on behalf of each such Holder from (and including) the date on which GSK ceases to hold a direct or indirect interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it
may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee Assumption Date”) the due payment of all principal of and other amounts on, each Note payable by the Issuer under this Indenture. In case of
the failure of GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer,” which term includes any successor Person under such Indenture), to punctually make any such
payment or satisfy any such obligation in respect of the U.S. Issuer Notes, or the failure of GSK Consumer Healthcare Capital UK plc, a public limited company incorporated under the laws of England and Wales (the “UK Issuer,” which
term includes any successor Person under such Indenture), to punctually make any such payment or satisfy any such obligation in respect of the UK Issuer Notes, in each case from (and including) the Guarantee Assumption Date, the Haleon Guarantor
hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date or by declaration of acceleration, call for
redemption or otherwise, and as if such payment were made by the relevant Issuer. 
 The indebtedness evidenced by this Haleon Guarantee
constitutes an unsubordinated and unsecured obligation of the Haleon Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the Haleon Guarantor (except for obligations which may rank
senior by operation of applicable law) and senior to all existing and future subordinated obligations of the Haleon Guarantor. 

  
 67 

 The Haleon Guarantor hereby agrees that its obligations hereunder shall be absolute and
unconditional, irrespective of, and shall be unaffected by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or
indulgence granted to the Issuer with respect thereto, by the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding
the foregoing, no such waiver, modification or indulgence shall, without the consent of the Haleon Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The
Haleon Guarantor hereby waives diligence, presentment, demand of payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer or UK Issuer, as applicable, any right to require a proceeding first against the U.S.
Issuer or UK Issuer, as applicable, protest or notice with respect to such Note or the indebtedness evidenced thereby or with respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that
this Haleon Guarantee will not be discharged except by payment or satisfaction in full of the principal of and Additional Amounts, if any, payable in respect of such Note. This Haleon Guarantee is a guarantee of payment and not of collection. 

The Haleon Guarantor shall be subrogated to all rights of the Holder of such Note and the Trustee against the U.S. Issuer or UK Issuer, as
applicable, in respect of any amounts paid to such Holder by the Haleon Guarantor pursuant to the provisions of this Haleon Guarantee; provided, however, that the Haleon Guarantor shall not be entitled to enforce, or to receive any payments
arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the Haleon Guarantor, which
are absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this Haleon Guarantee is endorsed. 

This Haleon Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this Haleon Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This Haleon Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 68 

 IN WITNESS WHEREOF, the Haleon Guarantor has caused this Haleon Guarantee to be duly executed this 24th day of March 2022. 
  

			
	 HALEON PLC,
 as the Haleon
Guarantor

		
	By:	 	 
		 	Name:
		 	Title:
		
	By:	 	 
		 	Name:
		 	Title:
		 	

 ARTICLE XIV. 

MISCELLANEOUS 

Section 14.1. Notices 

(a) Any notice or communication shall be in writing, in English, and delivered in person or sent by first-class mail, telex, facsimile
transmission or email directed as follows: 
 if to the UK Issuer: 

GSK Consumer Healthcare Capital UK plc 

980 Great West Road, 

Brentford, Middlesex, 
 TW8 9GS,
England 
 Attention: Timothy Woodthorpe (Group Treasurer) 

E-mail: cf.treasury@gsk.com 

if to the U.S. Issuer: 
 GSK
Consumer Healthcare Capital US LLC 
 184 Liberty Corner Road, Suite 200 

Warren NJ 07059 
 United States

 Attention: Timothy Woodthorpe (Group Treasurer) 

E-mail: cf.treasury@gsk.com 

Copy: Justin T. Huang (VP and Secretary), Charles David Simpson (VP 

and Treasurer) and Hatixhe Hoxha (Assistant Secretary) 

Email: US.CorpSec@gsk.com 
 if to
the GSK Guarantor: 
 GlaxoSmithKline plc 

980 Great West Road, 

Brentford, Middlesex, 
 TW8 9GS,
England 
 Attention: Victoria Whyte 

E-mail: company.secretary@gsk.com 

  
 69 

 if to the Haleon Guarantor: 

Haleon 
 980 Great West Road,

 Brentford, Middlesex, 
 TW8
9GS, England 
 Attention: Timothy Woodthorpe (Group Treasurer) 

E-mail: cf.treasury@gsk.com 

Copy: Victoria Whyte 
 Email:
victoria.a.whyte@gsk.com 
 if to the Trustee, the Principal Paying Agent, the Principal Calculating Agent or the Registrar: 

Deutsche Bank Trust Company Americas 

1 Columbus Circle 
 Trust and
Agency Services 
 Mail Stop NYC01-1710 

17th Floor, New York, NY, 10019 

Facsimile: +1 732-578-4635 

Attention: Corporates Team, GSK Consumer Healthcare, SF6791 

The Issuers, the Guarantors or the Trustee by notice to the others may designate additional or different addresses for subsequent notices or
communications. 
 (b) Notices to Holders will be mailed to them at their respective addresses in the register of Notes. So long as and to
the extent that the Notes are represented by Global Notes and such Global Notes are held by the Depositary or its nominee or a custodian therefor, notices to owners of beneficial interests in the Global Notes may be given by delivery of the relevant
notice to the Depositary for communication by it to entitled account holders. 
 (c) Failure to mail a notice or communication to a Holder
or any defect in it shall not affect its sufficiency with respect to other Holders. If a notice or communication is mailed in the manner provided above, it is duly given, whether or not the addressee receives it. 

(d) Any notice or communication delivered to an Issuer under the provisions herein shall constitute notice to the Guarantor. 

  
 70 

 Section 14.2. Certificate and Opinion as to Conditions Precedent 

(a) Upon any request or application by an Issuer to the Trustee to take or refrain from taking any action under this Indenture, the relevant
Issuer shall furnish to the Trustee: 
 (i) an Officer’s Certificate stating that, in the opinion of the signers, all
conditions precedent, if any, provided for in this Indenture relating to the proposed action have been complied with; and 

(ii) an Opinion of Counsel stating that, in the opinion of such counsel, all such conditions precedent have been complied with.

 (b) If an Issuer Order pursuant to Section 2.2 of this Indenture has been, or simultaneously is, delivered, any
instructions by the relevant Issuer to the Trustee with respect to endorsement, delivery or redelivery of a Note issued in global form shall be in writing but need not comply with Section 14.1(a) and need not be accompanied
by an Opinion of Counsel. 
 Section 14.3. Statements Required in Certificate or Opinion 

Each certificate or opinion with respect to compliance with a covenant or condition provided for in this Indenture shall include: 

(i) a statement that each person signing such certificate or opinion has read such covenant or condition and the definitions
relating thereto; 
 (ii) a brief statement as to the nature and scope of the examination or investigation upon which the
statements or opinions contained in such certificate or opinion are based; 
 (iii) a statement that, in the opinion of each
such person, he has made such examination or investigation as is necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been complied with; and 

(iv) a statement as to whether or not, in the opinion of each such person, such covenant or condition has been complied with;
provided, however, that, with respect to matters of fact, an Opinion of Counsel may rely on an Officer’s Certificate or certificates of public officials. 

Section 14.4. Rules by Trustee, Paying Agent and Registrar 

The Trustee may make reasonable rules for action by, or a meeting of, Holders, provided that such rules do not conflict with or
contradict the provisions of ARTICLE XIV hereof. The Registrar and the Paying Agent may make reasonable rules for their functions. 

  
 71 

 Section 14.5. Payment Date Other Than a Business Day 

If the Maturity Date, the stated maturity for any other payments due or the due date for any delivery of any amounts due upon exchange under
the Notes or this Indenture is not a Business Day, then payment of principal of, or other amounts on, and delivery of such amounts due on such Note, as the case may be, need not be made on such date, but may be made on the next succeeding Business
Day with the same force and effect as if made on at the Maturity Date or the stated maturity for any other payments or the due date for any delivery due under the Notes or this Indenture; provided that no interest shall accrue for the period
beginning and including such Maturity Date, maturity for any other payments due or the due date for any delivery under the Notes or this Indenture, as the case may be. 

Section 14.6. Governing Law, Etc. 

(a) THIS INDENTURE, THE GUARANTEE AND THE NOTES SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. THE
PARTIES HERETO EACH HEREBY WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS INDENTURE, THE GUARANTEE OR THE NOTES OR ANY TRANSACTION RELATED HERETO OR THERETO. 

(b) Each of the Issuers and the Guarantors hereby: 

(i) agrees that any suit, action or proceeding against it arising out of or relating to this Indenture or the Notes, as the
case may be, may be instituted in any Federal or state court sitting in The City of New York, 
 (ii) waives to the extent
permitted by applicable law, any objection which it may now or hereafter have to the laying of venue of any such suit, action or proceeding, and any claim that any suit, action or proceeding in such a court has been brought in an inconvenient forum,

 (iii) irrevocably submits to the non-exclusive jurisdiction of such courts in any
suit, action or proceeding, 
 (iv) agrees that final judgment in any such suit, action or proceeding brought in such a court
shall be conclusive and binding may be enforced in the courts of the jurisdiction of which it is subject by a suit upon judgment, and 

(v) agrees that service of process by mail to the addressed specified herein shall constitute personal service of such process
on it in any such suit, action or proceeding. 
 (c) The UK Issuer and each Guarantor have appointed the U.S. Issuer as the authorized agent
(the “Authorized Agent”) thereof for service of process in any action arising out of or based on the Notes, this Indenture, or the Guarantees, as the case may be (including any action based on or arising out of U.S. federal
securities laws) that may be instituted in a court of competent jurisdiction located in the State of New York. The UK Issuer and the Guarantors hereby represent and warrant that the Authorized Agent has accepted such appointment and has agreed to
act as said agent for service of process, and the UK Issuer and the Guarantors agree to take any and all action, including the filing of any and all documents, that may be necessary to continue each such appointment in full force and effect as
aforesaid so long as the Notes remain 

  
 72 

 
Outstanding. The UK Issuer and the Guarantors agree that the appointment of the Authorized Agent shall be irrevocable so long as any of the Notes remain Outstanding or until the irrevocable
appointment by the UK Issuer and the Guarantors of a successor agent in The City of New York, New York as each of their authorized agent for such purpose and the acceptance of such appointment by such successor. Service of process upon the
Authorized Agent shall be deemed, in every respect, effective service of process upon the UK Issuer and the Guarantors. 
 (d) To the extent
that any of the Issuers or the Guarantors have or hereafter may acquire any immunity (sovereign or otherwise) from any legal action, suit or proceeding, from jurisdiction of any court or from set-off or any
legal process (whether service or notice, attachment in aid or otherwise) with respect to itself or any of its property, the Issuers and the Guarantors hereby irrevocably waive and agree not to plead or claim such immunity in respect of their
obligations under this Indenture or the Notes. 
 (e) Nothing in this Section 14.6 shall affect the right of the
Trustee or any Holder of the Notes to serve process in any other manner permitted by law. 
 Section 14.7. No Recourse Against
Others 
 No recourse for the payment of the principal of or other amounts on any of the Notes or for any claim based thereon or
otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of each Issuer or each Guarantor in this Indenture, or in any of the Notes, or because of the creation of any indebtedness represented thereby, shall
be had against any incorporator, limited partner, stockholder, officer, director, employee or controlling person of each Issuer (other than GSK under the GSK Guarantee and Haleon under the Haleon Guarantee) or the Guarantors or of any successor
Persons thereof. Each Holder, by accepting the Notes, waives and releases all such liability. The waiver and release are part of the consideration for the issuance of the Notes. Such waiver may not be effective to waive liabilities under
U.S. federal securities laws. 
 Section 14.8. Successors 

All agreements of each Issuer and each Guarantor in this Indenture and the Notes shall bind their respective successors. All agreements of the
Trustee in this Indenture shall bind its successors. 
 Section 14.9. Duplicate and Counterpart Originals 

The parties may sign any number of copies of this Indenture. One signed copy is enough to prove this Indenture. This Indenture may be executed
in any number of counterparts, each of which so executed shall be an original, but all of them together represent the same agreement. 

Section 14.10. Severability 

In case any provision in this Indenture or in the Notes shall be invalid, illegal or unenforceable, the validity, legality and enforceability
of the remaining provisions shall not in any way be affected or impaired thereby. 

  
 73 

 Section 14.11. Judgment Currency 

Each Issuer and each Guarantor severally agree, to the fullest extent that they may effectively do so under applicable law, that (a) if
for the purpose of obtaining judgment in any court it is necessary to convert the sum due in U.S. dollars in respect of the principal of the Notes (the “Required Currency”) into a currency in which a judgment will be rendered (the
“Judgment Currency”), the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase in The City of New York the Required Currency with the Judgment Currency on the day
on which final unappealable judgment is entered, unless such day is not a Business Day in The City of New York, then, to the extent permitted by applicable law, the rate of exchange used shall be the rate at which in accordance with normal banking
procedures the Trustee could purchase in The City of New York the Required Currency with the Judgment Currency on the Business Day in The City of New York preceding the day on which a final unappealable judgment is entered and (b) their
obligations under this Indenture to make payments in the Required Currency (i) shall not be discharged or satisfied by any tender, or any recovery pursuant to any judgment (whether or not entered in accordance with subsection (a)), in any
currency other than the Required Currency, except to the extent that such tender or recovery shall result in the actual receipt, by the payee, of the full amount of the Required Currency expressed to be payable in respect of such payments,
(ii) shall be enforceable as an alternative or additional cause of action for the purpose of recovering in the Required Currency the amount, if any, by which such actual receipt shall fall short of the full amount of the Required Currency so
expressed to be payable and (iii) shall not be affected by judgment being obtained for any other sum due under this Indenture. 

Section 14.12. USA Patriot Act 

The parties hereto acknowledge that, in accordance with Section 326 of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (as amended, modified or supplemented from time to time, the “USA Patriot Act”), the Trustee, like all financial institutions, is required to obtain,
verify, record and update information that identifies each person or legal entity that opens an account. The parties to this Indenture agree that they will provide the Trustee with such information as the Trustee may request in order for the Trustee
to satisfy the requirements of the USA Patriot Act. 
 Section 14.13. No Personal Liability of Incorporators, Stockholders,
Officers, Directors or Employees 
 No recourse for the payment of the principal of or other amounts on any of the Notes or for any
claim based thereon or otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the relevant Issuer or the applicable Guarantor in this Indenture, or in any of the Notes, or because of the creation of any
indebtedness represented thereby, shall be had against any incorporator, limited partner, stockholder, officer, director, employee or controlling person of the relevant Issuer or the applicable Guarantor or of any successor persons thereof. Each
Holder, by accepting the Notes, waives and releases all such liability. The waiver and release are part of the consideration for the issuance of the Notes. Such waiver may not be effective to waive liabilities under United States federal securities
laws. 

  
 74 

 Section 14.14. Table of Contents; Headings 

The table of contents and headings of the Articles and Sections of this Indenture have been inserted for convenience of reference only, are
not intended to be considered a part hereof and shall not modify or restrict any of the terms or provisions hereof. 
 Section 14.15.
Force Majeure 
 In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its
obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural
catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Trustee shall use reasonable efforts which are consistent with accepted
practices in the banking industry to resume performance as soon as practicable under the circumstances. 

  
 75 

 IN WITNESS WHEREOF, the parties have caused this Indenture to be duly executed as of the
date first written above. 
  

			
	 GSK CONSUMER HEALTHCARE CAPITAL US LLC,

as U.S. Issuer,

		
	By:	 	/s/ Hatixhe Hoxha
		 	Name: Hatixhe Hoxha
		 	Title: Assistant Secretary
	
	 GSK CONSUMER HEALTHCARE CAPITAL UK PLC,

as UK Issuer,

		
	By:	 	/s/ Michael John Rowe
		 	Name: Michael John Rowe
		 	Title: Head of Treasury Consumer Healthcare
	
	GLAXOSMITHKLINE PLC, as Guarantor
		
	By:	 	/s/ Jemma Reynolds
		 	Name: Jemma Reynolds
		 	Title: VP, Corporate Finance
		
	By:	 	/s/ Tim Woodthorpe
		 	Name: Tim Woodthorpe
		 	Title: Group Treasurer

  
 76 

 
			
	HALEON PLC, as Guarantor
		
	By:	 	/s/ Michael John Rowe
		 	Name: Michael John Rowe
		 	Title: Head of Treasury Consumer Healthcare
		
	By:	 	/s/ Jemma Reynolds
		 	Name: Jemma Reynolds
		 	Title: Authorised Signatory

  
 77 

 
			
	 DEUTSCHE BANK TRUST COMPANY AMERICAS,

as Trustee, Principal Paying Agent, Transfer Agent and Registrar

		
	By:	 	/s/ Rodney Gaughan
		 	Name: Rodney Gaughan
		 	Title: Vice President
		
	By:	 	/s/ Irina Golovashchuk
		 	Name: Irina Golovashchuk
		 	Title: Vice President

  
 78 

 EXHIBIT A 

FORM OF 2025 FIXED RATE GLOBAL NOTE 

[Include the following legend for all Rule 144A Global Notes:] 

THIS NOTE AND THE GUARANTEES OF THIS NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND
INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR
BENEFIT OF, U.S. PERSONS EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, THE HOLDER (A) REPRESENTS, WARRANTS, ACKNOWLEDGES AND AGREES FOR THE BENEFIT OF THE ISSUER, THE GUARANTORS AND THE TRUSTEE THAT IT IS A
‘‘QUALIFIED INSTITUTIONAL BUYER’’ (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) PURCHASING THE SECURITIES FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS; (B) AGREES THAT IT WILL NOT
RESELL OR OTHERWISE TRANSFER THE SECURITIES OTHER THAN (1) TO THE ISSUER, (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, (3) IN THE UNITED STATES TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS A
QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A, OR
(4) IN AN OFFSHORE TRANSACTION TO A NON-U.S. PERSON IN COMPLIANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS OF THE
STATES OF THE UNITED STATES AND ANY OTHER JURISDICTION; AND (C) AGREES THAT IT WILL DELIVER TO EACH PERSON TO WHOM THIS NOTE IS TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. 

[Include the following legend for all Regulation S Global Notes:] 

THIS NOTE AND THE GUARANTEES OF THE NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND
INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE 

  
 A-1 

 
OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT OR PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT. UNTIL THE EXPIRY OF THE PERIOD OF 40 DAYS AFTER THE LATER OF (i) THE DATE ON WHICH THE OFFERING OF THIS NOTE TO
PERSONS OTHER THAN THE DISTRIBUTORS IN RELIANCE ON REGULATION S COMMENCED AND (ii) THE DATE OF ISSUANCE OF SUCH NOTE, SALES MAY NOT BE MADE IN THE UNITED STATES OR TO U.S. PERSONS UNLESS MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED IN, AND
IN TRANSACTIONS PURSUANT TO, RULE 144A UNDER THE SECURITIES ACT. 

  
 A-2 

 [FORM OF FACE OF 2025 FIXED RATE GLOBAL NOTE] 

GSK Consumer Healthcare Capital UK plc 

3.125% Fixed Rate Senior Note due 2025 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from and
including the Guarantee Assumption Date) 
 [Include the following for all Rule 144A Global Notes:] 

CUSIP No. (144A): 36264NAA2 
 ISIN
(144A): US36264NAA28 
 Common Code (144A): 246354308 

No.: 
 [Include the following
for all Regulation S Global Notes:] 
 CUSIP No. (Regulation S): G4164DAA6 

ISIN (Regulation S): USG4164DAA66 

Common Code (Regulation S): 246354189 

No.: 
  

							
		  		  		  	 Principal Amount $
  

as revised by Schedule A
 attached

hereto of Increases and
 Decreases in this 2025 Fixed

Rate Global Note

 This is to certify that CEDE & CO. is, as of the date hereof, the registered holder (the
“Holder”) of $                         of 3.125% Fixed Rate Senior Notes due 2025 represented by
this Global Note. GSK Consumer Healthcare Capital UK plc, a public limited company incorporated under the laws of England and Wales, promises to pay to the Holder, or registered assigns, the principal sum of
$                         as revised by the Schedule of Increases and Decreases in 2025 Fixed Rate Global Note attached
hereto, on March 24, 2025. 
 In the event of a redemption or cancellation of the 2025 Fixed Rate Notes in part only, the 2025 Fixed
Rate Notes evidenced by this 2025 Fixed Rate Global Note shall be reduced by the principal amount so redeemed or cancelled. Thereafter, the 2025 Fixed Rate Notes represented by this 2025 Fixed Rate Global Note shall be the principal amount of 2025
Fixed Rate Notes most recently entered by or on behalf of the Issuer in the relevant column in Schedule A attached hereto. 

  
 A-3 

 Reference is hereby made to the further provisions of this 2025 Fixed Rate Note as set forth
on the reverse hereof, which provisions shall for all purposes have the same effect as if set forth at this place. 
  

			
	GSK CONSUMER HEALTHCARE CAPITAL UK PLC
		
	By:	 	 
		 	Name:
		 	Title:

			
	 TRUSTEE’S CERTIFICATE OF AUTHENTICATION
	  	
		  	
	 Deutsche Bank Trust Company Americas,

as Trustee, certifies

that this is one of

the 2025 Fixed Rate Notes referred

to in the Indenture
	  	

  

			
	 By:
                                         
                   
	  	
	                Authorized Signatory	  	 Date:
                                         
               

  
 A-4 

 GUARANTEE OF GLAXOSMITHKLINE PLC 

For value received, GlaxoSmithKline plc, a public limited company incorporated under the laws of England and Wales, having its principal
executive offices at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “GSK Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this GSK Guarantee
is endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this GSK Guarantee is endorsed and to the Trustee on behalf of each such Holder prior to the date on which GSK ceases to hold a direct or indirect
interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee Assumption
Date”) the due payment of all principal of and other amounts on, each Note payable by GSK Consumer Healthcare Capital UK plc, a public limited company incorporated under the laws of England and Wales (the “UK Issuer”, which
term includes any successor Person under the Indenture) under the Indenture. In case of the failure of the UK Issuer to punctually make any such payment or satisfy any such obligation in respect of the UK Issuer Notes prior to the Guarantee
Assumption Date, the GSK Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date or by
declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the UK Issuer. 
 The indebtedness
evidenced by this GSK Guarantee constitutes an unsubordinated and unsecured obligation of the GSK Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the GSK Guarantor (except for
obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the GSK Guarantor. 

The GSK Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be unaffected
by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the UK Issuer with respect thereto, by
the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or indulgence
shall, without the consent of the GSK Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The GSK Guarantor hereby waives diligence, presentment, demand of
payment, filing of claims with a court in the event of merger or bankruptcy of the UK Issuer, any right to require a proceeding first against the UK Issuer, protest or notice with respect to such Note or the indebtedness evidenced thereby or with
respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this GSK Guarantee will not be discharged except by payment or satisfaction in full of the principal of and Additional Amounts,
if any, payable in respect of such Note. This GSK Guarantee is a guarantee of payment and not of collection. 

  
 A-5 

 The GSK Guarantor shall be subrogated to all rights of the Holder of such Note and the
Trustee against the UK Issuer in respect of any amounts paid to such Holder by the GSK Guarantor pursuant to the provisions of this GSK Guarantee; provided, however, that the GSK Guarantor shall not be entitled to enforce, or to receive any
payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the GSK Guarantor, which are
absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this GSK Guarantee is endorsed. 

This GSK Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this GSK Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This GSK Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 A-6 

 IN WITNESS WHEREOF, the GSK Guarantor has caused this GSK Guarantee to be duly executed this 24th day of March 2022.      
  

			
	 GLAXOSMITHKLINE PLC, as the GSK Guarantor

		
	 By:
	 	 
		 	 Name:

		 	 Title:

		
	 By:
	 	 
		 	 Name:

		 	 Title:

  
 A-7 

 GUARANTEE OF HALEON 

For value received, Haleon, a public limited company incorporated under the laws of England and Wales, having its principal executive offices
at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “Haleon Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this Haleon Guarantee is
endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this Haleon Guarantee is endorsed and to the Trustee on behalf of each such Holder from (and including) the date on which GSK ceases to hold a direct or
indirect interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee
Assumption Date”) the due payment of all principal of and other amounts on, each Note payable by GSK Consumer Healthcare Capital UK plc, a public limited company incorporated under the laws of England and Wales (the “UK
Issuer”, which term includes any successor Person under the Indenture) under the Indenture. In case of the failure of the UK Issuer, to punctually make any such payment or satisfy any such obligation in respect of the UK Issuer Notes from
(and including) the Guarantee Assumption Date, the Haleon Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the
stated maturity date or by declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the UK Issuer. 

The indebtedness evidenced by this Haleon Guarantee constitutes an unsubordinated and unsecured obligation of the Haleon Guarantor and ranks
equally and pari passu with all existing and future senior and unsecured obligations of the Haleon Guarantor (except for obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated
obligations of the Haleon Guarantor. 
 The Haleon Guarantor hereby agrees that its obligations hereunder shall be absolute and
unconditional, irrespective of, and shall be unaffected by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or
indulgence granted to the UK Issuer with respect thereto, by the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that,
notwithstanding the foregoing, no such waiver, modification or indulgence shall, without the consent of the Haleon Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date
thereof. The Haleon Guarantor hereby waives diligence, presentment, demand of payment, filing of claims with a court in the event of merger or bankruptcy of the UK Issuer, any right to require a proceeding first against the UK Issuer, protest or
notice with respect to such Note or the indebtedness evidenced thereby or with respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this Haleon Guarantee will not be discharged
except by payment or satisfaction in full of the principal of and Additional Amounts, if any, payable in respect of such Note. This Haleon Guarantee is a guarantee of payment and not of collection. 

  
 A-8 

 The Haleon Guarantor shall be subrogated to all rights of the Holder of such Note and the
Trustee against the UK Issuer in respect of any amounts paid to such Holder by the Haleon Guarantor pursuant to the provisions of this Haleon Guarantee; provided, however, that the Haleon Guarantor shall not be entitled to enforce, or to
receive any payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the Haleon Guarantor, which
are absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this Haleon Guarantee is endorsed. 

This Haleon Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this Haleon Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This Haleon Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 A-9 

 IN WITNESS WHEREOF, the Haleon Guarantor has caused this Haleon Guarantee to be duly executed this 24th day of March 2022. 
  

			
	 HALEON PLC, as the Haleon Guarantor

		
	 By:
	 	 
		 	 Name:

		 	 Title:

		
	 By:
	 	 
		 	 Name:

		 	 Title:

  
 A-10 

 [REVERSE SIDE OF NOTE] 

GSK Consumer Healthcare Capital UK plc 

3.125% Fixed Rate Senior Note due 2025 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from
and including the Guarantee Assumption Date) 
  

	1.	 Interest 

Interest on the 2025 Fixed Rate Notes will be payable at a rate of 3.125% per annum. 

Interest on the 2025 Fixed Rate Notes will be payable semi-annually in arrear on 24 March and 24 September of each year, commencing
on September 24, 2022 (each a “Fixed Rate Notes Interest Payment Date”) to the person in whose name this 2025 Fixed Rate Note is registered at the close of business on the Regular Record Date that precedes the applicable Fixed
Rate Notes Interest Payment Date. 
 The 2025 Fixed Rate Notes will accrue interest from (and including) the Issue Date, or from the most
recent Fixed Rate Notes Interest Payment Date, to (but excluding) the next succeeding Fixed Rate Notes Interest Payment Date. Interest on the 2025 Fixed Rate Notes will be paid on the basis of twelve 30-day
months assuming a 360-day year. 
  

	2.	 Method of Payment 

Not later than 11:00am New York City time on the due date for any payment due in respect of the 2025 Fixed Rate Notes and on the 2025 Fixed
Rate Notes Maturity Date, GSK Consumer Healthcare Capital UK plc (the “Issuer”) shall deposit with the relevant Paying Agent in same day immediately available funds an amount sufficient to make cash payments due on such due date of
payments of any other amounts or the Maturity Date, as the case may be. Holders must surrender 2025 Fixed Rate Notes to a Paying Agent to collect principal payments. The Issuer shall pay principal and other amounts in cash in U.S. dollars. 

Payments in respect of 2025 Fixed Rate Notes represented by a Global Note (including principal and other amounts) shall be made by the
transfer of immediately available funds to the accounts specified by the Depositary. The Issuer shall make all payments in respect of a Certificated Note (including principal and other amounts) by wire transfer to the specified account maintained by
the payee by giving written notice to the Trustee or the Paying Agent to such effect designating such account no later than 15 days immediately preceding the relevant due date for payment (or such other date as the Trustee may accept in its
discretion). 

  
 A-11 

	3.	 Paying Agent, Transfer Agent, Calculation Agent and Registrar 

Initially, Deutsche Bank Trust Company Americas (the “Trustee”) shall act as Trustee, Principal Paying Agent, Transfer Agent,
calculation agent and as Registrar. The Issuer may appoint and change any Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar without notice to any Holder. The Issuer or the
applicable Guarantor may act as Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar. 
  

	4.	 Indenture 

The Issuer issued the 2025 Fixed Rate Notes under an Indenture, dated as of March 24, 2022 (as it may be amended or supplemented from time
to time in accordance with the terms thereof, the “Indenture”), among the Issuers, the Guarantors, the Trustee, the Principal Paying Agent, the Transfer Agent and the Registrar. The terms of the 2025 Fixed Rate Notes include those
stated in the Indenture. Capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Indenture. The 2025 Fixed Rate Notes are subject to all such terms, and Holders are referred to the Indenture for a statement of
those terms. Each Holder by accepting a 2025 Fixed Rate Note agrees to be bound by all of the terms and provisions of the Indenture, as amended from time to time. 

The 2025 Fixed Rate Notes are general unsecured obligations of the Issuer limited to
$                             aggregate principal amount. 

Prior to the Guarantee Assumption Date, the 2025 Fixed Rate Notes are unconditionally and irrevocably guaranteed by the GSK Guarantor under
the GSK Guarantee. With effect from (and including) the Guarantee Assumption Date, the 2025 Fixed Rate Notes are unconditionally and irrevocably guaranteed by the Haleon Guarantor under the Haleon Guarantee, in each case for the benefit of the
Holders pursuant to the Indenture. 
  

	5.	 Redemption 

Unless earlier redeemed, purchased or cancelled as provided in the Indenture, the Notes will be redeemed by the Issuer at their principal
amount on March 24, 2025. 
 5.1 Optional Redemption for Tax Reasons  

The Issuer may redeem the 2025 Fixed Rate Notes in whole but not in part at any time prior to maturity, at a redemption price equal to 100% of
their principal amount plus accrued interest to the date fixed for redemption, if: 
 (a) the Issuer determines that, as a result of any
change in or amendment to the laws or any regulations or rulings promulgated thereunder of the United Kingdom or the United States, or any change in the application or official interpretation of such laws, regulations or rulings, or any change in
the application or official interpretation of, or any execution of or amendment to, any treaty or treaties affecting taxation to which any such jurisdiction is a party, which change, execution or amendment becomes effective on or after the Issue
Date: (i) the Issuer would be required to pay Additional Amounts on the 2025 Fixed Rate Notes on the next succeeding Interest Payment Date and the payment of such additional amounts cannot be avoided by the use of reasonable measures available
to the Issuer or the applicable Guarantor; or (ii) withholding tax has been or would be required to be withheld with respect to interest income received or receivable by the Issuer directly from the applicable Guarantor (or any Affiliate) and
such withholding tax obligation cannot be avoided by the use of reasonable measures available to the Issuer or the applicable Guarantor (or any Affiliate); or 

  
 A-12 

 (b) the Issuer determines, based upon an opinion of independent counsel of recognised
standing that, as a result of any action taken by any legislative body of, taxing authority of, or any action brought in a court of competent jurisdiction in, the United Kingdom or the United States, which action is taken or brought on after the
Issue Date, there is a substantial probability that the circumstances described above would exist; provided, however, that no such notice of redemption may be given earlier than 90 days prior to the earliest date on which the Issuer
would be obligated to pay such Additional Amounts. 
 5.2 Make-Whole Redemption 

At any time prior to the 2025 Fixed Rate Notes Maturity Date, the Issuer may redeem the 2025 Fixed Rate Notes, in whole or in part, at their
option at any time and from time to time at a redemption price equal to the greater of (i) 100% of the principal amount of the 2025 Fixed Rate Notes to be redeemed on that redemption date and (ii) as determined by the Issuer, the sum of the
present values of the remaining scheduled payments of principal and interest on the 2025 Fixed Rate Notes to be redeemed on that redemption date (not including any portion of such payments of interest accrued as to the redemption date) discounted to
the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 15 basis points, in each case plus
accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 
 5.3 Redemption upon a Change of Control Put
Event 
 If a Change of Control Put Event occurs with respect to the 2025 Fixed Rate Notes, the Holders will have the option to require
the Issuer to redeem or, at the Issuer’s option, purchase (or procure the purchase of) the whole, but not part, of such Holders’ 2025 Fixed Rate Notes not previously called for redemption on the Change of Control Put Date at the Change of
Control Redemption Amount together with interest accrued (but unpaid) to (but excluding) the Change of Control Put Date. 
 5.4 Special
Mandatory Early Redemption 
 If the Demerger has not completed by the first anniversary of the Issue Date or, if earlier, GSK releases
an announcement which makes public that it no longer intends to pursue the Demerger, a Special Mandatory Redemption Event shall occur in accordance with the terms of the Indenture, pursuant to which the Issuer shall redeem the 2025 Fixed Rate Notes
in whole, but not in part, at a redemption price equal to 101 per cent. of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

6. Denominations; Transfer 

The 2025 Fixed Rate Notes are in book-entry form only, and only in denominations of $250,000 and multiples of $1,000 in excess thereof. A
Holder may transfer 2025 Fixed Rate Notes in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish appropriate endorsements or transfer documents and to pay any taxes and fees required by law or permitted
by the Indenture. 

  
 A-13 

	7.	 Persons Deemed Owners 

The registered Holder of this 2025 Fixed Rate Note may be treated as the owner of it for all purposes. 

 

	8.	 Unclaimed Money 

Any money deposited with the Trustee or the Paying Agent, or then held by the Issuer, as banker for the payment of the principal of or other
amounts on, any 2025 Fixed Rate Note and remaining unclaimed for (a) 10 years after such principal has become due and payable or (b) five years after other amounts have become due and payable, shall promptly upon request be paid to
the Issuer or (if then held by the Issuer) shall be discharged from such trust. The Holder of such 2025 Fixed Rate Note shall thereafter, as an unsecured general creditor, look only to the Issuer for payment thereof, without interest and until such
amount must be remitted to the state under escheat or similar laws, and all liability of the Trustee or the Paying Agent with respect to such trust money, and all liability of the Issuer as trustee thereof, shall thereupon cease. 

 

	9.	 Amendment; Waiver 

Subject to certain exceptions set forth in the Indenture, (i) the Indenture, the 2025 Fixed Rate Notes or the Guarantees may be amended
with the consent of the Holders of a majority in principal amount of the 2025 Fixed Rate Notes then Outstanding and (ii) any past default or noncompliance with any provision may be waived with the consent of the Holders of a majority in
aggregate principal amount of the 2025 Fixed Rate Notes at the time Outstanding (including consents obtained in connection with a tender offer or exchange offer). Subject to certain exceptions set forth in the Indenture, without the consent of any
Holder, the Issuer and the Trustee may amend the Indenture to, among other things, cure any ambiguity, defect or inconsistency in the Indenture, to provide for the assumption by a successor of the obligations of the Issuer, to evidence and provide
for the acceptance of appointment by a successor Trustee, to make any change that does not materially and adversely affect the rights of any Holder or to provide for uncertificated 2025 Fixed Rate Notes in addition to or in place of certificated
2025 Fixed Rate Notes. 
  

	10.	 Defaults and Remedies 

If certain Events of Default with respect to the 2025 Fixed Rate Notes shall occur, the principal amount of all the 2025 Fixed Rate Notes may
be declared to become immediately due and payable. 
 Holders may not enforce the Indenture or the 2025 Fixed Rate Notes except as provided
in the Indenture. The Trustee may refuse to enforce the Indenture or the 2025 Fixed Rate Notes unless it receives reasonable indemnity and/or security. 

  
 A-14 

	11.	 Trustee Dealings with the Issuer 

Subject to certain limitations set forth in the Indenture, the Trustee under the Indenture, in its individual or any other capacity, may become
the owner or pledgee of 2025 Fixed Rate Notes and may otherwise deal with and collect obligations owed to it by the Issuer or its Affiliates and may otherwise deal with the Issuer or its Affiliates with the same rights it would have if it were not
Trustee. 
  

	12.	 No Recourse Against Others 

No recourse for the payment of the principal of or other amounts on any of the 2025 Fixed Rate Notes or for any claim based thereon or
otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Issuer or the applicable Guarantor in this Indenture, or in any of the 2025 Fixed Rate Notes, or because of the creation of any indebtedness
represented thereby, shall be had against any incorporator, limited partner, stockholder, officer, director, employee or controlling person of the Issuer (other than the applicable Guarantor under the Guarantees) or the applicable Guarantor or of
any successor Persons thereof. Each Holder, by accepting the 2025 Fixed Rate Notes, waives and releases all such liability. The waiver and release are part of the consideration for the issuance of the 2025 Fixed Rate Notes. Such waiver may not be
effective to waive liabilities under U.S. federal securities laws. 
  

	13.	 Authentication 

This 2025 Fixed Rate Note shall not be valid until an authorized signatory of the Trustee (or an authenticating agent acting on its behalf)
manually or electronically signs the certificate of authentication on the other side of this 2025 Fixed Rate Note. 
  

	14.	 CUSIP Numbers 

The Issuer in issuing the 2025 Fixed Rate Notes may use “CUSIP” numbers (if then generally in use). No representation is made as to
the accuracy of such numbers either as printed on the 2025 Fixed Rate Notes or as contained in any such notice and reliance may be placed only on the other identification numbers placed on the 2025 Fixed Rate Notes. The Issuer will promptly notify
the Trustee, in writing, of any change in the “CUSIP” number. 
  

	15.	 Governing Law 

THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 

 

	16.	 Demerger Capital Reduction 

By their holding of the 2025 Fixed Rate Note, each Holder shall be deemed without the need for any further action to have unconditionally and
irrevocably (i) consented to any reduction in the capital of Haleon which is implemented within 6 months of the Demerger, (ii) agreed not to object to the Demerger Capital Reduction, and (iii) appointed the Issuer, or such person
(other than the Trustee) as the Issuer shall nominate as its agent to undertake all such acts and take all such steps on its behalf (including, without limitation, the execution and delivery of any documents to any court) as may be necessary or
desirable for Haleon to implement the Demerger Capital Reduction. 

  
 A-15 

	17.	 Agent for Service; Submission to Jurisdiction; Waiver of Immunities 

The Issuer and each Guarantor have agreed that any suit, action or proceeding against the Issuer brought by any Holder or the Trustee arising
out of or based upon the Indenture or the 2025 Fixed Rate Notes may be instituted in any state or federal court in The City of New York, New York. The Issuer and each Guarantor have irrevocably submitted to the
non-exclusive jurisdiction of such courts for such purpose and waived, to the fullest extent permitted by law, trial by jury and any objection they may now or hereafter have to the laying of venue of any such
proceeding, and any claim they may now or hereafter have that any proceeding in any such court is brought in an inconvenient forum. The Issuer and the Guarantors each have appointed GSK Consumer Healthcare Capital US LLC as its Authorized Agent upon
whom all writs, process and summonses may be served in any suit, action or proceeding arising out of or based upon the Indenture or the 2025 Fixed Rate Notes which may be instituted in any state or federal court in The City of New York, New York. To
the extent that either of the Issuer and the applicable Guarantor have or hereafter may acquire any immunity (sovereign or otherwise) from any legal action, suit or proceeding, from jurisdiction of any court or from
set-off or any legal process (whether service or notice, attachment in aid or otherwise) with respect to themselves or any of their property, the Issuer and the applicable Guarantor have irrevocably waived and
agreed not to plead or claim such immunity in respect of their obligations under the Indenture or the 2025 Fixed Rate Notes. 
 The Issuer
shall furnish to any Holder upon written request and without charge to the Holder a copy of the Indenture which has in it the text of this 2025 Fixed Rate Note. Requests may be made to: GSK Consumer Healthcare Capital UK plc, attention: Timothy
Woodthorpe (Group Treasurer), e-mail: cf.treasury@gsk.com. 

  
 A-16 

 Schedule A 

SCHEDULE OF INCREASES OR DECREASES IN 2025 FIXED RATE GLOBAL NOTE 

The following increases or decreases in this 2025 Fixed Rate Global Note have been made: 

 

									
	 Date of

Exchange
	  	 Amount of decrease

in Principal Amount
 of this 2025
Fixed
 Rate Global Note
	  	 Amount of increase

in Principal Amount
 of this 2025
Fixed
 Rate Global Note
	  	 Principal Amount of

this 2025 Fixed Rate
Global Note

following such
 decrease or
increase
	  	 Signature of

authorized signatory
 of Trustee
or
 Registrar

	  
	  	  
	  	  
	  	  
	  	  

  
 A-17 

 EXHIBIT B 

FORM OF 2027 FIXED RATE GLOBAL NOTE 

[Include the following legend for all Rule 144A Global Notes:] 

THIS NOTE AND THE GUARANTEES OF THIS NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND
INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR
BENEFIT OF, U.S. PERSONS EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, THE HOLDER (A) REPRESENTS, WARRANTS, ACKNOWLEDGES AND AGREES FOR THE BENEFIT OF THE ISSUER, THE GUARANTORS AND THE TRUSTEE THAT IT IS A
‘‘QUALIFIED INSTITUTIONAL BUYER’’ (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) PURCHASING THE SECURITIES FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS; (B) AGREES THAT IT WILL NOT
RESELL OR OTHERWISE TRANSFER THE SECURITIES OTHER THAN (1) TO THE ISSUER, (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, (3) IN THE UNITED STATES TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS A
QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A, OR
(4) IN AN OFFSHORE TRANSACTION TO A NON-U.S. PERSON IN COMPLIANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS OF THE
STATES OF THE UNITED STATES AND ANY OTHER JURISDICTION; AND (C) AGREES THAT IT WILL DELIVER TO EACH PERSON TO WHOM THIS NOTE IS TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. 

[Include the following legend for all Regulation S Global Notes:] 

THIS NOTE AND THE GUARANTEES OF THE NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND INCLUDING)
THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS
AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE 

  
 B-1 

 
OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT OR PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT. UNTIL THE EXPIRY OF THE PERIOD OF 40 DAYS AFTER THE LATER OF (i) THE DATE ON WHICH THE OFFERING OF THIS NOTE TO
PERSONS OTHER THAN THE DISTRIBUTORS IN RELIANCE ON REGULATION S COMMENCED AND (ii) THE DATE OF ISSUANCE OF SUCH NOTE, SALES MAY NOT BE MADE IN THE UNITED STATES OR TO U.S. PERSONS UNLESS MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED IN, AND
IN TRANSACTIONS PURSUANT TO, RULE 144A UNDER THE SECURITIES ACT. 

  
 B-2 

 [FORM OF FACE OF 2027 FIXED RATE GLOBAL NOTE] 

GSK Consumer Healthcare Capital US LLC 

3.375% Fixed Rate Senior Note due 2027 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from and
including the Guarantee Assumption Date) 
 [Include the following for all Rule 144A Global Notes:] 

CUSIP No. (144A): 36264FAB7 
 ISIN
(144A): US36264FAB76 
 Common Code (144A): 246354260 

No.: 
 [Include the following for
all Regulation S Global Notes:] 
 CUSIP No. (Regulation S): U04020AB6 

ISIN (Regulation S): USU04020AB65 

Common Code (Regulation S): 246344272 

No.: 
  

					
		  		  	 Principal Amount $
 as revised by Schedule A

 attached
 hereto of Increases and

Decreases in this 2027 Fixed
 Rate Global Note

 This is to certify that CEDE & CO. is, as of the date hereof, the registered holder (the
“Holder”) of $                         of 3.375% Fixed Rate Senior Notes due 2027 represented by
this Global Note. GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware, promises to pay to the Holder, or registered assigns, the principal sum of
$                         as revised by the Schedule of Increases and Decreases in 2027 Fixed Rate Global Note attached
hereto, on March 24, 2027. 
 In the event of a redemption or cancellation of the 2027 Fixed Rate Notes in part only, the 2027 Fixed
Rate Notes evidenced by this 2027 Fixed Rate Global Note shall be reduced by the principal amount so redeemed or cancelled. Thereafter, the 2027 Fixed Rate Notes represented by this 2027 Fixed Rate Global Note shall be the principal amount of 2027
Fixed Rate Notes most recently entered by or on behalf of the Issuer in the relevant column in Schedule A attached hereto. 

  
 B-3 

 Reference is hereby made to the further provisions of this 2027 Fixed Rate Note as set forth
on the reverse hereof, which provisions shall for all purposes have the same effect as if set forth at this place. 
  

			
	GSK CONSUMER HEALTHCARE CAPITAL US LLC
		
	By:	 	 
	Name:	 	
	Title:	 	

			
	 TRUSTEE’S CERTIFICATE OF AUTHENTICATION
	  	
		
	 Deutsche Bank Trust Company Americas,

as Trustee, certifies

that this is one of

the 2027 Fixed Rate Notes referred

to in the Indenture
	  	

  

			
	 By:
                                         
                   
	  	
	                Authorized Signatory	  	 Date:
                                         
               

  
 B-4 

 GUARANTEE OF GLAXOSMITHKLINE PLC 

For value received, GlaxoSmithKline plc, a public limited company incorporated under the laws of England and Wales, having its principal
executive offices at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “GSK Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this GSK Guarantee
is endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this GSK Guarantee is endorsed and to the Trustee on behalf of each such Holder prior to the date on which GSK ceases to hold a direct or indirect
interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee Assumption
Date”) the due payment of all principal of and other amounts on, each Note payable by GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer”, which term
includes any successor Person under the Indenture) under the Indenture. In case of the failure of the U.S. Issuer to punctually make any such payment or satisfy any such obligation in respect of the U.S. Issuer Notes prior to the Guarantee
Assumption Date, the GSK Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date or by
declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the U.S. Issuer. 
 The indebtedness
evidenced by this GSK Guarantee constitutes an unsubordinated and unsecured obligation of the GSK Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the GSK Guarantor (except for
obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the GSK Guarantor. 

The GSK Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be unaffected
by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the U.S. Issuer with respect thereto, by
the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or indulgence
shall, without the consent of the GSK Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The GSK Guarantor hereby waives diligence, presentment, demand of
payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer, any right to require a proceeding first against the U.S. Issuer, protest or notice with respect to such Note or the indebtedness evidenced thereby or
with respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this GSK Guarantee will not be discharged except by payment or satisfaction in full of the principal of and Additional
Amounts, if any, payable in respect of such Note. This GSK Guarantee is a guarantee of payment and not of collection. 

  
 B-5 

 The GSK Guarantor shall be subrogated to all rights of the Holder of such Note and the
Trustee against the U.S. Issuer in respect of any amounts paid to such Holder by the GSK Guarantor pursuant to the provisions of this GSK Guarantee; provided, however, that the GSK Guarantor shall not be entitled to enforce, or to receive any
payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the GSK Guarantor, which are
absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this GSK Guarantee is endorsed. 

This GSK Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this GSK Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This GSK Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 B-6 

 IN WITNESS WHEREOF, the GSK Guarantor has caused this GSK Guarantee to be duly executed this
24th day of March 2022. 
  

			
	 GLAXOSMITHKLINE PLC,
 as the GSK
Guarantor

		
	By:	 	 
		 	Name:
		 	Title:
		
	By:	 	 
		 	Name:
		 	Title:

  
 B-7 

 GUARANTEE OF HALEON 

For value received, Haleon, a public limited company incorporated under the laws of England and Wales, having its principal executive offices
at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “Haleon Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this Haleon Guarantee is
endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this Haleon Guarantee is endorsed and to the Trustee on behalf of each such Holder from (and including) the date on which GSK ceases to hold a direct or
indirect interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee
Assumption Date”) the due payment of all principal of and other amounts on, each Note payable by GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer,”
which term includes any successor Person under the Indenture) under the Indenture. In case of the failure of the U.S. Issuer to punctually make any such payment or satisfy any such obligation in respect of the U.S. Issuer Notes, from (and including)
the Guarantee Assumption Date, the Haleon Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date
or by declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the U.S. Issuer. 
 The
indebtedness evidenced by this Haleon Guarantee constitutes an unsubordinated and unsecured obligation of the Haleon Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the Haleon
Guarantor (except for obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the Haleon Guarantor. 

The Haleon Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be
unaffected by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the U.S. Issuer with respect
thereto, by the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or
indulgence shall, without the consent of the Haleon Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The Haleon Guarantor hereby waives diligence,
presentment, demand of payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer, any right to require a proceeding first against the U.S., protest or notice with respect to such Note or the indebtedness
evidenced thereby or with respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this Haleon Guarantee will not be discharged except by payment or satisfaction in full of the
principal of and Additional Amounts, if any, payable in respect of such Note. This Haleon Guarantee is a guarantee of payment and not of collection. 

  
 B-8 

 The Haleon Guarantor shall be subrogated to all rights of the Holder of such Note and the
Trustee against the U.S. Issuer in respect of any amounts paid to such Holder by the Haleon Guarantor pursuant to the provisions of this Haleon Guarantee; provided, however, that the Haleon Guarantor shall not be entitled to enforce, or to
receive any payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the Haleon Guarantor, which
are absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this Haleon Guarantee is endorsed. 

This Haleon Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this Haleon Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This Haleon Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 B-9 

 IN WITNESS WHEREOF, the Haleon Guarantor has caused this Haleon Guarantee to be duly executed this 24th day of March 2022. 
  

			
	 HALEON PLC,
 as the Haleon
Guarantor

		
	By:	 	 
		 	Name:
		 	Title:
		
	By:	 	 
		 	Name:
		 	Title:

  
 B-10 

 [REVERSE SIDE OF NOTE] 

GSK Consumer Healthcare Capital US LLC 

3.375% Fixed Rate Senior Note due 2027 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from and
including the Guarantee Assumption Date) 
  

	1.	 Interest 

Interest on the 2027 Fixed Rate Notes will be payable at a rate of 3.375% per annum. 

Interest on the 2027 Fixed Rate Notes will be payable semi-annually in arrear on 24 March and 24 September of each year, commencing
on September 24, 2022 (each a “Fixed Rate Notes Interest Payment Date”) to the person in whose name this 2027 Fixed Rate Note is registered at the close of business on the Regular Record Date that precedes the applicable Fixed
Rate Notes Interest Payment Date. 
 The 2027 Fixed Rate Notes will accrue interest from (and including) the Issue Date, or from the most
recent Fixed Rate Notes Interest Payment Date, to (but excluding) the next succeeding Fixed Rate Notes Interest Payment Date. Interest on the 2027 Fixed Rate Notes will be paid on the basis of twelve 30-day
months assuming a 360-day year. 
  

	2.	 Method of Payment 

Not later than 11:00am New York City time on the due date for any payment due in respect of the 2027 Fixed Rate Notes and on the 2027 Fixed
Rate Notes Maturity Date, GSK Consumer Healthcare Capital US LLC (the “Issuer”) shall deposit with the relevant Paying Agent in same day immediately available funds an amount sufficient to make cash payments due on such due date of
payments of any other amounts or the Maturity Date, as the case may be. Holders must surrender 2027 Fixed Rate Notes to a Paying Agent to collect principal payments. The Issuer shall pay principal and other amounts in cash in U.S. dollars. 

Payments in respect of 2027 Fixed Rate Notes represented by a Global Note (including principal and other amounts) shall be made by the
transfer of immediately available funds to the accounts specified by the Depositary. The Issuer shall make all payments in respect of a Certificated Note (including principal and other amounts) by wire transfer to the specified account maintained by
the payee by giving written notice to the Trustee or the Paying Agent to such effect designating such account no later than 15 days immediately preceding the relevant due date for payment (or such other date as the Trustee may accept in its
discretion). 

  
 B-11 

	3.	 Paying Agent, Transfer Agent, Calculation Agent and Registrar 

Initially, Deutsche Bank Trust Company Americas (the “Trustee”) shall act as Trustee, Principal Paying Agent, Transfer Agent,
calculation agent and as Registrar. The Issuer may appoint and change any Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar without notice to any Holder. The Issuer or the
applicable Guarantor may act as Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar. 
  

	4.	 Indenture 

The Issuer issued the 2027 Fixed Rate Notes under an Indenture, dated as of March 24, 2022 (as it may be amended or supplemented from time
to time in accordance with the terms thereof, the “Indenture”), among the Issuers, the Guarantors, the Trustee, the Principal Paying Agent, the Transfer Agent and the Registrar. The terms of the 2027 Fixed Rate Notes include those
stated in the Indenture. Capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Indenture. The 2027 Fixed Rate Notes are subject to all such terms, and Holders are referred to the Indenture for a statement of
those terms. Each Holder by accepting a 2027 Fixed Rate Note agrees to be bound by all of the terms and provisions of the Indenture, as amended from time to time. 

The 2027 Fixed Rate Notes are general unsecured obligations of the Issuer limited to
$                 aggregate principal amount. 

Prior to the Guarantee Assumption Date, the 2027 Fixed Rate Notes are unconditionally and irrevocably guaranteed by the GSK Guarantor under
the GSK Guarantee. With effect from (and including) the Guarantee Assumption Date, the 2027 Fixed Rate Notes are unconditionally and irrevocably guaranteed by the Haleon Guarantor under the Haleon Guarantee, in each case for the benefit of the
Holders pursuant to the Indenture. 
  

	5.	 Redemption 

Unless earlier redeemed, purchased or cancelled as provided in the Indenture, the Notes will be redeemed by the Issuer at their principal
amount on March 24, 2027. 
 5.1 Optional Redemption for Tax Reasons  

The Issuer may redeem the 2027 Fixed Rate Notes in whole but not in part at any time prior to maturity, at a redemption price equal to 100% of
their principal amount plus accrued interest to the date fixed for redemption, if: 
 (a) the Issuer determines that, as a result of any
change in or amendment to the laws or any regulations or rulings promulgated thereunder of the United Kingdom or the United States, or any change in the application or official interpretation of such laws, regulations or rulings, or any change in
the application or official interpretation of, or any execution of or amendment to, any treaty or treaties affecting taxation to which any such jurisdiction is a party, which change, execution or amendment becomes effective on or after the Issue
Date: (i) the Issuer would be required to pay Additional Amounts on the 2027 Fixed Rate Notes on the next succeeding Interest Payment Date and the payment of such additional amounts cannot be avoided by the use of reasonable measures available
to the Issuer or the applicable Guarantor; or (ii) withholding tax has been or would be required to be withheld with respect to interest income received or receivable by the Issuer directly from the applicable Guarantor (or any Affiliate) and
such withholding tax obligation cannot be avoided by the use of reasonable measures available to the Issuer or the applicable Guarantor (or any Affiliate); or 

  
 B-12 

 (b) the Issuer determines, based upon an opinion of independent counsel of recognised
standing that, as a result of any action taken by any legislative body of, taxing authority of, or any action brought in a court of competent jurisdiction in, the United Kingdom or the United States, which action is taken or brought on after the
Issue Date, there is a substantial probability that the circumstances described above would exist; provided, however, that no such notice of redemption may be given earlier than 90 days prior to the earliest date on which the Issuer
would be obligated to pay such Additional Amounts. 
 5.2 Make-Whole and Par Redemption 

Prior to the 2027 Fixed Rate Notes Par Call Date, the Issuer may redeem the 2027 Fixed Rate Notes, in whole or in part, at its option at any
time and from time to time at a redemption price equal to the greater of (i) 100% of the principal amount of the 2027 Fixed Rate Notes to be redeemed on that redemption date and (ii) as determined by the Issuer, the sum of the present values of
the remaining scheduled payments of principal of and interest on the 2027 Fixed Rate Notes to be redeemed on that redemption date (not including any portion of such payments of interest accrued as of the redemption date) that would be due if the
2027 Fixed Rate Notes matured on the 2027 Fixed Rate Notes Par Call Date, discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve
30-day months) at the Treasury Rate plus 20 basis points, in each case plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

On or after the 2027 Fixed Rate Notes Par Call Date, the Issuer may redeem the 2027 Fixed Rate Notes, in whole or in part, at its option at
any time and from time to time at a redemption price equal to 100% of the principal amount of the 2027 Fixed Rate Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

5.3 Redemption upon a Change of Control Put Event 

If a Change of Control Put Event occurs with respect to the 2027 Fixed Rate Notes, the Holders will have the option to require the Issuer to
redeem or, at the Issuer’s option, purchase (or procure the purchase of) the whole, but not part, of such Holders’ 2027 Fixed Rate Notes not previously called for redemption on the Change of Control Put Date at the Change of Control
Redemption Amount together with interest accrued (but unpaid) to (but excluding) the Change of Control Put Date. 
 5.4 Special Mandatory
Early Redemption 
 If the Demerger has not completed by the first anniversary of the Issue Date or, if earlier, GSK releases an
announcement which makes public that it no longer intends to pursue the Demerger, a Special Mandatory Redemption Event shall occur in accordance with the terms of the Indenture, pursuant to which the Issuer shall redeem the 2027 Fixed Rate Notes in
whole, but not in part, at a redemption price equal to 101 per cent, of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

  
 B-13 

	6.	 Denominations; Transfer 

The 2027 Fixed Rate Notes are in book-entry form only, and only in denominations of $250,000 and multiples of $1,000 in excess thereof. A
Holder may transfer 2027 Fixed Rate Notes in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish appropriate endorsements or transfer documents and to pay any taxes and fees required by law or permitted
by the Indenture. 
  

	7.	 Persons Deemed Owners 

The registered Holder of this 2027 Fixed Rate Note may be treated as the owner of it for all purposes. 

 

	8.	 Unclaimed Money 

Any money deposited with the Trustee or the Paying Agent, or then held by the Issuer, as banker for the payment of the principal of or other
amounts on, any 2027 Fixed Rate Note and remaining unclaimed for (a) 10 years after such principal has become due and payable or (b) five years after other amounts have become due and payable, shall promptly upon request be paid to
the Issuer or (if then held by the Issuer) shall be discharged from such trust. The Holder of such 2027 Fixed Rate Note shall thereafter, as an unsecured general creditor, look only to the Issuer for payment thereof, without interest and until such
amount must be remitted to the state under escheat or similar laws, and all liability of the Trustee or the Paying Agent with respect to such trust money, and all liability of the Issuer as trustee thereof, shall thereupon cease. 

 

	9.	 Amendment; Waiver 

Subject to certain exceptions set forth in the Indenture, (i) the Indenture, the 2027 Fixed Rate Notes or the Guarantees may be amended
with the consent of the Holders of a majority in principal amount of the 2027 Fixed Rate Notes then Outstanding and (ii) any past default or noncompliance with any provision may be waived with the consent of the Holders of a majority in
aggregate principal amount of the 2027 Fixed Rate Notes at the time Outstanding (including consents obtained in connection with a tender offer or exchange offer). Subject to certain exceptions set forth in the Indenture, without the consent of any
Holder, the Issuer and the Trustee may amend the Indenture to, among other things, cure any ambiguity, defect or inconsistency in the Indenture, to provide for the assumption by a successor of the obligations of the Issuer, to evidence and provide
for the acceptance of appointment by a successor Trustee, to make any change that does not materially and adversely affect the rights of any Holder or to provide for uncertificated 2027 Fixed Rate Notes in addition to or in place of certificated
2027 Fixed Rate Notes. 

  
 B-14 

	10.	 Defaults and Remedies 

If certain Events of Default with respect to the 2027 Fixed Rate Notes shall occur, the principal amount of all the 2027 Fixed Rate Notes may
be declared to become immediately due and payable. 
 Holders may not enforce the Indenture or the 2027 Fixed Rate Notes except as provided
in the Indenture. The Trustee may refuse to enforce the Indenture or the 2027 Fixed Rate Notes unless it receives reasonable indemnity and/or security. 
  

	11.	 Trustee Dealings with the Issuer 

Subject to certain limitations set forth in the Indenture, the Trustee under the Indenture, in its individual or any other capacity, may become
the owner or pledgee of 2027 Fixed Rate Notes and may otherwise deal with and collect obligations owed to it by the Issuer or its Affiliates and may otherwise deal with the Issuer or its Affiliates with the same rights it would have if it were not
Trustee. 
  

	12.	 No Recourse Against Others 

No recourse for the payment of the principal of or other amounts on any of the 2027 Fixed Rate Notes or for any claim based thereon or
otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Issuer or the applicable Guarantor in this Indenture, or in any of the 2027 Fixed Rate Notes, or because of the creation of any indebtedness
represented thereby, shall be had against any incorporator, limited partner, stockholder, officer, director, employee or controlling person of the Issuer (other than the applicable Guarantor under the Guarantees) or the applicable Guarantor or of
any successor Persons thereof. Each Holder, by accepting the 2027 Fixed Rate Notes, waives and releases all such liability. The waiver and release are part of the consideration for the issuance of the 2027 Fixed Rate Notes. Such waiver may not be
effective to waive liabilities under U.S. federal securities laws. 
  

	13.	 Authentication 

This 2027 Fixed Rate Note shall not be valid until an authorized signatory of the Trustee (or an authenticating agent acting on its behalf)
manually or electronically signs the certificate of authentication on the other side of this 2027 Fixed Rate Note. 
  

	14.	 CUSIP Numbers 

The Issuer in issuing the 2027 Fixed Rate Notes may use “CUSIP” numbers (if then generally in use). No representation is made as to
the accuracy of such numbers either as printed on the 2027 Fixed Rate Notes or as contained in any such notice and reliance may be placed only on the other identification numbers placed on the 2027 Fixed Rate Notes. The Issuer will promptly notify
the Trustee, in writing, of any change in the “CUSIP” number. 

  
 B-15 

	15.	 Governing Law 

THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 

 

	16.	 Demerger Capital Reduction 

By their holding of the 2027 Fixed Rate Note, each Holder shall be deemed without the need for any further action to have unconditionally and
irrevocably (i) consented to any reduction in the capital of Haleon which is implemented within 6 months of the Demerger, (ii) agreed not to object to the Demerger Capital Reduction, and (iii) appointed the Issuer, or such person
(other than the Trustee) as the Issuer shall nominate as its agent to undertake all such acts and take all such steps on its behalf (including, without limitation, the execution and delivery of any documents to any court) as may be necessary or
desirable for Haleon to implement the Demerger Capital Reduction. 
  

	17.	 Agent for Service; Submission to Jurisdiction; Waiver of Immunities 

The Issuer and each Guarantor have agreed that any suit, action or proceeding against the Issuer brought by any Holder or the Trustee arising
out of or based upon the Indenture or the 2027 Fixed Rate Notes may be instituted in any state or federal court in The City of New York, New York. The Issuer and each Guarantor have irrevocably submitted to the
non-exclusive jurisdiction of such courts for such purpose and waived, to the fullest extent permitted by law, trial by jury and any objection they may now or hereafter have to the laying of venue of any such
proceeding, and any claim they may now or hereafter have that any proceeding in any such court is brought in an inconvenient forum. The Guarantors each have appointed the Issuer as its Authorized Agent upon whom all writs, process and summonses may
be served in any suit, action or proceeding arising out of or based upon the Indenture or the 2027 Fixed Rate Notes which may be instituted in any state or federal court in The City of New York, New York. To the extent that either of the Issuer and
the applicable Guarantor have or hereafter may acquire any immunity (sovereign or otherwise) from any legal action, suit or proceeding, from jurisdiction of any court or from set-off or any legal process
(whether service or notice, attachment in aid or otherwise) with respect to themselves or any of their property, the Issuer and the applicable Guarantor have irrevocably waived and agreed not to plead or claim such immunity in respect of their
obligations under the Indenture or the 2027 Fixed Rate Notes. 
 The Issuer shall furnish to any Holder upon written request and without
charge to the Holder a copy of the Indenture which has in it the text of this 2027 Fixed Rate Note. Requests may be made to: GSK Consumer Healthcare Capital US LLC, attention: Timothy Woodthorpe (Group Treasurer),
e-mail: cf.treasury@gsk.com, with copy to: Justin T. Huang (VP and Secretary), Charles David Simpson (VP and Treasurer) and Hatixhe Hoxha (Assistant Secretary), email address: US.CorpSec@gsk.com. 

  
 B-16 

 Schedule A 

SCHEDULE OF INCREASES OR DECREASES IN 2027 FIXED RATE GLOBAL NOTE 

The following increases or decreases in this 2027 Fixed Rate Global Note have been made: 

 

									
	 Date of

Exchange
	  	 Amount of decrease

in Principal Amount
 of this 2027
Fixed
 Rate Global Note
	  	 Amount of increase

in Principal Amount
 of this 2027
Fixed
 Rate Global Note
	  	 Principal Amount of

this 2027 Fixed Rate
 Global Note

following such
 decrease or
increase
	  	 Signature of

authorized signatory
 of Trustee
or
 Registrar

  
 B-17 

 EXHIBIT C 

FORM OF 2029 FIXED RATE GLOBAL NOTE 

[Include the following legend for all Rule 144A Global Notes:] 

THIS NOTE AND THE GUARANTEES OF THIS NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND
INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR
BENEFIT OF, U.S. PERSONS EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, THE HOLDER (A) REPRESENTS, WARRANTS, ACKNOWLEDGES AND AGREES FOR THE BENEFIT OF THE ISSUER, THE GUARANTORS AND THE TRUSTEE THAT IT IS A
‘‘QUALIFIED INSTITUTIONAL BUYER’’ (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) PURCHASING THE SECURITIES FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS; (B) AGREES THAT IT WILL NOT
RESELL OR OTHERWISE TRANSFER THE SECURITIES OTHER THAN (1) TO THE ISSUER, (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, (3) IN THE UNITED STATES TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS A
QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A, OR
(4) IN AN OFFSHORE TRANSACTION TO A NON-U.S. PERSON IN COMPLIANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS OF THE
STATES OF THE UNITED STATES AND ANY OTHER JURISDICTION; AND (C) AGREES THAT IT WILL DELIVER TO EACH PERSON TO WHOM THIS NOTE IS TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. 

[Include the following legend for all Regulation S Global Notes:] 

THIS NOTE AND THE GUARANTEES OF THE NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND
INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE 

  
 C-1 

 
OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT OR PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT. UNTIL THE EXPIRY OF THE PERIOD OF 40 DAYS AFTER THE LATER OF (i) THE DATE ON WHICH THE OFFERING OF THIS NOTE TO
PERSONS OTHER THAN THE DISTRIBUTORS IN RELIANCE ON REGULATION S COMMENCED AND (ii) THE DATE OF ISSUANCE OF SUCH NOTE, SALES MAY NOT BE MADE IN THE UNITED STATES OR TO U.S. PERSONS UNLESS MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED IN, AND
IN TRANSACTIONS PURSUANT TO, RULE 144A UNDER THE SECURITIES ACT. 

  
 C-2 

 [FORM OF FACE OF 2029 FIXED RATE GLOBAL NOTE] 

GSK Consumer Healthcare Capital US LLC 

3.375% Fixed Rate Senior Note due 2029 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from and
including the Guarantee Assumption Date) 
 [Include the following for all Rule 144A Global Notes:] 

CUSIP No. (144A): 36264FAC5 
 ISIN
(144A): US36264FAC59 
 Common Code (144A): 246354278 

No.: 
 [Include the following for
all Regulation S Global Notes:] 
 CUSIP No. (Regulation S): U04020AC4 

ISIN (Regulation S): USU04020AC49 

Common Code (Regulation S): 246354235 

No.: 
  

					
		 		  	Principal Amount $
			
		 		  	as revised by Schedule A 
		 		  	 attached
 hereto of Increases and Decreases in
this 2029 Fixed Rate Global Note

 This is to certify that CEDE & CO. is, as of the date hereof, the registered holder (the
“Holder”) of $                 of 3.375% Fixed Rate Senior Notes due 2029 represented by this Global Note. GSK Consumer Healthcare Capital
US LLC, a public limited company incorporated under the laws of Delaware, promises to pay to the Holder, or registered assigns, the principal sum of $                
as revised by the Schedule of Increases and Decreases in 2029 Fixed Rate Global Note attached hereto, on March 24, 2029. 
 In the
event of a redemption or cancellation of the 2029 Fixed Rate Notes in part only, the 2029 Fixed Rate Notes evidenced by this 2029 Fixed Rate Global Note shall be reduced by the principal amount so redeemed or cancelled. Thereafter, the 2029 Fixed
Rate Notes represented by this 2029 Fixed Rate Global Note shall be the principal amount of 2029 Fixed Rate Notes most recently entered by or on behalf of the Issuer in the relevant column in Schedule A attached hereto. 

  
 C-3 

 Reference is hereby made to the further provisions of this 2029 Fixed Rate Note as set forth
on the reverse hereof, which provisions shall for all purposes have the same effect as if set forth at this place. 
  

			
	GSK CONSUMER HEALTHCARE CAPITAL US LLC

 
			
		
	By:	 	 
		 	Name:
		 	Title:

  

			
	TRUSTEE’S CERTIFICATE OF	  	
	AUTHENTICATION	  	
		
	 Deutsche Bank Trust Company Americas,
 as
Trustee, certifies
 that this is one of
 the 2029 Fixed Rate
Notes referred
 to in the Indenture
	  	

  

			
	 By:
                                         
               
	  	
	
                Authorized
Signatory
	  	 Date:
                                         
           

  
 C-4 

 GUARANTEE OF GLAXOSMITHKLINE PLC 

For value received, GlaxoSmithKline plc, a public limited company incorporated under the laws of England and Wales, having its principal
executive offices at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “GSK Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this GSK Guarantee
is endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this GSK Guarantee is endorsed and to the Trustee on behalf of each such Holder prior to the date on which GSK ceases to hold a direct or indirect
interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee Assumption
Date”) the due payment of all principal of and other amounts on, each Note payable by GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer”, which term
includes any successor Person under the Indenture) under the Indenture. In case of the failure of the U.S. Issuer to punctually make any such payment or satisfy any such obligation in respect of the U.S. Issuer Notes prior to the Guarantee
Assumption Date, the GSK Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date or by
declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the U.S. Issuer. 
 The indebtedness
evidenced by this GSK Guarantee constitutes an unsubordinated and unsecured obligation of the GSK Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the GSK Guarantor (except for
obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the GSK Guarantor. 

The GSK Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be unaffected
by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the U.S. Issuer with respect thereto, by
the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or indulgence
shall, without the consent of the GSK Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The GSK Guarantor hereby waives diligence, presentment, demand of
payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer, any right to require a proceeding first against the U.S. Issuer, protest or notice with respect to such Note or the indebtedness evidenced thereby or
with respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this GSK Guarantee will not be discharged except by payment or satisfaction in full of the principal of and Additional
Amounts, if any, payable in respect of such Note. This GSK Guarantee is a guarantee of payment and not of collection. 

  
 C-5 

 The GSK Guarantor shall be subrogated to all rights of the Holder of such Note and the
Trustee against the U.S. Issuer in respect of any amounts paid to such Holder by the GSK Guarantor pursuant to the provisions of this GSK Guarantee; provided, however, that the GSK Guarantor shall not be entitled to enforce, or to receive any
payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the GSK Guarantor, which are
absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this GSK Guarantee is endorsed. 

This GSK Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this GSK Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This GSK Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 C-6 

 IN WITNESS WHEREOF, the GSK Guarantor has caused this GSK Guarantee to be duly executed this 24th day of March 2022. 
  

			
	 GLAXOSMITHKLINE PLC,
 as the GSK
Guarantor

		
	By:	 	 
		 	Name:
		 	Title:
	By:	 	 
		 	Name:
		 	Title:

  
 C-7 

 GUARANTEE OF HALEON 

For value received, Haleon, a public limited company incorporated under the laws of England and Wales, having its principal executive offices
at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “Haleon Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this Haleon Guarantee is
endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this Haleon Guarantee is endorsed and to the Trustee on behalf of each such Holder from (and including) the date on which GSK ceases to hold a direct or
indirect interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee
Assumption Date”) the due payment of all principal of and other amounts on, each Note payable by GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer,”
which term includes any successor Person under the Indenture) under the Indenture. In case of the failure of the U.S. Issuer to punctually make any such payment or satisfy any such obligation in respect of the U.S. Issuer Notes, from (and including)
the Guarantee Assumption Date, the Haleon Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date
or by declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the U.S. Issuer. 
 The
indebtedness evidenced by this Haleon Guarantee constitutes an unsubordinated and unsecured obligation of the Haleon Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the Haleon
Guarantor (except for obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the Haleon Guarantor. 

The Haleon Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be
unaffected by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the U.S. Issuer with respect
thereto, by the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or
indulgence shall, without the consent of the Haleon Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The Haleon Guarantor hereby waives diligence,
presentment, demand of payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer, any right to require a proceeding first against the U.S., protest or notice with respect to such Note or the indebtedness
evidenced thereby or with respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this Haleon Guarantee will not be discharged except by payment or satisfaction in full of the
principal of and Additional Amounts, if any, payable in respect of such Note. This Haleon Guarantee is a guarantee of payment and not of collection. 

  
 C-8 

 The Haleon Guarantor shall be subrogated to all rights of the Holder of such Note and the
Trustee against the U.S. Issuer in respect of any amounts paid to such Holder by the Haleon Guarantor pursuant to the provisions of this Haleon Guarantee; provided, however, that the Haleon Guarantor shall not be entitled to enforce, or to
receive any payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the Haleon Guarantor, which
are absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this Haleon Guarantee is endorsed. 

This Haleon Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this Haleon Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This Haleon Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 C-9 

 IN WITNESS WHEREOF, the Haleon Guarantor has caused this Haleon Guarantee to be duly executed this 24th day of March 2022. 
  

			
	 HALEON PLC, 

	 as the Haleon Guarantor

		
	 By:
	 	 
		 	 Name:

		 	 Title:

		
	 By:
	 	 
		 	 Name:

		 	 Title:

  
 C-10 

 [REVERSE SIDE OF NOTE] 

GSK Consumer Healthcare Capital US LLC 

3.375% Fixed Rate Senior Note due 2029 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from and
including the Guarantee Assumption Date) 
  

	1.	 Interest 

Interest on the 2029 Fixed Rate Notes will be payable at a rate of 3.375% per annum. 

Interest on the 2029 Fixed Rate Notes will be payable semi-annually in arrear on 24 March and 24 September of each year, commencing
on September 24, 2022 (each a “Fixed Rate Notes Interest Payment Date”) to the person in whose name this 2029 Fixed Rate Note is registered at the close of business on the Regular Record Date that precedes the applicable Fixed
Rate Notes Interest Payment Date. 
 The 2029 Fixed Rate Notes will accrue interest from (and including) the Issue Date, or from the most
recent Fixed Rate Notes Interest Payment Date, to (but excluding) the next succeeding Fixed Rate Notes Interest Payment Date. Interest on the 2029 Fixed Rate Notes will be paid on the basis of twelve 30-day
months assuming a 360-day year. 
  

	2.	 Method of Payment 

Not later than 11:00am New York City time on the due date for any payment due in respect of the 2029 Fixed Rate Notes and on the 2029 Fixed
Rate Notes Maturity Date, GSK Consumer Healthcare Capital US LLC (the “Issuer”) shall deposit with the relevant Paying Agent in same day immediately available funds an amount sufficient to make cash payments due on such due date of
payments of any other amounts or the Maturity Date, as the case may be. Holders must surrender 2029 Fixed Rate Notes to a Paying Agent to collect principal payments. The Issuer shall pay principal and other amounts in cash in U.S. dollars. 

Payments in respect of 2029 Fixed Rate Notes represented by a Global Note (including principal and other amounts) shall be made by the
transfer of immediately available funds to the accounts specified by the Depositary. The Issuer shall make all payments in respect of a Certificated Note (including principal and other amounts) by wire transfer to the specified account maintained by
the payee by giving written notice to the Trustee or the Paying Agent to such effect designating such account no later than 15 days immediately preceding the relevant due date for payment (or such other date as the Trustee may accept in its
discretion). 

  
 C-11 

	3.	 Paying Agent, Transfer Agent, Calculation Agent and Registrar 

Initially, Deutsche Bank Trust Company Americas (the “Trustee”) shall act as Trustee, Principal Paying Agent, Transfer Agent,
calculation agent and as Registrar. The Issuer may appoint and change any Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar without notice to any Holder. The Issuer or the
applicable Guarantor may act as Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar. 
  

	4.	 Indenture 

The Issuer issued the 2029 Fixed Rate Notes under an Indenture, dated as of March 24, 2022 (as it may be amended or supplemented from time
to time in accordance with the terms thereof, the “Indenture”), among the Issuers, the Guarantors, the Trustee, the Principal Paying Agent, the Transfer Agent and the Registrar. The terms of the 2029 Fixed Rate Notes include those
stated in the Indenture. Capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Indenture. The 2029 Fixed Rate Notes are subject to all such terms, and Holders are referred to the Indenture for a statement of
those terms. Each Holder by accepting a 2029 Fixed Rate Note agrees to be bound by all of the terms and provisions of the Indenture, as amended from time to time. 

The 2029 Fixed Rate Notes are general unsecured obligations of the Issuer limited to
$                 aggregate principal amount. 

Prior to the Guarantee Assumption Date, the 2029 Fixed Rate Notes are unconditionally and irrevocably guaranteed by the GSK Guarantor under
the GSK Guarantee. With effect from (and including) the Guarantee Assumption Date, the 2029 Fixed Rate Notes are unconditionally and irrevocably guaranteed by the Haleon Guarantor under the Haleon Guarantee, in each case for the benefit of the
Holders pursuant to the Indenture. 
  

	5.	 Redemption 

Unless earlier redeemed, purchased or cancelled as provided in the Indenture, the Notes will be redeemed by the Issuer at their principal
amount on March 24, 2029. 
  

	 	5.1	 Optional Redemption for Tax Reasons  

The Issuer may redeem the 2029 Fixed Rate Notes in whole but not in part at any time prior to maturity, at a redemption price equal to 100% of
their principal amount plus accrued interest to the date fixed for redemption, if: 
 (a) the Issuer determines that, as a result of any
change in or amendment to the laws or any regulations or rulings promulgated thereunder of the United Kingdom or the United States, or any change in the application or official interpretation of such laws, regulations or rulings, or any change in
the application or official interpretation of, or any execution of or amendment to, any treaty or treaties affecting taxation to which any such jurisdiction is a party, which change, execution or amendment becomes effective on or after the Issue
Date: (i) the Issuer would be required to pay Additional Amounts on the 2029 Fixed Rate Notes on the next succeeding Interest Payment Date and the payment of such additional amounts cannot be avoided by the use of reasonable measures available
to the Issuer or the applicable Guarantor; or (ii) withholding tax has been or would be required to be withheld with respect to interest income received or receivable by the Issuer directly from the applicable Guarantor (or any Affiliate) and
such withholding tax obligation cannot be avoided by the use of reasonable measures available to the Issuer or the applicable Guarantor (or any Affiliate); or 

  
 C-12 

 (b) the Issuer determines, based upon an opinion of independent counsel of recognised
standing that, as a result of any action taken by any legislative body of, taxing authority of, or any action brought in a court of competent jurisdiction in, the United Kingdom or the United States, which action is taken or brought on after the
Issue Date, there is a substantial probability that the circumstances described above would exist; provided, however, that no such notice of redemption may be given earlier than 90 days prior to the earliest date on which the Issuer
would be obligated to pay such Additional Amounts. 
  

	 	5.2	 Make-Whole and Par Redemption 

Prior to the 2029 Fixed Rate Notes Par Call Date, the Issuer may redeem the 2029 Fixed Rate Notes, in whole or in part, at its option at any
time and from time to time at a redemption price equal to the greater of (i) 100% of the principal amount of the 2029 Fixed Rate Notes to be redeemed on that redemption date and (ii) as determined by the Issuer, the sum of the present values of
the remaining scheduled payments of principal of and interest on the 2029 Fixed Rate Notes to be redeemed on that redemption date (not including any portion of such payments of interest accrued as of the redemption date) that would be due if the
2029 Fixed Rate Notes matured on the 2029 Fixed Rate Notes Par Call Date, discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve
30-day months) at the Treasury Rate plus 20 basis points, in each case plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

On or after the 2029 Fixed Rate Notes Par Call Date, the Issuer may redeem the 2029 Fixed Rate Notes, in whole or in part, at its option at
any time and from time to time at a redemption price equal to 100% of the principal amount of the 2029 Fixed Rate Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

 

	 	5.3	 Redemption upon a Change of Control Put Event 

If a Change of Control Put Event occurs with respect to the 2029 Fixed Rate Notes, the Holders will have the option to require the Issuer to
redeem or, at the Issuer’s option, purchase (or procure the purchase of) the whole, but not part, of such Holders’ 2029 Fixed Rate Notes not previously called for redemption on the Change of Control Put Date at the Change of Control
Redemption Amount together with interest accrued (but unpaid) to (but excluding) the Change of Control Put Date. 
  

	 	5.4	 Special Mandatory Early Redemption 

If the Demerger has not completed by the first anniversary of the Issue Date or, if earlier, GSK releases and announcement which makes public
that it no longer intends to pursue the Demerger, a Special Mandatory Redemption Event shall occur in accordance with the terms of the Indenture, pursuant to which the Issuer shall redeem the 2029 Fixed Rate Notes in whole, but not in part, at a
redemption price equal to 101 per cent, of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

  
 C-13 

	6.	 Denominations; Transfer 

The 2029 Fixed Rate Notes are in book-entry form only, and only in denominations of $250,000 and multiples of $1,000 in excess thereof. A
Holder may transfer 2029 Fixed Rate Notes in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish appropriate endorsements or transfer documents and to pay any taxes and fees required by law or permitted
by the Indenture. 
  

	7.	 Persons Deemed Owners 

The registered Holder of this 2029 Fixed Rate Note may be treated as the owner of it for all purposes. 

 

	8.	 Unclaimed Money 

Any money deposited with the Trustee or the Paying Agent, or then held by the Issuer, as banker for the payment of the principal of or other
amounts on, any 2029 Fixed Rate Note and remaining unclaimed for (a) 10 years after such principal has become due and payable or (b) five years after other amounts have become due and payable, shall promptly upon request be paid to
the Issuer or (if then held by the Issuer) shall be discharged from such trust. The Holder of such 2029 Fixed Rate Note shall thereafter, as an unsecured general creditor, look only to the Issuer for payment thereof, without interest and until such
amount must be remitted to the state under escheat or similar laws, and all liability of the Trustee or the Paying Agent with respect to such trust money, and all liability of the Issuer as trustee thereof, shall thereupon cease. 

 

	9.	 Amendment; Waiver 

Subject to certain exceptions set forth in the Indenture, (i) the Indenture, the 2029 Fixed Rate Notes or the Guarantees may be amended
with the consent of the Holders of a majority in principal amount of the 2029 Fixed Rate Notes then Outstanding and (ii) any past default or noncompliance with any provision may be waived with the consent of the Holders of a majority in
aggregate principal amount of the 2029 Fixed Rate Notes at the time Outstanding (including consents obtained in connection with a tender offer or exchange offer). Subject to certain exceptions set forth in the Indenture, without the consent of any
Holder, the Issuer and the Trustee may amend the Indenture to, among other things, cure any ambiguity, defect or inconsistency in the Indenture, to provide for the assumption by a successor of the obligations of the Issuer, to evidence and provide
for the acceptance of appointment by a successor Trustee, to make any change that does not materially and adversely affect the rights of any Holder or to provide for uncertificated 2029 Fixed Rate Notes in addition to or in place of certificated
2029 Fixed Rate Notes. 

  
 C-14 

	10.	 Defaults and Remedies 

If certain Events of Default with respect to the 2029 Fixed Rate Notes shall occur, the principal amount of all the 2029 Fixed Rate Notes may
be declared to become immediately due and payable. 
 Holders may not enforce the Indenture or the 2029 Fixed Rate Notes except as provided
in the Indenture. The Trustee may refuse to enforce the Indenture or the 2029 Fixed Rate Notes unless it receives reasonable indemnity and/or security. 
  

	11.	 Trustee Dealings with the Issuer 

Subject to certain limitations set forth in the Indenture, the Trustee under the Indenture, in its individual or any other capacity, may become
the owner or pledgee of 2029 Fixed Rate Notes and may otherwise deal with and collect obligations owed to it by the Issuer or its Affiliates and may otherwise deal with the Issuer or its Affiliates with the same rights it would have if it were not
Trustee. 
  

	12.	 No Recourse Against Others 

No recourse for the payment of the principal of or other amounts on any of the 2029 Fixed Rate Notes or for any claim based thereon or
otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Issuer or the applicable Guarantor in this Indenture, or in any of the 2029 Fixed Rate Notes, or because of the creation of any indebtedness
represented thereby, shall be had against any incorporator, limited partner, stockholder, officer, director, employee or controlling person of the Issuer (other than the applicable Guarantor under the Guarantees) or the applicable Guarantor or of
any successor Persons thereof. Each Holder, by accepting the 2029 Fixed Rate Notes, waives and releases all such liability. The waiver and release are part of the consideration for the issuance of the 2029 Fixed Rate Notes. Such waiver may not be
effective to waive liabilities under U.S. federal securities laws. 
  

	13.	 Authentication 

This 2029 Fixed Rate Note shall not be valid until an authorized signatory of the Trustee (or an authenticating agent acting on its behalf)
manually or electronically signs the certificate of authentication on the other side of this 2029 Fixed Rate Note. 
  

	14.	 CUSIP Numbers 

The Issuer in issuing the 2029 Fixed Rate Notes may use “CUSIP” numbers (if then generally in use). No representation is made as to
the accuracy of such numbers either as printed on the 2029 Fixed Rate Notes or as contained in any such notice and reliance may be placed only on the other identification numbers placed on the 2029 Fixed Rate Notes. The Issuer will promptly notify
the Trustee, in writing, of any change in the “CUSIP” number. 

  
 C-15 

	15.	 Governing Law 

THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 

 

	16.	 Demerger Capital Reduction 

By their holding of the 2029 Fixed Rate Note, each Holder shall be deemed without the need for any further action to have unconditionally and
irrevocably (i) consented to any reduction in the capital of Haleon which is implemented within 6 months of the Demerger, (ii) agreed not to object to the Demerger Capital Reduction, and (iii) appointed the Issuer, or such person
(other than the Trustee) as the Issuer shall nominate as its agent to undertake all such acts and take all such steps on its behalf (including, without limitation, the execution and delivery of any documents to any court) as may be necessary or
desirable for Haleon to implement the Demerger Capital Reduction. 
  

	17.	 Agent for Service; Submission to Jurisdiction; Waiver of Immunities 

The Issuer and each Guarantor have agreed that any suit, action or proceeding against the Issuer brought by any Holder or the Trustee arising
out of or based upon the Indenture or the 2029 Fixed Rate Notes may be instituted in any state or federal court in The City of New York, New York. The Issuer and each Guarantor have irrevocably submitted to the
non-exclusive jurisdiction of such courts for such purpose and waived, to the fullest extent permitted by law, trial by jury and any objection they may now or hereafter have to the laying of venue of any such
proceeding, and any claim they may now or hereafter have that any proceeding in any such court is brought in an inconvenient forum. The Guarantors each have appointed the Issuer as its Authorized Agent upon whom all writs, process and summonses may
be served in any suit, action or proceeding arising out of or based upon the Indenture or the 2029 Fixed Rate Notes which may be instituted in any state or federal court in The City of New York, New York. To the extent that either of the Issuer and
the applicable Guarantor have or hereafter may acquire any immunity (sovereign or otherwise) from any legal action, suit or proceeding, from jurisdiction of any court or from set-off or any legal process
(whether service or notice, attachment in aid or otherwise) with respect to themselves or any of their property, the Issuer and the applicable Guarantor have irrevocably waived and agreed not to plead or claim such immunity in respect of their
obligations under the Indenture or the 2029 Fixed Rate Notes. 
 The Issuer shall furnish to any Holder upon written request and without
charge to the Holder a copy of the Indenture which has in it the text of this 2029 Fixed Rate Note. Requests may be made to: GSK Consumer Healthcare Capital US LLC, attention: Timothy Woodthorpe (Group Treasurer),
e-mail: cf.treasury@gsk.com, with copy to: Justin T. Huang (VP and Secretary), Charles David Simpson (VP and Treasurer) and Hatixhe Hoxha (Assistant Secretary), email address: US.CorpSec@gsk.com. 

  
 C-16 

 Schedule A 

SCHEDULE OF INCREASES OR DECREASES IN 2029 FIXED RATE GLOBAL NOTE 

The following increases or decreases in this 2029 Fixed Rate Global Note have been made: 

 

									
	 Date of

Exchange
	  	 Amount of decrease

in Principal Amount
 of this 2029
Fixed
 Rate Global Note
	  	 Amount of increase

in Principal Amount
 of this 2029
Fixed
 Rate Global Note
	  	 Principal Amount of

this 2029 Fixed Rate
Global Note

following such
 decrease or
increase
	  	 Signature of

authorized signatory
 of Trustee
or
 Registrar

		  	  
	  	  
	  	  
	  	  

  

  
 C-17 

 EXHIBIT D 

FORM OF 2032 FIXED RATE GLOBAL NOTE 

[Include the following legend for all Rule 144A Global Notes:] 

THIS NOTE AND THE GUARANTEES OF THIS NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND
INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR
BENEFIT OF, U.S. PERSONS EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, THE HOLDER (A) REPRESENTS, WARRANTS, ACKNOWLEDGES AND AGREES FOR THE BENEFIT OF THE ISSUER, THE GUARANTORS AND THE TRUSTEE THAT IT IS A
‘‘QUALIFIED INSTITUTIONAL BUYER’’ (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) PURCHASING THE SECURITIES FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS; (B) AGREES THAT IT WILL NOT
RESELL OR OTHERWISE TRANSFER THE SECURITIES OTHER THAN (1) TO THE ISSUER, (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, (3) IN THE UNITED STATES TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS A
QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A, OR
(4) IN AN OFFSHORE TRANSACTION TO A NON-U.S. PERSON IN COMPLIANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS OF THE
STATES OF THE UNITED STATES AND ANY OTHER JURISDICTION; AND (C) AGREES THAT IT WILL DELIVER TO EACH PERSON TO WHOM THIS NOTE IS TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. 

[Include the following legend for all Regulation S Global Notes:] 

THIS NOTE AND THE GUARANTEES OF THE NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND INCLUDING)
THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS
AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE 

  
 D-1 

 
OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT OR PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT. UNTIL THE EXPIRY OF THE PERIOD OF 40 DAYS AFTER THE LATER OF (i) THE DATE ON WHICH THE OFFERING OF THIS NOTE TO
PERSONS OTHER THAN THE DISTRIBUTORS IN RELIANCE ON REGULATION S COMMENCED AND (ii) THE DATE OF ISSUANCE OF SUCH NOTE, SALES MAY NOT BE MADE IN THE UNITED STATES OR TO U.S. PERSONS UNLESS MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED IN, AND
IN TRANSACTIONS PURSUANT TO, RULE 144A UNDER THE SECURITIES ACT. 

  
 D-2 

 [FORM OF FACE OF 2032 FIXED RATE GLOBAL NOTE] 

GSK Consumer Healthcare Capital US LLC 

3.625% Fixed Rate Senior Note due 2032 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from and
including the Guarantee Assumption Date) 
 [Include the following for all Rule 144A Global Notes:] 

CUSIP No. (144A): 36264FAD3 
 ISIN
(144A): US36264FAD33 
 Common Code (144A): 246345058 

No.: 
 [Include the following for
all Regulation S Global Notes:] 
 CUSIP No. (Regulation S): U04020AD2 

ISIN (Regulation S): USU04020AD22 

Common Code (Regulation S): 246354243 

No.: 
  

			
		  	 Principal Amount $
  

as revised by Schedule A 
 attached

hereto of Increases and
 Decreases in this 2032 Fixed

Rate Global Note

 This is to certify that CEDE & CO. is, as of the date hereof, the registered holder (the
“Holder”) of $                     of 3.625% Fixed Rate Senior Notes due 2032 represented by this Global Note. GSK Consumer
Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware, promises to pay to the Holder, or registered assigns, the principal sum of
$                     as revised by the Schedule of Increases and Decreases in 2032 Fixed Rate Global Note attached hereto, on March 24,
2032. 
 In the event of a redemption or cancellation of the 2032 Fixed Rate Notes in part only, the 2032 Fixed Rate Notes evidenced by this
2032 Fixed Rate Global Note shall be reduced by the principal amount so redeemed or cancelled. Thereafter, the 2032 Fixed Rate Notes represented by this 2032 Fixed Rate Global Note shall be the principal amount of 2032 Fixed Rate Notes most recently
entered by or on behalf of the Issuer in the relevant column in Schedule A attached hereto. 

  
 D-3 

 Reference is hereby made to the further provisions of this 2032 Fixed Rate Note as set forth
on the reverse hereof, which provisions shall for all purposes have the same effect as if set forth at this place. 
  

			
	GSK CONSUMER HEALTHCARE CAPITAL US LLC
		
	 By:
	 	 
		 	 Name:

		 	 Title:

 

			
	 TRUSTEE’S CERTIFICATE OF
	  	
	 AUTHENTICATION
	  	
		
	 Deutsche Bank Trust Company Americas,

as Trustee, certifies

that this is one of

the 2032 Fixed Rate Notes referred

to in the Indenture
	  	

  

			
	 By:
                                         
               
	  	
	
                Authorized
Signatory
	  	 Date:
                                         
           

  
 D-4 

 GUARANTEE OF GLAXOSMITHKLINE PLC 

For value received, GlaxoSmithKline plc, a public limited company incorporated under the laws of England and Wales, having its principal
executive offices at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “GSK Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this GSK Guarantee
is endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this GSK Guarantee is endorsed and to the Trustee on behalf of each such Holder prior to the date on which GSK ceases to hold a direct or indirect
interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee Assumption
Date”) the due payment of all principal of and other amounts on, each Note payable by GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer”, which term
includes any successor Person under the Indenture) under the Indenture. In case of the failure of the U.S. Issuer to punctually make any such payment or satisfy any such obligation in respect of the U.S. Issuer Notes prior to the Guarantee
Assumption Date, the GSK Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date or by
declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the U.S. Issuer. 
 The indebtedness
evidenced by this GSK Guarantee constitutes an unsubordinated and unsecured obligation of the GSK Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the GSK Guarantor (except for
obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the GSK Guarantor. 

The GSK Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be unaffected
by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the U.S. Issuer with respect thereto, by
the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or indulgence
shall, without the consent of the GSK Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The GSK Guarantor hereby waives diligence, presentment, demand of
payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer, any right to require a proceeding first against the U.S. Issuer, protest or notice with respect to such Note or the indebtedness evidenced thereby or
with respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this GSK Guarantee will not be discharged except by payment or satisfaction in full of the principal of and Additional
Amounts, if any, payable in respect of such Note. This GSK Guarantee is a guarantee of payment and not of collection. 

  
 D-5 

 The GSK Guarantor shall be subrogated to all rights of the Holder of such Note and the
Trustee against the U.S. Issuer in respect of any amounts paid to such Holder by the GSK Guarantor pursuant to the provisions of this GSK Guarantee; provided, however, that the GSK Guarantor shall not be entitled to enforce, or to receive any
payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the GSK Guarantor, which are
absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this GSK Guarantee is endorsed. 

This GSK Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this GSK Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This GSK Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 D-6 

 IN WITNESS WHEREOF, the GSK Guarantor has caused this GSK Guarantee to be duly executed this 24th day of March 2022.      
  

			
	 GLAXOSMITHKLINE PLC,

as the GSK Guarantor

		
	 By:
	 	 
		 	 Name:

		 	 Title:

		
	 By:
	 	 
		 	 Name:

		 	 Title:

  
 D-7 

 GUARANTEE OF HALEON 

For value received, Haleon, a public limited company incorporated under the laws of England and Wales, having its principal executive offices
at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “Haleon Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this Haleon Guarantee is
endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this Haleon Guarantee is endorsed and to the Trustee on behalf of each such Holder from (and including) the date on which GSK ceases to hold a direct or
indirect interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee
Assumption Date”) the due payment of all principal of and other amounts on, each Note payable by GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer,”
which term includes any successor Person under the Indenture) under the Indenture. In case of the failure of the U.S. Issuer to punctually make any such payment or satisfy any such obligation in respect of the U.S. Issuer Notes, from (and including)
the Guarantee Assumption Date, the Haleon Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date
or by declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the U.S. Issuer. 
 The
indebtedness evidenced by this Haleon Guarantee constitutes an unsubordinated and unsecured obligation of the Haleon Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the Haleon
Guarantor (except for obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the Haleon Guarantor. 

The Haleon Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be
unaffected by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the U.S. Issuer with respect
thereto, by the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or
indulgence shall, without the consent of the Haleon Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The Haleon Guarantor hereby waives diligence,
presentment, demand of payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer, any right to require a proceeding first against the U.S., protest or notice with respect to such Note or the indebtedness
evidenced thereby or with respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this Haleon Guarantee will not be discharged except by payment or satisfaction in full of the
principal of and Additional Amounts, if any, payable in respect of such Note. This Haleon Guarantee is a guarantee of payment and not of collection. 

  
 D-8 

 The Haleon Guarantor shall be subrogated to all rights of the Holder of such Note and the
Trustee against the U.S. Issuer in respect of any amounts paid to such Holder by the Haleon Guarantor pursuant to the provisions of this Haleon Guarantee; provided, however, that the Haleon Guarantor shall not be entitled to enforce, or to
receive any payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the Haleon Guarantor, which
are absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this Haleon Guarantee is endorsed. 

This Haleon Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this Haleon Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This Haleon Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 D-9 

 IN WITNESS WHEREOF, the Haleon Guarantor has caused this Haleon Guarantee to be duly executed this 24th day of March 2022. 
  

			
	 HALEON PLC,

as the Haleon Guarantor

		
	 By:
	 	 
		 	 Name:

		 	 Title:

		
	 By:
	 	 
		 	 Name:

		 	 Title:

  
 D-10 

 [REVERSE SIDE OF NOTE] 

GSK Consumer Healthcare Capital US LLC 

3.625% Fixed Rate Senior Note due 2032 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from and
including the Guarantee Assumption Date) 
  

	1.	 Interest 

Interest on the 2032 Fixed Rate Notes will be payable at a rate of 3.625% per annum. 

Interest on the 2032 Fixed Rate Notes will be payable semi-annually in arrear on 24 March and 24 September of each year, commencing
on September 24, 2022 (each a “Fixed Rate Notes Interest Payment Date”) to the person in whose name this 2032 Fixed Rate Note is registered at the close of business on the Regular Record Date that precedes the applicable Fixed
Rate Notes Interest Payment Date. 
 The 2032 Fixed Rate Notes will accrue interest from (and including) the Issue Date, or from the most
recent Fixed Rate Notes Interest Payment Date, to (but excluding) the next succeeding Fixed Rate Notes Interest Payment Date. Interest on the 2032 Fixed Rate Notes will be paid on the basis of twelve 30-day
months assuming a 360-day year. 
  

	2.	 Method of Payment 

Not later than 11:00am New York City time on the due date for any payment due in respect of the 2032 Fixed Rate Notes and on the 2032 Fixed
Rate Notes Maturity Date, GSK Consumer Healthcare Capital US LLC (the “Issuer”) shall deposit with the relevant Paying Agent in same day immediately available funds an amount sufficient to make cash payments due on such due date of
payments of any other amounts or the Maturity Date, as the case may be. Holders must surrender 2032 Fixed Rate Notes to a Paying Agent to collect principal payments. The Issuer shall pay principal and other amounts in cash in U.S. dollars. 

Payments in respect of 2032 Fixed Rate Notes represented by a Global Note (including principal and other amounts) shall be made by the
transfer of immediately available funds to the accounts specified by the Depositary. The Issuer shall make all payments in respect of a Certificated Note (including principal and other amounts) by wire transfer to the specified account maintained by
the payee by giving written notice to the Trustee or the Paying Agent to such effect designating such account no later than 15 days immediately preceding the relevant due date for payment (or such other date as the Trustee may accept in its
discretion). 
  

	3.	 Paying Agent, Transfer Agent, Calculation Agent and Registrar 

Initially, Deutsche Bank Trust Company Americas (the “Trustee”) shall act as Trustee, Principal Paying Agent, Transfer Agent,
calculation agent and as Registrar. The Issuer may appoint and change any Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar without notice to any Holder. The Issuer or the
applicable Guarantor may act as Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar. 

  
 D-11 

	4.	 Indenture 

The Issuer issued the 2032 Fixed Rate Notes under an Indenture, dated as of March 24, 2022 (as it may be amended or supplemented from time
to time in accordance with the terms thereof, the “Indenture”), among the Issuers, the Guarantors, the Trustee, the Principal Paying Agent, the Transfer Agent and the Registrar. The terms of the 2032 Fixed Rate Notes include those
stated in the Indenture. Capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Indenture. The 2032 Fixed Rate Notes are subject to all such terms, and Holders are referred to the Indenture for a statement of
those terms. Each Holder by accepting a 2032 Fixed Rate Note agrees to be bound by all of the terms and provisions of the Indenture, as amended from time to time. 

The 2032 Fixed Rate Notes are general unsecured obligations of the Issuer limited to
$                         aggregate principal amount. 

Prior to the Guarantee Assumption Date, the 2032 Fixed Rate Notes are unconditionally and irrevocably guaranteed by the GSK Guarantor under
the GSK Guarantee. With effect from (and including) the Guarantee Assumption Date, the 2032 Fixed Rate Notes are unconditionally and irrevocably guaranteed by the Haleon Guarantor under the Haleon Guarantee, in each case for the benefit of the
Holders pursuant to the Indenture. 
  

	5.	 Redemption 

Unless earlier redeemed, purchased or cancelled as provided in the Indenture, the Notes will be redeemed by the Issuer at their principal
amount on March 24, 2032. 
 5.1 Optional Redemption for Tax Reasons  

The Issuer may redeem the 2032 Fixed Rate Notes in whole but not in part at any time prior to maturity, at a redemption price equal to 100% of
their principal amount plus accrued interest to the date fixed for redemption, if: 
 (a) the Issuer determines that, as a result of any
change in or amendment to the laws or any regulations or rulings promulgated thereunder of the United Kingdom or the United States, or any change in the application or official interpretation of such laws, regulations or rulings, or any change in
the application or official interpretation of, or any execution of or amendment to, any treaty or treaties affecting taxation to which any such jurisdiction is a party, which change, execution or amendment becomes effective on or after the Issue
Date: (i) the Issuer would be required to pay Additional Amounts on the 2032 Fixed Rate Notes on the next succeeding Interest Payment Date and the payment of such additional amounts cannot be avoided by the use of reasonable measures available
to the Issuer or the applicable Guarantor; or (ii) withholding tax has been or would be required to be withheld with respect to interest income received or receivable by the Issuer directly from the applicable Guarantor (or any Affiliate) and
such withholding tax obligation cannot be avoided by the use of reasonable measures available to the Issuer or the applicable Guarantor (or any Affiliate); or 

  
 D-12 

 (b) the Issuer determines, based upon an opinion of independent counsel of recognised
standing that, as a result of any action taken by any legislative body of, taxing authority of, or any action brought in a court of competent jurisdiction in, the United Kingdom or the United States, which action is taken or brought on after the
Issue Date, there is a substantial probability that the circumstances described above would exist; provided, however, that no such notice of redemption may be given earlier than 90 days prior to the earliest date on which the Issuer
would be obligated to pay such Additional Amounts. 
 5.2 Make-Whole and Par Redemption 

Prior to the 2032 Fixed Rate Notes Par Call Date, the Issuer may redeem the 2032 Fixed Rate Notes, in whole or in part, at its option at any
time and from time to time at a redemption price equal to the greater of (i) 100% of the principal amount of the 2032 Fixed Rate Notes to be redeemed on that redemption date and (ii) as determined by the Issuer, the sum of the present values of
the remaining scheduled payments of principal of and interest on the 2032 Fixed Rate Notes to be redeemed on that redemption date (not including any portion of such payments of interest accrued as of the redemption date) that would be due if the
2032 Fixed Rate Notes matured on the 2032 Fixed Rate Notes Par Call Date, discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve
30-day months) at the Treasury Rate plus 25 basis points, in each case plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

On or after the 2032 Fixed Rate Notes Par Call Date, the Issuer may redeem the 2032 Fixed Rate Notes, in whole or in part, at its option at
any time and from time to time at a redemption price equal to 100% of the principal amount of the 2032 Fixed Rate Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

5.3 Redemption upon a Change of Control Put Event 

If a Change of Control Put Event occurs with respect to the 2032 Fixed Rate Notes, the Holders will have the option to require the Issuer to
redeem or, at the Issuer’s option, purchase (or procure the purchase of) the whole, but not part, of such Holders’ 2032 Fixed Rate Notes not previously called for redemption on the Change of Control Put Date at the Change of Control
Redemption Amount together with interest accrued (but unpaid) to (but excluding) the Change of Control Put Date. 
 5.4 Special Mandatory
Early Redemption 
 If the Demerger has not completed by the first anniversary of the Issue Date or, if earlier, GSK releases an
announcement which makes public that it no longer intends to pursue the Demerger, a Special Mandatory Redemption Event shall occur in accordance with the terms of the Indenture, pursuant to which the Issuer shall redeem the 2032 Fixed Rate Notes in
whole, but not in part, at a redemption price equal to 101 per cent of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

  
 D-13 

	6.	 Denominations; Transfer 

The 2032 Fixed Rate Notes are in book-entry form only, and only in denominations of $250,000 and multiples of $1,000 in excess thereof. A
Holder may transfer 2032 Fixed Rate Notes in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish appropriate endorsements or transfer documents and to pay any taxes and fees required by law or permitted
by the Indenture. 
  

	7.	 Persons Deemed Owners 

The registered Holder of this 2032 Fixed Rate Note may be treated as the owner of it for all purposes. 

 

	8.	 Unclaimed Money 

Any money deposited with the Trustee or the Paying Agent, or then held by the Issuer, as banker for the payment of the principal of or other
amounts on, any 2032 Fixed Rate Note and remaining unclaimed for (a) 10 years after such principal has become due and payable or (b) five years after other amounts have become due and payable, shall promptly upon request be paid to
the Issuer or (if then held by the Issuer) shall be discharged from such trust. The Holder of such 2032 Fixed Rate Note shall thereafter, as an unsecured general creditor, look only to the Issuer for payment thereof, without interest and until such
amount must be remitted to the state under escheat or similar laws, and all liability of the Trustee or the Paying Agent with respect to such trust money, and all liability of the Issuer as trustee thereof, shall thereupon cease. 

 

	9.	 Amendment; Waiver 

Subject to certain exceptions set forth in the Indenture, (i) the Indenture, the 2032 Fixed Rate Notes or the Guarantees may be amended
with the consent of the Holders of a majority in principal amount of the 2032 Fixed Rate Notes then Outstanding and (ii) any past default or noncompliance with any provision may be waived with the consent of the Holders of a majority in
aggregate principal amount of the 2032 Fixed Rate Notes at the time Outstanding (including consents obtained in connection with a tender offer or exchange offer). Subject to certain exceptions set forth in the Indenture, without the consent of any
Holder, the Issuer and the Trustee may amend the Indenture to, among other things, cure any ambiguity, defect or inconsistency in the Indenture, to provide for the assumption by a successor of the obligations of the Issuer, to evidence and provide
for the acceptance of appointment by a successor Trustee, to make any change that does not materially and adversely affect the rights of any Holder or to provide for uncertificated 2032 Fixed Rate Notes in addition to or in place of certificated
2032 Fixed Rate Notes. 

  
 D-14 

	10.	 Defaults and Remedies 

If certain Events of Default with respect to the 2032 Fixed Rate Notes shall occur, the principal amount of all the 2032 Fixed Rate Notes may
be declared to become immediately due and payable. 
 Holders may not enforce the Indenture or the 2032 Fixed Rate Notes except as provided
in the Indenture. The Trustee may refuse to enforce the Indenture or the 2032 Fixed Rate Notes unless it receives reasonable indemnity and/or security. 
  

	11.	 Trustee Dealings with the Issuer 

Subject to certain limitations set forth in the Indenture, the Trustee under the Indenture, in its individual or any other capacity, may become
the owner or pledgee of 2032 Fixed Rate Notes and may otherwise deal with and collect obligations owed to it by the Issuer or its Affiliates and may otherwise deal with the Issuer or its Affiliates with the same rights it would have if it were not
Trustee. 
  

	12.	 No Recourse Against Others 

No recourse for the payment of the principal of or other amounts on any of the 2032 Fixed Rate Notes or for any claim based thereon or
otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Issuer or the applicable Guarantor in this Indenture, or in any of the 2032 Fixed Rate Notes, or because of the creation of any indebtedness
represented thereby, shall be had against any incorporator, limited partner, stockholder, officer, director, employee or controlling person of the Issuer (other than the applicable Guarantor under the Guarantees) or the applicable Guarantor or of
any successor Persons thereof. Each Holder, by accepting the 2032 Fixed Rate Notes, waives and releases all such liability. The waiver and release are part of the consideration for the issuance of the 2032 Fixed Rate Notes. Such waiver may not be
effective to waive liabilities under U.S. federal securities laws. 
  

	13.	 Authentication 

This 2032 Fixed Rate Note shall not be valid until an authorized signatory of the Trustee (or an authenticating agent acting on its behalf)
manually or electronically signs the certificate of authentication on the other side of this 2032 Fixed Rate Note. 
  

	14.	 CUSIP Numbers 

The Issuer in issuing the 2032 Fixed Rate Notes may use “CUSIP” numbers (if then generally in use). No representation is made as to
the accuracy of such numbers either as printed on the 2032 Fixed Rate Notes or as contained in any such notice and reliance may be placed only on the other identification numbers placed on the 2032 Fixed Rate Notes. The Issuer will promptly notify
the Trustee, in writing, of any change in the “CUSIP” number. 

  
 D-15 

	15.	 Governing Law 

THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 

 

	16.	 Demerger Capital Reduction 

By their holding of the 2032 Fixed Rate Note, each Holder shall be deemed without the need for any further action to have unconditionally and
irrevocably (i) consented to any reduction in the capital of Haleon which is implemented within 6 months of the Demerger, (ii) agreed not to object to the Demerger Capital Reduction, and (iii) appointed the Issuer, or such person
(other than the Trustee) as the Issuer shall nominate as its agent to undertake all such acts and take all such steps on its behalf (including, without limitation, the execution and delivery of any documents to any court) as may be necessary or
desirable for Haleon to implement the Demerger Capital Reduction. 
  

	17.	 Agent for Service; Submission to Jurisdiction; Waiver of Immunities 

The Issuer and each Guarantor have agreed that any suit, action or proceeding against the Issuer brought by any Holder or the Trustee arising
out of or based upon the Indenture or the 2032 Fixed Rate Notes may be instituted in any state or federal court in The City of New York, New York. The Issuer and each Guarantor have irrevocably submitted to the
non-exclusive jurisdiction of such courts for such purpose and waived, to the fullest extent permitted by law, trial by jury and any objection they may now or hereafter have to the laying of venue of any such
proceeding, and any claim they may now or hereafter have that any proceeding in any such court is brought in an inconvenient forum. The Guarantors each have appointed the Issuer as its Authorized Agent upon whom all writs, process and summonses may
be served in any suit, action or proceeding arising out of or based upon the Indenture or the 2032 Fixed Rate Notes which may be instituted in any state or federal court in The City of New York, New York. To the extent that either of the Issuer and
the applicable Guarantor have or hereafter may acquire any immunity (sovereign or otherwise) from any legal action, suit or proceeding, from jurisdiction of any court or from set-off or any legal process
(whether service or notice, attachment in aid or otherwise) with respect to themselves or any of their property, the Issuer and the applicable Guarantor have irrevocably waived and agreed not to plead or claim such immunity in respect of their
obligations under the Indenture or the 2032 Fixed Rate Notes. 
 The Issuer shall furnish to any Holder upon written request and without
charge to the Holder a copy of the Indenture which has in it the text of this 2032 Fixed Rate Note. Requests may be made to: GSK Consumer Healthcare Capital US LLC, attention: Timothy Woodthorpe (Group Treasurer),
e-mail: cf.treasury@gsk.com, with copy to: Justin T. Huang (VP and Secretary), Charles David Simpson (VP and Treasurer) and Hatixhe Hoxha (Assistant Secretary), email address: US.CorpSec@gsk.com. 

  
 D-16 

 Schedule A 

SCHEDULE OF INCREASES OR DECREASES IN 2032 FIXED RATE GLOBAL NOTE 

The following increases or decreases in this 2032 Fixed Rate Global Note have been made: 

 

									
	 Date of
Exchange
	  	 Amount of decrease
in Principal Amount
of this 2032
Fixed
Rate Global Note
	  	 Amount of increase
in Principal Amount
of this 2032
Fixed
Rate Global Note
	  	 Principal Amount of
this 2032 Fixed Rate
Global
Note
following such
decrease or increase
	  	 Signature of
authorized signatory
of Trustee
or
Registrar

  

  
 D-17 

 EXHIBIT E 

FORM OF 2052 FIXED RATE GLOBAL NOTE 

[Include the following legend for all Rule 144A Global Notes:] 

THIS NOTE AND THE GUARANTEES OF THIS NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND
INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR
BENEFIT OF, U.S. PERSONS EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, THE HOLDER (A) REPRESENTS, WARRANTS, ACKNOWLEDGES AND AGREES FOR THE BENEFIT OF THE ISSUER, THE GUARANTORS AND THE TRUSTEE THAT IT IS A
‘‘QUALIFIED INSTITUTIONAL BUYER’’ (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) PURCHASING THE SECURITIES FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS; (B) AGREES THAT IT WILL NOT
RESELL OR OTHERWISE TRANSFER THE SECURITIES OTHER THAN (1) TO THE ISSUER, (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, (3) IN THE UNITED STATES TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS A
QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A, OR
(4) IN AN OFFSHORE TRANSACTION TO A NON-U.S. PERSON IN COMPLIANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS OF THE
STATES OF THE UNITED STATES AND ANY OTHER JURISDICTION; AND (C) AGREES THAT IT WILL DELIVER TO EACH PERSON TO WHOM THIS NOTE IS TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. 

[Include the following legend for all Regulation S Global Notes:] 

THIS NOTE AND THE GUARANTEES OF THE NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND
INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE 

  
 E-1 

 
OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT OR PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT. UNTIL THE EXPIRY OF THE PERIOD OF 40 DAYS AFTER THE LATER OF (i) THE DATE ON WHICH THE OFFERING OF THIS NOTE TO
PERSONS OTHER THAN THE DISTRIBUTORS IN RELIANCE ON REGULATION S COMMENCED AND (ii) THE DATE OF ISSUANCE OF SUCH NOTE, SALES MAY NOT BE MADE IN THE UNITED STATES OR TO U.S. PERSONS UNLESS MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED IN, AND
IN TRANSACTIONS PURSUANT TO, RULE 144A UNDER THE SECURITIES ACT. 

  
 E-2 

 [FORM OF FACE OF 2052 FIXED RATE GLOBAL NOTE] 

GSK Consumer Healthcare Capital US LLC 

4.000% Fixed Rate Senior Note due 2052 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from and
including the Guarantee Assumption Date) 
 [Include the following for all Rule 144A Global Notes:] 

CUSIP No. (144A): 36264FAE1 
 ISIN
(144A): US36264FAE16 
 Common Code (144A): 246354286 

No.: 
 [Include the following for
all Regulation S Global Notes:] 
 CUSIP No. (Regulation S): U04020AE0 

ISIN (Regulation S): USU04020AE05 

Common Code (Regulation S): 246354251 

No.: 
 Principal Amount
$                
 as revised by Schedule
A       

attached                   
               
 hereto of Increases
and          
 Decreases in this 2052 Fixed 

Rate Global Note                  

 This is to certify that CEDE & CO. is, as of the date hereof, the registered holder (the “Holder”) of
$                     of 4.000% Fixed Rate Senior Notes due 2052 represented by this Global Note. GSK Consumer Healthcare Capital US LLC, a
public limited company incorporated under the laws of Delaware, promises to pay to the Holder, or registered assigns, the principal sum of
$                     as revised by the Schedule of Increases and Decreases in 2052 Fixed Rate Global Note attached hereto, on March 24,
2052. 
 In the event of a redemption or cancellation of the 2052 Fixed Rate Notes in part only, the 2052 Fixed Rate Notes evidenced by this
2052 Fixed Rate Global Note shall be reduced by the principal amount so redeemed or cancelled. Thereafter, the 2052 Fixed Rate Notes represented by this 2052 Fixed Rate Global Note shall be the principal amount of 2052 Fixed Rate Notes most recently
entered by or on behalf of the Issuer in the relevant column in Schedule A attached hereto. 

  
 E-3 

 Reference is hereby made to the further provisions of this 2052 Fixed Rate Note as set forth
on the reverse hereof, which provisions shall for all purposes have the same effect as if set forth at this place. 
  

			
	GSK CONSUMER HEALTHCARE CAPITAL US LLC
		
	By:	 	 
		 	Name:
		 	Title:

  

			
	TRUSTEE’S CERTIFICATE OF
	AUTHENTICATION
	
	Deutsche Bank Trust Company Americas, as Trustee, certifies that this is one of the 2052 Fixed Rate Notes referred to in the Indenture

 

			
	 By:
                                         
               
	  	
	
                Authorized
Signatory
	  	 Date:
                                         
           

  
 E-4 

 GUARANTEE OF GLAXOSMITHKLINE PLC 

For value received, GlaxoSmithKline plc, a public limited company incorporated under the laws of England and Wales, having its principal
executive offices at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “GSK Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this GSK Guarantee
is endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this GSK Guarantee is endorsed and to the Trustee on behalf of each such Holder prior to the date on which GSK ceases to hold a direct or indirect
interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee Assumption
Date”) the due payment of all principal of and other amounts on, each Note payable by GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer”, which term
includes any successor Person under the Indenture) under the Indenture. In case of the failure of the U.S. Issuer to punctually make any such payment or satisfy any such obligation in respect of the U.S. Issuer Notes prior to the Guarantee
Assumption Date, the GSK Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date or by
declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the U.S. Issuer. 
 The indebtedness
evidenced by this GSK Guarantee constitutes an unsubordinated and unsecured obligation of the GSK Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the GSK Guarantor (except for
obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the GSK Guarantor. 

The GSK Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be unaffected
by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the U.S. Issuer with respect thereto, by
the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or indulgence
shall, without the consent of the GSK Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The GSK Guarantor hereby waives diligence, presentment, demand of
payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer, any right to require a proceeding first against the U.S. Issuer, protest or notice with respect to such Note or the indebtedness evidenced thereby or
with respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this GSK Guarantee will not be discharged except by payment or satisfaction in full of the principal of and Additional
Amounts, if any, payable in respect of such Note. This GSK Guarantee is a guarantee of payment and not of collection. 

  
 E-5 

 The GSK Guarantor shall be subrogated to all rights of the Holder of such Note and the
Trustee against the U.S. Issuer in respect of any amounts paid to such Holder by the GSK Guarantor pursuant to the provisions of this GSK Guarantee; provided, however, that the GSK Guarantor shall not be entitled to enforce, or to receive any
payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the GSK Guarantor, which are
absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this GSK Guarantee is endorsed. 

This GSK Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this GSK Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This GSK Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 E-6 

 IN WITNESS WHEREOF, the GSK Guarantor has caused this GSK Guarantee to be duly executed this 24th day of March 2022.      
  

			
	GLAXOSMITHKLINE PLC,
as the GSK Guarantor
		
	By:	 	 
		 	Name:
		 	Title:
		
	By:	 	 
		 	Name:
		 	Title:

  
 E-7 

 GUARANTEE OF HALEON 

For value received, Haleon, a public limited company incorporated under the laws of England and Wales, having its principal executive offices
at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “Haleon Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this Haleon Guarantee is
endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this Haleon Guarantee is endorsed and to the Trustee on behalf of each such Holder from (and including) the date on which GSK ceases to hold a direct or
indirect interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee
Assumption Date”) the due payment of all principal of and other amounts on, each Note payable by GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer,”
which term includes any successor Person under the Indenture) under the Indenture. In case of the failure of the U.S. Issuer to punctually make any such payment or satisfy any such obligation in respect of the U.S. Issuer Notes, from (and including)
the Guarantee Assumption Date, the Haleon Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date
or by declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the U.S. Issuer. 
 The
indebtedness evidenced by this Haleon Guarantee constitutes an unsubordinated and unsecured obligation of the Haleon Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the Haleon
Guarantor (except for obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the Haleon Guarantor. 

The Haleon Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be
unaffected by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the U.S. Issuer with respect
thereto, by the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or
indulgence shall, without the consent of the Haleon Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The Haleon Guarantor hereby waives diligence,
presentment, demand of payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer, any right to require a proceeding first against the U.S., protest or notice with respect to such Note or the indebtedness
evidenced thereby or with respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this Haleon Guarantee will not be discharged except by payment or satisfaction in full of the
principal of and Additional Amounts, if any, payable in respect of such Note. This Haleon Guarantee is a guarantee of payment and not of collection. 

  
 E-8 

 The Haleon Guarantor shall be subrogated to all rights of the Holder of such Note and the
Trustee against the U.S. Issuer in respect of any amounts paid to such Holder by the Haleon Guarantor pursuant to the provisions of this Haleon Guarantee; provided, however, that the Haleon Guarantor shall not be entitled to enforce, or to
receive any payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the Haleon Guarantor, which
are absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this Haleon Guarantee is endorsed. 

This Haleon Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this Haleon Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This Haleon Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 E-9 

 IN WITNESS WHEREOF, the Haleon Guarantor has caused this Haleon Guarantee to be duly executed this 24th day of March 2022. 
  

			
	HALEON PLC,
as the Haleon Guarantor
		
	By:	 	 
		 	Name:
		 	Title:
		
	By:	 	 
		 	Name:
		 	Title:

  
 E-10 

 [REVERSE SIDE OF NOTE] 

GSK Consumer Healthcare Capital US LLC 

4.000% Fixed Rate Senior Note due 2052 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from and
including the Guarantee Assumption Date) 
  

	1.	 Interest 

Interest on the 2052 Fixed Rate Notes will be payable at a rate of 4.000% per annum. 

Interest on the 2052 Fixed Rate Notes will be payable semi-annually in arrear on 24 March and 24 September of each year, commencing
on September 24, 2022 (each a “Fixed Rate Notes Interest Payment Date”) to the person in whose name this 2052 Fixed Rate Note is registered at the close of business on the Regular Record Date that precedes the applicable Fixed
Rate Notes Interest Payment Date. 
 The 2052 Fixed Rate Notes will accrue interest from (and including) the Issue Date, or from the most
recent Fixed Rate Notes Interest Payment Date, to (but excluding) the next succeeding Fixed Rate Notes Interest Payment Date. Interest on the 2052 Fixed Rate Notes will be paid on the basis of twelve 30-day
months assuming a 360-day year. 
  

	2.	 Method of Payment 

Not later than 11:00am New York City time on the due date for any payment due in respect of the 2052 Fixed Rate Notes and on the 2052 Fixed
Rate Notes Maturity Date, GSK Consumer Healthcare US LLC (the “Issuer”) shall deposit with the relevant Paying Agent in same day immediately available funds an amount sufficient to make cash payments due on such due date of payments
of any other amounts or the Maturity Date, as the case may be. Holders must surrender 2052 Fixed Rate Notes to a Paying Agent to collect principal payments. The Issuer shall pay principal and other amounts in cash in U.S. dollars. 

Payments in respect of 2052 Fixed Rate Notes represented by a Global Note (including principal and other amounts) shall be made by the
transfer of immediately available funds to the accounts specified by the Depositary. The Issuer shall make all payments in respect of a Certificated Note (including principal and other amounts) by wire transfer to the specified account maintained by
the payee by giving written notice to the Trustee or the Paying Agent to such effect designating such account no later than 15 days immediately preceding the relevant due date for payment (or such other date as the Trustee may accept in its
discretion). 
  

	3.	 Paying Agent, Transfer Agent, Calculation Agent and Registrar 

Initially, Deutsche Bank Trust Company Americas (the “Trustee”) shall act as Trustee, Principal Paying Agent, Transfer Agent,
calculation agent and as Registrar. The Issuer may appoint and change any Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar without notice to any Holder. The Issuer or the
applicable Guarantor may act as Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar. 

  
 E-11 

	4.	 Indenture 

The Issuer issued the 2052 Fixed Rate Notes under an Indenture, dated as of March 24, 2022 (as it may be amended or supplemented from time
to time in accordance with the terms thereof, the “Indenture”), among the Issuers, the Guarantors, the Trustee, the Principal Paying Agent, the Transfer Agent and the Registrar. The terms of the 2052 Fixed Rate Notes include those
stated in the Indenture. Capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Indenture. The 2052 Fixed Rate Notes are subject to all such terms, and Holders are referred to the Indenture for a statement of
those terms. Each Holder by accepting a 2052 Fixed Rate Note agrees to be bound by all of the terms and provisions of the Indenture, as amended from time to time. 

The 2052 Fixed Rate Notes are general unsecured obligations of the Issuer limited to
$                     aggregate principal amount. 

Prior to the Guarantee Assumption Date, the 2052 Fixed Rate Notes are unconditionally and irrevocably guaranteed by the GSK Guarantor under
the GSK Guarantee. With effect from (and including) the Guarantee Assumption Date, the 2052 Fixed Rate Notes are unconditionally and irrevocably guaranteed by the Haleon Guarantor under the Haleon Guarantee, in each case for the benefit of the
Holders pursuant to the Indenture. 
  

	5.	 Redemption 

Unless earlier redeemed, purchased or cancelled as provided in the Indenture, the Notes will be redeemed by the Issuer at their principal
amount on March 24, 2052. 
 5.1 Optional Redemption for Tax Reasons  

The Issuer may redeem the 2052 Fixed Rate Notes in whole but not in part at any time prior to maturity, at a redemption price equal to 100% of
their principal amount plus accrued interest to the date fixed for redemption, if: 
 (a) the Issuer determines that, as a result of any
change in or amendment to the laws or any regulations or rulings promulgated thereunder of the United Kingdom or the United States, or any change in the application or official interpretation of such laws, regulations or rulings, or any change in
the application or official interpretation of, or any execution of or amendment to, any treaty or treaties affecting taxation to which any such jurisdiction is a party, which change, execution or amendment becomes effective on or after the Issue
Date: (i) the Issuer would be required to pay Additional Amounts on the 2052 Fixed Rate Notes on the next succeeding Interest Payment Date and the payment of such additional amounts cannot be avoided by the use of reasonable measures available
to the Issuer or the applicable Guarantor; or (ii) withholding tax has been or would be required to be withheld with respect to interest income received or receivable by the Issuer directly from the applicable Guarantor (or any Affiliate) and
such withholding tax obligation cannot be avoided by the use of reasonable measures available to the Issuer or the applicable Guarantor (or any Affiliate); or 

  
 E-12 

 (b) the Issuer determines, based upon an opinion of independent counsel of recognised
standing that, as a result of any action taken by any legislative body of, taxing authority of, or any action brought in a court of competent jurisdiction in, the United Kingdom or the United States, which action is taken or brought on after the
Issue Date, there is a substantial probability that the circumstances described above would exist; provided, however, that no such notice of redemption may be given earlier than 90 days prior to the earliest date on which the Issuer
would be obligated to pay such Additional Amounts. 
 5.2 Make-Whole and Par Redemption 

Prior to the 2052 Fixed Rate Notes Par Call Date, the Issuer may redeem the 2052 Fixed Rate Notes, in whole or in part, at its option at any
time and from time to time at a redemption price equal to the greater of (i) 100% of the principal amount of the 2052 Fixed Rate Notes to be redeemed on that redemption date and (ii) as determined by the Issuer, the sum of the present values of
the remaining scheduled payments of principal of and interest on the 2052 Fixed Rate Notes to be redeemed on that redemption date (not including any portion of such payments of interest accrued as of the redemption date) that would be due if the
2052 Fixed Rate Notes matured on the 2052 Fixed Rate Notes Par Call Date, discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve
30-day months) at the Treasury Rate plus 25 basis points, in each case plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

On or after the 2052 Fixed Rate Notes Par Call Date, the Issuer may redeem the 2052 Fixed Rate Notes, in whole or in part, at its option at
any time and from time to time at a redemption price equal to 100% of the principal amount of the 2052 Fixed Rate Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

5.3 Redemption upon a Change of Control Put Event 

If a Change of Control Put Event occurs with respect to the 2052 Fixed Rate Notes, the Holders will have the option to require the Issuer to
redeem or, at the Issuer’s option, purchase (or procure the purchase of) the whole, but not part, of such Holders’ 2052 Fixed Rate Notes not previously called for redemption on the Change of Control Put Date at the Change of Control
Redemption Amount together with interest accrued (but unpaid) to (but excluding) the Change of Control Put Date. 
 5.4 Special Mandatory
Early Redemption 
 If the Demerger has not completed by the first anniversary of the Issue Date or, if earlier, GSK releases an
announcement which makes public that it no longer intends to pursue the Demerger, a Special Mandatory Redemption Event shall occur in accordance with the terms of the Indenture, pursuant to which the Issuer shall redeem the 2052 Fixed Rate Notes in
whole, but not in part, at a redemption price equal to 101 per cent, of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

  
 E-13 

	6.	 Denominations; Transfer 

The 2052 Fixed Rate Notes are in book-entry form only, and only in denominations of $250,000 and multiples of $1,000 in excess thereof. A
Holder may transfer 2052 Fixed Rate Notes in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish appropriate endorsements or transfer documents and to pay any taxes and fees required by law or permitted
by the Indenture. 
  

	7.	 Persons Deemed Owners 

The registered Holder of this 2052 Fixed Rate Note may be treated as the owner of it for all purposes. 

 

	8.	 Unclaimed Money 

Any money deposited with the Trustee or the Paying Agent, or then held by the Issuer, as banker for the payment of the principal of or other
amounts on, any 2052 Fixed Rate Note and remaining unclaimed for (a) 10 years after such principal has become due and payable or (b) five years after other amounts have become due and payable, shall promptly upon request be paid to
the Issuer or (if then held by the Issuer) shall be discharged from such trust. The Holder of such 2052 Fixed Rate Note shall thereafter, as an unsecured general creditor, look only to the Issuer for payment thereof, without interest and until such
amount must be remitted to the state under escheat or similar laws, and all liability of the Trustee or the Paying Agent with respect to such trust money, and all liability of the Issuer as trustee thereof, shall thereupon cease. 

 

	9.	 Amendment; Waiver 

Subject to certain exceptions set forth in the Indenture, (i) the Indenture, the 2052 Fixed Rate Notes or the Guarantees may be amended
with the consent of the Holders of a majority in principal amount of the 2052 Fixed Rate Notes then Outstanding and (ii) any past default or noncompliance with any provision may be waived with the consent of the Holders of a majority in
aggregate principal amount of the 2052 Fixed Rate Notes at the time Outstanding (including consents obtained in connection with a tender offer or exchange offer). Subject to certain exceptions set forth in the Indenture, without the consent of any
Holder, the Issuer and the Trustee may amend the Indenture to, among other things, cure any ambiguity, defect or inconsistency in the Indenture, to provide for the assumption by a successor of the obligations of the Issuer, to evidence and provide
for the acceptance of appointment by a successor Trustee, to make any change that does not materially and adversely affect the rights of any Holder or to provide for uncertificated 2052 Fixed Rate Notes in addition to or in place of certificated
2052 Fixed Rate Notes. 

  
 E-14 

	10.	 Defaults and Remedies 

If certain Events of Default with respect to the 2052 Fixed Rate Notes shall occur, the principal amount of all the 2052 Fixed Rate Notes may
be declared to become immediately due and payable. 
 Holders may not enforce the Indenture or the 2052 Fixed Rate Notes except as provided
in the Indenture. The Trustee may refuse to enforce the Indenture or the 2052 Fixed Rate Notes unless it receives reasonable indemnity and/or security. 
  

	11.	 Trustee Dealings with the Issuer 

Subject to certain limitations set forth in the Indenture, the Trustee under the Indenture, in its individual or any other capacity, may become
the owner or pledgee of 2052 Fixed Rate Notes and may otherwise deal with and collect obligations owed to it by the Issuer or its Affiliates and may otherwise deal with the Issuer or its Affiliates with the same rights it would have if it were not
Trustee. 
  

	12.	 No Recourse Against Others 

No recourse for the payment of the principal of or other amounts on any of the 2052 Fixed Rate Notes or for any claim based thereon or
otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Issuer or the applicable Guarantor in this Indenture, or in any of the 2052 Fixed Rate Notes, or because of the creation of any indebtedness
represented thereby, shall be had against any incorporator, limited partner, stockholder, officer, director, employee or controlling person of the Issuer (other than the applicable Guarantor under the Guarantees) or the applicable Guarantor or of
any successor Persons thereof. Each Holder, by accepting the 2052 Fixed Rate Notes, waives and releases all such liability. The waiver and release are part of the consideration for the issuance of the 2052 Fixed Rate Notes. Such waiver may not be
effective to waive liabilities under U.S. federal securities laws. 
  

	13.	 Authentication 

This 2052 Fixed Rate Note shall not be valid until an authorized signatory of the Trustee (or an authenticating agent acting on its behalf)
manually or electronically signs the certificate of authentication on the other side of this 2052 Fixed Rate Note. 
  

	14.	 CUSIP Numbers 

The Issuer in issuing the 2052 Fixed Rate Notes may use “CUSIP” numbers (if then generally in use). No representation is made as to
the accuracy of such numbers either as printed on the 2052 Fixed Rate Notes or as contained in any such notice and reliance may be placed only on the other identification numbers placed on the 2052 Fixed Rate Notes. The Issuer will promptly notify
the Trustee, in writing, of any change in the “CUSIP” number. 

  
 E-15 

	15.	 Governing Law 

THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 

 

	16.	 Demerger Capital Reduction 

By their holding of the 2052 Fixed Rate Note, each Holder shall be deemed without the need for any further action to have unconditionally and
irrevocably (i) consented to any reduction in the capital of Haleon which is implemented within 6 months of the Demerger, (ii) agreed not to object to the Demerger Capital Reduction, and (iii) appointed the Issuer, or such person
(other than the Trustee) as the Issuer shall nominate as its agent to undertake all such acts and take all such steps on its behalf (including, without limitation, the execution and delivery of any documents to any court) as may be necessary or
desirable for Haleon to implement the Demerger Capital Reduction. 
  

	17.	 Agent for Service; Submission to Jurisdiction; Waiver of Immunities 

The Issuer and each Guarantor have agreed that any suit, action or proceeding against the Issuer brought by any Holder or the Trustee arising
out of or based upon the Indenture or the 2052 Fixed Rate Notes may be instituted in any state or federal court in The City of New York, New York. The Issuer and each Guarantor have irrevocably submitted to the
non-exclusive jurisdiction of such courts for such purpose and waived, to the fullest extent permitted by law, trial by jury and any objection they may now or hereafter have to the laying of venue of any such
proceeding, and any claim they may now or hereafter have that any proceeding in any such court is brought in an inconvenient forum. The Guarantors each have appointed the Issuer as its Authorized Agent upon whom all writs, process and summonses may
be served in any suit, action or proceeding arising out of or based upon the Indenture or the 2052 Fixed Rate Notes which may be instituted in any state or federal court in The City of New York, New York. To the extent that either of the Issuer and
the applicable Guarantor have or hereafter may acquire any immunity (sovereign or otherwise) from any legal action, suit or proceeding, from jurisdiction of any court or from set-off or any legal process
(whether service or notice, attachment in aid or otherwise) with respect to themselves or any of their property, the Issuer and the applicable Guarantor have irrevocably waived and agreed not to plead or claim such immunity in respect of their
obligations under the Indenture or the 2052 Fixed Rate Notes. 
 The Issuer shall furnish to any Holder upon written request and without
charge to the Holder a copy of the Indenture which has in it the text of this 2052 Fixed Rate Note. Requests may be made to: GSK Consumer Healthcare Capital US LLC, attention: Timothy Woodthorpe (Group Treasurer),
e-mail: cf.treasury@gsk.com, with copy to: Justin T. Huang (VP and Secretary), Charles David Simpson (VP and Treasurer) and Hatixhe Hoxha (Assistant Secretary), email address: US.CorpSec@gsk.com. 

  
 E-16 

 Schedule A 

SCHEDULE OF INCREASES OR DECREASES IN 2052 FIXED RATE GLOBAL NOTE 

The following increases or decreases in this 2052 Fixed Rate Global Note have been made: 

 

									
	 Date of Exchange
	  	
Amount of decrease
in Principal Amount
of this 2052 Fixed
Rate Global Note
	  	
Amount of increase
in Principal Amount
of this 2052 Fixed
Rate Global Note
	  	
Principal Amount of
this 2052 Fixed Rate
Global Note
following such
decrease or increase
	  	 Signature of
authorized signatory
of Trustee
or
Registrar

  

  
 E-17 

 EXHIBIT F 

FORM OF CALLABLE FIXED RATE GLOBAL NOTE 

[Include the following legend for all Rule 144A Global Notes:] 

THIS NOTE AND THE GUARANTEES OF THIS NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND
INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR
BENEFIT OF, U.S. PERSONS EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, THE HOLDER (A) REPRESENTS, WARRANTS, ACKNOWLEDGES AND AGREES FOR THE BENEFIT OF THE ISSUER, THE GUARANTORS AND THE TRUSTEE THAT IT IS A
‘‘QUALIFIED INSTITUTIONAL BUYER’’ (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) PURCHASING THE SECURITIES FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS; (B) AGREES THAT IT WILL NOT
RESELL OR OTHERWISE TRANSFER THE SECURITIES OTHER THAN (1) TO THE ISSUER, (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, (3) IN THE UNITED STATES TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS A
QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A, OR
(4) IN AN OFFSHORE TRANSACTION TO A NON-U.S. PERSON IN COMPLIANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS OF THE
STATES OF THE UNITED STATES AND ANY OTHER JURISDICTION; AND (C) AGREES THAT IT WILL DELIVER TO EACH PERSON TO WHOM THIS NOTE IS TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. 

[Include the following legend for all Regulation S Global Notes:] 

THIS NOTE AND THE GUARANTEES OF THE NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND
INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE 

  
 F-1 

 
OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT OR PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT. UNTIL THE EXPIRY OF THE PERIOD OF 40 DAYS AFTER THE LATER OF (i) THE DATE ON WHICH THE OFFERING OF THIS NOTE TO
PERSONS OTHER THAN THE DISTRIBUTORS IN RELIANCE ON REGULATION S COMMENCED AND (ii) THE DATE OF ISSUANCE OF SUCH NOTE, SALES MAY NOT BE MADE IN THE UNITED STATES OR TO U.S. PERSONS UNLESS MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED IN, AND
IN TRANSACTIONS PURSUANT TO, RULE 144A UNDER THE SECURITIES ACT. 

  
 F-2 

 [FORM OF FACE OF CALLABLE FIXED RATE GLOBAL NOTE] 

GSK Consumer Healthcare Capital US LLC 

3.024% Callable Fixed Rate Senior Note due 2024 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from
and including the Guarantee Assumption Date) 
 [Include the following for all Rule 144A Global Notes:] 

CUSIP No. (144A): 36264FAA9 
 ISIN
(144A): US36264FAA93 
 Common Code (144A): 246354294 

No.: 
 [Include the following
for all Regulation S Global Notes:] 
 CUSIP No. (Regulation S): U04020AA8 

ISIN (Regulation S): USU04020AA82 

Common Code (Regulation S): 246354227 

No.: 
  

			
		 	 Principal Amount $        
  

as revised by Schedule A
 attached

hereto of Increases and
 Decreases in this Callable

Fixed Rate Global Note

  
 This is to certify that CEDE &
CO. is, as of the date hereof, the registered holder (the “Holder”) of $                 of 3.024% Callable Fixed Rate Senior Notes due
2024 represented by this Global Note. GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware, promises to pay to the Holder, or registered assigns, the principal sum of
$                 as revised by the Schedule of Increases and Decreases in Callable Fixed Rate Global Note attached hereto, on March 24, 2024. 

In the event of a redemption or cancellation of the Callable Fixed Rate Notes in part only, the Callable Fixed Rate Notes evidenced by this
Callable Fixed Rate Global Note shall be reduced by the principal amount so redeemed or cancelled. Thereafter, the Callable Fixed Rate Notes represented by this Callable Fixed Rate Global Note shall be the principal amount of Callable Fixed Rate
Notes most recently entered by or on behalf of the Issuer in the relevant column in Schedule A attached hereto. 

  
 F-3 

 Reference is hereby made to the further provisions of this Callable Fixed Rate Note as set
forth on the reverse hereof, which provisions shall for all purposes have the same effect as if set forth at this place. 
  

			
	GSK CONSUMER HEALTHCARE CAPITAL US LLC
		
	By:	 	 
		 	Name:
		 	Title:

  

									
	TRUSTEE’S CERTIFICATE OF AUTHENTICATION	 		 	
			
	Deutsche Bank Trust Company Americas, as Trustee, certifies that this is one of the Callable Fixed Rate Notes referred to in the Indenture	 		 	

  

			
	 By:
                                         
               
	  	
	
                Authorized
Signatory
	  	 Date:
                                         
           

  
 F-4 

 GUARANTEE OF GLAXOSMITHKLINE PLC 

For value received, GlaxoSmithKline plc, a public limited company incorporated under the laws of England and Wales, having its principal
executive offices at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “GSK Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this GSK Guarantee
is endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this GSK Guarantee is endorsed and to the Trustee on behalf of each such Holder prior to the date on which GSK ceases to hold a direct or indirect
interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee Assumption
Date”) the due payment of all principal of and other amounts on, each Note payable by GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer”, which term
includes any successor Person under the Indenture) under the Indenture. In case of the failure of the U.S. Issuer to punctually make any such payment or satisfy any such obligation in respect of the U.S. Issuer Notes prior to the Guarantee
Assumption Date, the GSK Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date or by
declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the U.S. Issuer. 
 The indebtedness
evidenced by this GSK Guarantee constitutes an unsubordinated and unsecured obligation of the GSK Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the GSK Guarantor (except for
obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the GSK Guarantor. 

The GSK Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be unaffected
by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the U.S. Issuer with respect thereto, by
the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or indulgence
shall, without the consent of the GSK Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The GSK Guarantor hereby waives diligence, presentment, demand of
payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer, any right to require a proceeding first against the U.S. Issuer, protest or notice with respect to such Note or the indebtedness evidenced thereby or
with respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this GSK Guarantee will not be discharged except by payment or satisfaction in full of the principal of and Additional
Amounts, if any, payable in respect of such Note. This GSK Guarantee is a guarantee of payment and not of collection. 

  
 F-5 

 The GSK Guarantor shall be subrogated to all rights of the Holder of such Note and the
Trustee against the U.S. Issuer in respect of any amounts paid to such Holder by the GSK Guarantor pursuant to the provisions of this GSK Guarantee; provided, however, that the GSK Guarantor shall not be entitled to enforce, or to receive any
payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the GSK Guarantor, which are
absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this GSK Guarantee is endorsed. 

This GSK Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this GSK Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This GSK Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 F-6 

 IN WITNESS WHEREOF, the GSK Guarantor has caused this GSK Guarantee to be duly executed this 24th day of March 2022.      
  

			
	GLAXOSMITHKLINE PLC, as the GSK Guarantor

 
			
		
	By:	 	 
		 	Name:
		 	Title:
		
	By:	 	 
		 	Name:
		 	Title:

  
 F-7 

 GUARANTEE OF HALEON 

For value received, Haleon, a public limited company incorporated under the laws of England and Wales, having its principal executive offices
at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “Haleon Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this Haleon Guarantee is
endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this Haleon Guarantee is endorsed and to the Trustee on behalf of each such Holder from (and including) the date on which GSK ceases to hold a direct or
indirect interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee
Assumption Date”) the due payment of all principal of and other amounts on, each Note payable by GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer,”
which term includes any successor Person under the Indenture) under the Indenture. In case of the failure of the U.S. Issuer to punctually make any such payment or satisfy any such obligation in respect of the U.S. Issuer Notes, from (and including)
the Guarantee Assumption Date, the Haleon Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date
or by declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the U.S. Issuer. 
 The
indebtedness evidenced by this Haleon Guarantee constitutes an unsubordinated and unsecured obligation of the Haleon Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the Haleon
Guarantor (except for obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the Haleon Guarantor. 

The Haleon Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be
unaffected by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the U.S. Issuer with respect
thereto, by the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or
indulgence shall, without the consent of the Haleon Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The Haleon Guarantor hereby waives diligence,
presentment, demand of payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer, any right to require a proceeding first against the U.S., protest or notice with respect to such Note or the indebtedness
evidenced thereby or with respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this Haleon Guarantee will not be discharged except by payment or satisfaction in full of the
principal of and Additional Amounts, if any, payable in respect of such Note. This Haleon Guarantee is a guarantee of payment and not of collection. 

  
 F-8 

 The Haleon Guarantor shall be subrogated to all rights of the Holder of such Note and the
Trustee against the U.S. Issuer in respect of any amounts paid to such Holder by the Haleon Guarantor pursuant to the provisions of this Haleon Guarantee; provided, however, that the Haleon Guarantor shall not be entitled to enforce, or to
receive any payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the Haleon Guarantor, which
are absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this Haleon Guarantee is endorsed. 

This Haleon Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this Haleon Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This Haleon Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 F-9 

 IN WITNESS WHEREOF, the Haleon Guarantor has caused this Haleon Guarantee to be duly executed this 24th day of March 2022. 
  

			
	HALEON PLC, as the Haleon Guarantor

 
			
		
	By:	 	 
		 	Name:
		 	Title:
		
	By:	 	 
		 	Name:
		 	Title:

  
 F-10 

 [REVERSE SIDE OF NOTE] 

GSK Consumer Healthcare Capital US LLC 

3.024% Callable Fixed Rate Senior Note due 2024 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from
and including the Guarantee Assumption Date) 
  

	1.	 Interest 

Interest on the Callable Fixed Rate Notes will be payable at a rate of 3.024% per annum. 

Interest on the Callable Fixed Rate Notes will be payable semi-annually in arrear on 24 March and 24 September of each year,
commencing on September 24, 2022 (each a “Fixed Rate Notes Interest Payment Date”) to the person in whose name this Callable Fixed Rate Note is registered at the close of business on the Regular Record Date that precedes the
applicable Fixed Rate Notes Interest Payment Date. 
 The Callable Fixed Rate Notes will accrue interest from (and including) the Issue
Date, or from the most recent Fixed Rate Notes Interest Payment Date, to (but excluding) the next succeeding Fixed Rate Notes Interest Payment Date. Interest on the Callable Fixed Rate Notes will be paid on the basis of twelve 30-day months assuming a 360-day year. 
  

	2.	 Method of Payment 

Not later than 11:00am New York City time on the due date for any payment due in respect of the Callable Fixed Rate Notes and on the Callable
Fixed Rate Notes Maturity Date, GSK Consumer Healthcare Capital US LLC (the “Issuer”) shall deposit with the relevant Paying Agent in same day immediately available funds an amount sufficient to make cash payments due on such due
date of payments of any other amounts or the Maturity Date, as the case may be. Holders must surrender Callable Fixed Rate Notes to a Paying Agent to collect principal payments. The Issuer shall pay principal and other amounts in cash in U.S.
dollars. 
 Payments in respect of Callable Fixed Rate Notes represented by a Global Note (including principal and other amounts) shall be
made by the transfer of immediately available funds to the accounts specified by the Depositary. The Issuer shall make all payments in respect of a Certificated Note (including principal and other amounts) by wire transfer to the specified account
maintained by the payee by giving written notice to the Trustee or the Paying Agent to such effect designating such account no later than 15 days immediately preceding the relevant due date for payment (or such other date as the Trustee may
accept in its discretion). 
  

	3.	 Paying Agent, Transfer Agent, Calculation Agent and Registrar 

Initially, Deutsche Bank Trust Company Americas (the “Trustee”) shall act as Trustee, Principal Paying Agent, Transfer Agent,
calculation agent and as Registrar. The Issuer may appoint and change any Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar without notice to any Holder. The Issuer or the
applicable Guarantor may act as Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar. 

  
 F-11 

	4.	 Indenture 

The Issuer issued the Callable Fixed Rate Notes under an Indenture, dated as of March 24, 2022 (as it may be amended or supplemented from
time to time in accordance with the terms thereof, the “Indenture”), among the Issuers, the Guarantors, the Trustee, the Principal Paying Agent, the Transfer Agent and the Registrar. The terms of the Callable Fixed Rate Notes
include those stated in the Indenture. Capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Indenture. The Callable Fixed Rate Notes are subject to all such terms, and Holders are referred to the Indenture
for a statement of those terms. Each Holder by accepting a Callable Fixed Rate Note agrees to be bound by all of the terms and provisions of the Indenture, as amended from time to time. 

The Callable Fixed Rate Notes are general unsecured obligations of the Issuer limited to
$                 aggregate principal amount. 

Prior to the Guarantee Assumption date, the Callable Fixed Rate Notes are unconditionally and irrevocably guaranteed by the GSK Guarantor
under the GSK Guarantee. With effect from (and including) the Guarantee Assumption Date, the Callable Fixed Rate Notes are unconditionally and irrevocably guaranteed by the Haleon Guarantor under the Haleon Guarantee, in each case for the benefit of
the Holders pursuant to the Indenture. 
  

	5.	 Redemption 

Unless earlier redeemed, purchased or cancelled as provided in the Indenture, the Notes will be redeemed by the Issuer at their principal
amount on March 24, 2024. 
 5.1 Optional Redemption for Tax Reasons  

The Issuer may redeem the Callable Fixed Rate Notes in whole but not in part at any time prior to maturity, at a redemption price equal to 100%
of their principal amount plus accrued interest to the date fixed for redemption, if: 
 (a) the Issuer determines that, as a result of any
change in or amendment to the laws or any regulations or rulings promulgated thereunder of the United Kingdom or the United States, or any change in the application or official interpretation of such laws, regulations or rulings, or any change in
the application or official interpretation of, or any execution of or amendment to, any treaty or treaties affecting taxation to which any such jurisdiction is a party, which change, execution or amendment becomes effective on or after the Issue
Date: (i) the Issuer would be required to pay Additional Amounts on the Callable Fixed Rate Notes on the next succeeding Interest Payment Date and the payment of such additional amounts cannot be avoided by the use of reasonable measures
available to the Issuer or the applicable Guarantor; or (ii) withholding tax has been or would be required to be withheld with respect to interest income received or receivable by the Issuer directly from the applicable Guarantor (or any
Affiliate) and such withholding tax obligation cannot be avoided by the use of reasonable measures available to the Issuer or the applicable Guarantor (or any Affiliate); or 

  
 F-12 

 (b) the Issuer determines, based upon an opinion of independent counsel of recognised
standing that, as a result of any action taken by any legislative body of, taxing authority of, or any action brought in a court of competent jurisdiction in, the United Kingdom or the United States, which action is taken or brought on after the
Issue Date, there is a substantial probability that the circumstances described above would exist; provided, however, that no such notice of redemption may be given earlier than 90 days prior to the earliest date on which the Issuer
would be obligated to pay such Additional Amounts. 
 5.2 Make-Whole and Par Redemption 

Prior to the Callable Fixed Rate Notes Par Call Date, the Issuer may redeem the Callable Fixed Rate Notes, in whole or in part, at its option
at any time and from time to time at a redemption price equal to the greater of (i) 100% of the principal amount of the Callable Fixed Rate Notes to be redeemed on that redemption date and (ii) as determined by the Issuer, the sum of the
present values of the remaining scheduled payments of principal of and interest on the Callable Fixed Rate Notes to be redeemed on that redemption date (not including any portion of such payments of interest accrued as of the redemption date) that
would be due if the Callable Fixed Rate Notes matured on the Callable Fixed Rate Notes Par Call Date, discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 15 basis points, in each case plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

On or after the Callable Fixed Rate Notes Par Call Date, the Issuer may redeem the Callable Fixed Rate Notes, in whole or in part, at its
option at any time and from time to time at a redemption price equal to 100% of the principal amount of the Callable Fixed Rate Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

5.3 Redemption upon a Change of Control Put Event 

If a Change of Control Put Event occurs with respect to the Callable Fixed Rate Notes, the Holders will have the option to require the Issuer
to redeem or, at the Issuer’s option, purchase (or procure the purchase of) the whole, but not part, of such Holders’ Callable Fixed Rate Notes not previously called for redemption on the Change of Control Put Date at the Change of Control
Redemption Amount together with interest accrued (but unpaid) to (but excluding) the Change of Control Put Date. 
 5.4 Special Mandatory
Early Redemption 
 If the Demerger has not completed by the first anniversary of the Issue Date or, if earlier, GSK releases an
announcement which makes public that it no longer intends to pursue the Demerger, a Special Mandatory Redemption Event shall occur in accordance with the terms of the Indenture, pursuant to which the Issuer shall redeem the Callable Fixed Rate Notes
in whole, but not in part, at a redemption price equal to 101 per cent, of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

  
 F-13 

	6.	 Denominations; Transfer 

The Callable Fixed Rate Notes are in book-entry form only, and only in denominations of $250,000 and multiples of $1,000 in excess thereof. A
Holder may transfer Callable Fixed Rate Notes in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish appropriate endorsements or transfer documents and to pay any taxes and fees required by law or
permitted by the Indenture. 
  

	7.	 Persons Deemed Owners 

The registered Holder of this Callable Fixed Rate Note may be treated as the owner of it for all purposes. 

 

	8.	 Unclaimed Money 

Any money deposited with the Trustee or the Paying Agent, or then held by the Issuer, as banker for the payment of the principal of or other
amounts on, any Callable Fixed Rate Note and remaining unclaimed for (a) 10 years after such principal has become due and payable or (b) five years after other amounts have become due and payable, shall promptly upon request be paid
to the Issuer or (if then held by the Issuer) shall be discharged from such trust. The Holder of such Callable Fixed Rate Note shall thereafter, as an unsecured general creditor, look only to the Issuer for payment thereof, without interest and
until such amount must be remitted to the state under escheat or similar laws, and all liability of the Trustee or the Paying Agent with respect to such trust money, and all liability of the Issuer as trustee thereof, shall thereupon cease. 

 

	9.	 Amendment; Waiver 

Subject to certain exceptions set forth in the Indenture, (i) the Indenture, the Callable Fixed Rate Notes or the Guarantees may be
amended with the consent of the Holders of a majority in principal amount of the Callable Fixed Rate Notes then Outstanding and (ii) any past default or noncompliance with any provision may be waived with the consent of the Holders of a
majority in aggregate principal amount of the Callable Fixed Rate Notes at the time Outstanding (including consents obtained in connection with a tender offer or exchange offer). Subject to certain exceptions set forth in the Indenture, without the
consent of any Holder, the Issuer and the Trustee may amend the Indenture to, among other things, cure any ambiguity, defect or inconsistency in the Indenture, to provide for the assumption by a successor of the obligations of the Issuer, to
evidence and provide for the acceptance of appointment by a successor Trustee, to make any change that does not materially and adversely affect the rights of any Holder or to provide for uncertificated Callable Fixed Rate Notes in addition to or in
place of certificated Callable Fixed Rate Notes. 

  
 F-14 

	10.	 Defaults and Remedies 

If certain Events of Default with respect to the Callable Fixed Rate Notes shall occur, the principal amount of all the Callable Fixed Rate
Notes may be declared to become immediately due and payable. 
 Holders may not enforce the Indenture or the Callable Fixed Rate Notes
except as provided in the Indenture. The Trustee may refuse to enforce the Indenture or the Callable Fixed Rate Notes unless it receives reasonable indemnity and/or security. 
  

	11.	 Trustee Dealings with the Issuer 

Subject to certain limitations set forth in the Indenture, the Trustee under the Indenture, in its individual or any other capacity, may become
the owner or pledgee of Callable Fixed Rate Notes and may otherwise deal with and collect obligations owed to it by the Issuer or its Affiliates and may otherwise deal with the Issuer or its Affiliates with the same rights it would have if it were
not Trustee. 
  

	12.	 No Recourse Against Others 

No recourse for the payment of the principal of or other amounts on any of the Callable Fixed Rate Notes or for any claim based thereon or
otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Issuer or the applicable Guarantor in this Indenture, or in any of the Callable Fixed Rate Notes, or because of the creation of any indebtedness
represented thereby, shall be had against any incorporator, limited partner, stockholder, officer, director, employee or controlling person of the Issuer (other than the applicable Guarantor under the Guarantees) or the applicable Guarantor or of
any successor Persons thereof. Each Holder, by accepting the Callable Fixed Rate Notes, waives and releases all such liability. The waiver and release are part of the consideration for the issuance of the Callable Fixed Rate Notes. Such waiver may
not be effective to waive liabilities under U.S. federal securities laws. 
  

	13.	 Authentication 

This Callable Fixed Rate Note shall not be valid until an authorized signatory of the Trustee (or an authenticating agent acting on its behalf)
manually or electronically signs the certificate of authentication on the other side of this Callable Fixed Rate Note. 
  

	14.	 CUSIP Numbers 

The Issuer in issuing the Callable Fixed Rate Notes may use “CUSIP” numbers (if then generally in use). No representation is made as
to the accuracy of such numbers either as printed on the Callable Fixed Rate Notes or as contained in any such notice and reliance may be placed only on the other identification numbers placed on the Callable Fixed Rate Notes. The Issuer will
promptly notify the Trustee, in writing, of any change in the “CUSIP” number. 

  
 F-15 

	15.	 Governing Law 

THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 

 

	16.	 Demerger Capital Reduction 

By their holding of the Callable Fixed Rate Note, each Holder shall be deemed without the need for any further action to have unconditionally
and irrevocably (i) consented to any reduction in the capital of Haleon which is implemented within 6 months of the Demerger, (ii) agreed not to object to the Demerger Capital Reduction, and (iii) appointed the Issuer, or such person
(other than the Trustee) as the Issuer shall nominate as its agent to undertake all such acts and take all such steps on its behalf (including, without limitation, the execution and delivery of any documents to any court) as may be necessary or
desirable for Haleon to implement the Demerger Capital Reduction. 
  

	17.	 Agent for Service; Submission to Jurisdiction; Waiver of Immunities 

The Issuer and each Guarantor have agreed that any suit, action or proceeding against the Issuer brought by any Holder or the Trustee arising
out of or based upon the Indenture or the Callable Fixed Rate Notes may be instituted in any state or federal court in The City of New York, New York. The Issuer and each Guarantor have irrevocably submitted to the
non-exclusive jurisdiction of such courts for such purpose and waived, to the fullest extent permitted by law, trial by jury and any objection they may now or hereafter have to the laying of venue of any such
proceeding, and any claim they may now or hereafter have that any proceeding in any such court is brought in an inconvenient forum. The Guarantors each have appointed the Issuer as its Authorized Agent upon whom all writs, process and summonses may
be served in any suit, action or proceeding arising out of or based upon the Indenture or the Callable Fixed Rate Notes which may be instituted in any state or federal court in The City of New York, New York. To the extent that either of the Issuer
and the applicable Guarantor have or hereafter may acquire any immunity (sovereign or otherwise) from any legal action, suit or proceeding, from jurisdiction of any court or from set-off or any legal process
(whether service or notice, attachment in aid or otherwise) with respect to themselves or any of their property, the Issuer and the applicable Guarantor have irrevocably waived and agreed not to plead or claim such immunity in respect of their
obligations under the Indenture or the Callable Fixed Rate Notes. 
 The Issuer shall furnish to any Holder upon written request and without
charge to the Holder a copy of the Indenture which has in it the text of this Callable Fixed Rate Note. Requests may be made to: GSK Consumer Healthcare Capital US LLC, attention: Timothy Woodthorpe (Group Treasurer),
e-mail: cf.treasury@gsk.com, with copy to: Justin T. Huang (VP and Secretary), Charles David Simpson (VP and Treasurer) and Hatixhe Hoxha (Assistant Secretary), email address: US.CorpSec@gsk.com. 

  
 F-16 

 Schedule A 

SCHEDULE OF INCREASES OR DECREASES IN CALLABLE FIXED RATE GLOBAL NOTE 

The following increases or decreases in this Callable Fixed Rate Global Note have been made: 

 

									
	 Date of

Exchange
	  	 Amount of decrease

in Principal Amount
 of this Callable
Fixed
 Rate Global Note
	  	 Amount of increase

in Principal Amount
 of this Callable
Fixed
 Rate Global Note
	  	 Principal Amount of

this Callable Fixed
 Rate Global
Note
following such
 decrease or increase
	  	 Signature of

authorized signatory

of Trustee or
Registrar

  

  
 F-17 

 EXHIBIT G 

FORM OF CALLABLE FLOATING RATE GLOBAL NOTE 

[Include the following legend for all Rule 144A Global Notes:] 

THIS NOTE AND THE GUARANTEES OF THIS NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND
INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR
BENEFIT OF, U.S. PERSONS EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, THE HOLDER (A) REPRESENTS, WARRANTS, ACKNOWLEDGES AND AGREES FOR THE BENEFIT OF THE ISSUER, THE GUARANTORS AND THE TRUSTEE THAT IT IS A
‘‘QUALIFIED INSTITUTIONAL BUYER’’ (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) PURCHASING THE SECURITIES FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS; (B) AGREES THAT IT WILL NOT
RESELL OR OTHERWISE TRANSFER THE SECURITIES OTHER THAN (1) TO THE ISSUER, (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, (3) IN THE UNITED STATES TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS A
QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A, OR
(4) IN AN OFFSHORE TRANSACTION TO A NON-U.S. PERSON IN COMPLIANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS OF THE
STATES OF THE UNITED STATES AND ANY OTHER JURISDICTION; AND (C) AGREES THAT IT WILL DELIVER TO EACH PERSON TO WHOM THIS NOTE IS TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. 

[Include the following legend for all Regulation S Global Notes:] 

THIS NOTE AND THE GUARANTEES OF THE NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC, EFFECTIVE FROM (AND
INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF 

  
 G-1 

 
ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS
EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT OR PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT. UNTIL THE EXPIRY OF THE PERIOD OF 40 DAYS AFTER THE LATER OF
(i) THE DATE ON WHICH THE OFFERING OF THIS NOTE TO PERSONS OTHER THAN THE DISTRIBUTORS IN RELIANCE ON REGULATION S COMMENCED AND (ii) THE DATE OF ISSUANCE OF SUCH NOTE, SALES MAY NOT BE MADE IN THE UNITED STATES OR TO U.S. PERSONS UNLESS
MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED IN, AND IN TRANSACTIONS PURSUANT TO, RULE 144A UNDER THE SECURITIES ACT. 

  
 G-2 

 [FORM OF FACE OF CALLABLE FLOATING RATE GLOBAL NOTE] 

GSK Consumer Healthcare Capital US LLC 

Callable Senior Floating Rate Note due 2024 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from and
including the Guarantee Assumption Date) 
 [Include the following for all Rule 144A Global Notes:] 

CUSIP No. (144A): 36264GAB5 
 ISIN
(144A): US36264GAB59 
 Common Code (144A): 246354324 

No.: 
 [Include the following for
all Regulation S Global Notes:] 
 CUSIP No. (Regulation S): U0396GAB9 

ISIN (Regulation S): USU0396GAB96 

Common Code (Regulation S): 246354219 

No.: 
  

					
		  		  	 Principal Amount $    
  

as revised by Schedule A 
 attached

hereto of Increases and

Decreases in this Callable

Floating Rate Global Note

 This is to certify that CEDE & CO. is, as of the date hereof, the registered holder (the
“Holder”) of $                     of Callable Senior Floating Rate Notes due 2024 represented by this Global Note. GSK
Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of England and Wales, promises to pay to the Holder, or registered assigns, the principal sum of
$                     as revised by the Schedule of Increases and Decreases in Callable Floating Rate Global Note attached hereto, on
March 24, 2024. 
 In the event of a redemption or cancellation of the Callable Floating Rate Notes in part only, the Callable Floating
Rate Notes evidenced by this Callable Floating Rate Global Note shall be reduced by the principal amount so redeemed or cancelled. Thereafter, the Callable Floating Rate Notes represented by this Callable Floating Rate Global Note shall be the
principal amount of Callable Floating Rate Notes most recently entered by or on behalf of the Issuer in the relevant column in Schedule A attached hereto. 

  
 G-3 

 Reference is hereby made to the further provisions of this Callable Floating Rate Note as
set forth on the reverse hereof, which provisions shall for all purposes have the same effect as if set forth at this place. 
  

			
	GSK CONSUMER HEALTHCARE CAPITAL US LLC
		
	By:	 	 
		 	Name:
		 	Title:

			
		
	 TRUSTEE’S CERTIFICATE OF
	  	
	 AUTHENTICATION
	  	
		
	 Deutsche Bank Trust Company Americas,
 as
Trustee, certifies
 that this is one of
 the Callable Floating
Rate Notes referred
 to in the Indenture
	  	

											
						
	 By:
	 	 	  		  		  		  	
		 	 Authorized Signatory
	  		  	Date:	  	 	  	

  
 G-4 

 GUARANTEE OF GLAXOSMITHKLINE PLC 

For value received, GlaxoSmithKline plc, a public limited company incorporated under the laws of England and Wales, having its principal
executive offices at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “GSK Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this GSK Guarantee
is endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this GSK Guarantee is endorsed and to the Trustee on behalf of each such Holder prior to the date on which GSK ceases to hold a direct or indirect
interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee Assumption
Date”) the due payment of all principal of and other amounts on, each Note payable by GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer”, which term
includes any successor Person under the Indenture) under the Indenture. In case of the failure of the U.S. Issuer to punctually make any such payment or satisfy any such obligation in respect of the U.S. Issuer Notes prior to the Guarantee
Assumption Date, the GSK Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date or by
declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the U.S. Issuer. 
 The indebtedness
evidenced by this GSK Guarantee constitutes an unsubordinated and unsecured obligation of the GSK Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the GSK Guarantor (except for
obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the GSK Guarantor. 

The GSK Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be unaffected
by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the U.S. Issuer with respect thereto, by
the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or indulgence
shall, without the consent of the GSK Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The GSK Guarantor hereby waives diligence, presentment, demand of
payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer, any right to require a proceeding first against the U.S. Issuer, protest or notice with respect to such Note or the indebtedness evidenced thereby or
with respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this GSK Guarantee will not be discharged except by payment or satisfaction in full of the principal of and Additional
Amounts, if any, payable in respect of such Note. This GSK Guarantee is a guarantee of payment and not of collection. 

  
 G-5 

 The GSK Guarantor shall be subrogated to all rights of the Holder of such Note and the
Trustee against the U.S. Issuer in respect of any amounts paid to such Holder by the GSK Guarantor pursuant to the provisions of this GSK Guarantee; provided, however, that the GSK Guarantor shall not be entitled to enforce, or to receive any
payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the GSK Guarantor, which are
absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this GSK Guarantee is endorsed. 

This GSK Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this GSK Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This GSK Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 G-6 

 IN WITNESS WHEREOF, the GSK Guarantor has caused this GSK Guarantee to be duly executed this 24th day of March 2022.      
  

			
	 GLAXOSMITHKLINE PLC,
 as the GSK
Guarantor

		
	By:	 	 
		 	Name:
		 	Title:
		
	By:	 	 
		 	Name:
		 	Title:

  
 G-7 

 GUARANTEE OF HALEON 

For value received, Haleon, a public limited company incorporated under the laws of England and Wales, having its principal executive offices
at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (the “Haleon Guarantor,” which term includes any Person as a successor Guarantor under the Indenture referred to in the Note upon which this Haleon Guarantee is
endorsed), hereby fully and unconditionally guarantees to the Holder of the Note upon which this Haleon Guarantee is endorsed and to the Trustee on behalf of each such Holder from (and including) the date on which GSK ceases to hold a direct or
indirect interest in the share capital of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger (the “Guarantee
Assumption Date”) the due payment of all principal of and other amounts on, each Note payable by GSK Consumer Healthcare Capital US LLC, a public limited company incorporated under the laws of Delaware (the “U.S. Issuer,”
which term includes any successor Person under the Indenture) under the Indenture. In case of the failure of the U.S. Issuer to punctually make any such payment or satisfy any such obligation in respect of the U.S. Issuer Notes, from (and including)
the Guarantee Assumption Date, the Haleon Guarantor hereby agrees to cause any such payment or obligation to be made or satisfied punctually when and as the same shall become due, payable or otherwise deliverable, whether on the stated maturity date
or by declaration of acceleration, call for redemption or otherwise, and as if such payment were made by the U.S. Issuer. 
 The
indebtedness evidenced by this Haleon Guarantee constitutes an unsubordinated and unsecured obligation of the Haleon Guarantor and ranks equally and pari passu with all existing and future senior and unsecured obligations of the Haleon
Guarantor (except for obligations which may rank senior by operation of applicable law) and senior to all existing and future subordinated obligations of the Haleon Guarantor. 

The Haleon Guarantor hereby agrees that its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be
unaffected by, any invalidity, irregularity or unenforceability of such Note or such Indenture, any failure to enforce the provisions of such Note or such Indenture, or any waiver, modification or indulgence granted to the U.S. Issuer with respect
thereto, by the Holder of such Note or the Trustee or any other circumstance that may otherwise constitute a legal or equitable discharge of a guarantor; provided, however, that, notwithstanding the foregoing, no such waiver, modification or
indulgence shall, without the consent of the Haleon Guarantor, increase the principal of such Note, or increase the amounts due in respect of the Notes, or alter the stated maturity date thereof. The Haleon Guarantor hereby waives diligence,
presentment, demand of payment, filing of claims with a court in the event of merger or bankruptcy of the U.S. Issuer, any right to require a proceeding first against the U.S., protest or notice with respect to such Note or the indebtedness
evidenced thereby or with respect to any sinking fund or analogous payment required under such Note and all demands whatsoever, and covenants that this Haleon Guarantee will not be discharged except by payment or satisfaction in full of the
principal of and Additional Amounts, if any, payable in respect of such Note. This Haleon Guarantee is a guarantee of payment and not of collection. 

  
 G-8 

 The Haleon Guarantor shall be subrogated to all rights of the Holder of such Note and the
Trustee against the U.S. Issuer in respect of any amounts paid to such Holder by the Haleon Guarantor pursuant to the provisions of this Haleon Guarantee; provided, however, that the Haleon Guarantor shall not be entitled to enforce, or to
receive any payments arising out of or based upon such right of subrogation until the principal of and Additional Amounts, if any, payable or deliverable in respect of all Notes issued under such Indenture shall have been paid in full. 

No reference herein to such Indenture and no provision of such Indenture shall alter or impair the guarantees of the Haleon Guarantor, which
are absolute and unconditional, of the due and punctual payment or delivery of the principal of and Additional Amounts, if any, payable in respect of, the Note upon which this Haleon Guarantee is endorsed. 

This Haleon Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication of such Note shall have been
manually or electronically executed by or on behalf of the Trustee under such Indenture. 
 All terms used in this Haleon Guarantee that are
defined in such Indenture shall have the meanings assigned to them in such Indenture. 
 This Haleon Guarantee shall be governed by and
construed in accordance with the laws of the State of New York. 

  
 G-9 

 IN WITNESS WHEREOF, the Haleon Guarantor has caused this Haleon Guarantee to be duly executed this 24th day of March 2022.      
  

			
	 HALEON PLC, as the Haleon Guarantor

		
	 By:
	 	 
		 	 Name:

		 	 Title:

		
	 By:
	 	 
		 	 Name:

		 	 Title:

  
 G-10 

 [REVERSE SIDE OF NOTE] 

GSK Consumer Healthcare Capital US LLC 

Callable Senior Floating Rate Note due 2024 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from and
including the Guarantee Assumption Date) 
  

	1.	 Interest 

The initial interest rate on the Callable Floating Rate Notes for the first Callable Floating Rate Notes Interest Period will be equal to the
Benchmark plus 0.89% per annum (the “Callable Floating Rate Notes Margin”). Thereafter, the interest rate on the Callable Floating Rate Notes for any Callable Floating Rate Notes Interest Period will be a per annum rate equal to the
Benchmark, as determined on the applicable Interest Determination Date plus the Callable Floating Rate Notes Margin. 
 The interest rate on
the Callable Floating Rate Notes will be calculated quarterly on the date that is two USGS Business Days before each Callable Floating Rate Notes Interest Payment Date (each such date, an “Interest Determination Date”). 

Interest on the Callable Floating Rate Notes will be payable quarterly in arrear on 24 March, 24 June, 24 September and
24 December of each year, commencing on June 24, 2022 (each a “Callable Floating Rate Notes Interest Payment Date”), to the person in whose name a Callable Floating Rate Note is registered at the close of business on the
Regular Record Date that precedes the applicable Callable Floating Rate Notes Interest Payment Date. Interest on the Callable Floating Rate Notes will be calculated on the basis of the actual number of days in each Callable Floating Rate Notes
Interest Period, assuming a 360-day year. 
 Should a Benchmark Transition Event occur, certain
transitional provisions relating to the calculation of the Benchmark will apply, as set out in the Indenture. 
  

	2.	 Method of Payment 

Not later than 11:00am New York City time on the due date for any payment due in respect of the Callable Floating Rate Notes and on the
Callable Floating Rate Notes Maturity Date, GSK Consumer Healthcare Capital US LLC (the “Issuer”) shall deposit with the relevant Paying Agent in same day immediately available funds an amount sufficient to make cash payments due on
such due date of payments of any other amounts or the Maturity Date, as the case may be. Holders must surrender Callable Floating Rate Notes to a Paying Agent to collect principal payments. The Issuer shall pay principal and other amounts in cash in
U.S. dollars. 
 Payments in respect of Callable Floating Rate Notes represented by a Global Note (including principal and other amounts)
shall be made by the transfer of immediately available funds to the accounts specified by the Depositary. The Issuer shall make all payments in respect of a Certificated Note (including principal and other amounts) by wire transfer to the specified
account maintained by the payee by giving written notice to the Trustee or the Paying Agent to such effect designating such account no later than 15 days immediately preceding the relevant due date for payment (or such other date as the Trustee
may accept in its discretion). 

  
 G-11 

	3.	 Paying Agent, Transfer Agent, Calculation Agent and Registrar 

Initially, Deutsche Bank Trust Company Americas (the “Trustee”) shall act as Trustee, Principal Paying Agent, Transfer Agent
and as Registrar. The Issuer may appoint and change any Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar without notice to any Holder. The Issuer or the applicable Guarantor may
act as Paying Agent, Transfer Agent, calculation agent and Registrar or co-registrar. 
  

	4.	 Indenture 

The Issuer issued the Callable Floating Rate Notes under an Indenture, dated as of March 24, 2022 (as it may be amended or supplemented
from time to time in accordance with the terms thereof, the “Indenture”), among the Issuers, the Guarantors, the Trustee, the Principal Paying Agent, the Transfer Agent and the Registrar. The terms of the Callable Floating Rate
Notes include those stated in the Indenture. Capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Indenture. The Callable Floating Rate Notes are subject to all such terms, and Holders are referred to the
Indenture for a statement of those terms. Each Holder by accepting a Callable Floating Rate Note agrees to be bound by all of the terms and provisions of the Indenture, as amended from time to time. 

The Callable Floating Rate Notes are general unsecured obligations of the Issuer limited to
$                 aggregate principal amount. 

Prior to the Guarantee Assumption Date, the Callable Floating Rate Notes are unconditionally and irrevocably guaranteed by the GSK Guarantor
under the GSK Guarantee. With effect from (and including) the Guarantee Assumption Date, the Callable Floating Rate Notes are unconditionally and irrevocably guaranteed by the Haleon Guarantor under the Haleon Guarantee, in each case for the benefit
of the Holders pursuant to the Indenture. 
  

	5.	 Redemption 

Unless earlier redeemed, purchased or cancelled as provided in the Indenture, the Notes will be redeemed by the Issuer at their principal
amount on March 24, 2024. 
 5.1 Optional Redemption for Tax Reasons 

The Issuer may redeem the Callable Floating Rate Notes in whole but not in part at any time prior to maturity, at a redemption price equal to
100% of their principal amount plus accrued interest to the date fixed for redemption, if: 
 (a) the Issuer determines that, as a result of
any change in or amendment to the laws or any regulations or rulings promulgated thereunder of the United Kingdom or the United States, or any change in the application or official interpretation of such laws, regulations or rulings, or any change
in the application or official interpretation of, or any execution of or 

  
 G-12 

 
amendment to, any treaty or treaties affecting taxation to which any such jurisdiction is a party, which change, execution or amendment becomes effective on or after the Issue Date: (i) the
Issuer would be required to pay Additional Amounts on the Callable Floating Rate Notes on the next succeeding Interest Payment Date and the payment of such additional amounts cannot be avoided by the use of reasonable measures available to the
Issuer or the applicable Guarantor; or (ii) withholding tax has been or would be required to be withheld with respect to interest income received or receivable by the Issuer directly from the applicable Guarantor (or any Affiliate) and such
withholding tax obligation cannot be avoided by the use of reasonable measures available to the Issuer or the applicable Guarantor (or any Affiliate); or 

(b) the Issuer determines, based upon an opinion of independent counsel of recognised standing that, as a result of any action taken by any
legislative body of, taxing authority of, or any action brought in a court of competent jurisdiction in, the United Kingdom or the United States, which action is taken or brought on after the Issue Date, there is a substantial probability that the
circumstances described above would exist; provided, however, that no such notice of redemption may be given earlier than 90 days prior to the earliest date on which the Issuer would be obligated to pay such Additional Amounts. 

5.2 Par Redemption 
 On
or after the Callable Floating Rate Notes Par Call Date, the Issuer may redeem the Callable Floating Rate Notes, in whole or in part, at its option at any time and from time to time at a redemption price equal to 100% of the principal amount of the
Callable Floating Rate Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

5.3 Redemption upon a Change of Control Put Event 

If a Change of Control Put Event occurs with respect to the Callable Floating Rate Notes, the Holders will have the option to require the
Issuer to redeem or, at the Issuer’s option, purchase (or procure the purchase of) the whole, but not part, of such Holders’ Callable Floating Rate Notes not previously called for redemption on the Change of Control Put Date at the Change
of Control Redemption Amount together with interest accrued (but unpaid) to (but excluding) the Change of Control Put Date. 
 5.4
Special Mandatory Early Redemption 
 If the Demerger has not completed by the first anniversary of the Issue Date or, if earlier,
GSK releases an announcement which makes public that it no longer intends to pursue the Demerger, a Special Mandatory Redemption Event shall occur in accordance with the terms of the Indenture, pursuant to which the Issuer shall redeem the Callable
Floating Rate Notes in whole, but not in part, at a redemption price equal to 101 per cent, of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. 

  
 G-13 

	6.	 Denominations; Transfer 

The Callable Floating Rate Notes are in book-entry form only, and only in denominations of $250,000 and multiples of $1,000 in excess thereof.
A Holder may transfer Callable Floating Rate Notes in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish appropriate endorsements or transfer documents and to pay any taxes and fees required by law or
permitted by the Indenture. 
  

	7.	 Persons Deemed Owners 

The registered Holder of this Callable Floating Rate Note may be treated as the owner of it for all purposes. 

 

	8.	 Unclaimed Money 

Any money deposited with the Trustee or the Paying Agent, or then held by the Issuer, as banker for the payment of the principal of or other
amounts on, any Callable Floating Rate Note and remaining unclaimed for (a) 10 years after such principal has become due and payable or (b) five years after other amounts have become due and payable, shall promptly upon request be
paid to the Issuer or (if then held by the Issuer) shall be discharged from such trust. The Holder of such Callable Floating Rate Note shall thereafter, as an unsecured general creditor, look only to the Issuer for payment thereof, without interest
and until such amount must be remitted to the state under escheat or similar laws, and all liability of the Trustee or the Paying Agent with respect to such trust money, and all liability of the Issuer as trustee thereof, shall thereupon cease. 

 

	9.	 Amendment; Waiver 

Subject to certain exceptions set forth in the Indenture, (i) the Indenture, the Callable Floating Rate Notes or the Guarantees may be
amended with the consent of the Holders of a majority in principal amount of the Callable Floating Rate Notes then Outstanding and (ii) any past default or noncompliance with any provision may be waived with the consent of the Holders of a
majority in aggregate principal amount of the Callable Floating Rate Notes at the time Outstanding (including consents obtained in connection with a tender offer or exchange offer). Subject to certain exceptions set forth in the Indenture, without
the consent of any Holder, the Issuer and the Trustee may amend the Indenture to, among other things, cure any ambiguity, defect or inconsistency in the Indenture, to provide for the assumption by a successor of the obligations of the Issuer, to
evidence and provide for the acceptance of appointment by a successor Trustee, to make any change that does not materially and adversely affect the rights of any Holder or to provide for uncertificated Callable Floating Rate Notes in addition to or
in place of certificated Callable Floating Rate Notes. 
  

	10.	 Defaults and Remedies 

If certain Events of Default with respect to the Callable Floating Rate Notes shall occur, the principal amount of all the Callable Floating
Rate Notes may be declared to become immediately due and payable. 

  
 G-14 

 Holders may not enforce the Indenture or the Callable Floating Rate Notes except as provided
in the Indenture. The Trustee may refuse to enforce the Indenture or the Callable Floating Rate Notes unless it receives reasonable indemnity and/or security. 
  

	11.	 Trustee Dealings with the Issuer 

Subject to certain limitations set forth in the Indenture, the Trustee under the Indenture, in its individual or any other capacity, may become
the owner or pledgee of Callable Floating Rate Notes and may otherwise deal with and collect obligations owed to it by the Issuer or its Affiliates and may otherwise deal with the Issuer or its Affiliates with the same rights it would have if it
were not Trustee. 
  

	12.	 No Recourse Against Others 

No recourse for the payment of the principal of or other amounts on any of the Callable Floating Rate Notes or for any claim based thereon or
otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Issuer or the applicable Guarantor in this Indenture, or in any of the Callable Floating Rate Notes, or because of the creation of any
indebtedness represented thereby, shall be had against any incorporator, limited partner, stockholder, officer, director, employee or controlling person of the Issuer (other than the applicable Guarantor under the Guarantees) or the applicable
Guarantor or of any successor Persons thereof. Each Holder, by accepting the Callable Floating Rate Notes, waives and releases all such liability. The waiver and release are part of the consideration for the issuance of the Callable Floating Rate
Notes. Such waiver may not be effective to waive liabilities under U.S. federal securities laws. 
  

	13.	 Authentication 

This Callable Floating Rate Note shall not be valid until an authorized signatory of the Trustee (or an authenticating agent acting on its
behalf) manually or electronically signs the certificate of authentication on the other side of this Callable Floating Rate Note. 
  

	14.	 CUSIP Numbers 

The Issuer in issuing the Callable Floating Rate Notes may use “CUSIP” numbers (if then generally in use). No representation is made
as to the accuracy of such numbers either as printed on the Callable Floating Rate Notes or as contained in any such notice and reliance may be placed only on the other identification numbers placed on the Callable Floating Rate Notes. The Issuer
will promptly notify the Trustee, in writing, of any change in the “CUSIP” number. 
  

	15.	 Governing Law 

THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 

  
 G-15 

	16.	 Demerger Capital Reduction 

By their holding of the Callable Floating Rate Note, each Holder shall be deemed without the need for any further action to have
unconditionally and irrevocably (i) consented to any reduction in the capital of Haleon which is implemented within 6 months of the Demerger, (ii) agreed not to object to the Demerger Capital Reduction, and (iii) appointed the Issuer,
or such person (other than the Trustee) as the Issuer shall nominate as its agent to undertake all such acts and take all such steps on its behalf (including, without limitation, the execution and delivery of any documents to any court) as may be
necessary or desirable for Haleon to implement the Demerger Capital Reduction. 
  

	17.	 Agent for Service; Submission to Jurisdiction; Waiver of Immunities 

The Issuer and each Guarantor have agreed that any suit, action or proceeding against the Issuer brought by any Holder or the Trustee arising
out of or based upon the Indenture or the Callable Floating Rate Notes may be instituted in any state or federal court in The City of New York, New York. The Issuer and each Guarantor have irrevocably submitted to the
non-exclusive jurisdiction of such courts for such purpose and waived, to the fullest extent permitted by law, trial by jury and any objection they may now or hereafter have to the laying of venue of any such
proceeding, and any claim they may now or hereafter have that any proceeding in any such court is brought in an inconvenient forum. The Guarantors each have appointed the Issuer as its Authorized Agent upon whom all writs, process and summonses may
be served in any suit, action or proceeding arising out of or based upon the Indenture or the Callable Floating Rate Notes which may be instituted in any state or federal court in The City of New York, New York. To the extent that either of the
Issuer and the applicable Guarantor have or hereafter may acquire any immunity (sovereign or otherwise) from any legal action, suit or proceeding, from jurisdiction of any court or from set-off or any legal
process (whether service or notice, attachment in aid or otherwise) with respect to themselves or any of their property, the Issuer and the applicable Guarantor have irrevocably waived and agreed not to plead or claim such immunity in respect of
their obligations under the Indenture or the Callable Floating Rate Notes. 
 The Issuer shall furnish to any Holder upon written request
and without charge to the Holder a copy of the Indenture which has in it the text of this Callable Floating Rate Note. Requests may be made to: GSK Consumer Healthcare Capital US LLC, attention: Timothy Woodthorpe (Group Treasurer), e-mail: cf.treasury@gsk.com, with copy to: Justin T. Huang (VP and Secretary), Charles David Simpson (VP and Treasurer) and Hatixhe Hoxha (Assistant Secretary), email address: US.CorpSec@gsk.com. 

  
 G-16 

 Schedule A 

SCHEDULE OF INCREASES OR DECREASES IN CALLABLE FLOATING RATE GLOBAL NOTE 

The following increases or decreases in this Callable Floating Rate Global Note have been made: 

 

									
	 Date of

Exchange
	  	 Amount of decrease

in Principal Amount
 of this
Callable
 Floating Rate Global

Note
	  	 Amount of increase

in Principal Amount
 of this
Callable
 Floating Rate Global

Note
	  	 Principal Amount of

this Callable Floating
 Rate Global
Note
following such
 decrease or increase
	  	 Signature of

authorized signatory
 of Trustee
or
 Registrar

  
 G-17 

 EXHIBIT H-A 

FORM OF A RULE 144A CERTIFICATED NOTE 

[Include the following legend for all Rule 144A Certificated Notes:] 

THE NOTES EVIDENCED BY THIS CERTIFICATED NOTE MAY BE PURCHASED AND TRANSFERRED ONLY IN MINIMUM PRINCIPAL AMOUNTS OF $250,000 AND INTEGRAL MULTIPLES OF $1,000
IN EXCESS THEREOF. 
 THIS NOTE AND THE GUARANTEES OF THIS NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC,
EFFECTIVE FROM (AND INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE
US SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR
THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, THE HOLDER (A) REPRESENTS, WARRANTS, ACKNOWLEDGES AND AGREES FOR THE BENEFIT OF THE ISSUER, THE GUARANTORS AND THE TRUSTEE THAT IT
IS A ‘‘QUALIFIED INSTITUTIONAL BUYER’’ (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) PURCHASING THE SECURITIES FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS; (B) AGREES THAT IT
WILL NOT RESELL OR OTHERWISE TRANSFER THE SECURITIES OTHER THAN (1) TO THE ISSUER, (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, (3) IN THE UNITED STATES TO A PERSON WHO THE SELLER REASONABLY BELIEVES
IS A QUALIFIED INSTITUTIONAL BUYER WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ONE OR MORE QUALIFIED INSTITUTIONAL BUYERS IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A, OR
(4) IN AN OFFSHORE TRANSACTION TO A NON-U.S. PERSON IN COMPLIANCE WITH RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS OF THE
STATES OF THE UNITED STATES AND ANY OTHER JURISDICTION; AND (C) AGREES THAT IT WILL DELIVER TO EACH PERSON TO WHOM THIS NOTE IS TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. 

  
 H-A-1 

 [FORM OF FACE OF CERTIFICATED NOTE] 

[GSK Consumer Healthcare Capital US LLC] 

[GSK Consumer Healthcare Capital UK PLC] 

[3.125% Fixed Rate Senior Notes due 2025] 

[3.375% Fixed Rate Senior Notes due 2027] 

[3.375% Fixed Rate Senior Notes due 2029] 

[3.625% Fixed Rate Senior Notes due 2032] 

[4.000% Fixed Rate Senior Notes due 2052] 

[Callable Senior Floating Rate Notes due 2024] 

[3.024% Callable Fixed Rate Senior Notes due 2024] 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from and
including the Guarantee Assumption Date) 
 CUSIP No. (144A): [•] 

ISIN (144A): [•] 
 Common Code
(144A): [•] 
  

			
	 No.
	  	Principal Amount $                

 This is to certify that: 

							
				
	            	  	 	  		  	

 of 

							
				
	            	  	 	  		  	
				
		  	 	  		  	
				
		  	 	  		  	
				
		  	 	  		  	

 is the person registered in the register maintained by the Registrar in relation to the Notes (the “Note
Register”) as the duly registered holder of the Notes represented by this Certificated Note or, if more than one person is so registered, the first named of such persons (the “Holder”). [GSK Consumer Healthcare Capital US
LLC]/[GSK Consumer Healthcare Capital UK plc] (the “Issuer”), a public limited company incorporated under the laws of [Delaware]/[England and Wales], promises to pay to the Holder the principal sum of
$                on [•]. 

  
 H-A-2 

 Reference is hereby made to the further provisions of this Note as set forth on the reverse
hereof, which provisions shall for all purposes have the same effect as if set forth at this place. 
  

			
	[GSK CONSUMER HEALTHCARE CAPITAL US LLC]
	[GSK CONSUMER HEALTHCARE CAPITAL UK PLC]
		
	By:	 	 
		 	Name:
		 	Title:

			
		
	 TRUSTEE’S CERTIFICATE OF
	  	
	 AUTHENTICATION
	  	
		
	 Deutsche Bank Trust Company Americas,
 as
Trustee, certifies
 that this is one of
 the Notes referred

to in the Indenture.
	  	

											
						
	 By:
	 	 	  		  		  		  	
		 	 Authorized Signatory
	  		  	Date:	  	 	  	

 [Attach REVERSE SIDE OF RELEVANT SERIES OF NOTE AND GUARANTEE set forth in
Exhibits A to G, excluding Schedule A thereto] 

  
 H-A-3 

 EXHIBIT H-B 

FORM OF A REGULATION S CERTIFICATED NOTE 

[Include the following legend for all Regulation S Certificated Notes:] 

THE NOTES EVIDENCED BY THIS CERTIFICATED NOTE MAY BE PURCHASED AND TRANSFERRED ONLY IN MINIMUM PRINCIPAL AMOUNTS OF $250,000 AND INTEGRAL MULTIPLES OF $1,000
IN EXCESS THEREOF. 
 THIS NOTE AND THE GUARANTEES OF THE NOTE BY GLAXOSMITHKLINE PLC, EFFECTIVE BEFORE THE GUARANTEE ASSUMPTION DATE, AND HALEON PLC,
EFFECTIVE FROM (AND INCLUDING) THE GUARANTEE ASSUMPTION DATE (UPON WHICH THE GUARANTEE OF GLAXOSMITHKLINE PLC WILL BE AUTOMATICALLY AND UNCONDITIONALLY TERMINATED AND RELEASED) (TOGETHER “THE GUARANTORS”) HAVE NOT BEEN REGISTERED UNDER THE
US SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR
THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT OR PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT. UNTIL THE EXPIRY OF
THE PERIOD OF 40 DAYS AFTER THE LATER OF (i) THE DATE ON WHICH THE OFFERING OF THIS NOTE TO PERSONS OTHER THAN THE DISTRIBUTORS IN RELIANCE ON REGULATION S COMMENCED AND (ii) THE DATE OF ISSUANCE OF SUCH NOTE, SALES MAY NOT BE MADE IN THE
UNITED STATES OR TO U.S. PERSONS UNLESS MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED IN, AND IN TRANSACTIONS PURSUANT TO, RULE 144A UNDER THE SECURITIES ACT. 

  
 H-B-1 

 [FORM OF FACE OF CERTIFICATED NOTE] 

[GSK Consumer Healthcare Capital US LLC] 

[GSK Consumer Healthcare Capital UK PLC] 

[3.125% Fixed Rate Senior Notes due 2025] 

[3.375% Fixed Rate Senior Notes due 2027] 

[3.375% Fixed Rate Senior Notes due 2029] 

[3.625% Fixed Rate Senior Notes due 2032] 

[4.000% Fixed Rate Senior Notes due 2052] 

[Callable Floating Rate Notes due 2024] 

[3.024% Callable Fixed Rate Senior Notes due 2024] 

Guaranteed on a Senior Basis by 

GlaxoSmithKline plc (prior to the Guarantee Assumption Date) 

and 
 Haleon plc (from and
including the Guarantee Assumption Date) 
 CUSIP No. (Regulation S): [•] 

ISIN (Regulation S): [•] 

Common Code (Regulation S): [•] 
  

			
	 No.
	  	Principal Amount $                

 This is to certify that: 

							
				
	            	  	 	  		  	

 of 

							
				
	            	  	 	  		  	
				
		  	 	  		  	
				
		  	 	  		  	
				
		  	 	  		  	

 is the person registered in the register maintained by the Registrar in relation to the Notes (the
“Note Register”) as the duly registered holder of the Notes represented by this Certificated Note or, if more than one person is so registered, the first named of such persons (the “Holder”). [GSK Consumer
Healthcare Capital US LLC]/[GSK Consumer Healthcare Capital UK plc] (the “Issuer”), a public limited company incorporated under the laws of [Delaware]/[England and Wales], promises to pay to the Holder the principal sum of
$                on [•]. 

  
 H-B-2 

 Reference is hereby made to the further provisions of this Note as set forth on the reverse
hereof, which provisions shall for all purposes have the same effect as if set forth at this place. 
  

			
	[GSK CONSUMER HEALTHCARE CAPITAL US LLC]
	[GSK CONSUMER HEALTHCARE CAPITAL UK PLC]
		
	By:	 	 
		 	Name:
		 	Title:

			
		
	 TRUSTEE’S CERTIFICATE OF
	  	
	 AUTHENTICATION
	  	
		
	 Deutsche Bank Trust Company Americas,
 as
Trustee, certifies
 that this is one of
 the Notes referred

to in the Indenture.
	  	

											
						
	 By:
	 	 	  		  		  		  	
		 	 Authorized Signatory
	  		  	Date:	  	 	  	

 [Attach REVERSE SIDE OF RELEVANT SERIES OF NOTE AND GUARANTEE set forth in
Exhibits A to G, excluding Schedule A thereto] 

  
 H-B-3 

 EXHIBIT I 

FORM OF CERTIFICATE FOR TRANSFER TO QIB 

[Date] 
 Deutsche Bank Trust Company
Americas 
 c/o DB Services Americas, Inc. 
 Attention: Reorg.
Department 
 5022 Gate Parkway, Suite 200 
 Jacksonville, FL
32256 
 Attn: Transfer Department 
 E-mail: transfer.operations@db.com 
  

	 	Re:	 [Include description of relevant Notes] (the “Notes”) of [GSK Consumer Healthcare
Capital US LLC]/[GSK Consumer Healthcare Capital UK plc] (the “Issuer”) 

 Ladies and Gentleman: 

Reference is hereby made to the Indenture, dated as of March 24, 2022 (as amended and supplemented from time to time, the
“Indenture”), between GSK Consumer Healthcare Capital US LLC, GSK Consumer Healthcare Capital UK plc, the Guarantors and Deutsche Bank Trust Company Americas, as Trustee, Principal Paying Agent, Transfer Agent and Registrar.
Capitalized terms used but not defined herein shall have the meanings given to them in the Indenture. 
 This letter relates to
US$[                         ] aggregate principal amount of Notes, which represents an interest in a Regulation S
Global Note beneficially owned by the undersigned (the “Transferor”), to effect the transfer of such Notes in exchange for an equivalent beneficial interest in the Rule 144A Global Note. 

In connection with such request, and with respect to such Notes, the Transferor does hereby certify that such Notes are being transferred in
accordance with Rule 144A under the Securities Act of 1933, as amended (“Rule 144A”), to a transferee that the Transferor reasonably believes is purchasing the Notes for its own account or an account with respect to which the
transferee exercises sole investment discretion, and the transferee, as well as any such account, is a “qualified institutional buyer” within the meaning of Rule 144A, in a transaction meeting the requirements of Rule 144A and in
accordance with applicable securities laws of any state of the United States or any other jurisdiction. 
 You and the Issuer are entitled
to rely upon this letter and are irrevocably authorized to produce this letter or a copy hereof to any interested party in any administrative or legal proceedings or official inquiry with respect to the matters covered hereby. 

  
 I-1 

 
			
	Very truly yours,
	
	[Name of Transferor]
		
	By:	 	 
		 	Authorized Signature

  
 I-2 

 EXHIBIT J 

FORM OF CERTIFICATE FOR TRANSFER PURSUANT TO REGULATION S 

[Date] 
 Deutsche Bank Trust Company
Americas 
 c/o DB Services Americas, Inc. 
 Attention: Reorg.
Department 
 5022 Gate Parkway, Suite 200 
 Jacksonville, FL
32256 
 Attn: Transfer Department 
 E-mail: transfer.operations@db.com 
  

	 	Re:	 [Include description of relevant Notes] (the “Notes”) of [GSK Consumer Healthcare
Capital US LLC]/[GSK Consumer Healthcare Capital UK plc] (the “Issuer”) 

 Ladies and Gentleman: 

Reference is hereby made to the Indenture, dated as of March 24, 2022 (as amended and supplemented from time to time, the
“Indenture”), between GSK Consumer Healthcare Capital US LLC, GSK Consumer Healthcare Capital UK plc, the Guarantors and Deutsche Bank Trust Company Americas, as Trustee, Principal Paying Agent, Transfer Agent and Registrar.
Capitalized terms used but not defined herein shall have the meanings given to them in the Indenture. 
 In connection with our proposed
sale of US$[                     ] aggregate principal amount of the Notes, which represents an interest in a 144A Global Note
beneficially owned by the undersigned (the “Transferor”), to effect the transfer of such Notes in exchange for an equivalent beneficial interest in the Regulation S Global Note. 

We confirm that such sale has been effected pursuant to and in accordance with Regulation S under the Securities Act of 1933, as amended (the
“Securities Act”), and, accordingly, we represent that: 
 (a) the offer of the Notes was not made to a person in the
United States; 
 (b) either (i) at the time the buy order was originated, the transferee was outside the United States or we and any
person acting on our behalf reasonably believed that the transferee was outside the United States or (ii) the transaction was executed in, on or through the facilities of a designated off-shore securities
market and neither we nor any person acting on our behalf knows that the transaction has been pre-arranged with a buyer in the United States; 

(c) no directed selling efforts have been made in the United States in contravention of the requirements of Rule 903(b) or Rule 904(b) of
Regulation S, as applicable; 

  
 J-1 

 (d) the transaction is not part of a plan or scheme to evade the registration requirements
of the Securities Act; and 
 (e) we are the beneficial owner of the principal amount of Notes being transferred. 

In addition, if the sale is made during a Distribution Compliance Period and the provisions of Rule 904(b)(1) or Rule 904(b)(2) of Regulation
S are applicable thereto, we confirm that such sale has been made in accordance with the applicable provisions of Rule 904(b)(1) or Rule 904(b)(2), as the case may be. 

You and the Issuer are entitled to rely upon this letter and are irrevocably authorized to produce this letter or a copy hereof to any
interested party in any administrative or legal proceedings or official inquiry with respect to the matters covered hereby. Terms used in this letter have the meanings set forth in Regulation S. 

 

			
	Very truly yours,
	
	[Name of Transferor]
		
	By:	 	 
		 	Authorized Signature

  
 J-2 

 EXHIBIT K 

FORM OF CERTIFICATE FOR TRANSFER PURSUANT TO RULE 144 

[Date] 
 Deutsche Bank Trust Company
Americas 
 c/o DB Services Americas, Inc. 
 Attention: Reorg.
Department 
 5022 Gate Parkway, Suite 200 
 Jacksonville, FL
32256 
 Attn: Transfer Department 
 E-mail: transfer.operations@db.com 
  

	 	Re:	 [Include description of relevant Notes] (the “Notes”) of [GSK Consumer Healthcare
Capital US LLC]/[GSK Consumer Healthcare Capital UK plc] (the “Issuer”) 

 Ladies and Gentleman: 

Reference is hereby made to the Indenture, dated as of March 24, 2022 (as amended and supplemented from time to time, the
“Indenture”), between GSK Consumer Healthcare Capital US LLC, GSK Consumer Healthcare Capital UK plc, the Guarantors and Deutsche Bank Trust Company Americas, as Trustee, Principal Paying Agent, Transfer Agent and Registrar.
Capitalized terms used but not defined herein shall have the meanings given to them in the Indenture. 
 In connection with our proposed
sale of US$[                     ] aggregate principal amount of the Notes, which represent an interest in a 144A Global Note
beneficially owned by the undersigned (the “Transferor”), we confirm that such sale has been effected pursuant to and in accordance with Rule 144 under the Securities Act. 

You and the Issuer are entitled to rely upon this letter and are irrevocably authorized to produce this letter or a copy hereof to any
interested party in any administrative or legal proceedings or official inquiry with respect to the matters covered hereby. 
  

			
	Very truly yours,
	
	[Name of Transferor]
		
	By:	 	 
		 	Authorized Signature

  
 K-1EX-4.18

 Exhibit 4.18 

Registration Rights Agreement 

GSK Consumer Healthcare Capital US LLC 

$700,000,000 3.024% Callable Fixed Rate Senior Notes due 2024 

$300,000,000 Callable Floating Rate Senior Notes due 2024 

$2,000,000,000 3.375% Fixed Rate Senior Notes due 2027 

$1,000,000,000 3.375% Fixed Rate Senior Notes due 2029 

$2,000,000,000 3.625% Fixed Rate Senior Notes due 2032 

$1,000,000,000 4.000% Fixed Rate Senior Notes due 2052 

GSK Consumer Healthcare Capital UK plc 

$1,750,000,000 3.125% Fixed Rate Senior Notes due 2025 

This Registration Rights Agreement dated March 24, 2022 (this “Agreement”) is entered into by and between GSK Consumer
Healthcare Capital US LLC (the “US Issuer”), GSK Consumer Healthcare Capital UK plc (the “UK Issuer”) as issuers (each, an “Issuer” and, together, the “Issuers”), GlaxoSmithKline
plc (“GSK”) and Haleon plc (“Haleon”) as guarantors (each, a “Guarantor” and, together, the “Guarantors”), BofA Securities, Inc., Citigroup Global Markets Inc., HSBC Securities
(USA) Inc. and Mizuho Securities USA LLC, as representatives (the “Representatives”) of the several initial purchasers (the “Represented Initial Purchasers”) named in the Purchase Agreement (as defined below), and
Goldman Sachs International (“GSI” and, together with the Represented Initial Purchasers, the “Initial Purchasers”). 

The Issuers, the Guarantors, the Representatives and GSI are parties to the Purchase Agreement dated March 21, 2022 (the
“Purchase Agreement”), which provides for (i) the sale by the US Issuer to the Initial Purchasers of its 3.024% callable fixed rate senior notes due 2024 in an aggregate principal amount of $700,000,000 (the “Callable
Fixed Rate Notes”), callable floating rate senior notes due 2024 in an aggregate principal amount of $300,000,000 (the “Callable Floating Rate Notes”), 3.375% senior notes due 2027 in an aggregate principal amount of
$2,000,000,000 (the “2027 Fixed Rate Notes”), 3.375% senior notes due 2029 in an aggregate principal amount of $1,000,000,000 (the “2029 Fixed Rate Notes”), 3.625 % senior notes due 2032 in an aggregate
principal amount of $ 2,000,000,000 (the “2032 Fixed Rate Notes”) and 4.000 % senior notes due 2052 in an aggregate principal amount of $1,000,000,000 (the “2052 Fixed Rate Notes” and, together with the
Callable Fixed Rate Notes, the Callable Floating Rate Notes, the 2027 Fixed Rate Notes, the 2029 Fixed Rate Notes and the 2032 Fixed Rate Notes, the “US Issuer Notes”); and (ii) the sale by the UK Issuer to the Initial
Purchasers of its 3.125 % Fixed Rate Senior Notes due 2025 in an aggregate principal amount of $1,750,000,000 (the “2025 Fixed Rate Notes” or the “UK Issuer Notes” and, collectively with the US Issuer Notes,
the “Notes”). Each of the Notes are sometimes referred to herein as a “Series” of Notes. As an inducement to the Initial Purchasers to enter into the Purchase Agreement, each the US Issuer and the UK Issuer has
agreed to provide to the Initial Purchasers and their direct and indirect transferees the registration rights set forth in this Agreement in relation to the US Issuer Notes and the UK Issuer Notes, respectively. The execution and delivery of this
Agreement is a condition to the closing under the Purchase Agreement. 
 Prior to the Guarantee Assumption Date, the Notes will be fully and
unconditionally guaranteed as to payment of principal, premium, if any, and interest by GSK (the “GSK Guarantee”). With effect from (and including) the Guarantee Assumption Date, the Notes will be fully and unconditionally
guaranteed as to payment of principal, premium, if any, and interest by Haleon (the “Haleon Guarantee”). 

 In consideration of the foregoing, the parties hereto agree as follows: 

1. Definitions. As used in this Agreement, the following terms shall have the following meanings: 

“Additional Interest” shall have the meaning set forth in Section 2(l) hereof. 

“Business Day” shall mean any day other than a Saturday, a Sunday or a day on which banking institutions in the City of New
York or London, England are authorized or obligated by law, regulation or executive order to be closed. For purposes of this Agreement, if the day on which any deadline specified in this Agreement expires is not a Business Day, such deadline shall
be deemed to expire on the next succeeding Business Day. 
 “Demerger” shall have the meaning set forth in the Purchase
Agreement. 
 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time. 

“Exchange Act Report” shall mean any report to be filed by Haleon under the Exchange Act. 

“Exchange Dates” shall have the meaning set forth in Section 2(c)(ii) hereof. 

“Exchange Offer” shall mean the exchange offer by the relevant Issuer and Haleon of Exchange Notes for Registrable Securities
pursuant to Section 2(a) hereof. 
 “Exchange Offer Registration” shall mean a registration under the Securities Act
effected pursuant to Section 2(a) hereof. 
 “Exchange Offer Registration Statement” shall mean an exchange offer
registration statement on Form F-4 (or, if applicable, on another appropriate form) and all amendments and supplements to such registration statement, in each case including the Prospectus contained therein or
deemed a part thereof, all exhibits thereto and any document incorporated by reference therein. 
 “Exchange Notes” shall
mean (i) with respect to the US Issuer Registrable Securities of each Series, senior notes issued by the US Issuer; and (ii) with respect to the UK Issuer Registrable Securities of each Series, senior notes issued by the UK Issuer, and in
each case guaranteed by Haleon under the Indenture containing terms identical to the Notes of such Series (except that the Exchange Notes will not be (i) subject to restrictions on transfer, (ii) guaranteed by GSK, (iii) subject to
special mandatory redemption provisions, or (iv) subject to any increase in annual interest rate for failure to comply with this Agreement) and to be offered to Holders of Notes of such Series in exchange for Notes of such Series pursuant to
the Exchange Offer. 
 “FINRA” means the Financial Industry Regulatory Authority, Inc. 

“Free Writing Prospectus” means each free writing prospectus (as defined in Rule 405 under the Securities Act) prepared by or
on behalf of an Issuer or used or referred to by an Issuer or Haleon in connection with the sale of the Notes or the Exchange Notes. 

“Guarantee Assumption Date” means the date on which GSK ceases to hold a direct or indirect interest in the share capital of
GlaxoSmithKline Consumer Healthcare Holdings (No.2) Ltd, other than as a result of any interest it may have in the share capital of Haleon, in order to implement the Demerger, as defined in the Purchase Agreement. 

“Guarantee” shall mean (i) prior to the Guarantee Assumption Date, the GSK Guarantee; and (ii) with effect from
(and including) the Guarantee Assumption Date, the Haleon Guarantee. 
 “Holders” shall mean the Initial Purchasers, for so
long as they own any Registrable Securities, and each of their successors, assigns and direct and indirect transferees who become owners of Registrable Securities under the Indenture; provided that, for purposes of Section 4 and
Section 5 hereof, the term “Holders” shall include Participating Broker-Dealers. 
 “Indemnified
Person” shall have the meaning set forth in Section 5(c) hereof. 

  
 2 

 “Indemnifying Person” shall have the meaning set forth in Section 5(c)
hereof. 
 “Indenture” shall mean the Indenture relating to the Notes dated as of March 24, 2022, among the Issuers,
the Guarantors and Deutsche Bank Trust Company Americas, as trustee, as the same may be amended or supplemented from time to time in accordance with the terms thereof. 

“Initial Purchasers” shall have the meaning set forth in the preamble. 

“Issuers” shall have the meaning set forth in the preamble. 

“Majority Holders” shall mean, with respect to any Series of Notes, the Holders of a majority of the aggregate principal
amount of the outstanding Registrable Securities of such Series; provided that whenever the consent or approval of Holders of a specified percentage of Registrable Securities of such Series is required hereunder, any Registrable Securities of
such Series owned directly or indirectly by the relevant Issuer or the Guarantors or any of their respective controlled affiliates shall not be counted in determining whether such consent or approval was given by the Holders of such required
percentage or amount; and provided, further, that if the relevant Issuer or the Guarantors shall issue any additional Notes under the Indenture prior to consummation of the Exchange Offer or, if applicable, the effectiveness of any
Shelf Registration Statement, such additional Notes of such Series and the Registrable Securities of such Series to which this Agreement relates shall be treated together as one class for purposes of determining whether the consent or approval of
Holders of a specified percentage of Registrable Securities has been obtained. 
 “Notes” shall have the meaning set forth
in the preamble. 
 “Notice and Questionnaire” shall mean a notice of registration statement and selling security holder
questionnaire distributed to a Holder by the relevant Issuer upon receipt of a Shelf Request from such Holder. 
 “Participating
Broker-Dealers” shall have the meaning set forth in Section 4(a) hereof. 
 “Participating Holder” shall mean
any Holder of Registrable Securities that has returned a completed and signed Notice and Questionnaire to the relevant Issuer in accordance with Section 2(h) hereof. 

“Person” shall mean an individual, partnership, limited liability company, corporation, trust or unincorporated organization,
or a government or agency or political subdivision thereof. 
 “Prospectus” shall mean the prospectus included in, or,
pursuant to the rules and regulations of the Securities Act, deemed a part of, a Registration Statement, including any preliminary prospectus, and any such prospectus as amended or supplemented by any prospectus supplement, including a prospectus
supplement with respect to the terms of the offering of any portion of the Registrable Securities covered by a Shelf Registration Statement, and by all other amendments and supplements to such prospectus, and in each case including any document
incorporated by reference therein. 
 “Purchase Agreement” shall have the meaning set forth in the preamble. 

“Registrable Securities” shall mean the US Issuer Registrable Securities or the UK Issuer Registrable Securities. 

“Registration Default” shall mean, as to any Series of Notes, the occurrence of any of the following: (i) the Exchange
Offer, with respect to such Series of Notes, is not completed on or prior to the Target Registration Date, (ii) the Shelf Registration Statement, with respect to such Series of Notes, if required pursuant to Section 2(h)(i) hereof, has not
become effective on or prior to the Target Registration Date, (iii) if the relevant Issuer receives a Shelf Request pursuant to Section 2(h)(ii), the Shelf Registration Statement required to be filed thereby has not become effective by the
later of (a) the Target Registration Date and (b) 90 days after delivery of such Shelf Request, or (iv) the Shelf Registration Statement, if required by this Agreement, has become effective and thereafter ceases to be effective or the
Prospectus contained therein ceases to be usable, in each case whether or not permitted by this Agreement, at any time during the Shelf Effectiveness Period, and such failure to remain effective or usable exists for more than 180 days (whether or
not consecutive) in any 12-month period. 

  
 3 

 “Registration Expenses” shall mean any and all expenses incident to
performance of or compliance by the relevant Issuer and Haleon with this Agreement, including without limitation: (i) all SEC or FINRA registration and filing fees, (ii) all fees and expenses incurred in connection with compliance with
state securities or blue sky laws to the extent required hereunder, (iii) all expenses in preparing or assisting in preparing, word processing, printing and distributing any Registration Statement, any Prospectus, any Free Writing Prospectus
and any amendments or supplements thereto, any underwriting agreements, securities sales agreements or other similar agreements and any other documents relating to the performance of and compliance with this Agreement, (iv) all rating agency
fees, (v) all fees and disbursements relating to the qualification of the Indenture under applicable securities laws, (vi) the fees and disbursements of the Trustee and its counsel, (vii) the fees and disbursements of counsel for the
relevant Issuer and Haleon and (viii) the fees and disbursements of the independent registered public accountants of the relevant Issuer and Haleon, including the expenses of any special audits or “comfort” letters required by or
incident to the performance of and compliance with this Agreement, but excluding in all cases fees and expenses of counsel to the Underwriters or the Holders and underwriting discounts and commissions, brokerage commissions and transfer taxes, if
any, relating to the sale or disposition of Registrable Securities by a Holder and any other costs or expenses of the Underwriters or the Holders. 

“Registration Statement” shall mean any registration statement of the Issuers and Haleon that covers any of the Exchange
Notes or Registrable Securities pursuant to the provisions of this Agreement and all amendments and supplements to any such registration statement, including post-effective amendments, in each case including the Prospectus contained therein or
deemed a part thereof, all exhibits thereto and any document incorporated by reference therein. 
 “Representatives” shall
have the meaning set forth in the preamble. 
 “SEC” shall mean the United States Securities and Exchange Commission. 

“Securities Act” shall mean the Securities Act of 1933, as amended from time to time. 

“Shelf Effectiveness Period” shall have the meaning set forth in Section 2(h) hereof. 

“Shelf Registration” shall mean a registration effected pursuant to Section 2(h) hereof. 

“Shelf Registration Statement” shall mean a “shelf” registration statement of the US Issuer, the UK Issuer and
Haleon that covers all or a portion of the US Issuer Registrable Securities (with respect to the US Issuer) and the UK Issuer Registrable Securities (with respect to the UK Issuer) on an appropriate form under Rule 415 under the Securities Act, or
any similar rule that may be adopted by the SEC, and all amendments and supplements to such registration statement, including post-effective amendments, in each case including the Prospectus contained therein or deemed a part thereof, all exhibits
thereto and any document incorporated by reference therein. 
 “Shelf Request” shall have the meaning set forth in
Section 2(h) hereof. 
 “Staff” shall mean the staff of the SEC. 

“Target Registration Date” shall mean 365 days after the Guarantee Assumption Date. 

“Trust Indenture Act” shall mean the Trust Indenture Act of 1939, as amended from time to time. 

“Trustee” shall mean the trustee with respect to the Notes under the Indenture. 

“UK Issuer” shall have the meaning set forth in the preamble. 

“UK Issuer Notes” shall have the meaning set forth in the preamble. 

  
 4 

 “UK Issuer Registrable Securities” shall mean the UK Issuer Notes and the
Guarantee; provided that any UK Issuer Notes shall cease to be Registrable Securities at the earliest date (i) when a Registration Statement with respect to such UK Issuer Notes has become effective under the Securities Act and such UK
Issuer Notes have been exchanged or disposed of pursuant to such Registration Statement, (ii) when such UK Issuer Notes cease to be outstanding, (iii) except in the case of UK Issuer Notes that otherwise remain Registrable Securities and
that are held by an Initial Purchaser and that are ineligible to be exchanged in the Exchange Offer, when the Exchange Offer is consummated or (iv) when such UK Issuer Notes are freely tradeable, without restriction, under federal or state
securities laws. 
 “Underwriter” shall have the meaning set forth in Section 3(e) hereof. 

“Underwritten Offering” shall mean an offering in which Registrable Securities are sold to an Underwriter for reoffering to
the public. 
 “US Issuer” shall have the meaning set forth in the preamble. 

“US Issuer Notes” shall have the meaning set forth in the preamble. 

“US Issuer Registrable Securities” shall mean the US Issuer Notes and the Guarantee; provided that any US Issuer Notes
shall cease to be Registrable Securities at the earliest date (i) when a Registration Statement with respect to such US Issuer Notes has become effective under the Securities Act and such US Issuer Notes have been exchanged or disposed of
pursuant to such Registration Statement, (ii) when such US Issuer Notes cease to be outstanding, (iii) except in the case of US Issuer Notes that otherwise remain Registrable Securities and that are held by an Initial Purchaser and that
are ineligible to be exchanged in the Exchange Offer, when the Exchange Offer is consummated or (iv) when such US Issuer Notes are freely tradeable, without restriction, under federal or state securities laws. 

2. Registration under the Securities Act 

(a) To the extent not prohibited by any applicable law or applicable interpretations of the Staff, following the Guarantee Assumption Date,
the US Issuer and Haleon shall use their commercially reasonable efforts to (x) cause to be filed an Exchange Offer Registration Statement covering an offer to the Holders to exchange all the US Issuer Registrable Securities for Exchange Notes
and (y) have such Registration Statement become and remain effective until 90 days after the last Exchange Date for use by one or more Participating Broker-Dealers. 

(b) To the extent not prohibited by any applicable law or applicable interpretations of the Staff, following the Guarantee Assumption Date,
the UK Issuer and Haleon shall use their commercially reasonable efforts to (x) cause to be filed an Exchange Offer Registration Statement covering an offer to the Holders to exchange all the UK Issuer Registrable Securities for Exchange Notes
and (y) have such Registration Statement become and remain effective until 90 days after the last Exchange Date for use by one or more Participating Broker-Dealers. 

(c) The relevant Issuer and Haleon shall commence the Exchange Offer by mailing or making available the related Prospectus, appropriate
letters of transmittal and other accompanying documents to each Holder stating, in addition to such other disclosures as are required by applicable law, substantially the following: 

(i) that the Exchange Offer is being made pursuant to this Agreement and that all US Issuer Registrable Securities (with
respect to the US Issuer) or UK Issuer Registrable Securities (with respect to the UK Issuer) validly tendered and not properly withdrawn will be accepted for exchange; 

(ii) the period of acceptance for exchange (which shall be a period of at least 20 Business Days from the date such notice is
mailed or made available) (the “Exchange Dates”); 
 (iii) that any Registrable Security not tendered will
remain outstanding and continue to accrue interest but will not retain any rights under this Agreement, except as otherwise specified herein; 

  
 5 

 (iv) that any Holder electing to have a Registrable Security exchanged
pursuant to the Exchange Offer will be required to (A) surrender such Registrable Security, together with the appropriate letters of transmittal, to the institution and at the address and in the manner specified in the notice, or
(B) effect such exchange otherwise in compliance with the applicable procedures of the depositary for such Registrable Security, in each case on or prior to the last Exchange Date; and 

(v) that any Holder will be entitled to withdraw its election, not later than the last Exchange Date, by (A) sending to
the institution and at the address specified in the notice, a telegram, facsimile transmission or letter setting forth the name of such Holder, the principal amount of Registrable Securities delivered for exchange and a statement that such Holder is
withdrawing its election to have such Notes exchanged or (B) effecting such withdrawal in compliance with the applicable procedures of the depositary for the Registrable Securities. 

(d) As a condition to participating in the Exchange Offer, a Holder will be required to represent to the relevant Issuer and Haleon that
(1) any Exchange Notes to be received by it will be acquired in the ordinary course of its business, (2) at the time of the commencement of the Exchange Offer it has no arrangement or understanding with any Person to participate in the
distribution (within the meaning of the Securities Act) of the Exchange Notes in violation of the provisions of the Securities Act, (3) it is not an “affiliate” (within the meaning of Rule 405 under the Securities Act) of the relevant
Issuer or Haleon and (4) if such Holder is a broker-dealer that will receive Exchange Notes for its own account in exchange for Registrable Securities that were acquired as a result of market-making or other trading activities, then such Holder
will deliver a Prospectus (or, to the extent permitted by law, make available a Prospectus to purchasers) in connection with any resale of such Exchange Notes. 

(e) As soon as reasonably practicable after the last Exchange Date, the relevant Issuer and Haleon shall: 

(i) accept for exchange US Issuer Registrable Securities (with respect to the US Issuer) or UK Issuer Registrable Securities
(with respect to the UK Issuer) or portions thereof validly tendered and not properly withdrawn pursuant to the Exchange Offer; and 

(ii) deliver, or cause to be delivered, to the Trustee for cancellation all US Issuer Registrable Securities or UK Issuer
Registrable Securities or portions thereof so accepted for exchange by the US Issuer or the UK Issuer, respectively, and issue, and cause the Trustee to promptly authenticate and deliver to each Holder, Exchange Notes equal in principal amount to
the principal amount of the Registrable Securities tendered by such Holder. 
 (f) Each of the Issuers and Haleon shall use its commercially
reasonable efforts to complete the Exchange Offer as provided above and shall comply in all material respects with the applicable requirements of the Securities Act, the Exchange Act and other applicable laws and regulations in connection with the
Exchange Offer. 
 (g) For the avoidance of doubt, notwithstanding any provision herein purporting to require physical mailing, delivery or
acceptance of any document or instrument, each Issuer and Haleon may conduct the Exchange Offer exclusively through the automated tender offer program of the Depository Trust Company or any successor or similar system permitting electronic
transmittal, tender and acceptance of documents and instruments, provided that this provision shall apply only to Registrable Securities held in the form of beneficial interests in a global note deposited with (or held by a custodian for) the
Depository Trust Company. 
 (h) In the event that (i) an Issuer and Haleon determine that the Exchange Offer Registration provided for
in Section 2(a) hereof would violate any applicable law or applicable interpretations of the Staff or (ii) upon receipt of a written request (a “Shelf Request”) from any Initial Purchaser representing that it holds
Registrable Securities that are or were ineligible to be exchanged in the Exchange Offer, such Issuer and Haleon shall use their commercially reasonable efforts to cause to be filed as soon as reasonably practicable after such determination or Shelf
Request, as the case may be, a Shelf Registration Statement providing for the sale of all the US Issuer Registrable Securities (in case of the US Issuer) or all the UK Issuer Registrable Securities (in case of the UK Issuer) by the Holders thereof
and to have such Shelf Registration Statement become effective; provided that no Holder will be entitled to have any Registrable Securities included in any Shelf Registration Statement, or entitled to use the prospectus forming a part of such
Shelf Registration Statement, until such Holder shall have delivered a completed and signed Notice and Questionnaire and provided such other information regarding such Holder to the relevant Issuer as is contemplated by Section 3(b) hereof.

  
 6 

 (i) In the event that an Issuer and Haleon are required to file a Shelf Registration
Statement pursuant to clause (ii) of Section 2(h), such Issuer and Haleon shall use their commercially reasonable efforts to file and have become effective both an Exchange Offer Registration Statement pursuant to Section 2(a) hereof
with respect to all US Issuer Registrable Securities (with respect to the US Issuer) or all UK Issuer Registrable Securities (with respect to the UK Issuer) and a Shelf Registration Statement (which may be a combined Registration Statement with the
Exchange Offer Registration Statement) with respect to offers and sales of such Registrable Securities held by the Initial Purchasers after completion of the Exchange Offer. 

(j) The relevant Issuer and Haleon shall use their commercially reasonable efforts to keep the Shelf Registration Statement, if required,
continuously effective until the earliest of (x) the date the US Issuer Notes (with respect to the US Issuer) or the UK Issuer Notes (with respect to the UK Issuer) cease to be US Issuer Registrable Securities or UK Issuer Registrable
Securities, respectively, (y) one year after the Guarantee Assumption Date, and (z) the date when Holders, other than Holders that are “affiliates” (as defined in Rule 144) of the relevant Issuer, are able to sell such Notes
without restriction, and without reliance as to the availability of current public information, pursuant to Rule 144 promulgated under the Securities Act (the “Shelf Effectiveness Period”). Further, the relevant Issuer and Haleon
shall supplement or amend the Shelf Registration Statement, the related Prospectus and any Free Writing Prospectus if required by the rules, regulations or instructions applicable to the registration form used by such Issuer for such Shelf
Registration Statement or by the Securities Act or by any other rules and regulations thereunder or if reasonably requested by a Holder of Registrable Securities with respect to information relating to such Holder, and use their commercially
reasonable efforts to cause any such amendment to become effective, if required, and such Shelf Registration Statement, Prospectus or Free Writing Prospectus, as the case may be, to become usable as soon as thereafter reasonably practicable subject
to Section 3(d) below. The relevant Issuer and Haleon shall furnish to the Participating Holders copies of any such supplement or amendment promptly after its being used or filed with the SEC. 

(k) The relevant Issuer and Haleon shall pay all Registration Expenses in connection with any registration pursuant to Section 2(a) or
Section 2(h) hereof. Each Holder shall pay all underwriting discounts and commissions, brokerage commissions and transfer taxes, if any, relating to the sale or disposition of such Holder’s Registrable Securities pursuant to the Shelf
Registration Statement. 
 (l) If a Registration Default occurs with respect to the Registrable Securities of a Series, the interest rate on
the Registrable Securities of such Series will be increased by (i) 0.25% per annum for the first 90-day period beginning on the day immediately following such Registration Default and (ii) an additional
0.25% per annum with respect to each subsequent 90-day period, in each case until and including the date such Registration Default ends, up to a maximum increase of 0.50% per annum (such interest referred to
in clauses (i) and (ii) above, “Additional Interest”); provided that in no event shall Additional Interest accrue after the Shelf Effectiveness Period. A Registration Default, with respect to the Registrable Securities
of a Series, ends when the Notes of such Series cease to be Registrable Securities or, if earlier, (1) in the case of a Registration Default under clause (i) of the definition thereof, when the Exchange Offer is completed, (2) in the
case of a Registration Default under clause (ii) or clause (iii) of the definition thereof, when the Shelf Registration Statement becomes effective or (3) in the case of a Registration Default under clause (iv) of the definition
thereof, when the Shelf Registration Statement again becomes effective or the Prospectus again becomes usable. If at any time more than one Registration Default has occurred and is continuing, then, until the next date that there is no Registration
Default, the increase in interest rate provided for by this paragraph shall apply as if there occurred a single Registration Default that begins on the date that the earliest such Registration Default occurred and ends on such next date that there
is no Registration Default. The Representatives acknowledge and agree that the relevant Issuer and Haleon will not be required to pay Additional Interest hereunder once the Notes become freely tradeable under Rule 144 under the Securities Act. 

(m) It is acknowledged that the Additional Interest set forth above is the sole remedy for any default hereunder. 

  
 7 

 3. Registration Procedures. 

(a) In connection with their obligations pursuant to Section 2(a) and Section 2(h) hereof, the relevant Issuer and Haleon shall:

 (i) use their commercially reasonable efforts to prepare and file with the SEC a Registration Statement on the appropriate
form under the Securities Act, which form (A) shall be selected by the relevant Issuer and Haleon, (B) shall, in the case of a Shelf Registration, be available for the sale of the Registrable Securities by the Holders thereof and
(C) shall comply as to form in all material respects with the requirements of the applicable form and include all financial statements required by the SEC to be filed therewith; and use their commercially reasonable efforts to cause such
Registration Statement to become effective and remain effective for the applicable period in accordance with Section 2 hereof; 

(ii) subject to Section 3(d) below, (A) prepare and file with the SEC such amendments and post-effective amendments
to each Registration Statement as may be necessary to keep such Registration Statement effective for the applicable period in accordance with Section 2 hereof and cause each Prospectus to be supplemented by any required prospectus supplement
and, as so supplemented, to be filed pursuant to Rule 424 under the Securities Act; and (B) keep each Prospectus current during the period described in Section 4(a)(3) of and Rule 174 under the Securities Act that is applicable to
transactions by brokers or dealers with respect to the Registrable Securities or Exchange Notes; 
 (iii) to the extent any
Free Writing Prospectus is used, file with the SEC any Free Writing Prospectus that is required to be filed by such Issuer or Haleon with the SEC in accordance with the Securities Act and to retain any Free Writing Prospectus not required to be
filed; 
 (iv) in the case of a Shelf Registration, furnish to each Participating Holder, to counsel for such Participating
Holders and to each Underwriter of an Underwritten Offering of Registrable Securities, if any, without charge, as many copies of each Prospectus, preliminary prospectus or Free Writing Prospectus, and any amendment or supplement thereto, as such
Participating Holder, counsel or Underwriter may reasonably request in order to facilitate the sale or other disposition of the Registrable Securities thereunder; and, subject to Section 3(c) hereof, the relevant Issuer and Haleon consent to
the use of such Prospectus, preliminary prospectus or such Free Writing Prospectus and any amendment or supplement thereto in accordance with applicable law by each of the Participating Holders and any such Underwriters in connection with the
offering and sale of the Registrable Securities covered by and in the manner described in such Prospectus, preliminary prospectus or such Free Writing Prospectus or any amendment or supplement thereto in accordance with applicable law; 

(v) in the case of a Shelf Registration, use their commercially reasonable efforts to register or qualify the Registrable
Securities under all applicable state securities or blue sky laws of such jurisdictions as any Participating Holder shall reasonably request in writing by the time the applicable Registration Statement becomes effective; cooperate with such
Participating Holders in connection with any filings required to be made with FINRA; provided that neither the relevant Issuer nor Haleon shall be required to (1) qualify or be authorized, as applicable, as a foreign corporation or other
entity or as a dealer in securities, investment firm or other entity under financial supervision in any such jurisdiction where it would not otherwise be required to so qualify or be authorized, (2) file any general consent to service of
process in any such jurisdiction, (3) subject itself to taxation in any such jurisdiction if it is not so subject or (4) make any changes to incorporating or organizational documents (including its deed of incorporation, articles of
association, board rules or any charter); 
 (vi) in the case of a Shelf Registration, notify each Participating Holder and
counsel for such Participating Holders promptly and, if requested by any such Participating Holder or counsel, confirm such advice in writing (1) when a Registration Statement has become effective, when any post-effective amendment thereto has
been filed and becomes effective, when any Free Writing Prospectus has been filed or any amendment or supplement to the Prospectus or any Free Writing Prospectus has been filed, (2) of any request by the SEC or any state securities authority
for amendments and supplements to a Registration Statement, Prospectus or any Free Writing Prospectus or for additional information after the Registration 

  
 8 

 
Statement has become effective, (3) of the issuance by the SEC or any state securities authority of any stop order suspending the effectiveness of a Registration Statement or the initiation
of any proceedings for that purpose, including the receipt by such Issuer of any notice of objection of the SEC to the use of a Shelf Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act,
(4) if, between the applicable effective date of a Shelf Registration Statement and the closing of any sale of Registrable Securities covered thereby, such Issuer or Haleon receives any notification with respect to the suspension of the
qualification of the Registrable Securities for sale in any jurisdiction or the initiation of any proceeding for such purpose, (5) of the happening of any event during the period a Registration Statement is effective that makes any statement
made in such Registration Statement or the related Prospectus or any Free Writing Prospectus untrue in any material respect or that requires the making of any changes in such Registration Statement or Prospectus or any Free Writing Prospectus in
order to make the statements therein not misleading and (6) of any determination by such Issuer or Haleon that a post-effective amendment to a Registration Statement or any amendment or supplement to the Prospectus or any Free Writing
Prospectus would be appropriate; 
 (vii) subject to Section 3(d) below, use their commercially reasonable efforts to
obtain the withdrawal of any order suspending the effectiveness of a Registration Statement or, in the case of a Shelf Registration, the resolution of any objection of the SEC pursuant to Rule 401(g)(2) under the Securities Act, including by filing
an amendment to such Registration Statement on the proper form, as soon as reasonably practicable and provide prompt notice to each Holder or Participating Holder of the withdrawal of any such order or such resolution; 

(viii) in the case of a Shelf Registration, furnish to each Participating Holder upon request, without charge, at least one
conformed copy of each Registration Statement and any post-effective amendment thereto (without any documents incorporated therein by reference or exhibits thereto, unless requested); 

(ix) in the case of a Shelf Registration, cooperate with the Participating Holders to facilitate the timely preparation and
delivery of certificates representing the US Issuer Registrable Securities (in case of the US Issuer) or the UK Issuer Registrable Securities (in case of the UK Issuer) to be sold and not bearing any restrictive legends and enable such Registrable
Securities to be issued in such denominations and registered in such names (consistent with the provisions of the Indenture) as such Participating Holders may reasonably request at least one Business Day prior to the closing of any sale of such
Registrable Securities; 
 (x) upon the occurrence of any event contemplated by Section 3(a)(vi)(5) hereof, subject to
Section 3(d) below, use their commercially reasonable efforts to prepare and file with the SEC a supplement or post-effective amendment to the applicable Exchange Offer Registration Statement or Shelf Registration Statement or the related
Prospectus or any Free Writing Prospectus or any document incorporated therein by reference or file any other required document so that, as thereafter delivered (or, to the extent permitted by law, made available) to purchasers of the Registrable
Securities, such Prospectus or Free Writing Prospectus, as the case may be, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading; and the relevant Issuer shall notify the Participating Holders (in the case of a Shelf Registration Statement) and the Initial Purchasers and any Participating Broker-Dealers known to such Issuer (in the case of
an Exchange Offer Registration Statement) to suspend use of the Prospectus or any Free Writing Prospectus as promptly as practicable after the occurrence of such an event, and such Participating Holders, such Participating Broker-Dealers and the
Initial Purchasers, as applicable, hereby agree to suspend use of the Prospectus or any Free Writing Prospectus, as the case may be, upon receipt of such notice from the relevant Issuer until such Issuer and Haleon have amended or supplemented the
Prospectus or the Free Writing Prospectus, as the case may be, to correct such misstatement or omission; 
 (xi) not, at any
time after initial filing of a Registration Statement, use or file any Prospectus, any Free Writing Prospectus, any amendment of or supplement to a Registration Statement or a Prospectus or a Free Writing Prospectus, or any document that is to be
incorporated by reference into a Registration Statement (other than an Exchange Act Report), a Prospectus or a Free Writing Prospectus, of which the 

  
 9 

 
Initial Purchasers and their counsel (and, in the case of a Shelf Registration Statement, the Participating Holders and their counsel) shall not have previously been advised and furnished a copy
or to which the Initial Purchasers or their counsel or the Participating Holders or their counsel shall reasonably object; 

(xii) obtain a CUSIP number for all relevant Exchange Notes or Registrable Securities, as the case may be, not later than the
initial effective date of a Registration Statement; 
 (xiii) cause the Indenture to be qualified under the Trust Indenture
Act in connection with the registration of the relevant Exchange Notes or Registrable Securities, as the case may be; cooperate with the Trustee and the Holders to effect such changes to the Indenture as may be required for the Indenture to be so
qualified in accordance with the terms of the Trust Indenture Act; and execute, and use their commercially reasonable efforts to cause the Trustee to execute, all documents as may be required to effect such changes and all other forms and documents
required to be filed with the SEC to enable the Indenture to be so qualified in a timely manner; 
 (xiv) if reasonably
requested by any Participating Holder, promptly include in a Prospectus supplement or post-effective amendment such information with respect to such Participating Holder as such Participating Holder reasonably requests to be included therein and
make all required filings of such Prospectus supplement or such post-effective amendment as soon as the Company has received notification of the matters to be so included in such filing; and 

(b) In the case of a Shelf Registration Statement, the relevant Issuer may require, as a condition to including a Holder’s Registrable
Securities in the Registration Statement, each Holder of Registrable Securities to furnish to such Issuer a Notice and Questionnaire and such other information regarding such Holder and the proposed disposition by such Holder of such Registrable
Securities as such Issuer may from time to time reasonably request in writing. No Holder of Registrable Securities shall be entitled to include any of its Registrable Securities in any Shelf Registration pursuant to this Agreement unless such Holder
furnishes to the relevant Issuer in writing, within 20 days after receipt of a written request therefor, such information as such Issuer may reasonably request for inclusion in any Shelf Registration or Prospectus included therein, and no such
Holder shall be entitled to Additional Interest pursuant hereto. 
 (c) Each Participating Holder agrees that, upon receipt of any notice
from the relevant Issuer of the happening of any event of the kind described in Section 3(a)(vi)(3) or Section 3(a)(vi)(5) hereof or any notice pursuant to Section 3(d), such Participating Holder will forthwith discontinue disposition
of Registrable Securities pursuant to the Shelf Registration Statement until such Participating Holder’s receipt of the copies of the supplemented or amended Prospectus and any Free Writing Prospectus contemplated by Section 3(a)(x) hereof
or notice that the period referred to in Section 3(d) has ended and, if so directed by such Issuer, such Participating Holder will deliver to such Issuer all copies in its possession, other than permanent file copies then in such Participating
Holder’s possession, of the Prospectus and any Free Writing Prospectus covering such Registrable Securities that is current at the time of receipt of such notice. 

(d) Notwithstanding any other provisions of this Agreement to the contrary, an Issuer may postpone effecting an Exchange Offer Registration or
a Shelf Registration (or the maintenance of its effectiveness and usability) (i) during the regular quarterly period during which directors and executive officers of such Issuer and/or Haleon are not permitted to trade under the insider trading
policy of such Issuer and/or Haleon then in effect until the expiration of such quarterly period (but in no event later than two Business Days after the date of such Issuer’ Haleon’s quarterly results announcement or annual report is
published, as applicable ) and (ii) for a period of up to 90 days if such Issuer and/or Haleon determine in good faith that such Exchange Offer Registration or a Shelf Registration, as the case may be, would (A) reasonably be expected to
materially impede, delay, interfere with or otherwise have a material adverse effect on any material acquisition of assets (other than in the ordinary course of business), merger, consolidation, tender offer, financing or any other material business
transaction by Haleon or any of its subsidiaries or (B) require disclosure of information that has not been disclosed to the public, the disclosure of which would not be in the best interests of Haleon. Any such suspensions shall not exceed 180
days in the aggregate during any 365-day period. 

  
 10 

 (e) The Participating Holders who desire to do so may sell such Registrable Securities in an
Underwritten Offering. In any such Underwritten Offering, the investment bank or investment banks and manager or managers (each an “Underwriter”) that will administer the offering will be selected by the Holders of a majority in
principal amount of the Registrable Securities included in such offering and shall be reasonably acceptable to the relevant Issuer and Haleon. The relevant Issuer and Haleon shall use commercially reasonable efforts to comply in all material
respects with any reasonable and customary request, including the provision of opinions of counsel, accountants’ comfort letters and officers’ certificates, of the Participating Holders or Underwriters made in connection with such
Underwritten Offering to the extent such request does not create an undue burden or expense for the Issuer, Haleon or their subsidiaries. All expenses of the Underwritten Offering (other than Registration Expenses and expenses of the Issuer, Haleon
and their subsidiaries) shall be borne by the Participating Holders and the Underwriters, as agreed amongst them. 
 (f) Each Holder agrees
that such Holder shall not take any action that would result in the relevant Issuer or Haleon being required to file with the SEC a free writing prospectus, as defined in Rule 405, as amended, under the Securities Act, prepared by or on behalf of
such Holder that otherwise would not be required to be filed by the relevant Issuer or Haleon thereunder, but for the action of such Holder. 

4. Participation of Broker-Dealers in Exchange Offer. 

(a) The Staff has taken the position that any broker-dealer that receives Exchange Notes for its own account in the Exchange Offer in exchange
for Notes that were acquired by such broker-dealer as a result of market-making or other trading activities (a “Participating Broker-Dealer”) may be deemed to be an “underwriter” within the meaning of the Securities Act
and must deliver a prospectus meeting the requirements of the Securities Act in connection with any resale of such Exchange Notes. 
 The
Issuers and Haleon understand that it is the Staff’s position that if the Prospectus contained in the Exchange Offer Registration Statement includes a plan of distribution containing a statement to the above effect and the means by which
Participating Broker-Dealers may resell the Exchange Notes, without naming the Participating Broker-Dealers or specifying the amount of Exchange Notes owned by them, such Prospectus may be delivered by Participating Broker-Dealers (or, to the extent
permitted by law, made available to purchasers) to satisfy their prospectus delivery obligation under the Securities Act in connection with resales of Exchange Notes for their own accounts, so long as the Prospectus otherwise meets the requirements
of the Securities Act. 
 (b) In light of the above, and subject to Section 3(d), the relevant Issuer and Haleon shall amend or
supplement the Prospectus contained in the Exchange Offer Registration Statement for a period of up to 90 days after the last Exchange Date, in order to expedite or facilitate the disposition of any Exchange Notes by Participating Broker-Dealers
consistent with the positions of the Staff recited in Section 4(a) above. The relevant Issuer and Haleon further acknowledge that Participating Broker-Dealers shall be authorized, subject to Section 3(d), to deliver such Prospectus (or, to
the extent permitted by law, make available) during such period in connection with the resales contemplated by this Section 4. 
 (c)
The Initial Purchasers shall have no liability to the Issuers, Haleon or any Holder with respect to any request that they may make pursuant to Section 4(b) hereof. 

5. Indemnification and Contribution. 

(a) Each of the relevant Issuer and Haleon, jointly and severally, shall indemnify and hold harmless each Initial Purchaser and each Holder
and their respective affiliates, and each Person, if any, who controls any Initial Purchaser or any Holder within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any and all losses,
claims, damages and liabilities (including, without limitation, reasonable and documented legal fees and other expenses reasonably incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are
incurred), joint or several, that arise out of, or are based upon, (1) any untrue statement or alleged untrue statement of a material fact contained in any Registration Statement or any omission or alleged omission to state therein a material
fact required to be stated therein or necessary in order to make the statements therein not misleading, or (2) any untrue statement or alleged untrue statement of a material fact contained in any Prospectus or any Free Writing Prospectus, or
any omission or alleged omission to state therein a 

  
 11 

 
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, in each case except insofar as such losses, claims,
damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Initial Purchaser or information relating
to any Holder furnished to the relevant Issuer or Haleon in writing by or on behalf of such parties expressly for use in any Registration Statement, any Prospectus and any Free Writing Prospectus. In connection with any Underwritten Offering
permitted by Section 3, the relevant Issuer and Haleon, jointly and severally, shall also indemnify the Underwriters, if any, selling brokers, dealers and similar securities industry professionals participating in the distribution, their
respective affiliates and each Person who controls such Persons (within the meaning of the Securities Act and the Exchange Act) to the same extent as provided above with respect to the indemnification of the Holders, if requested in connection with
any Registration Statement, any Prospectus or any Free Writing Prospectus. 
 (b) Each Holder agrees, severally and not jointly, to
indemnify and hold harmless the relevant Issuer, Haleon, the Initial Purchasers and the other selling Holders, and each of the directors and officers of such Issuer and Haleon and each Person, if any, who controls such Issuer, Haleon, any Initial
Purchaser and any other selling Holder within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above, but only with respect to any losses,
claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Holder furnished to such
Issuer or Haleon in writing by such Holder expressly for use in any Registration Statement, any Prospectus and any Free Writing Prospectus. 

(c) If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be brought or asserted
against any Person in respect of which indemnification may be sought pursuant to either paragraph (a) or (b) above, such Person (the “Indemnified Person”) shall promptly notify the Person against whom such indemnification may
be sought (the “Indemnifying Person”) in writing; provided that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under paragraph (a) or (b) above except to the extent
that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided, further, that the failure to notify the Indemnifying Person shall not relieve it from any liability that
it may have to an Indemnified Person otherwise than under paragraph (a) or (b) above. If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying
Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person (which consent shall not be unreasonably withheld or delayed), be counsel to the Indemnifying Person) to
represent the Indemnified Person and any others entitled to indemnification pursuant to this Section 5 that the Indemnifying Person may designate in such proceeding and shall pay the fees and expenses of such proceeding and shall pay the
reasonable and documented fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at
the expense of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii) the Indemnifying Person has failed within a reasonable time to retain counsel reasonably
satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or
(iv) the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or
potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one
separate firm (in addition to one local counsel per jurisdiction) for all Indemnified Persons, and that all such fees and expenses shall be reasonable and documented and shall be reimbursed as they are incurred. Any such separate firm (x) for
any Initial Purchaser, its affiliates, directors and officers and any control Persons of such Initial Purchaser shall be designated in writing by the Representatives, (y) for any Holder, its directors and officers and any control Persons of
such Holder shall be designated in writing by the Majority Holders and (z) in all other cases shall be designated in writing by Issuer or Haleon. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without
its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement or
judgment. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any 

  
 12 

 
pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless
such settlement (A) includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and
(B) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person. 

(d) If the indemnification provided for in paragraphs (a) and (b) above is unavailable to an Indemnified Person or insufficient in
respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such
Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the relevant Issuer and Haleon from the offering of the Notes and the Exchange
Notes, on the one hand, and by the Holders from receiving Notes or Exchange Notes registered under the Securities Act, on the other hand, or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) but also the relative fault of the relevant Issuer and Haleon on the one hand and the Holders on the other in connection with the statements or
omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative fault of the relevant Issuer and Haleon on the one hand and the Holders on the other shall be determined by
reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the relevant Issuer and Haleon or by the Holders and
the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 
 (e)
The Issuers, Haleon and the Holders agree that it would not be just and equitable if contribution pursuant to this Section 5 were determined by pro rata allocation (even if the Holders were treated as one entity for such purpose) or by
any other method of allocation that does not take account of the equitable considerations referred to in paragraph (d) above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities
referred to in paragraph (d) above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the
provisions of this Section 5, in no event shall a Holder be required to contribute any amount in excess of the amount by which the total price at which the Notes or Exchange Notes sold by such Holder exceeds the amount of any damages that such
Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall
be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. The Holders’ obligations to contribute pursuant to this Section 5 are several and not joint. 

(f) The remedies provided for in this Section 5 are not exclusive and shall not limit any rights or remedies that may otherwise be
available to any Indemnified Person at law or in equity. 
 (g) The indemnity and contribution provisions contained in this Section 5
shall remain operative and in full force and effect regardless of (i) any termination of this Agreement, (ii) any investigation made by or on behalf of the Initial Purchasers or any Holder or any Person controlling any Initial Purchaser or
any Holder, or by or on behalf of the relevant Issuer or Haleon or the officers or directors of or any Person controlling the relevant Issuer or Haleon, (iii) acceptance of any of the Exchange Notes and (iv) any sale of Registrable
Securities pursuant to a Shelf Registration Statement. 
 6. General. 

(a) No Inconsistent Agreements. Each of the Issuers represents, warrants and agrees that (i) the rights granted to the Holders
hereunder do not in any way conflict in any material respect with and are not inconsistent with the rights granted to the holders of any other outstanding securities issued or guaranteed by such Issuer or any Guarantor under any other agreement and
(ii) neither such Issuer nor any Guarantor has entered into, or on or after the date of this Agreement will enter into, any agreement that is inconsistent with the rights granted to the Holders of Registrable Securities in this Agreement or
otherwise conflicts in any material respect with the provisions hereof. 

  
 13 

 (b) Amendments and Waivers. The provisions of this Agreement, including the
provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given unless such Issuers have obtained the written consent of Holders of at least a majority in
aggregate principal amount of the outstanding Registrable Securities affected by such amendment, modification, supplement, waiver or consent; provided that, with respect to any amendment, modification, supplement, waiver or consent to
Section 5 above that directly or indirectly affects the rights of any Initial Purchaser hereunder, the Issuers shall obtain the written consent of each such Initial Purchaser against which such amendment, modification, supplement, waiver or
consent is to be effective. Any amendments, modifications, supplements, waivers or consents pursuant to this Section 6(b) shall be by a writing executed by each of the parties hereto. 

(c) Notices. All notices and other communications provided for or permitted hereunder shall be made in writing by hand-delivery,
registered first- class mail, electronic mail, facsimile, or any courier guaranteeing overnight delivery (i) if to a Holder, at the most current address given by such Holder to the relevant Issuer by means of a notice given in accordance with
the provisions of this Section 6(c), which address initially is, with respect to the Initial Purchasers, the address set forth in the Purchase Agreement; (ii) if to the Issuers and the Guarantors, initially at the address set forth in the
Purchase Agreement and thereafter at such other address, notice of which is given in accordance with the provisions of this Section 6(c); and (iii) to such other persons at their respective addresses as provided in the Purchase Agreement
and thereafter at such other address, notice of which is given in accordance with the provisions of this Section 6(c). All such notices and communications shall be deemed to have been duly given: at the time delivered by hand, if personally
delivered; five Business Days after being deposited in the mail, postage prepaid, if mailed; when receipt is acknowledged, if e-mailed or facsimiled; and on the next Business Day if timely delivered to an air
courier guaranteeing overnight delivery. Copies of all such notices, demands or other communications shall be concurrently delivered by the Person giving the same to the Trustee, at the address specified in the Indenture. 

(d) Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors, assigns and transferees of
each of the parties, including, without limitation and without the need for an express assignment, subsequent Holders; provided that nothing herein shall be deemed to permit any assignment, transfer or other disposition of Registrable
Securities in violation of the terms of the Purchase Agreement or the Indenture. If any transferee of any Holder shall acquire Registrable Securities in any manner, whether by operation of law or otherwise, such Registrable Securities shall be held
subject to all the terms of this Agreement, and by taking and holding such Registrable Securities such Person shall be conclusively deemed to have agreed to be bound by and to perform all of the terms and provisions of this Agreement and such Person
shall be entitled to receive the benefits hereof. The Initial Purchasers (in their capacity as Initial Purchasers) shall have no liability or obligation to the Issuers or the Guarantors with respect to any failure by a Holder to comply with, or any
breach by any Holder of, any of the obligations of such Holder under this Agreement. 
 (e) Third Party Beneficiaries. Each Holder
shall be a third party beneficiary to the agreements made hereunder (excluding those agreements made in Section 5 hereto) between the Issuer, on the one hand, and the Initial Purchasers, on the other hand, and shall have the right to enforce
such agreements directly to the extent it deems such enforcement necessary or advisable to protect its rights or the rights of other Holders hereunder. 

(f) Counterparts. This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each
of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. 

(g) Headings. The headings in this Agreement are for convenience of reference only, are not a part of this Agreement and shall not
limit or otherwise affect the meaning hereof. 
 (h) Governing Law. This Agreement, and any claim, controversy or dispute arising
under or related to this Agreement, shall be governed by and construed in accordance with the internal laws of the State of New York. 
 (i)
Submission to Jurisdiction; Appointment of Agent for Service. (a) The Issuers and the Guarantors irrevocably submit to the non-exclusive jurisdiction of any New York State or United States Federal
court sitting in The City of New York (the “Specified Courts”) over any suit, action or proceeding arising out of or relating to this Agreement (each, a “Related Proceeding”). The Issuers and the Guarantors
irrevocably waive, to the fullest extent 

  
 14 

 
permitted by law, any objection that it may now or hereafter have to the laying of venue of any Related Proceeding brought in such a court and any claim that any such Related Proceeding brought
in such a court has been brought in an inconvenient forum. (b) The Guarantors and the UK Issuer hereby irrevocably designate, appoint, and empower the US Issuer, as the designee, appointee and agent to receive, accept and acknowledge for and on
their behalf, service of any and all legal process, summons, notices and documents that may be served in any action, suit or proceeding brought against the Guarantors or the UK Issuer in any such United States or State court with respect to any
matter arising out of or based upon this Agreement and that may be made on such designee, appointee and agent in accordance with legal procedures prescribed for such courts. Each of the Guarantors and the UK Issuer further hereby irrevocably
consents and agrees to the service of any and all legal process, summons, notices and documents in any such action, suit or proceeding against it by serving a copy thereof upon the relevant agent for service of process referred to in this
Section 6(i) (whether or not the appointment of such agent shall for any reason prove to be ineffective or such agent shall accept or acknowledge such service). Each of the Guarantors and the UK Issuer agrees that the failure of any such
designee, appointee and agent to give any notice of such service to it shall not impair or affect in any way the validity of such service or any judgment rendered in any such action or proceeding based thereon. The Issuers and the Guarantors hereby
irrevocably and unconditionally waive, to the fullest extent permitted by law, any objection that it may now or hereafter have to the laying of venue of any of the aforesaid actions, suits or proceedings arising out of or based upon this Agreement
brought in the United States federal courts located in The City of New York or the courts of the State of New York located in The City of New York and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such
court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. 
 (j) Entire
Agreement; Severability. This Agreement contains the entire agreement between the parties relating to the subject matter hereof and supersedes all oral statements and prior writings with respect thereto. If any term, provision, covenant or
restriction contained in this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable or against public policy, the remainder of the terms, provisions, covenants and restrictions contained herein shall remain in
full force and effect and shall in no way be affected, impaired or invalidated. The Issuers, the Guarantors and the Initial Purchasers shall endeavor in good faith negotiations to replace the invalid, void or unenforceable provisions with valid
provisions the economic effect of which comes as close as possible to that of the invalid, void or unenforceable provisions. 

[Signatures on following pages] 

  
 15 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	GSK CONSUMER HEALTHCARE CAPITAL US LLC,
		
	By:	 	/s/ Hatixhe Hoxha
		 	Name: Hatixhe Hoxha
		 	Title: Assistant Secretary

 [Signature Page to the Registration Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	GSK CONSUMER HEALTHCARE CAPITAL UK PLC,
		
	By:	 	 /s/ Michael John Rowe

		 	Name: Michael John Rowe
		 	Title: Head of Treasury Consumer Healthcare

 [Signature Page to the Registration Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	GLAXOSMITHKLINE PLC,
		
	By:	 	/s/ Jemma Reynolds
		 	Name: Jemma Reynolds
		 	Title: VP, Corporate Finance

 [Signature Page to the Registration Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	HALEON PLC,
		
	By:	 	/s/ Michael John Rowe
		 	Name: Michael John Rowe
		 	Title: Head of Treasury Consumer Healthcare

 [Signature Page to the Registration Rights Agreement] 

			
	Confirmed and accepted as of the date first above written for themselves and on behalf of the several Initial Purchasers:
	
	 BOFA SECURITIES, INC.,
 For itself
and the Represented Initial Purchasers

		
	By:	 	/s/ Laurie Campbell
	Name:	 	Laurie Campbell
	Title:	 	Managing Director

 [Signature Page to the Registration Rights Agreement] 

			
	 CITIGROUP GLOBAL MARKETS INC.,
 For
itself and the Represented Initial Purchasers

		
	By:	 	/s/ Brian D. Bednarski
	Name:	 	Brian D. Bednarski
	Title:	 	Managing Director

 [Signature Page to the Registration Rights Agreement] 

			
	 HSBC SECURITIES (USA) INC.,
 For
itself and the Represented Initial Purchasers

		
	By:	 	/s/ Patrice Altongy
	Name:	 	Patrice Altongy
	Title:	 	Managing Director

 [Signature Page to the Registration Rights Agreement] 

			
	Mizuho Securities USA LLC,
For itself and the Represented Initial Purchasers
		
	By:	 	/s/ Joseph Santaniello
	Name:	 	Joseph Santaniello
	Title:	 	Director

 [Signature Page to the Registration Rights Agreement] 

			
	GOLDMAN SACHS INTERNATIONAL
		
	By:	 	/s/ Elis Wyn Jones
	Name:	 	Elis Wyn Jones
	Title:	 	Managing Director

 [Signature Page to the Registration Rights Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]